prednisone has been researched along with Arthritis, Rheumatoid in 1088 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Arthritis, Rheumatoid: A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
| Excerpt | Relevance | Reference |
|---|---|---|
| "com identifier: 70365169), patients with early rheumatoid arthritis (RA) initiated an MTX-based strategy and were randomized to concomitant prednisone (MTX + pred) or placebo (MTX + PBO) for 24 months." | 9.41 | Current Smoking Negatively Affects the Response to Methotrexate in Rheumatoid Arthritis in a Dose-responsive Way, Independently of Concomitant Prednisone Use. ( de Hair, MJH; Jacobs, JWG; Safy-Khan, M; van Laar, JM; Welsing, PMJ, 2021) |
| " High-risk patients (n=290) were randomised to 1/3 treatment strategies: combination therapy for early rheumatoid arthritis (COBRA) Classic (methotrexate (MTX)+ sulfasalazine+60 mg prednisone tapered to 7." | 9.20 | Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. ( Corluy, L; De Brabanter, G; De Cock, D; Durnez, A; Geens, E; Geusens, P; Joly, J; Joos, R; Langenaken, C; Lenaerts, J; Meyfroidt, S; Raeman, F; Ravelingien, I; Remans, J; Sileghem, A; Taelman, V; Van der Elst, K; Van Essche, E; Vander Cruyssen, B; Vandevyvere, K; Vanhoof, J; Verschueren, P; Westhovens, R, 2015) |
| "To assess the efficacy and safety of low-dose prednisone chronotherapy using a new modified-release (MR) formulation for the treatment of rheumatoid arthritis (RA)." | 9.17 | Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). ( Alten, RE; Boers, M; Buttgereit, F; Kirwan, J; Mehta, D; Romer, U; Saag, KG; Supronik, J; Szechinski, J; Szombati, I; Witte, S, 2013) |
| "To clarify whether increase of body weight in patients with early rheumatoid arthritis (RA) upon administration of prednisone is a side effect of prednisone or a result of better control of disease activity, we examined the association of prednisone and disease activity with a subsequent change in body mass index (BMI)." | 9.17 | Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: side effect of the prednisone or better control of disease activity? ( Bakker, MF; Bijlsma, JW; Bossema, ER; Ehrlich, JC; Geenen, R; Jacobs, JW; Jurgens, MS; Lafeber, FP; van Albada-Kuipers, IA; Welsing, PM, 2013) |
| "Addition of 10 mg prednisone daily to a methotrexate-based tight control strategy does not lead to bone loss in early rheumatoid arthritis (RA) patients receiving preventive treatment for osteoporosis." | 9.17 | Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? ( Bakker, MF; Bijlsma, JW; Jacobs, JW; Jurgens, MS; van der Goes, MC; van der Veen, MJ; van der Werf, JH; Welsing, PM, 2013) |
| "To determine the efficacy of oral vitamin D [25(OH)D] in patients with active rheumatoid arthritis (RA) who are in methotrexate (MTX) therapy, patients receiving stable doses of MTX were randomized to one of two dose groups and received 12 weeks of double-blind vitamin D[25(OH)D] (50,000 IU per week) or matching placebo." | 9.16 | Efficacy of vitamin D in patients with active rheumatoid arthritis receiving methotrexate therapy. ( Farajzadegan, Z; Salesi, M, 2012) |
| "In early rheumatoid arthritis (RA), low-dose oral prednisone (PDN) co-medication yields better clinical results than monotherapy with disease-modifying anti-rheumatic drugs (DMARDs)." | 9.16 | Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. ( Caporali, R; Montecucco, C; Sakellariou, G; Scirè, CA; Todoerti, M, 2012) |
| "To investigate the effect of atorvastatin therapy on inflammation, disease activity, endothelial dysfunction, and arterial stiffness in patients with rheumatoid arthritis (RA)." | 9.15 | Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis. ( El-Barbary, AM; Hamouda, HE; Hussein, MS; Ismail, RG; Rageh, EM; Wagih, AA, 2011) |
| "A randomised double-blind placebo controlled withdrawal clinical trial of prednisone versus placebo in patients with rheumatoid arthritis (RA), treated in usual clinical care with 1-4 mg/day prednisone, withdrawn to the same dose of 1 mg prednisone or identical placebo tablets." | 9.14 | Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial. ( Luta, G; Pincus, T; Sokka, T; Swearingen, CJ, 2009) |
| "To compare the benefits and side effects of TwHF extract with those of sulfasalazine for the treatment of active rheumatoid arthritis." | 9.14 | Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. ( Costello, R; Csako, G; Fleischmann, R; Goldbach-Mansky, R; Kempf, P; Kivitz, A; Lipsky, PE; Olsen, N; Pham, TH; Pucino, F; Sherrer, Y; Silverfield, J; Snyder, C; Tao, X; van der Heijde, D; Wesley, R; Wilson, M, 2009) |
| "In order to identify rate and stability of remission induced by low-dose prednisone comedication in early rheumatoid arthritis (RA), we evaluated patients with early RA (<1 year) who were randomized to receive (P) or not (non-P) low-dose prednisone in association with step-up disease-modifying antirheumatic drug therapy over 2 years." | 9.14 | Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. ( Boffini, N; Bugatti, S; Caporali, R; Montecucco, C; Scirè, CA; Todoerti, M, 2010) |
| "This 9-month open-label extension of the Circadian Administration of Prednisone in Rheumatoid Arthritis Study (CAPRA 1) investigated the long-term safety and efficacy of prednisone chronotherapy with a novel modified-release (MR) prednisone for up to 12 months." | 9.14 | Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. ( Alten, R; Buttgereit, F; Doering, G; Gromnica-Ihle, E; Jeka, S; Krueger, K; Schaeffler, A; Sierakowski, S; Szechinski, J; Witte, S, 2010) |
| "To investigate the effects of longterm low-dose chronotherapy with modified-release (MR) prednisone for rheumatoid arthritis (RA) on the hypothalamus-pituitary-adrenal (HPA) axis as part of the Circadian Administration of Prednisone in Rheumatoid Arthritis (CAPRA-1) study." | 9.14 | Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. ( Alten, R; Buttgereit, F; Cutolo, M; Döring, G; Gromnica-Ihle, E; Straub, R; Witte, S, 2010) |
| "In a 12-week, multicentre, randomised, double-blind trial, 288 patients with active rheumatoid arthritis were randomly assigned to either a modified-release prednisone tablet (n=144) or to an immediate-release prednisone tablet (n=144)." | 9.13 | Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. ( Alten, R; Buttgereit, F; Doering, G; Gromnica-Ihle, E; Jeka, S; Krueger, K; Schaeffler, A; Sierakowski, S; Szechinski, J; Witte, S, 2008) |
| "To determine the efficacy of subsequent disease modifying antirheumatic drug (DMARD) therapies after initial methotrexate (MTX) failure in patients with recent onset rheumatoid arthritis (RA), treated according to the DAS for 2 years." | 9.12 | Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. ( Allaart, CF; Breedveld, FC; de Vries-Bouwstra, JK; Dijkmans, BA; Gerards, AH; Goekoop-Ruiterman, YP; Hazes, JM; Kerstens, PJ; van der Kooij, SM; van Groenendael, JH; van Zeben, D, 2007) |
| "Evaluation of effectiveness and safety of leflunomide treatment in patients with active rheumatoid arthritis in whom methotrexate was ineffective or contraindicated." | 9.12 | [Leflunomide as a second choice treatment in patients with rheumatoid arthritis]. ( Bachta, A; Dudek, A; Raczkiewicz-Papierska, A; Sułek, M; Tłustochowicz, M; Zawadyl, B, 2007) |
| "To investigate the Chinese herbal medicine in enhancing effect of prednisone for treatment of refractory rheumatoid arthritis (RA)." | 9.12 | [Effect of chinese herbs in enhancing prednisone for treatment of refractory rheumatoid arthritis]. ( Liu, W; Liu, XY; Wang, Y, 2007) |
| "To evaluate the role of serum osteoprotegerin (OPG) as a biochemical marker for disease activity assessment and drug monitoring in patients with rheumatoid arthritis (RA) treated with cyclical etidronate." | 9.10 | Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. ( Koivula, MK; Konttinen, YT; Laasonen, L; Mandelin, J; Risteli, J; Valleala, H, 2003) |
| "Prednisone, 10 mg/d, provides clinical benefit, particularly in the first 6 months, and substantially inhibits progression of radiologic joint damage in patients with early active rheumatoid arthritis and no previous treatment with disease-modifying antirheumatic drugs." | 9.10 | Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. ( Bijlsma, JW; Jacobs, JW; Siewertsz Van Reesema, DR; van Everdingen, AA, 2002) |
| "To evaluate the effects of a 12 month, weight bearing, aerobic exercise program on disease activity, physical function, and bone mineral density (BMD) in women with rheumatoid arthritis (RA) taking low dose prednisone." | 9.09 | A randomized controlled trial to evaluate the effectiveness of an exercise program in women with rheumatoid arthritis taking low dose prednisone. ( Berkowitz, J; Rangno, KK; Wade, JP; Westby, MD, 2000) |
| "The aim of this study was to evaluate the efficacy of fludarabine treatment in patients suffering from refractory rheumatoid arthritis." | 9.09 | Unsuccessful treatment with fludarabine in four cases of refractory rheumatoid arthritis. ( Bambara, LM; Biasi, D; Caramaschi, P; Carletto, A, 2000) |
| "Prednisone is frequently used in the treatment of elderly-onset rheumatoid arthritis (RA), but the balance between efficacy and toxicity, including the effect on bone mass, has not been investigated in long-term studies." | 9.08 | Prednisone treatment of elderly-onset rheumatoid arthritis. Disease activity and bone mass in comparison with chloroquine treatment. ( Breedveld, FC; Dijkmans, BA; Han, KH; Papapoulos, S; Pauwels, EK; Valkema, R; van Schaardenburg, D; Zwinderman, AH, 1995) |
| "To assess the safety and efficacy of minocycline in the treatment of rheumatoid arthritis." | 9.08 | Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. ( Alarcón, GS; Buckley, L; Clegg, DO; Cooper, SM; Duncan, H; Fowler, SE; Heyse, SP; Kaplan, DA; Leisen, JC; Neuner, R; Pillemer, SR; Tilley, BC; Trentham, DE; Tuttleman, M, 1995) |
| "To determine the effects of low dose methotrexate (MTX) on bone mineral density (BMD) of patients with rheumatoid arthritis (RA)." | 9.08 | Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. ( Buckley, LM; Cartularo, KS; Cooper, SM; Leib, ES; Vacek, PM, 1997) |
| "The objective was to assess the efficacy of therapy with danazol in refractory immune thrombocytopenia associated with different rheumatic diseases." | 9.08 | Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases. ( Blanco, R; González-Gay, MA; Martinez-Taboada, VM; Rodriguez-Valverde, V; Sanchez-Andrade, A, 1997) |
| "Ninety-six patients with refractory rheumatoid arthritis were treated with methotrexate for 48 months." | 9.08 | [The effect of low dose methotrexate on the course of rheumatoid arthritis--four years of observation]. ( Lacki, JK; Mackiewicz, SH, 1997) |
| "To conclude observations of efficacy of longterm methotrexate (MTX) treatment of rheumatoid arthritis (RA)." | 9.08 | Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. ( Coblyn, JS; Fraser, PA; Maier, AL; Weinblatt, ME, 1998) |
| "To evaluate the efficacy and tolerability of oral methotrexate (MTX) in rheumatoid arthritis (RA) in a long-term prospective trial." | 9.07 | Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. ( Anderson, L; Block, S; Gall, E; Germain, BF; Kaplan, H; Merriman, RC; Solomon, SD; Wall, B; Weinblatt, ME; Wolfe, F, 1994) |
| "To determine whether men with rheumatoid arthritis (RA) have abnormal hypothalamic-pituitary-gonadal axis function and to measure the effects of low dose prednisone therapy in these patients." | 9.07 | Decreased testosterone levels in men with rheumatoid arthritis: effect of low dose prednisone therapy. ( Bremner, WJ; Dugowson, CE; Martens, HF; Sheets, PK; Starkebaum, G; Tenover, JS, 1994) |
| "The long-term anti-inflammatory and immunosuppressive properties and the safety of deflazacort (Calcort, CAS 14484-47-0) were assessed investigating the effect on clinical symptoms and safety parameters in patients with rheumatoid arthritis compared to prednisone as standard therapy in a randomized double-blind controlled clinical trial." | 9.07 | Long-term therapy with the new glucocorticosteroid deflazacort in rheumatoid arthritis. Double-blind controlled randomized 12-months study against prednisone. ( Eberhardt, R; Gross, W; Krüger, K; Reiter, W; Zwingers, T, 1994) |
| "To determine the long-term efficacy and safety of low-dose methotrexate (MTX) in rheumatoid arthritis (RA)." | 9.07 | Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. ( Coblyn, JS; Falchuk, KR; Fraser, PA; Holdsworth, DE; Maier, AL; Weinblatt, ME; Weissman, BN, 1992) |
| "The therapeutic effect of prednisone combined with azathioprine was studied in 28 patients with rheumatoid vasculitis." | 9.07 | Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. ( Breedveld, FC; Heurkens, AH; Westedt, ML, 1991) |
| "Prednisone, 5 mg taken each morning, was added to other drugs in 18 patients with rheumatoid arthritis." | 9.05 | Low dose prednisone therapy in rheumatoid arthritis: a double blind study. ( Emkey, RD; Harris, ED; Newberg, A; Nichols, JE, 1983) |
| " Slow turnover rates of the metal were demonstrated in seven out of eight patients with active rheumatoid arthritis, in one with hydralazine disease, but not in one arthritic undergoing an impressive, spontaneous remission." | 9.03 | Slow turnover of manganese in active rheumatoid arthritis accelerated by prednisone. ( Borg, DC; Cotzias, GC; Hughes, ER; Papavasiliou, PS; Tang, L, 1968) |
| "In this article, we reviewed the recent clinical trials evaluating the efficacy of MR prednisone in RA patients, including two randomized controlled double-blind clinical trials Circadian Administration of Prednisone in Rheumatoid Arthritis - 1 (CAPRA-1) and CAPRA-2 and other nonrandomized observational studies." | 8.95 | Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis. ( Bruno, C; Grembiale, RD; Naty, S; Ursini, F, 2017) |
| "Prednisone is a well-established treatment option in rheumatoid arthritis." | 8.89 | Modified-release prednisone: in patients with rheumatoid arthritis. ( Henness, S; Yang, LP, 2013) |
| "There has been a renewed interest in the use of low doses of prednisone in the treatment of early rheumatoid arthritis." | 8.82 | New role for an old friend: prednisone is a disease-modifying agent in early rheumatoid arthritis. ( Conn, DL; Lim, SS, 2003) |
| "Use of methotrexate to treat rheumatoid arthritis is associated with pulmonary adverse effects in 3% to 5% of cases." | 8.79 | Pneumocystis carinii pneumonia in rheumatoid arthritis patients treated with methotrexate. A report of two cases. ( Cortet, B; Delcambre, B; Duquesnoy, B; Flipo, RM; Lafitte, JJ; Roux, N; Tonnel, AB, 1996) |
| "A review of the literature on the longterm use of methotrexate in patients with rheumatoid arthritis (RA) showed that many questions on protocol remain unanswered." | 8.77 | Longterm methotrexate therapy in rheumatoid arthritis: a review. ( Kremer, JM, 1985) |
| "Children who are prednisone-exposed in utero (low dose) have no increased risk for insulin resistance at the age of approximately 7 years." | 8.31 | Does prednisone use in pregnant women with rheumatoid arthritis induce insulin resistance in the offspring? ( de Steenwinkel, FDO; Dolhain, RJEM; Hazes, JMW; Hokken-Koelega, ACS, 2023) |
| "Recently, the use of targeted synthetic or biological disease-modifying anti-rheumatic drugs (ts/bDMARDs) in addition to conventional synthetic (cs)DMARDs including methotrexate (MTX) for rheumatoid arthritis (RA) has increased." | 8.02 | Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. ( Akashi, K; Asaoku, H; Ayano, M; Fujisaki, T; Harada, T; Iwasaki, H; Kato, K; Kohno, K; Mitoma, H; Miyamoto, T; Miyamura, T; Miyoshi, H; Mori, Y; Muta, T; Niiro, H; Ohshima, K; Oryoji, K; Oshiro, Y; Sakamoto, A; Sawabe, T; Takase, K; Takeshita, M; Urata, S; Yamamoto, H; Yoshimoto, G, 2021) |
| "Methotrexate (MTX), often combined with low moderately dosed prednisone, is still the cornerstone of initial treatment for early rheumatoid arthritis (RA)." | 7.91 | Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-I ( Bijlsma, JW; Borm, ME; de Hair, MJ; Jacobs, JW; Lafeber, FP; Linn-Rasker, SP; Pethoe-Schramm, A; Teitsma, XM; Tekstra, J; Ter Borg, EJ; van Laar, JM; Verhoeven, MM; Welsing, PM, 2019) |
| "Determine the effect of daily low divided or single daily dose of prednisone on the longitudinal change in the number of tender and swollen joints and HAQ scores in African Americans (AA) with early rheumatoid arthritis (RA) from the Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis (CLEAR) 1 Registry." | 7.88 | Effect of daily low dose prednisone, divided or single daily dose, in the treatment of African Americans with early rheumatoid arthritis. ( Bao, G; Conn, DL; Easley, KA; Li, S; Tiliakos, A, 2018) |
| "To characterize prednisone use in pregnant women with rheumatoid arthritis using individual-level heat-maps and clustering individual trajectories of prednisone dose, and to evaluate the association between prednisone dose trajectory groups and gestational length." | 7.88 | Patterns of prednisone use during pregnancy in women with rheumatoid arthritis: Daily and cumulative dose. ( Chambers, CD; Clowse, MEB; Hebert, MF; Palmsten, K; Rolland, M; Schatz, M; Xu, R, 2018) |
| "In the second Computer-Assisted Management in Early Rheumatoid Arthritis trial, patients had started with methotrexate and 10 mg prednisone (MTX+pred) or placebo (MTX+plac)." | 7.85 | Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial. ( Bijlsma, J; de Hair, M; IJff, ND; Jacobs, J; Safy, M; van Laar, JM, 2017) |
| "An increased risk of lymphoproliferative disorders (LPD) has been demonstrated in patients treated with methotrexate (MTX) for rheumatoid arthritis (RA)." | 7.83 | [Immunodeficiency-associated Burkitt lymphoma developed in a patient receiving a long-term methotrexate therapy for rheumatoid arthritis]. ( Iwashige, A; Katsuragi, T; Tsukada, J, 2016) |
| "To evaluate gastrointestinal (GI) perforation in rheumatoid arthritis (RA) patients receiving tofacitinib, tocilizumab, or other biologic agents." | 7.83 | Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. ( Bernatsky, S; Curtis, JR; Xie, F; Yun, H, 2016) |
| " We assessed the hepatotoxicity of methotrexate and prednisolone combination therapy in the background of hepatitis B virus infection." | 7.80 | Fibrosing cholestatic hepatitis after methotrexate and prednisone therapy for rheumatoid arthritis. ( Çalık, A; Çeşmecioğlu, E; Çobanoğlu, Ü; Kalaycı, O; Topaloğlu, S; Uzun, Y, 2014) |
| "We report an extremely rare case of massive methotrexate-associated lymphoproliferative disorder (MTX-LPD) arising in the retromolar triangle and lung of a patient with rheumatoid arthritis." | 7.80 | Methotrexate-associated lymphoproliferative disorder arising in the retromolar triangle and lung of a patient with rheumatoid arthritis. ( Harada, H; Ishii, Y; Kudoh, M; Matsumoto, K; Omura, K; Sato, Y, 2014) |
| "Methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis (RA) but data concerning the effectiveness of treatment with this compound are lacking in the Congolese population." | 7.79 | Treatment of rheumatoid arthritis with methotrexate in Congolese patients. ( Bossuyt, X; Malemba, JJ; Mbuyi Muamba, JM; Mukaya, J; Verschueren, P; Westhovens, R, 2013) |
| "To evaluate the clinical efficacy and safety of methotrexate (MTX) plus low dose glucocorticoid in the treatment of rheumatoid arthritis (RA) from the "target control" point of view." | 7.79 | [The short-term efficacy and safety of methotrexate plus low dose prednisone in patients with rheumatoid arthritis]. ( He, YJ; Liu, SY; Yang, L; Zhang, L; Zhang, X, 2013) |
| "To analyze prednisone treatment from 1980-2004 in 308 patients with rheumatoid arthritis (RA), including 75 monitored over 4-8 years and 73 monitored over >8 years, for initial dose, long-term doses and effectiveness, and adverse events." | 7.79 | Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. ( Castrejón, I; Cutolo, M; Pincus, T; Sokka, T, 2013) |
| " Here, we present a case of chronic rheumatoid meningitis occurring during treatment with methotrexate and the tumour necrosis factor (TNF) alpha antibody adalimumab." | 7.78 | Rheumatoid meningitis occurring during adalimumab and methotrexate treatment. ( Guerne, PA; Horvath, J; Huys, AC, 2012) |
| "The efficacy of initial and long-term prednisone < 5 mg/ day in treatment of rheumatoid arthritis (RA) by one academic rheumatologist over 25 years from 1980 to 2004 is summarized." | 7.78 | Effective initial and long-term prednisone in doses of less than 5 mg/day to treat rheumatoid arthritis--documentation using a patient self-report Multidimensional Health Assessment Questionnaire (MDHAQ). ( Castrejón, I; Pincus, T, 2012) |
| "To investigate whether anti-inflammatory effects of HMG-CoA reductase inhibitor simvastatin (SMV) in rheumatoid arthritis (RA) is mediated by Toll-like receptor-2 (TLR-2) signal via inhibiting activation of RhoA, a small Rho GTPase that plays an important role in inflammatory responses." | 7.77 | HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients. ( Chen, G; Fan, J; Fu, D; Liang, L; Lin, H; Sun, L; Xiao, Y; Xu, H; Yang, X; Ye, Y, 2011) |
| "MTX, TNF antagonists and prednisone at doses >10 mg daily were associated with increased risks of overall infections." | 7.76 | Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. ( Bishai, W; Greenberg, JD; Hochberg, MC; Kavanaugh, A; Kremer, JM; Reed, G; Tindall, E; Zheng, C, 2010) |
| "The effects of low dose prednisone (PD) alone or in combination with leflunomide (LEF) were tested on inflammatory gene expression in early rheumatoid arthritis (RA)." | 7.76 | Inflammatory gene profile in early rheumatoid arthritis and modulation by leflunomide and prednisone treatment. ( Bonassi, S; Cutolo, M; Gallo, F; Montagna, P; Moretti, S; Paolino, S; Pizzorni, C; Seriolo, B; Soldano, S; Sulli, A; Villaggio, B, 2010) |
| "To determine the relationship between current hydroxychloroquine (HCQ) use and 2 indicators of glycemic control, fasting glucose and insulin sensitivity, in nondiabetic women with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)." | 7.76 | Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. ( Elliott, JR; Kao, AH; Kuller, L; Manzi, S; Penn, SK; Schott, LL; Toledo, FG; Wasko, MC, 2010) |
| "We report two cases of hydroxychloroquine-induced hyperpigmentation presenting in a 50-year-old Caucasian female (case 1) and a 78-year-old female (case 2), both receiving 400 mg per day." | 7.74 | Hydroxychloroquine-induced hyperpigmentation: the staining pattern. ( Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W, 2008) |
| "The aim of this study was to determine the difference between bone mineral density (BMD) of rheumatoid arthritis (RA) patients on low-dose prednisone and matched RA patients without prior systemic corticosteroid therapy." | 7.73 | The effect of low-dose prednisone on bone mineral density in Peruvian rheumatoid arthritis patients. ( Chung, CP; Russell, AS; Segami, MI; Ugarte, CA, 2005) |
| "After adjustment for covariates, prednisone use increased the risk of pneumonia hospitalization (hazard ratio [HR] 1." | 7.73 | Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. ( Caplan, L; Michaud, K; Wolfe, F, 2006) |
| "In a previous clinical trial of patients with early rheumatoid arthritis (RA), it was determined that patients who received 10 mg of prednisone per day for 2 years had less radiographic joint damage compared with those who received placebo." | 7.73 | Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. ( Bijlsma, JW; Jacobs, JW; van Everdingen, AA; Verstappen, SM, 2006) |
| "To determine the longterm outcome including disease activity, mortality, and adverse events in patients with rheumatoid arthritis (RA) treated with prednisone." | 7.69 | Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. ( Haga, M; McDougall, R; Russell, A; Sibley, J, 1994) |
| "To correlate the serum levels of keratan sulfate (KS) in patients with rheumatoid arthritis (RA) with different clinical and radiographic variables." | 7.69 | Serum keratan sulfate levels in rheumatoid arthritis: inverse correlation with radiographic staging. ( Goulet, JR; Haraoui, B; Martel-Pelletier, J; Ouellet, M; Pelletier, JP; Raynauld, JP; Thonar, EJ, 1994) |
| "To test for and estimate variation among rheumatologists in their prescribing of prednisone and second-line agents for the treatment of rheumatoid arthritis (RA), after taking into account the characteristics of their patients." | 7.69 | Variation among rheumatologists in the use of prednisone and second-line agents for the treatment of rheumatoid arthritis. ( Criswell, LA; Redfearn, WJ, 1994) |
| "To determine the extent to which characteristics of rheumatologists and their practices explain the variation in their use of prednisone and 2nd line agents for the treatment of rheumatoid arthritis (RA)." | 7.69 | What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis? ( Criswell, LA; Henke, CJ, 1995) |
| "The aim of this study was to evaluate CD8 lymphocyte subsets in active polymyalgia rheumatica (PMR), to determine whether low percentages of CD8+ cells could be used to differentiate PMR from elderly-onset (EORA) and adult rheumatoid arthritis (RA), and to investigate the effects of prednisone on CD8 lymphocyte subsets." | 7.69 | CD8 lymphocyte subsets in active polymyalgia rheumatica: comparison with elderly-onset and adult rheumatoid arthritis and influence of prednisone therapy. ( Beltrandi, E; Boiardi, L; Casadei Maldini, M; Macchioni, P; Mancini, R; Portioli, I; Salvarani, C, 1996) |
| ") gold, hydroxychloroquine, and prednisone for rheumatoid arthritis (RA) treatment among patients managed by rheumatologists and nonrheumatologists." | 7.69 | Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists. ( Criswell, LA; Such, CL; Yelin, EH, 1997) |
| "Ovine corticotropin-releasing hormone (oCRH) stimulation tests were performed in 8 female patients with active rheumatoid arthritis treated chronically with daily low dose prednisone and 16 age matched female controls." | 7.68 | Pituitary-adrenal axis responsiveness to ovine corticotropin releasing hormone in patients with rheumatoid arthritis treated with low dose prednisone. ( Cash, JM; Chrousos, GP; Crofford, LJ; Gallucci, WT; Gold, PW; Sternberg, EM; Wilder, RL, 1992) |
| "To assess whether low doses of prednisone produce generalized alterations in skeletal homeostasis in rheumatoid arthritis (RA), indices of calcium metabolism and bone mineral density (BMD) were measured in 22 women with RA treated without or with prednisone (6." | 7.68 | Low dose prednisone does not affect calcium homeostasis or bone density in postmenopausal women with rheumatoid arthritis. ( el-Hajj Fuleihan, G; Leboff, MS; Liang, MH; Mackowiak, S; Wade, JP; Zangari, M, 1991) |
| "We performed a 10-year retrospective analysis of the frequency of local postoperative infectious complications in methotrexate (MTX)-treated rheumatoid arthritis patients who underwent total joint arthroplasty." | 7.68 | Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. ( Clough, JD; Perhala, RS; Segal, AM; Wilke, WS, 1991) |
| "Herpes zoster occurred in nine patients with methotrexate-treated rheumatoid arthritis." | 7.68 | Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. ( Antonelli, MA; Brick, JE; Moreland, LW, 1991) |
| "A patient with rheumatoid arthritis developed nephrotic syndrome with reversible renal failure following gold therapy." | 7.67 | Nephrotic syndrome with reversible severe renal failure after gold therapy. ( Aviram, A; Blum, M; Liron, M, 1984) |
| " In 27 patients with rheumatoid arthritis, we measured the pulmonary excretion of pentane, a product released during lipid peroxidation." | 7.67 | Breath pentane excretion as a marker of disease activity in rheumatoid arthritis. ( Clapper, M; Humad, S; Skosey, JL; Zarling, E, 1988) |
| "Twenty-nine patients participated in a prospective study of the safety and efficacy of oral methotrexate in the treatment of refractory rheumatoid arthritis." | 7.67 | The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. ( Kremer, JM; Lee, JK, 1986) |
| "Eight patients with long-standing rheumatoid arthritis and cutaneous vasculitis ulcerations resistant to conventional therapy were treated successfully with a low-dose intermittent regimen of oral methotrexate." | 7.67 | Oral methotrexate therapy for chronic rheumatoid arthritis ulcerations. ( Espinoza, CG; Espinoza, LR; Germain, BF; Vasey, FB, 1986) |
| "Myositis was diagnosed twenty months after starting treatment with d-penicillamine in a patient suffering from uncomplicated rheumatoid arthritis for nearly three years." | 7.66 | [Is myositis in chronic polyarthritis using d-penicillamine drug-induced?]. ( Bussmann, HU; Jerusalem, F; Schlumpf, U, 1981) |
| "Thrombocytopenia developed in 23 patients with rheumatoid arthritis treated with gold salts over 25 years." | 7.66 | Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients. ( Coblyn, JS; Glass, D; Holdsworth, D; Weinblatt, M, 1981) |
| "The transcapillary escape rate of albumin was measured in 27 consecutive patients with inflammatory rheumatic diseases before and after 1 and 7 days of prednisone treatment in doses of 45 mg/day." | 7.66 | Prednisone effect on microvascular permeability in patients with inflammatory rheumatic diseases. ( Hansen, TM; Junker, P; Lorenzen, I; Manthorpe, R; Utne, HE, 1979) |
| "Sequential measurements of serum C-reactive protein (CRP), serum haptoglobin (Hp), and erythrocyte sedimentation rate (ESR) were made in 209 patients with rheumatoid arthritis (RA); 78 of them were treated with gold, 71 with dapsone, and 60 with prednisone." | 7.66 | Effects of gold, dapsone, and prednisone on serum C-reactive protein and haptoglobin and the erythrocyte sedimentation rate in rheumatoid arthritis. ( Amos, RS; Butler, M; Constable, TJ; Crockson, AP; Crockson, RA; Davies, P; McConkey, B, 1979) |
| "2 women, 62 and 69 years old, both suffering from rheumatoid arthritis, were treated for 1 and 1 1/2 years, respectively, with penicillamine." | 7.66 | Two cases of penicillamine-induced pemphigus erythematosus. ( Thorvaldsen, J, 1979) |
| "The longterm administration of prednisone and gold to patients with rheumatoid arthritis (RA), in doses that decreased the sedimentation rate (p less than 0." | 7.65 | Antirheumatic drugs, the ESR, and the hypohistidinemia of rheumatoid arthritis. ( Gerber, DA, 1977) |
| "The results of a five-year study of chlorambucil in patients suffering from rheumatoid arthritis are presented." | 7.65 | Rheumatoid arthritis treated with chlorambucil: a five-year follow-up. ( Thorpe, P, 1976) |
| "A study of sera from 285 patients with definite or classical rheumatoid arthritis (including 37 patients receiving no anti-inflammatory drugs) and sera from 67 healthy subjects has confirmed 10 published reports of a statistically significant decreased blood histidine concentration in patients with rheumatoid arthritis." | 7.65 | Low free serum histidine concentration in rheumatoid arthritis. A measure of disease activity. ( Gerber, DA, 1975) |
| "Ionic permeability of the gastric mucosa was measured in six patients with an acute exacerbation of severe generalized rheumatoid arthritis receiving either aspirin and prednisone or aspirin and indomethacin as therapy." | 7.65 | Back diffusion of hydrogen ions across gastric mucosa of patients with gastric ulcer and rheumatoid arthritis. ( Clifton, JA; Ivey, KJ, 1974) |
| "Glucocorticoids have anti-inflammatory, transrepression-mediated effects, although adverse events (AEs; transactivation-mediated effects) limit long-term use in patients with rheumatoid arthritis (RA)." | 6.90 | Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study. ( Buttgereit, F; Genet, A; Hey-Hadavi, J; Lee, EB; McCabe, D; Rojo, R; Simon-Campos, A; Strand, V; Tammara, B, 2019) |
| " There was no substantial difference in pharmacokinetic parameters of the formulations apart from the programmed delay in release of glucocorticoid from the modified-release tablets (C(max) 97%, AUC(0-∞) 101%, 90% confidence intervals within the requisite range for bioequivalence)." | 6.78 | Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis. ( Clarke, L; Derendorf, H; Kirwan, JR; Ruebsamen, K; Schaeffler, A, 2013) |
| "Alendronate has been described to have a bone-sparing effect in patients treated with moderate and high dosages of prednisone for heterogeneous diseases, however no data are available on groups of patients with the same underlying diseases who receive chronic low-dose prednisone treatment." | 6.72 | Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. ( Bijlsma, JW; Dijkmans, BA; Geusens, P; Lems, WF; Lips, P; Lodder, MC; Schrameijer, N; van de Ven, CM, 2006) |
| "To compare pharmacokinetic variables of a 7." | 6.68 | Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months. ( Hamilton, RA; Kremer, JM; Petrillo, GF, 1995) |
| " It is our view that the use of methotrexate in rheumatoid arthritis should still be considered cautiously until further data on the risk-benefit ratio of long-term use become available." | 6.39 | [Fatal outcome of pneumocystis-carinii pneumonia under low-dose methotrexate and prednisone therapy for chronic rheumatoid arthritis. Case report and literature review]. ( Kuhn, M; Luzi, HP; Reinhart, WH; Wyss, E, 1994) |
| "Although the rapid onset of effect of glucocorticoids (GCs) allows rapid control of rheumatoid arthritis (RA) symptoms, their chronic use may be associated with several adverse events." | 5.91 | Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib. ( Ceccarelli, F; Conti, F; Garufi, C; Mancuso, S; Spinelli, FR; Truglia, S, 2023) |
| "Prednisone use was associated with a significantly increased risk of mortality in patients with RA." | 5.43 | Prednisone Use and Risk of Mortality in Patients With Rheumatoid Arthritis: Moderation by Use of Disease-Modifying Antirheumatic Drugs. ( Chester Wasko, M; Dasgupta, A; Fries, JF; Ilse Sears, G; Ward, MM, 2016) |
| "The treatment with theophylline and nitric oxide modulators were done from day 14 to day 28." | 5.42 | Protective role of theophylline and their interaction with nitric oxide (NO) in adjuvant-induced rheumatoid arthritis in rats. ( Babu, S; Chaudhary, MJ; Pal, R; Pant, KK; Tiwari, PC, 2015) |
| "com identifier: 70365169), patients with early rheumatoid arthritis (RA) initiated an MTX-based strategy and were randomized to concomitant prednisone (MTX + pred) or placebo (MTX + PBO) for 24 months." | 5.41 | Current Smoking Negatively Affects the Response to Methotrexate in Rheumatoid Arthritis in a Dose-responsive Way, Independently of Concomitant Prednisone Use. ( de Hair, MJH; Jacobs, JWG; Safy-Khan, M; van Laar, JM; Welsing, PMJ, 2021) |
| "Prednisone is an old and very valuable drug in clinical use for over 60 years by now." | 5.40 | The current relevance and use of prednisone in rheumatoid arthritis. ( Baerwald, C; Krasselt, M, 2014) |
| " Secondary endpoints include AIRs during the 24 h following their second infusion and any adverse events experienced during the 26-week study; efficacy measures were also followed as secondary endpoints." | 5.38 | A safety analysis of oral prednisone as a pretreatment for rituximab in rheumatoid arthritis. ( Carter, JD; McNeil, A; Ricca, LR; Sebba, AI; Valeriano-Marcet, J; Vasey, FB; Zarabadi, SA, 2012) |
| "Pericarditis has not recurred after discontinuance of MTX over 3 years ago." | 5.34 | Pericarditis: a rare complication of methotrexate therapy. ( Elyan, M; Kushner, I; Mohyuddin, T, 2007) |
| "Both membranous glomerulopathy and acute interstitial nephritis have been reported to occur following treatment with non-steroidal anti-inflammatory drugs." | 5.32 | Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib. ( Appel, GB; D'Agati, VD; Falkowitz, DC; Imaizumi, S; Isom, R; Markowitz, GS; Zaki, M, 2003) |
| " The prodrug fosdagrocorat (PF-04171327), with active DAGR metabolite PF-00251802 (Metabolite-1), is postulated to show superior efficacy over placebo and prednisone in patients with moderate to severe rheumatoid arthritis (RA)." | 5.27 | Population Pharmacokinetics of Fosdagrocorat (PF-04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid Arthritis. ( McFadyen, L; Tammara, B; Weatherley, B, 2018) |
| "Flurbiprofen was better tolerated (p less than 0." | 5.27 | Steroid-sparing action of flurbiprofen and indomethacin in rheumatoid arthritis: a nine-week study. ( Benvenuti, C; Longoni, A; Viara, M, 1983) |
| "Deflazacort (DFC) is a new glucocorticoid which, when compared with prednisone (PDN), has similar anti-inflammatory actions, but lacks several unwanted side effects on mineral and carbohydrate metabolism." | 5.27 | Effects of a new heterocyclic glucocorticoid, deflazacort (DFC), on the functions of lymphocytes from patients with rheumatoid arthritis (RA). ( Imbimbo, B; Indiveri, F; Piccardo, C; Piovano, P; Scudeletti, M, 1987) |
| " Case Presentation: A 62-year-old woman with rheumatoid arthritis (RA) refractory to methotrexate and prednisone was treated with adalimumab (ADA)." | 5.22 | TNF-induced Lupus. A Case-Based Review. ( Drosos, AA; Pelechas, E; Skalkou, A; Voulgari, PV, 2022) |
| " High-risk patients (n=290) were randomised to 1/3 treatment strategies: combination therapy for early rheumatoid arthritis (COBRA) Classic (methotrexate (MTX)+ sulfasalazine+60 mg prednisone tapered to 7." | 5.20 | Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. ( Corluy, L; De Brabanter, G; De Cock, D; Durnez, A; Geens, E; Geusens, P; Joly, J; Joos, R; Langenaken, C; Lenaerts, J; Meyfroidt, S; Raeman, F; Ravelingien, I; Remans, J; Sileghem, A; Taelman, V; Van der Elst, K; Van Essche, E; Vander Cruyssen, B; Vandevyvere, K; Vanhoof, J; Verschueren, P; Westhovens, R, 2015) |
| "Although the Computer Assisted Management in Early Rheumatoid Arthritis Trial-II (CAMERA-II) showed favorable clinical effects in the most intensive methotrexate (MTX)-based strategy with prednisone (MTX ± prednisone) compared to that with placebo (MTX + placebo), this beneficial difference was only seen in 1 of the 3 analyses of remission." | 5.20 | Alternative Ways to Quantify Sustained Remission: Applying the Continuity Rewarded Score and Patient Vector Graph. ( Bijlsma, JW; Boers, M; Jacobs, JW; Jurgens, MS; Lafeber, FP; van der Goes, MC; van der Veen, MJ, 2015) |
| "To assess morning stiffness in rheumatoid arthritis (RA) patients switched from immediate-release (IR) to delayed-release (DR) prednisone." | 5.20 | Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone. ( Alten, R; Buttgereit, F; Gibofsky, A; Grahn, A; Holt, R; Kent, J; Rice, P, 2015) |
| "610 patients with early rheumatoid arthritis (RA 2010 criteria) or undifferentiated arthritis (UA) started treatment with methotrexate (MTX) and a tapered high dose of prednisone." | 5.19 | A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. ( Allaart, CF; Bijkerk, C; de Buck, MP; de Sonnaville, PB; Goekoop, RJ; Grillet, BA; Harbers, JB; Heimans, L; Huizinga, TW; Speyer, I; van Oosterhout, M; Visser, K; Wevers-de Boer, KV, 2014) |
| "The influence of methotrexate and inflammation on infliximab clearance suggests that individual adjustment of infliximab doses according to disease activity may be useful in RA." | 5.19 | Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. ( Corondan, A; Devauchelle-Pensec, V; Ducourau, E; Goupille, P; Le Goff, B; Mulleman, D; Paintaud, G; Perdriger, A; Solau-Gervais, E; Ternant, D; Watier, H, 2014) |
| "In this study, 610 patients with early rheumatoid arthritis (RA) or undifferentiated arthritis (UA) were treated with methotrexate (MTX) and tapered high dose of prednisone." | 5.17 | Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study. ( Allaart, CF; Goekoop-Ruiterman, YP; Grillet, BA; Harbers, JB; Heimans, L; Huizinga, TW; Koudijs, KK; Lard, LR; Steup-Beekman, GM; Visser, K; Wevers-de Boer, KV, 2013) |
| "To assess the efficacy and safety of low-dose prednisone chronotherapy using a new modified-release (MR) formulation for the treatment of rheumatoid arthritis (RA)." | 5.17 | Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). ( Alten, RE; Boers, M; Buttgereit, F; Kirwan, J; Mehta, D; Romer, U; Saag, KG; Supronik, J; Szechinski, J; Szombati, I; Witte, S, 2013) |
| "To clarify whether increase of body weight in patients with early rheumatoid arthritis (RA) upon administration of prednisone is a side effect of prednisone or a result of better control of disease activity, we examined the association of prednisone and disease activity with a subsequent change in body mass index (BMI)." | 5.17 | Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: side effect of the prednisone or better control of disease activity? ( Bakker, MF; Bijlsma, JW; Bossema, ER; Ehrlich, JC; Geenen, R; Jacobs, JW; Jurgens, MS; Lafeber, FP; van Albada-Kuipers, IA; Welsing, PM, 2013) |
| "Addition of 10 mg prednisone daily to a methotrexate-based tight control strategy does not lead to bone loss in early rheumatoid arthritis (RA) patients receiving preventive treatment for osteoporosis." | 5.17 | Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? ( Bakker, MF; Bijlsma, JW; Jacobs, JW; Jurgens, MS; van der Goes, MC; van der Veen, MJ; van der Werf, JH; Welsing, PM, 2013) |
| "To determine the efficacy of oral vitamin D [25(OH)D] in patients with active rheumatoid arthritis (RA) who are in methotrexate (MTX) therapy, patients receiving stable doses of MTX were randomized to one of two dose groups and received 12 weeks of double-blind vitamin D[25(OH)D] (50,000 IU per week) or matching placebo." | 5.16 | Efficacy of vitamin D in patients with active rheumatoid arthritis receiving methotrexate therapy. ( Farajzadegan, Z; Salesi, M, 2012) |
| "In early rheumatoid arthritis (RA), low-dose oral prednisone (PDN) co-medication yields better clinical results than monotherapy with disease-modifying anti-rheumatic drugs (DMARDs)." | 5.16 | Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. ( Caporali, R; Montecucco, C; Sakellariou, G; Scirè, CA; Todoerti, M, 2012) |
| "To investigate the effect of atorvastatin therapy on inflammation, disease activity, endothelial dysfunction, and arterial stiffness in patients with rheumatoid arthritis (RA)." | 5.15 | Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis. ( El-Barbary, AM; Hamouda, HE; Hussein, MS; Ismail, RG; Rageh, EM; Wagih, AA, 2011) |
| "A randomised double-blind placebo controlled withdrawal clinical trial of prednisone versus placebo in patients with rheumatoid arthritis (RA), treated in usual clinical care with 1-4 mg/day prednisone, withdrawn to the same dose of 1 mg prednisone or identical placebo tablets." | 5.14 | Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial. ( Luta, G; Pincus, T; Sokka, T; Swearingen, CJ, 2009) |
| "To compare the benefits and side effects of TwHF extract with those of sulfasalazine for the treatment of active rheumatoid arthritis." | 5.14 | Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. ( Costello, R; Csako, G; Fleischmann, R; Goldbach-Mansky, R; Kempf, P; Kivitz, A; Lipsky, PE; Olsen, N; Pham, TH; Pucino, F; Sherrer, Y; Silverfield, J; Snyder, C; Tao, X; van der Heijde, D; Wesley, R; Wilson, M, 2009) |
| "In order to identify rate and stability of remission induced by low-dose prednisone comedication in early rheumatoid arthritis (RA), we evaluated patients with early RA (<1 year) who were randomized to receive (P) or not (non-P) low-dose prednisone in association with step-up disease-modifying antirheumatic drug therapy over 2 years." | 5.14 | Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. ( Boffini, N; Bugatti, S; Caporali, R; Montecucco, C; Scirè, CA; Todoerti, M, 2010) |
| "This 9-month open-label extension of the Circadian Administration of Prednisone in Rheumatoid Arthritis Study (CAPRA 1) investigated the long-term safety and efficacy of prednisone chronotherapy with a novel modified-release (MR) prednisone for up to 12 months." | 5.14 | Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. ( Alten, R; Buttgereit, F; Doering, G; Gromnica-Ihle, E; Jeka, S; Krueger, K; Schaeffler, A; Sierakowski, S; Szechinski, J; Witte, S, 2010) |
| "To investigate the effects of longterm low-dose chronotherapy with modified-release (MR) prednisone for rheumatoid arthritis (RA) on the hypothalamus-pituitary-adrenal (HPA) axis as part of the Circadian Administration of Prednisone in Rheumatoid Arthritis (CAPRA-1) study." | 5.14 | Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. ( Alten, R; Buttgereit, F; Cutolo, M; Döring, G; Gromnica-Ihle, E; Straub, R; Witte, S, 2010) |
| "In a 12-week, multicentre, randomised, double-blind trial, 288 patients with active rheumatoid arthritis were randomly assigned to either a modified-release prednisone tablet (n=144) or to an immediate-release prednisone tablet (n=144)." | 5.13 | Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. ( Alten, R; Buttgereit, F; Doering, G; Gromnica-Ihle, E; Jeka, S; Krueger, K; Schaeffler, A; Sierakowski, S; Szechinski, J; Witte, S, 2008) |
| "To determine the efficacy of subsequent disease modifying antirheumatic drug (DMARD) therapies after initial methotrexate (MTX) failure in patients with recent onset rheumatoid arthritis (RA), treated according to the DAS for 2 years." | 5.12 | Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. ( Allaart, CF; Breedveld, FC; de Vries-Bouwstra, JK; Dijkmans, BA; Gerards, AH; Goekoop-Ruiterman, YP; Hazes, JM; Kerstens, PJ; van der Kooij, SM; van Groenendael, JH; van Zeben, D, 2007) |
| "Evaluation of effectiveness and safety of leflunomide treatment in patients with active rheumatoid arthritis in whom methotrexate was ineffective or contraindicated." | 5.12 | [Leflunomide as a second choice treatment in patients with rheumatoid arthritis]. ( Bachta, A; Dudek, A; Raczkiewicz-Papierska, A; Sułek, M; Tłustochowicz, M; Zawadyl, B, 2007) |
| "To investigate the Chinese herbal medicine in enhancing effect of prednisone for treatment of refractory rheumatoid arthritis (RA)." | 5.12 | [Effect of chinese herbs in enhancing prednisone for treatment of refractory rheumatoid arthritis]. ( Liu, W; Liu, XY; Wang, Y, 2007) |
| "Our previous analysis of patients with early active rheumatoid arthritis (RA) treated with prednisone or placebo revealed the following discrepancy: although a significant retardation of joint damage was observed in the prednisone group compared with the placebo group, no differences in clinical variables between the 2 groups were observed, due to greater use of additional therapy in the placebo group." | 5.11 | The clinical effect of glucocorticoids in patients with rheumatoid arthritis may be masked by decreased use of additional therapies. ( Bijlsma, JW; Jacobs, JW; Siewertsz van Reesema, DR; van Everdingen, AA, 2004) |
| " Adult patients (>21 years old) with early RA (symptom duration <1 year) and severe joint pain under maximal dose of nonsteroidal anti-inflammatory drugs (NSAIDS) were started on low-dose prednisone (10 mg/day)." | 5.11 | Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids. ( Habib, GS; Haj, S, 2005) |
| "To evaluate the role of serum osteoprotegerin (OPG) as a biochemical marker for disease activity assessment and drug monitoring in patients with rheumatoid arthritis (RA) treated with cyclical etidronate." | 5.10 | Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. ( Koivula, MK; Konttinen, YT; Laasonen, L; Mandelin, J; Risteli, J; Valleala, H, 2003) |
| "Prednisone, 10 mg/d, provides clinical benefit, particularly in the first 6 months, and substantially inhibits progression of radiologic joint damage in patients with early active rheumatoid arthritis and no previous treatment with disease-modifying antirheumatic drugs." | 5.10 | Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. ( Bijlsma, JW; Jacobs, JW; Siewertsz Van Reesema, DR; van Everdingen, AA, 2002) |
| "To evaluate the effects of a 12 month, weight bearing, aerobic exercise program on disease activity, physical function, and bone mineral density (BMD) in women with rheumatoid arthritis (RA) taking low dose prednisone." | 5.09 | A randomized controlled trial to evaluate the effectiveness of an exercise program in women with rheumatoid arthritis taking low dose prednisone. ( Berkowitz, J; Rangno, KK; Wade, JP; Westby, MD, 2000) |
| "The aim of this study was to evaluate the efficacy of fludarabine treatment in patients suffering from refractory rheumatoid arthritis." | 5.09 | Unsuccessful treatment with fludarabine in four cases of refractory rheumatoid arthritis. ( Bambara, LM; Biasi, D; Caramaschi, P; Carletto, A, 2000) |
| "The efficacy of oral prednisone as bridge therapy in rheumatoid arthritis (RA) was studied." | 5.08 | Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. ( Haagsma, CJ; Laan, RF; van de Putte, LB; van Gestel, AM; van Riel, PL, 1995) |
| "Prednisone is frequently used in the treatment of elderly-onset rheumatoid arthritis (RA), but the balance between efficacy and toxicity, including the effect on bone mass, has not been investigated in long-term studies." | 5.08 | Prednisone treatment of elderly-onset rheumatoid arthritis. Disease activity and bone mass in comparison with chloroquine treatment. ( Breedveld, FC; Dijkmans, BA; Han, KH; Papapoulos, S; Pauwels, EK; Valkema, R; van Schaardenburg, D; Zwinderman, AH, 1995) |
| "To assess the safety and efficacy of minocycline in the treatment of rheumatoid arthritis." | 5.08 | Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. ( Alarcón, GS; Buckley, L; Clegg, DO; Cooper, SM; Duncan, H; Fowler, SE; Heyse, SP; Kaplan, DA; Leisen, JC; Neuner, R; Pillemer, SR; Tilley, BC; Trentham, DE; Tuttleman, M, 1995) |
| "To determine the effects of low dose methotrexate (MTX) on bone mineral density (BMD) of patients with rheumatoid arthritis (RA)." | 5.08 | Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. ( Buckley, LM; Cartularo, KS; Cooper, SM; Leib, ES; Vacek, PM, 1997) |
| "The objective was to assess the efficacy of therapy with danazol in refractory immune thrombocytopenia associated with different rheumatic diseases." | 5.08 | Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases. ( Blanco, R; González-Gay, MA; Martinez-Taboada, VM; Rodriguez-Valverde, V; Sanchez-Andrade, A, 1997) |
| "To determine the efficacy of sodium fluoride (40 mg/day) in preventing rheumatoid arthritis (RA) induced bone loss, which may lead to osteoporosis." | 5.08 | Fluoride therapy in prevention of rheumatoid arthritis induced bone loss. ( Adachi, JD; Bell, MJ; Bensen, WG; Bianchi, F; Cividino, A; Goldsmith, C; Gordon, M; Ioannidis, G; Sebaldt, RJ, 1997) |
| "Ninety-six patients with refractory rheumatoid arthritis were treated with methotrexate for 48 months." | 5.08 | [The effect of low dose methotrexate on the course of rheumatoid arthritis--four years of observation]. ( Lacki, JK; Mackiewicz, SH, 1997) |
| "To conclude observations of efficacy of longterm methotrexate (MTX) treatment of rheumatoid arthritis (RA)." | 5.08 | Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. ( Coblyn, JS; Fraser, PA; Maier, AL; Weinblatt, ME, 1998) |
| "To evaluate the efficacy and tolerability of oral methotrexate (MTX) in rheumatoid arthritis (RA) in a long-term prospective trial." | 5.07 | Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. ( Anderson, L; Block, S; Gall, E; Germain, BF; Kaplan, H; Merriman, RC; Solomon, SD; Wall, B; Weinblatt, ME; Wolfe, F, 1994) |
| "To determine whether men with rheumatoid arthritis (RA) have abnormal hypothalamic-pituitary-gonadal axis function and to measure the effects of low dose prednisone therapy in these patients." | 5.07 | Decreased testosterone levels in men with rheumatoid arthritis: effect of low dose prednisone therapy. ( Bremner, WJ; Dugowson, CE; Martens, HF; Sheets, PK; Starkebaum, G; Tenover, JS, 1994) |
| "The long-term anti-inflammatory and immunosuppressive properties and the safety of deflazacort (Calcort, CAS 14484-47-0) were assessed investigating the effect on clinical symptoms and safety parameters in patients with rheumatoid arthritis compared to prednisone as standard therapy in a randomized double-blind controlled clinical trial." | 5.07 | Long-term therapy with the new glucocorticosteroid deflazacort in rheumatoid arthritis. Double-blind controlled randomized 12-months study against prednisone. ( Eberhardt, R; Gross, W; Krüger, K; Reiter, W; Zwingers, T, 1994) |
| " In this paper, the therapeutic efficacy of two glucocorticoids, deflazacort (DFZ) and prednisone (PDN), are discussed in relation to a group of 30 patients with systemic lupus erythematosus (n = 12) or rheumatoid arthritis (n = 18)." | 5.07 | Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases. ( Bosco, O; Imbimbo, B; Indiveri, F; Iudice, A; Lanza, L; Mantovani, L; Puppo, F; Scudeletti, M, 1993) |
| "To determine the long-term efficacy and safety of low-dose methotrexate (MTX) in rheumatoid arthritis (RA)." | 5.07 | Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. ( Coblyn, JS; Falchuk, KR; Fraser, PA; Holdsworth, DE; Maier, AL; Weinblatt, ME; Weissman, BN, 1992) |
| "The therapeutic effect of prednisone combined with azathioprine was studied in 28 patients with rheumatoid vasculitis." | 5.07 | Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. ( Breedveld, FC; Heurkens, AH; Westedt, ML, 1991) |
| "Deflazacort and prednisone were given to 26 patients with rheumatoid arthritis, polymyalgia rheumatica, or other chronic inflammatory diseases, in a double-blind study." | 5.07 | A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. ( Coulton, L; de Broe, M; Doherty, SM; Galloway, J; Gray, RE; Kanis, JA, 1991) |
| "Prednisone, 5 mg taken each morning, was added to other drugs in 18 patients with rheumatoid arthritis." | 5.05 | Low dose prednisone therapy in rheumatoid arthritis: a double blind study. ( Emkey, RD; Harris, ED; Newberg, A; Nichols, JE, 1983) |
| "A single-blind, non-crossover study of the effectiveness of paracetamol, compared with aspirin and indomethacin has been carried out in 143 patients suffering from rheumatoid arthritis." | 5.04 | Therapeutic effectiveness of paracetamol in rheumatoid arthritis. ( Anderson, J; Buchanan, W; Lee, P; Watson, M; Webb, J, 1975) |
| "A 14-day, single-blind trial of prednisone, aspirin, and placebo was carried out in 128 patients suffering from rheumatoid arthritis, using subjective criteria only (severity of pain daily on a pain chart and assessment of the drug for effectiveness)." | 5.04 | Method for assessing therapeutic potential of anti-inflammatory antirheumatic drugs in rheumatoid arthritis. ( Anderson, J; Buchanan, WW; Lee, P; Webb, J, 1973) |
| " Potential differences were also recorded in nine patients with rheumatoid arthritis being treated with long-term aspirin and five patients on long-term prednisone." | 5.04 | Effect of several drugs on gastric potential difference in man. ( Cooke, AR; Murray, HS; Strottman, MP, 1974) |
| " Slow turnover rates of the metal were demonstrated in seven out of eight patients with active rheumatoid arthritis, in one with hydralazine disease, but not in one arthritic undergoing an impressive, spontaneous remission." | 5.03 | Slow turnover of manganese in active rheumatoid arthritis accelerated by prednisone. ( Borg, DC; Cotzias, GC; Hughes, ER; Papavasiliou, PS; Tang, L, 1968) |
| "In this article, we reviewed the recent clinical trials evaluating the efficacy of MR prednisone in RA patients, including two randomized controlled double-blind clinical trials Circadian Administration of Prednisone in Rheumatoid Arthritis - 1 (CAPRA-1) and CAPRA-2 and other nonrandomized observational studies." | 4.95 | Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis. ( Bruno, C; Grembiale, RD; Naty, S; Ursini, F, 2017) |
| "We report a case of cervicofacial actinomycosis in an 86-year-old woman undergoing immunosuppressive therapy with azathioprine and prednisone for rheumatoid arthritis." | 4.90 | Cervicofacial actinomycosis: a long forgotten infectious complication of immunosuppression - report of a case and review of the literature. ( Aceto, L; Hafner, J; Hombach, M; Kamarshev, J; Kolm, I; Urosevic-Maiwald, M, 2014) |
| "5 mg/day prednisone) in the treatment of rheumatoid arthritis is still controversial." | 4.90 | Glucocorticoid treatment in rheumatoid arthritis. ( Rau, R, 2014) |
| "Prednisone is a well-established treatment option in rheumatoid arthritis." | 4.89 | Modified-release prednisone: in patients with rheumatoid arthritis. ( Henness, S; Yang, LP, 2013) |
| "The effect of low dose corticosteroids, equivalent to 15 mg prednisolone daily or less, in patients with rheumatoid arthritis has been questioned." | 4.82 | Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. ( Gotzsche, PC; Johansen, HK, 2003) |
| "There has been a renewed interest in the use of low doses of prednisone in the treatment of early rheumatoid arthritis." | 4.82 | New role for an old friend: prednisone is a disease-modifying agent in early rheumatoid arthritis. ( Conn, DL; Lim, SS, 2003) |
| "The effect of low dose corticosteroids, equivalent to 15 mg prednisolone daily or less, in patients with rheumatoid arthritis has been questioned." | 4.82 | Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. ( Gotzsche, PC; Johansen, HK, 2004) |
| "We report a case of B-cell lymphoma with the larynx as the primary site of presentation in a rheumatoid arthritis patient previously treated with methotrexate." | 4.82 | B-cell lymphoma of the larynx in a patient with rheumatoid arthritis. ( Freeland, AP; Patiar, S; Ramsden, JD, 2005) |
| "Use of methotrexate to treat rheumatoid arthritis is associated with pulmonary adverse effects in 3% to 5% of cases." | 4.79 | Pneumocystis carinii pneumonia in rheumatoid arthritis patients treated with methotrexate. A report of two cases. ( Cortet, B; Delcambre, B; Duquesnoy, B; Flipo, RM; Lafitte, JJ; Roux, N; Tonnel, AB, 1996) |
| "We describe a 68-year-old woman suffering from rheumatoid arthritis treated with low doses of prednisone who developed Kaposi's sarcoma (KS)." | 4.78 | Rheumatoid arthritis, corticosteroid therapy and Kaposi's sarcoma: a coincidence? A case and review of literature. ( Casoli, P; Tumiati, B, 1992) |
| "A review of the literature on the longterm use of methotrexate in patients with rheumatoid arthritis (RA) showed that many questions on protocol remain unanswered." | 4.77 | Longterm methotrexate therapy in rheumatoid arthritis: a review. ( Kremer, JM, 1985) |
| "Children who are prednisone-exposed in utero (low dose) have no increased risk for insulin resistance at the age of approximately 7 years." | 4.31 | Does prednisone use in pregnant women with rheumatoid arthritis induce insulin resistance in the offspring? ( de Steenwinkel, FDO; Dolhain, RJEM; Hazes, JMW; Hokken-Koelega, ACS, 2023) |
| "Previous miscarriages and ANA positivity are independent risk factors for APOs in RA patients, while adverse pregnancy outcomes and low-dose prednisone have no effect on offspring health." | 4.12 | Risk factors for adverse pregnancy outcomes in women with rheumatoid arthritis and follow-up of their offspring. ( Li, C; Li, X; Luo, L; Yan, R; Zhang, H, 2022) |
| "Recently, the use of targeted synthetic or biological disease-modifying anti-rheumatic drugs (ts/bDMARDs) in addition to conventional synthetic (cs)DMARDs including methotrexate (MTX) for rheumatoid arthritis (RA) has increased." | 4.02 | Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. ( Akashi, K; Asaoku, H; Ayano, M; Fujisaki, T; Harada, T; Iwasaki, H; Kato, K; Kohno, K; Mitoma, H; Miyamoto, T; Miyamura, T; Miyoshi, H; Mori, Y; Muta, T; Niiro, H; Ohshima, K; Oryoji, K; Oshiro, Y; Sakamoto, A; Sawabe, T; Takase, K; Takeshita, M; Urata, S; Yamamoto, H; Yoshimoto, G, 2021) |
| "This study was to investigate the effect of methotrexate in combination therapy by the characteristic cytokine in Th17 cells and the frequency of Tregs, which involved in the induction and pathological progress of rheumatoid arthritis (RA)." | 3.91 | Effectiveness of methotrexate in combination therapy in a rat collagen-induced arthritis model. ( Lin, D; Luo, X; Mo, H; Zhou, J; Zhuang, C, 2019) |
| " She had a history of rheumatoid arthritis and was prescribed 20 mg leflunomide and 16 mg corticosteroid daily." | 3.91 | Atypical Presentation of Choroidal Folds: Steroid-induced Central Serous Chorioretinopathy-like Maculopathy ( Afrashi, F; Çeper, SB; Değirmenci, C; Nalçacı, S, 2019) |
| "Methotrexate (MTX), often combined with low moderately dosed prednisone, is still the cornerstone of initial treatment for early rheumatoid arthritis (RA)." | 3.91 | Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-I ( Bijlsma, JW; Borm, ME; de Hair, MJ; Jacobs, JW; Lafeber, FP; Linn-Rasker, SP; Pethoe-Schramm, A; Teitsma, XM; Tekstra, J; Ter Borg, EJ; van Laar, JM; Verhoeven, MM; Welsing, PM, 2019) |
| " For asthma, albuterol was reported most frequently (77." | 3.88 | Agreement Between Maternal Report and Medical Records During Pregnancy: Medications for Rheumatoid Arthritis and Asthma. ( Ansari, S; Bandoli, G; Chambers, CD; Hulugalle, A; Kuo, GM; Palmsten, K; Xu, R, 2018) |
| "Determine the effect of daily low divided or single daily dose of prednisone on the longitudinal change in the number of tender and swollen joints and HAQ scores in African Americans (AA) with early rheumatoid arthritis (RA) from the Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis (CLEAR) 1 Registry." | 3.88 | Effect of daily low dose prednisone, divided or single daily dose, in the treatment of African Americans with early rheumatoid arthritis. ( Bao, G; Conn, DL; Easley, KA; Li, S; Tiliakos, A, 2018) |
| "To characterize prednisone use in pregnant women with rheumatoid arthritis using individual-level heat-maps and clustering individual trajectories of prednisone dose, and to evaluate the association between prednisone dose trajectory groups and gestational length." | 3.88 | Patterns of prednisone use during pregnancy in women with rheumatoid arthritis: Daily and cumulative dose. ( Chambers, CD; Clowse, MEB; Hebert, MF; Palmsten, K; Rolland, M; Schatz, M; Xu, R, 2018) |
| " Patients treated with leflunomide had increases in BP and a greater risk of incident hypertension compared with patients treated with methotrexate (hazard ratio, 1." | 3.88 | Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure. ( Baker, JF; Cannella, A; Cannon, GW; Caplan, L; Davis, LA; England, BR; George, M; Ibrahim, S; Michaud, K; Mikuls, TR; OʼDell, J; Sauer, B; Teng, CC, 2018) |
| "In the second Computer-Assisted Management in Early Rheumatoid Arthritis trial, patients had started with methotrexate and 10 mg prednisone (MTX+pred) or placebo (MTX+plac)." | 3.85 | Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial. ( Bijlsma, J; de Hair, M; IJff, ND; Jacobs, J; Safy, M; van Laar, JM, 2017) |
| "An increased risk of lymphoproliferative disorders (LPD) has been demonstrated in patients treated with methotrexate (MTX) for rheumatoid arthritis (RA)." | 3.83 | [Immunodeficiency-associated Burkitt lymphoma developed in a patient receiving a long-term methotrexate therapy for rheumatoid arthritis]. ( Iwashige, A; Katsuragi, T; Tsukada, J, 2016) |
| "To evaluate gastrointestinal (GI) perforation in rheumatoid arthritis (RA) patients receiving tofacitinib, tocilizumab, or other biologic agents." | 3.83 | Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. ( Bernatsky, S; Curtis, JR; Xie, F; Yun, H, 2016) |
| "To determine a concentration-effect curve of adalimumab in rheumatoid arthritis (RA) patients taking into account the effect of methotrexate (MTX) on concentration and effect and to identify a therapeutic range for adalimumab concentrations." | 3.81 | Key findings towards optimising adalimumab treatment: the concentration-effect curve. ( Aarden, L; Krieckaert, CL; Nurmohamed, MT; Pouw, MF; Rispens, T; van der Kleij, D; Wolbink, G, 2015) |
| "Twelve clinical trials have documented that prednisone or prednisolone in doses of 10 mg/day or less is efficacious to improve function, maintain status and/or slow radiographic progression in patients with rheumatoid arthritis (RA)." | 3.81 | Clinical trials documenting the efficacy of low-dose glucocorticoids in rheumatoid arthritis. ( Cutolo, M; Pincus, T, 2015) |
| "To identify the rheumatoid arthritis (RA) characteristics associated with increased herpes zoster (HZ) risk in the Corrona registry RA patients, and to evaluate the risk in initiators of tumor necrosis factor inhibitors (TNFi) or non-TNFi biologic agents or (among those who were currently on or had been previously treated with methotrexate [MTX]) conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) other than MTX." | 3.81 | Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs. ( Curtis, JR; Greenberg, JD; Hooper, MM; Kremer, JM; Pappas, DA; Reed, G; Shan, Y; Wenkert, D, 2015) |
| "Prednisone use during pregnancy is associated with a higher daytime cortisol level, in the prepubertal offspring, not yet accompanied with clinical outcomes." | 3.80 | The influence of foetal prednisone exposure on the cortisol levels in the offspring. ( de Steenwinkel, FD; Dolhain, RJ; Hazes, JM; Hokken-Koelega, AC, 2014) |
| "Prednisone use and active disease are associated with reduced bone mineral density (BMD) in patients with rheumatoid arthritis (RA)." | 3.80 | Brief report: does medication use or disease activity during pregnancy in patients with rheumatoid arthritis affect bone density in their prepubertal offspring? ( de Steenwinkel, FD; Dolhain, RJ; Hazes, JM; Hokken-Koelega, AC, 2014) |
| " We assessed the hepatotoxicity of methotrexate and prednisolone combination therapy in the background of hepatitis B virus infection." | 3.80 | Fibrosing cholestatic hepatitis after methotrexate and prednisone therapy for rheumatoid arthritis. ( Çalık, A; Çeşmecioğlu, E; Çobanoğlu, Ü; Kalaycı, O; Topaloğlu, S; Uzun, Y, 2014) |
| "In the past, patients with rheumatoid arthritis (RA) were treated with monotherapy with conventional drugs, such as sulfasalazine, methotrexate, and intramuscular gold, which often leads to persistent arthritis, loss of functional capacity, and decreased quality of life." | 3.80 | Are glucocorticoids harmful to bone in early rheumatoid arthritis? ( Lems, WF, 2014) |
| "We report an extremely rare case of massive methotrexate-associated lymphoproliferative disorder (MTX-LPD) arising in the retromolar triangle and lung of a patient with rheumatoid arthritis." | 3.80 | Methotrexate-associated lymphoproliferative disorder arising in the retromolar triangle and lung of a patient with rheumatoid arthritis. ( Harada, H; Ishii, Y; Kudoh, M; Matsumoto, K; Omura, K; Sato, Y, 2014) |
| "Methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis (RA) but data concerning the effectiveness of treatment with this compound are lacking in the Congolese population." | 3.79 | Treatment of rheumatoid arthritis with methotrexate in Congolese patients. ( Bossuyt, X; Malemba, JJ; Mbuyi Muamba, JM; Mukaya, J; Verschueren, P; Westhovens, R, 2013) |
| "To evaluate the clinical efficacy and safety of methotrexate (MTX) plus low dose glucocorticoid in the treatment of rheumatoid arthritis (RA) from the "target control" point of view." | 3.79 | [The short-term efficacy and safety of methotrexate plus low dose prednisone in patients with rheumatoid arthritis]. ( He, YJ; Liu, SY; Yang, L; Zhang, L; Zhang, X, 2013) |
| "To analyze prednisone treatment from 1980-2004 in 308 patients with rheumatoid arthritis (RA), including 75 monitored over 4-8 years and 73 monitored over >8 years, for initial dose, long-term doses and effectiveness, and adverse events." | 3.79 | Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. ( Castrejón, I; Cutolo, M; Pincus, T; Sokka, T, 2013) |
| " Here, we present a case of chronic rheumatoid meningitis occurring during treatment with methotrexate and the tumour necrosis factor (TNF) alpha antibody adalimumab." | 3.78 | Rheumatoid meningitis occurring during adalimumab and methotrexate treatment. ( Guerne, PA; Horvath, J; Huys, AC, 2012) |
| " We present the first case of human skin and soft tissue infection caused by this species in a patient with rheumatoid arthritis receiving prednisone and methotrexate therapy." | 3.78 | Nocardia neocaledoniensis [corrected] as a cause of skin and soft tissue infection. ( Brown-Elliott, BA; Carpenter, J; Fader, R; McGhie, T; Vasireddy, R; Wallace, RJ, 2012) |
| "The efficacy of initial and long-term prednisone < 5 mg/ day in treatment of rheumatoid arthritis (RA) by one academic rheumatologist over 25 years from 1980 to 2004 is summarized." | 3.78 | Effective initial and long-term prednisone in doses of less than 5 mg/day to treat rheumatoid arthritis--documentation using a patient self-report Multidimensional Health Assessment Questionnaire (MDHAQ). ( Castrejón, I; Pincus, T, 2012) |
| "To investigate whether anti-inflammatory effects of HMG-CoA reductase inhibitor simvastatin (SMV) in rheumatoid arthritis (RA) is mediated by Toll-like receptor-2 (TLR-2) signal via inhibiting activation of RhoA, a small Rho GTPase that plays an important role in inflammatory responses." | 3.77 | HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients. ( Chen, G; Fan, J; Fu, D; Liang, L; Lin, H; Sun, L; Xiao, Y; Xu, H; Yang, X; Ye, Y, 2011) |
| "A 68-year-old woman diagnosed with erosive rheumatoid arthritis (RA) was treated with intramuscular methotrexate 15 mg weekly and oral prednisone 5 mg daily." | 3.77 | Rheumatoid arthritis and renal light-chain deposition disease: long-term effectiveness of TNF-α blockade with etanercept. ( Bobbio-Pallavicini, F; Caporali, R; Cavagna, L; Mangione, F; Montecucco, C; Sepe, V, 2011) |
| "MTX, TNF antagonists and prednisone at doses >10 mg daily were associated with increased risks of overall infections." | 3.76 | Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. ( Bishai, W; Greenberg, JD; Hochberg, MC; Kavanaugh, A; Kremer, JM; Reed, G; Tindall, E; Zheng, C, 2010) |
| "The effects of low dose prednisone (PD) alone or in combination with leflunomide (LEF) were tested on inflammatory gene expression in early rheumatoid arthritis (RA)." | 3.76 | Inflammatory gene profile in early rheumatoid arthritis and modulation by leflunomide and prednisone treatment. ( Bonassi, S; Cutolo, M; Gallo, F; Montagna, P; Moretti, S; Paolino, S; Pizzorni, C; Seriolo, B; Soldano, S; Sulli, A; Villaggio, B, 2010) |
| "To determine the relationship between current hydroxychloroquine (HCQ) use and 2 indicators of glycemic control, fasting glucose and insulin sensitivity, in nondiabetic women with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)." | 3.76 | Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. ( Elliott, JR; Kao, AH; Kuller, L; Manzi, S; Penn, SK; Schott, LL; Toledo, FG; Wasko, MC, 2010) |
| "We describe a 72-year-old white man with erosive rheumatoid arthritis in whom subacute neurologic and psychiatric symptoms developed after 3 years of treatment with infliximab, prednisone, and methotrexate." | 3.76 | A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. ( Berger, RG; Bouldin, TW; Kumar, D, 2010) |
| "We report four patients with rheumatoid arthritis, treated with methotrexate and prednisone who developed cutaneous leishmaniasis." | 3.75 | [Cutaneous leishmaniasis in rheumatoid arthritis]. ( Akrout, R; Baklouti, S; Fourati, H; Hachicha, I; Hdiji, N; Sellami, M, 2009) |
| " To examine the independent influence of prednisone use and disease activity on birth weight, regression analyses were performed, with adjustments for gestational age of the child at delivery, the sex of the newborn, and the mother's smoking status, education level, parity, and use of an assisted reproduction technique." | 3.75 | Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. ( de Groot, CJ; de Man, YA; Dolhain, RJ; Hazes, JM; Steegers, EA; van der Heide, H; Willemsen, SP, 2009) |
| "We report two cases of hydroxychloroquine-induced hyperpigmentation presenting in a 50-year-old Caucasian female (case 1) and a 78-year-old female (case 2), both receiving 400 mg per day." | 3.74 | Hydroxychloroquine-induced hyperpigmentation: the staining pattern. ( Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W, 2008) |
| "The aim of this study was to determine the difference between bone mineral density (BMD) of rheumatoid arthritis (RA) patients on low-dose prednisone and matched RA patients without prior systemic corticosteroid therapy." | 3.73 | The effect of low-dose prednisone on bone mineral density in Peruvian rheumatoid arthritis patients. ( Chung, CP; Russell, AS; Segami, MI; Ugarte, CA, 2005) |
| "After adjustment for covariates, prednisone use increased the risk of pneumonia hospitalization (hazard ratio [HR] 1." | 3.73 | Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. ( Caplan, L; Michaud, K; Wolfe, F, 2006) |
| "In a previous clinical trial of patients with early rheumatoid arthritis (RA), it was determined that patients who received 10 mg of prednisone per day for 2 years had less radiographic joint damage compared with those who received placebo." | 3.73 | Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. ( Bijlsma, JW; Jacobs, JW; van Everdingen, AA; Verstappen, SM, 2006) |
| "Among 127 consenting patients, 81 with rheumatoid arthritis taking nonsteroidal antiinflammatory drugs (13 diclofenac, 20 naproxen) or disease modifying antirheumatic drugs (25 sulfasalazine, 23 methotrexate), 17 patients with polymyalgia rheumatica taking prednisone, and 29 patients with gout taking daily prophylactic colchicine (n = 12) or the uric acid lowering drugs allopurinol (10) or benzbromaron (7), 104 used their medication from a regular medication bottle fitted with a special cap containing microelectronics capable of recording time and date of opening and closing, defined as a medication event." | 3.72 | The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. ( de Klerk, E; Landewé, R; van der Linden, S; van der Tempel, H; van der Heijde, D, 2003) |
| " Fifteen non-CNS-SLE patients, 15 RA patients and 15 HC participants similar in age, education, and gender (female) were compared on tests of cognition, depression, and plasma levels of interleukin-6 (IL-6), dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S) and cortisol." | 3.71 | Inflammatory and hormonal measures predict neuropsychological functioning in systemic lupus erythematosus and rheumatoid arthritis patients. ( Kozora, E; Laudenslager, M; Lemieux, A; West, SG, 2001) |
| "Fifteen patients with refractory rheumatoid arthritis were treated with infliximab--monoclonal antibody direct to TNF alpha--in association with methotrexate or azathioprine." | 3.71 | [Infliximab in aggressive and refractory rheumatoid arthritis. A pilot study]. ( Bambara, LM; Biasi, D; Canestrini, S; Caramaschi, P; Carletto, A; Scambi, C; Scarperi, A, 2002) |
| "To measure the anatomic and physiologic changes in the synovium of patients with active rheumatoid arthritis (RA) before and after the initiation of treatment with low-dose systemic glucocorticoids and methotrexate (MTX)." | 3.69 | Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. ( Fischman, A; Palmer, WE; Polisson, RP; Rosenthal, D; Rubin, R; Schoenberg, OI; Simon, LS, 1995) |
| "To determine the longterm outcome including disease activity, mortality, and adverse events in patients with rheumatoid arthritis (RA) treated with prednisone." | 3.69 | Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. ( Haga, M; McDougall, R; Russell, A; Sibley, J, 1994) |
| "To correlate the serum levels of keratan sulfate (KS) in patients with rheumatoid arthritis (RA) with different clinical and radiographic variables." | 3.69 | Serum keratan sulfate levels in rheumatoid arthritis: inverse correlation with radiographic staging. ( Goulet, JR; Haraoui, B; Martel-Pelletier, J; Ouellet, M; Pelletier, JP; Raynauld, JP; Thonar, EJ, 1994) |
| "The purpose of this study was to better define the toxicity of low dose (less than or equal to 15 mg/d prednisone or equivalent) long-term (greater than 1 year) corticosteroids in the treatment of rheumatoid arthritis (RA)." | 3.69 | Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. ( Brasington, R; Burmeister, LF; Caldwell, JR; Furst, DE; Koehnke, R; Kohler, JA; Saag, KG; Zimmerman, B, 1994) |
| "To test for and estimate variation among rheumatologists in their prescribing of prednisone and second-line agents for the treatment of rheumatoid arthritis (RA), after taking into account the characteristics of their patients." | 3.69 | Variation among rheumatologists in the use of prednisone and second-line agents for the treatment of rheumatoid arthritis. ( Criswell, LA; Redfearn, WJ, 1994) |
| "To determine the extent to which characteristics of rheumatologists and their practices explain the variation in their use of prednisone and 2nd line agents for the treatment of rheumatoid arthritis (RA)." | 3.69 | What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis? ( Criswell, LA; Henke, CJ, 1995) |
| "The aim of this study was to evaluate CD8 lymphocyte subsets in active polymyalgia rheumatica (PMR), to determine whether low percentages of CD8+ cells could be used to differentiate PMR from elderly-onset (EORA) and adult rheumatoid arthritis (RA), and to investigate the effects of prednisone on CD8 lymphocyte subsets." | 3.69 | CD8 lymphocyte subsets in active polymyalgia rheumatica: comparison with elderly-onset and adult rheumatoid arthritis and influence of prednisone therapy. ( Beltrandi, E; Boiardi, L; Casadei Maldini, M; Macchioni, P; Mancini, R; Portioli, I; Salvarani, C, 1996) |
| "Serum bone Gla protein (BGP), carboxyterminal cross-linked telopeptide of type I collagen (ICTP) and aminoterminal propeptide of type III procollagen (PIIINP) levels were determined in 8 patients with autoimmune disorders (2 with systemic lupus erythematosus, 3 with rheumatoid arthritis, 2 with Sjögren's syndrome and 1 with mixed connective tissue disease) before and after 1, 2 and 4 months of treatment with oral prednisone (at a dosage of 1 mg/kg bw/day, p." | 3.69 | Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy. ( Ambrosi, B; Conti, A; Ferrario, S; Ferrero, S; Sartorio, A, 1996) |
| "The first patient was an 86-year-old woman who had been treated with oral colchicine because of rheumatoid arthritis." | 3.69 | Delay of corneal wound healing in patients treated with colchicine. ( Alster, Y; Lazar, M; Loewenstein, A; Varssano, D, 1997) |
| ") gold, hydroxychloroquine, and prednisone for rheumatoid arthritis (RA) treatment among patients managed by rheumatologists and nonrheumatologists." | 3.69 | Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists. ( Criswell, LA; Such, CL; Yelin, EH, 1997) |
| " Multivariate analyses identified the following factors to be associated with fracturing: years taking prednisone, previous diagnosis of osteoporosis, disability, age, lack of physical activity, female sex, disease duration, impaired grip strength, and low body mass." | 3.68 | Fractures in rheumatoid arthritis: an evaluation of associated risk factors. ( Bloch, DA; Fries, JF; Michel, BA; Wolfe, F, 1993) |
| "To investigate the effect of low doses of 2 different glucocorticoids on bone mass, sex hormone status and bone metabolic indices, a study was undertaken in 16 postmenopausal women with rheumatoid arthritis (RA) receiving < 15 mg/day of deflazacort and in 16 patients with RA matched for age, years postmenopause and disease duration, receiving < 10 mg/day of prednisone." | 3.68 | Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids. ( Caporali, R; Caprotti, M; Caprotti, P; Montecucco, C; Notario, A, 1992) |
| "Ovine corticotropin-releasing hormone (oCRH) stimulation tests were performed in 8 female patients with active rheumatoid arthritis treated chronically with daily low dose prednisone and 16 age matched female controls." | 3.68 | Pituitary-adrenal axis responsiveness to ovine corticotropin releasing hormone in patients with rheumatoid arthritis treated with low dose prednisone. ( Cash, JM; Chrousos, GP; Crofford, LJ; Gallucci, WT; Gold, PW; Sternberg, EM; Wilder, RL, 1992) |
| "Pulmonary toxicity associated with gold salt treatment of rheumatoid arthritis is unusual." | 3.68 | [Pulmonary toxicity of gold salts]. ( Casas, HA; Fernández Casares, M; Leczycki, H, 1991) |
| "To assess whether low doses of prednisone produce generalized alterations in skeletal homeostasis in rheumatoid arthritis (RA), indices of calcium metabolism and bone mineral density (BMD) were measured in 22 women with RA treated without or with prednisone (6." | 3.68 | Low dose prednisone does not affect calcium homeostasis or bone density in postmenopausal women with rheumatoid arthritis. ( el-Hajj Fuleihan, G; Leboff, MS; Liang, MH; Mackowiak, S; Wade, JP; Zangari, M, 1991) |
| "We describe a case of pulmonary nocardiosis in a patient with rheumatoid arthritis (RA) receiving treatment with combined immunosuppressive agents and prednisone." | 3.68 | Nocardia asteroides infection complicating rheumatoid arthritis. ( Bank, I; Gruberg, L; Pras, M; Rozenman, J; Thaler, M, 1991) |
| "We performed a 10-year retrospective analysis of the frequency of local postoperative infectious complications in methotrexate (MTX)-treated rheumatoid arthritis patients who underwent total joint arthroplasty." | 3.68 | Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. ( Clough, JD; Perhala, RS; Segal, AM; Wilke, WS, 1991) |
| "Herpes zoster occurred in nine patients with methotrexate-treated rheumatoid arthritis." | 3.68 | Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. ( Antonelli, MA; Brick, JE; Moreland, LW, 1991) |
| "The bone mineral content (BMC) in both forearms (highly correlated to total body calcium) was measured by photon absorptiometry in a representative sample of rheumatoid arthritis outpatients comprising 129 patients treated with either gold salts (n = 29), penicillamine (n = 61), prednisone (n = 24), or other anti-RA drugs (n = 15)." | 3.67 | Prevalence of decreased bone mass in rheumatoid arthritis. Relation to anti-inflammatory treatment. ( Als, OS; Christiansen, C; Hellesen, C, 1984) |
| "A patient with rheumatoid arthritis developed nephrotic syndrome with reversible renal failure following gold therapy." | 3.67 | Nephrotic syndrome with reversible severe renal failure after gold therapy. ( Aviram, A; Blum, M; Liron, M, 1984) |
| " In 27 patients with rheumatoid arthritis, we measured the pulmonary excretion of pentane, a product released during lipid peroxidation." | 3.67 | Breath pentane excretion as a marker of disease activity in rheumatoid arthritis. ( Clapper, M; Humad, S; Skosey, JL; Zarling, E, 1988) |
| "Cutaneous Kaposi's sarcoma developed eight months after initiation of prednisone treatment in a 58-year-old man with systemic rheumatoid disease (rheumatoid arthritis, Felty's syndrome, rheumatoid vasculitis, and myositis)." | 3.67 | Kaposi's sarcoma in rheumatoid arthritis. ( Hurd, ER; Schottstaedt, MW; Stone, MJ, 1987) |
| "Twenty-nine patients participated in a prospective study of the safety and efficacy of oral methotrexate in the treatment of refractory rheumatoid arthritis." | 3.67 | The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. ( Kremer, JM; Lee, JK, 1986) |
| "Eight patients with long-standing rheumatoid arthritis and cutaneous vasculitis ulcerations resistant to conventional therapy were treated successfully with a low-dose intermittent regimen of oral methotrexate." | 3.67 | Oral methotrexate therapy for chronic rheumatoid arthritis ulcerations. ( Espinoza, CG; Espinoza, LR; Germain, BF; Vasey, FB, 1986) |
| "The relationship between the effect of chloroquine treatment on circulating immune complexes in patients with rheumatoid arthritis (RA) was determined by the 125I Clq binding assay." | 3.67 | Effect of antimalarial treatment on circulating immune complexes in rheumatoid arthritis. ( Arturi, AS; Babini, JC; Fraguela, JM; Marcos, JC; Segal-Eiras, A; Segura, GM, 1985) |
| "A 47-year-old woman with rheumatoid arthritis (RA) had been treated with greater than 7 g of gold sodium thiomalate over a 5 year period when aplastic anemia developed." | 3.67 | Gold induced aplastic anemia. Complete response to corticosteroids, plasmapheresis, and N-acetylcysteine infusion. ( Csuka, ME; Hansen, RM; McCarty, DJ; Saryan, LA, 1985) |
| "Myositis was diagnosed twenty months after starting treatment with d-penicillamine in a patient suffering from uncomplicated rheumatoid arthritis for nearly three years." | 3.66 | [Is myositis in chronic polyarthritis using d-penicillamine drug-induced?]. ( Bussmann, HU; Jerusalem, F; Schlumpf, U, 1981) |
| "Thrombocytopenia developed in 23 patients with rheumatoid arthritis treated with gold salts over 25 years." | 3.66 | Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients. ( Coblyn, JS; Glass, D; Holdsworth, D; Weinblatt, M, 1981) |
| " Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy." | 3.66 | Membranous nephropathy in rheumatoid arthritis. ( Figueroa, JE; Waxman, J, 1982) |
| " Thereapy with systemic prednisone had been used to suppress active synovitis for almost four years and was associated with moon facies, hirsutism, truncal obesity, thinning of the skin, extensive purpura on the extremities, and other manifestations of hypercortisolism." | 3.66 | Spontaneous skin tearing during systemic corticosteroid treatment. ( Gottlieb, NL; Penneys, NS, 1980) |
| "The transcapillary escape rate of albumin was measured in 27 consecutive patients with inflammatory rheumatic diseases before and after 1 and 7 days of prednisone treatment in doses of 45 mg/day." | 3.66 | Prednisone effect on microvascular permeability in patients with inflammatory rheumatic diseases. ( Hansen, TM; Junker, P; Lorenzen, I; Manthorpe, R; Utne, HE, 1979) |
| "Sequential measurements of serum C-reactive protein (CRP), serum haptoglobin (Hp), and erythrocyte sedimentation rate (ESR) were made in 209 patients with rheumatoid arthritis (RA); 78 of them were treated with gold, 71 with dapsone, and 60 with prednisone." | 3.66 | Effects of gold, dapsone, and prednisone on serum C-reactive protein and haptoglobin and the erythrocyte sedimentation rate in rheumatoid arthritis. ( Amos, RS; Butler, M; Constable, TJ; Crockson, AP; Crockson, RA; Davies, P; McConkey, B, 1979) |
| "2 women, 62 and 69 years old, both suffering from rheumatoid arthritis, were treated for 1 and 1 1/2 years, respectively, with penicillamine." | 3.66 | Two cases of penicillamine-induced pemphigus erythematosus. ( Thorvaldsen, J, 1979) |
| "The clinical history of a patient with rheumatoid arthritis and bacteriologic findings from a pulmonary abscess occurring during prednisone therapy are presented." | 3.66 | Actinomycotic pulmonary abscess in an immunosuppressed patient. ( Angevine, JM; Baron, EJ; Sundstrom, W, 1979) |
| "The effect of 1alpha-hydroxyvitamin D3 (1alpha-OHD3) and 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) on the intestinal calcium absorption was studied in twenty patients with rheumatoid arthritis treated with prednisone at daily doses of 5--15 mg for 1/2--20 years." | 3.65 | Effect of 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on intestine and bone in glucocorticoid-treated patients. ( Andersen, RB; Friis, T; Hjorth, L; Jørgensen, FS; Lund, B; Norman, AW; Sørensen, OH, 1977) |
| "The longterm administration of prednisone and gold to patients with rheumatoid arthritis (RA), in doses that decreased the sedimentation rate (p less than 0." | 3.65 | Antirheumatic drugs, the ESR, and the hypohistidinemia of rheumatoid arthritis. ( Gerber, DA, 1977) |
| "The results of a five-year study of chlorambucil in patients suffering from rheumatoid arthritis are presented." | 3.65 | Rheumatoid arthritis treated with chlorambucil: a five-year follow-up. ( Thorpe, P, 1976) |
| "A study of sera from 285 patients with definite or classical rheumatoid arthritis (including 37 patients receiving no anti-inflammatory drugs) and sera from 67 healthy subjects has confirmed 10 published reports of a statistically significant decreased blood histidine concentration in patients with rheumatoid arthritis." | 3.65 | Low free serum histidine concentration in rheumatoid arthritis. A measure of disease activity. ( Gerber, DA, 1975) |
| "Progressive multifocal leukoencephalopathy developed in a patient with rheumatoid arthritis after treatment with an immunosuppressive agent (chlorambucil)." | 3.65 | Progressive multifocal leukoencephalopathy: a complication of immunosuppressive treatment. ( Malamud, N; McCulloch, JR; Smith, JK; Sponzilli, EE, 1975) |
| "Ionic permeability of the gastric mucosa was measured in six patients with an acute exacerbation of severe generalized rheumatoid arthritis receiving either aspirin and prednisone or aspirin and indomethacin as therapy." | 3.65 | Back diffusion of hydrogen ions across gastric mucosa of patients with gastric ulcer and rheumatoid arthritis. ( Clifton, JA; Ivey, KJ, 1974) |
| " Salicylates are preferred to adrenocortical steroids in the treatment of the ordinary patient with acute rheumatic fever." | 3.64 | NONSPECIFIC ANTI-INFLAMMATORY AGENTS. SOME NOTES ON THEIR PRACTICAL APPLICATION, ESPECIALLY IN RHEUMATIC DISORDERS. ( BOLAND, EW, 1964) |
| "To appraise the efficiency of complemental antacid administration in preventing and reducing digestive disturbances during prolonged treatment with prednisone and prednisolone, 100 patients with active rheumatoid arthritis who were maintained on combined antacid and prednisone or prednisolone therapy for periods of one year or longer, were studied clinically and roentgenographically." | 3.63 | Effectiveness of antacids in reducing digestive disturbances in patients treated with prednisone and prednisolone. ( BOLAND, EW, 1958) |
| " Overall, safety risks increased with increasing dose and/or duration, but evidence on which dose is safe was conflicting." | 3.01 | Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. ( Aletaha, D; Bergstra, SA; Caporali, R; de Souza, S; Edwards, CJ; Hyrich, KL; Kerschbaumer, A; Landewé, RBM; Pope, JE; Schoones, JW; Sepriano, A; Smolen, JS; Stamm, TA; Takeuchi, T; van der Heijde, D; Verschueren, P; Winthrop, KL, 2023) |
| " The primary outcome investigated was adverse events (AEs)." | 3.01 | Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis. ( Boers, M; Boyadzhieva, Z; Buttgereit, F; Christensen, R; Da Silva, JAP; Dejaco, C; Hartman, L; Kirwan, J; Nielsen, SM; Palmowski, A; Pankow, A; Schneider, A; Wassenberg, S, 2023) |
| "Patients with inflammatory diseases, such as rheumatoid arthritis, often receive glucocorticoids, but long-term use can produce adverse effects." | 2.94 | Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. ( Álvaro-Gracia, JM; Bernasconi, C; Burmester, GR; Buttgereit, F; Castro, N; Donath, MY; Dougados, M; Gabay, C; John, MR; Nebesky, JM; Pethoe-Schramm, A; Salvarani, C; van Laar, JM, 2020) |
| "Glucocorticoids have anti-inflammatory, transrepression-mediated effects, although adverse events (AEs; transactivation-mediated effects) limit long-term use in patients with rheumatoid arthritis (RA)." | 2.90 | Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study. ( Buttgereit, F; Genet, A; Hey-Hadavi, J; Lee, EB; McCabe, D; Rojo, R; Simon-Campos, A; Strand, V; Tammara, B, 2019) |
| "Prednisone-treated dogs were more likely to develop polyuria, polydipsia, and polyphagia than were cyclosporine-treated dogs." | 2.82 | Comparison of the efficacy of prednisone and cyclosporine for treatment of dogs with primary immune-mediated polyarthritis. ( Herrera, MA; Kass, PH; Rhoades, AC; Sykes, JE; Vernau, W, 2016) |
| " There was no substantial difference in pharmacokinetic parameters of the formulations apart from the programmed delay in release of glucocorticoid from the modified-release tablets (C(max) 97%, AUC(0-∞) 101%, 90% confidence intervals within the requisite range for bioequivalence)." | 2.78 | Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis. ( Clarke, L; Derendorf, H; Kirwan, JR; Ruebsamen, K; Schaeffler, A, 2013) |
| "The intensity of joint pain decreased in the active vs placebo group at the end of treatment, although these differences were not statistically significant." | 2.74 | Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial. ( Aguirre, V; Arriagada, S; Bertoglio, JC; Burgos, RA; Cáceres, DD; Calvo, M; Hancke, JL, 2009) |
| "Thus, these findings indicate that memory deficits observed under chronically elevated glucocorticoid levels result, at least in part, from acute and reversible glucocorticoid effects on memory retrieval." | 2.73 | Glucocorticoid therapy-induced memory deficits: acute versus chronic effects. ( Coluccia, D; de Quervain, DJ; Forster, A; Kollias, S; Roozendaal, B; Wolf, OT, 2008) |
| "Cortisone was introduced in the treatment of rheumatoid arthritis (RA) in 1948 by Hench and colleagues at the Mayo Clinic which resulted in dramatic improvement of inflammation, function and sense of well-being." | 2.72 | The Story Behind the Use of Glucocorticoids in the Treatment of Rheumatoid Arthritis. ( Conn, DL, 2021) |
| "Alendronate has been described to have a bone-sparing effect in patients treated with moderate and high dosages of prednisone for heterogeneous diseases, however no data are available on groups of patients with the same underlying diseases who receive chronic low-dose prednisone treatment." | 2.72 | Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. ( Bijlsma, JW; Dijkmans, BA; Geusens, P; Lems, WF; Lips, P; Lodder, MC; Schrameijer, N; van de Ven, CM, 2006) |
| "To compare pharmacokinetic variables of a 7." | 2.68 | Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months. ( Hamilton, RA; Kremer, JM; Petrillo, GF, 1995) |
| " Long-term use of corticosteroids can lead to loss of bone mineral density and higher risk for vertebral fractures." | 2.68 | Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. ( Buckley, LM; Cartularo, KS; Cooper, SM; Leib, ES; Vacek, PM, 1996) |
| "During a one month followup period, adverse reactions occurred with equal frequency among patients with RA and healthy controls." | 2.67 | Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. ( Chalmers, A; Patterson, C; Scheifele, D; Shuckett, R; Teufel, A; Weber, J; Williams, D, 1994) |
| "Least toxic was hydroxychloroquine (mean +/- SEM score 1." | 2.67 | The relative toxicity of disease-modifying antirheumatic drugs. ( Bloch, DA; Fries, JF; Ramey, D; Williams, CA, 1993) |
| "The prednisone therapy was differentiated by improvement from that of a placebo by six of the nine parameters evaluated." | 2.67 | Endocrine control of inflammation: rheumatoid arthritis double-blind, crossover clinical trial. ( Fiechtner, JJ; Johnson, LK; Miller, DR; Rice, JR; Stenberg, VI, 1992) |
| " Nevertheless, glucocorticoid administration, in long-term especially, is also seen critically because of its potential adverse conditions." | 2.61 | New concepts to reduce glucocorticoid toxicity. ( Alten, R; Mischkewitz, M, 2019) |
| "DR prednisone has been approved in 16 European countries as well as Australia and Israel." | 2.48 | A fresh look at glucocorticoids how to use an old ally more effectively. ( Buttgereit, F, 2012) |
| "MALT lymphoma was not reported in rheumatoid arthritis." | 2.46 | Primary thyroid marginal zone B-cell lymphoma MALT-type in a patient with rheumatoid arthritis. ( Ertenli, I; Kalyoncu, U; Serefhanoglu, S; Tapan, U; Uner, A, 2010) |
| "Glucocorticoids (GCs) provide one of the most effective treatments for rheumatoid arthritis (RA); however, their long-term use is marred by undesired side effects." | 2.46 | Pharmacology of glucocorticoids in rheumatoid arthritis. ( Bijlsma, JW; Burmester, GR; Buttgereit, F; Spies, CM, 2010) |
| "RA associated interstitial lung disease (ILD) is often subtle in onset, slowly progressive and of unclear etiology and response to treatment." | 2.42 | Rheumatoid arthritis associated interstitial lung disease. ( Horton, MR, 2004) |
| "We report a case of hairy cell leukemia with seropositive rheumatoid arthritis." | 2.40 | Chronic immunity-driven polyarthritis in hairy cell leukemia. Report of a case and review of the literature. ( Bannwarth, B; Dehais, J; Fach, J; Lequen, L; Schaeverbeke, T; Vernhes, JP, 1997) |
| "The thrombus was identified by transesophageal echocardiography and was successfully removed by aortic thromboendarterectomy." | 2.40 | Recurrent embolism caused by floating thrombus in the thoracic aorta. ( Garcia, F; Gomez, FT; Julia, J; Lozano, P; M-Rimbau, E, 1998) |
| " It is our view that the use of methotrexate in rheumatoid arthritis should still be considered cautiously until further data on the risk-benefit ratio of long-term use become available." | 2.39 | [Fatal outcome of pneumocystis-carinii pneumonia under low-dose methotrexate and prednisone therapy for chronic rheumatoid arthritis. Case report and literature review]. ( Kuhn, M; Luzi, HP; Reinhart, WH; Wyss, E, 1994) |
| "Pyoderma gangrenosum is a dermatological disease of unknown origin." | 2.39 | Pyoderma gangrenosum with hepatopancreatic manifestations in a patient with rheumatoid arthritis. ( Arpurt, JP; Bartel, HR; Bodock, I; Caroli-Bosc, FX; Delmont, JP; Dumas, R; Harris, AG; Hastier, P; Maes, B; Taillan, B, 1996) |
| "Osteopenia was a consistent preexisting radiographic feature." | 2.38 | Rapidly progressive protrusio acetabuli in patients with rheumatoid arthritis. ( Damron, TA; Heiner, JP, 1993) |
| "When a thymoma is present, it should be resected since a remission is produced in 29 per cent of these patients." | 2.35 | Diagnosis and treatment of pure red cell aplasia. ( Krantz, SB, 1976) |
| "Prednisone ≥ 10 mg/day was associated with lower odds of death." | 1.91 | Outcomes of Filipinos with inflammatory rheumatic diseases developing COVID-19 prior to vaccinations and new variants: a historical perspective. ( Cortez, KJC; Del Rosario, AG; Gutierrez-Rubio, AKM; Lichauco, JJT; Rivera-Go, ICT; Salido, EO; Suilan, KEA; Villo, JGB; Zamora-Abrahan, GT, 2023) |
| "Oral prednisone was used in 17 (81%) cases." | 1.91 | Childhood-onset rheumatoid arthritis at a tertiary hospital in Senegal, West Africa. ( Deme, A; Lissimo, H; Sabounji, MM, 2023) |
| "Although the rapid onset of effect of glucocorticoids (GCs) allows rapid control of rheumatoid arthritis (RA) symptoms, their chronic use may be associated with several adverse events." | 1.91 | Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib. ( Ceccarelli, F; Conti, F; Garufi, C; Mancuso, S; Spinelli, FR; Truglia, S, 2023) |
| "Leprosy is rare within non-endemic countries such as Canada, where cases are almost exclusively imported from endemic regions, often presenting after an incubation period of as many as 20 years." | 1.91 | Leprosy with type 1 reaction in a patient from Ontario, Canada without recent travel misdiagnosed as vasculitic neuropathy: a case report. ( Driedger, M; Roth, V; Teo, I, 2023) |
| "Reactive arthritis was diagnosed in 1 patient who presented with swelling in both hands and wrists 2 days after being diagnosed with COVID-19." | 1.72 | Rheumatologic Manifestations of Post SARS-CoV-2 Infection: A Case Series. ( Aung, T; Ballester, A; Cheav, S; Chen, C; Metyas, S, 2022) |
| "To generate initial data on the frequency and effect of symptomatic adverse events (AEs) associated with rheumatoid arthritis (RA) drug therapy from the patient perspective." | 1.72 | Frequency of Symptomatic Adverse Events in Rheumatoid Arthritis: An Exploratory Online Survey. ( Bartlett, SJ; Bykerk, V; Hazlewood, GS; Hull, PM; Mujaab, K; Proulx, L; Richards, D; Schieir, O; Tugwell, P; Wells, G, 2022) |
| "Herein, we report a case of systemic lupus erythematosus complicated with JA without bone erosion." | 1.72 | Case report: Joint deformity associated with systemic lupus erythematosus. ( Chen, SL; Lin, CS; Xu, Q; Zhang, LY; Zheng, HJ, 2022) |
| "Sarcopenia is significantly more common in patients with RA compared with controls using the EWGSOP2 criteria." | 1.72 | Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition. ( Armbrecht, G; Borucki, D; Buehring, B; Buttgereit, F; Detzer, C; Dietzel, R; Schaumburg, D; Wiegmann, S; Zeiner, KN, 2022) |
| "Prednisone was discontinued when DAS ≤2." | 1.62 | Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies. ( Allaart, CF; Bergstra, SA; Dos Santos Sobrín, R; Goekoop, R; Huizinga, TWJ; Maassen, JM, 2021) |
| "Despite significant progress in treatment of rheumatoid arthritis (RA), a considerable part of patients remains resistant to the current therapy, apparently for the reasons of undefined mechanisms of its pathogenesis." | 1.56 | ASSOCIATIONS BETWEEN EFFICACY OF THE THERAPY AND CIRCADIAN FLUCTUATIONS OF ENDOTHELIAL NITRIC OXIDE SYNTHASE WITH TOLL-LIKE RECEPTORS 2 EXPRESSION, AND NOS3 POLYMORPHISM IN FEMALES WITH RHEUMATOID ARTHRITIS. ( Khomenko, V; Stanislavchuk, M; Zaichko, K; Zaichko, N, 2020) |
| "Methotrexate-induced hypersensitivity pneumonitis usually occurs in the initial few weeks to months of starting treatment with methotrexate; however, it can occur late during therapy too, and prompt diagnosis is crucial as it is a reversible condition when diagnosed early." | 1.46 | Methotrexate-induced Hypersensitivity Pneumonitis appearing after 30 years of use: a case report. ( Khaing, M; Miller, R; Salehi, M, 2017) |
| "Hydroxychloroquine was the most frequently filled DMARD (13." | 1.46 | End-stage renal disease in patients with rheumatoid arthritis. ( Bethel, M; Brown, S; Carbone, L; Chen, CC; Nahman, NS; Paudyal, S; Rice, C; Skelton, M; Yang, FM, 2017) |
| "Prednisone use was associated with a significantly increased risk of mortality in patients with RA." | 1.43 | Prednisone Use and Risk of Mortality in Patients With Rheumatoid Arthritis: Moderation by Use of Disease-Modifying Antirheumatic Drugs. ( Chester Wasko, M; Dasgupta, A; Fries, JF; Ilse Sears, G; Ward, MM, 2016) |
| "Treatment with prednisone was associated with greater weight gain (β = 0." | 1.43 | Changes in Body Mass Related to the Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis. ( Baker, JF; Cannella, A; Cannon, GW; Caplan, L; Davis, L; Ibrahim, S; Jorgenson, E; Michaud, K; Mikuls, TR; Sauer, BC; Teng, CC, 2016) |
| " Cox's proportional hazards models estimated fracture risk adjusted for demographics and baseline clinical characteristics to assess dose-response relationships with current (daily) and prior (cumulative) dose, and by time since discontinuation." | 1.43 | Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. ( Adler, RA; Balasubramanian, A; Curtis, JR; Lin, CJF; Maricic, M; O'Malley, CD; Saag, K; Wade, SW, 2016) |
| "Pneumonia was the most common (3." | 1.43 | Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease. ( Crowson, CS; Krause, ML; Matteson, EL; Ryu, JH; Zamora-Legoff, JA, 2016) |
| "Paradoxically, this treatment induces sarcoidosis in a small population of RA patients as a class effect." | 1.43 | Sarcoidosis during etanercept treatment for rheumatoid arthritis in women with a history of bilateral oophorectomy. ( Bando, M; Miki, A; Muto, S; Sawahata, M; Sigiyama, Y; Yamamoto, H; Yamasawa, H, 2016) |
| " It is possible that in patients treated with high-dose CS, the main objective of the clinician is to reduce dosage of CS rather than RA activity." | 1.42 | Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. ( Constant, E; Devilliers, H; Fortunet, C; Gaudin, P; Godfrin-Valnet, M; Jorgensen, C; Lambert, J; Maillefert, JF; Pers, YM; Prades, BP; Wendling, D, 2015) |
| "The treatment with theophylline and nitric oxide modulators were done from day 14 to day 28." | 1.42 | Protective role of theophylline and their interaction with nitric oxide (NO) in adjuvant-induced rheumatoid arthritis in rats. ( Babu, S; Chaudhary, MJ; Pal, R; Pant, KK; Tiwari, PC, 2015) |
| " For the cumulative dose of glucocorticoids, the minimum dosage associated with all-cause mortality was 40 gm (HR 1." | 1.40 | Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. ( Battafarano, DF; del Rincón, I; Erikson, JM; Escalante, A; Restrepo, JF, 2014) |
| " When used in a dosage of 5-10 mg, most adverse effects can adequately be monitored, though accurate monitoring and awareness for infections are important." | 1.40 | Glucocorticoids in the treatment of rheumatoid arthritis: still used after 65 years. ( Bijlsma, JW; Jacobs, JW, 2014) |
| "Prednisone is an old and very valuable drug in clinical use for over 60 years by now." | 1.40 | The current relevance and use of prednisone in rheumatoid arthritis. ( Baerwald, C; Krasselt, M, 2014) |
| "Immune-mediated scleritis is a rare condition, and the information on the clinical course and complications is scarce." | 1.40 | Five-year outcome in immune-mediated scleritis. ( Bernauer, W; Brunner, M; Pleisch, B, 2014) |
| "Although various drugs for the treatment of rheumatoid arthritis (RA) have been used in clinics, RA is not completely curable to date." | 1.38 | Activity study of a hydroxynaphthoquinone fraction from Arnebia euchroma in experimental arthritis. ( Che, X; Fan, H; Liu, K; Meng, Q; Xu, H; Yang, M; Zhang, Z, 2012) |
| " Secondary endpoints include AIRs during the 24 h following their second infusion and any adverse events experienced during the 26-week study; efficacy measures were also followed as secondary endpoints." | 1.38 | A safety analysis of oral prednisone as a pretreatment for rituximab in rheumatoid arthritis. ( Carter, JD; McNeil, A; Ricca, LR; Sebba, AI; Valeriano-Marcet, J; Vasey, FB; Zarabadi, SA, 2012) |
| "Crusted Norwegian scabies is an extremely rare hyperkeratotic variant of scabies infestation." | 1.37 | Crusted Norwegian scabies, an opportunistic infection, with tocilizumab in rheumatoid arthritis. ( Aractingi, S; Baccouche, K; Berenbaum, F; Guegan, S; Sellam, J, 2011) |
| " GC dosing during the year before and the year after TNFi initiation were compared." | 1.37 | Tumour necrosis factor-α inhibitors are glucocorticoid-sparing in rheumatoid arthritis. ( Christensen, AF; Junker, P; Lindegaard, HM; Nilsson, AC, 2011) |
| "Interstitial lung disease is a common manifestation of rheumatoid arthritis; however, little is known about factors that influence its prognosis." | 1.36 | Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. ( Collard, HR; Elicker, BM; Kim, EJ; King, TE; Lee, JS; Maldonado, F; Ryu, JH; Van Uden, JH; Webb, WR, 2010) |
| "Other causes included hypersensitivity pneumonitis, multiple carcinoid tumorlets, Sjögren's syndrome, paraneoplastic pemphigus, inflammatory bowel disease and Swyer-James syndrome." | 1.35 | Obstructive bronchiolar disease identified by CT in the non-transplant population: analysis of 29 consecutive cases. ( Parambil, JG; Ryu, JH; Yi, ES, 2009) |
| "Mean prednisone dose was reduced to 11." | 1.35 | Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. ( Guillevin, L; Lafforgue, P; Marcelli, C; Mariette, X; Mejjad, O; Miceli-Richard, C; Puéchal, X; Solau-Gervais, E; Steinfeld, S; Trèves, R; Villoutreix, C, 2008) |
| "Spontaneous hemopneumothorax is characterized by an accumulation of air and blood in the pleural space without any apparent cause." | 1.34 | Massive spontaneous hemopneumothorax complicating rheumatoid lung disease. ( Basoglu, A; Celik, B; Yetim, TD, 2007) |
| "Pericarditis has not recurred after discontinuance of MTX over 3 years ago." | 1.34 | Pericarditis: a rare complication of methotrexate therapy. ( Elyan, M; Kushner, I; Mohyuddin, T, 2007) |
| "Strongyloidiasis is epidemic in tropical and subtropical regions where the regional prevalence may exceed 25%." | 1.34 | Strongyloides stercoralis hyperinfection in a patient with rheumatoid arthritis after anti-TNF-alpha therapy. ( Dincer, HE; Krishnamurthy, R; Whittemore, D, 2007) |
| "The etiology of rheumatoid nodules is still unknown." | 1.34 | Etanercept-related extensive pulmonary nodulosis in a patient with rheumatoid arthritis. ( Creemers, MC; den Broeder, A; van Ede, A; van Riel, P; Wagenaar, M, 2007) |
| "We report a case of renal cortical necrosis in a patient with type III cryoglobulinemia." | 1.33 | Type III cryoglobulinemia complicated by renal cortical necrosis. ( Aaron, L; Alyanakian, MA; Desbene, C; Fakhouri, F; Karras, A; Lesavre, P; Noël, LH; Thaunat, O, 2005) |
| "Rheumatoid pleural effusion is an unusual complication of rheumatoid disease that typically presents subsequent to other more common manifestations of rheumatoid illness." | 1.33 | Rheumatoid pleural effusion in the absence of arthritic disease. ( Allan, JS; Donahue, DM; Garrity, JM, 2005) |
| " We also examined how glucocorticoid dosage affected osteoporosis management in adjusted models." | 1.33 | Osteoporosis management in patients with rheumatoid arthritis: Evidence for improvement. ( Bukowski, JF; Cabral, D; Coblyn, JS; Katz, JN; Patrick, AR; Solomon, DH, 2006) |
| "Both membranous glomerulopathy and acute interstitial nephritis have been reported to occur following treatment with non-steroidal anti-inflammatory drugs." | 1.32 | Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib. ( Appel, GB; D'Agati, VD; Falkowitz, DC; Imaizumi, S; Isom, R; Markowitz, GS; Zaki, M, 2003) |
| "Patients with rheumatoid arthritis are at high risk for acute myocardial infarction (AMI)." | 1.32 | Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. ( Krishnan, E; Lingala, VB; Singh, G, 2004) |
| " The mean daily dosage of prednisone (or its equivalent) was 8." | 1.31 | Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. ( Coblyn, J; Jacobs, JP; Katz, JN; La Tourette, AM; Solomon, DH, 2002) |
| "Trazodone (Desyrel) is a second-generation, nontricyclic antidepressant that has been in use in North America since the early 1980s." | 1.31 | Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity. ( Fernandes, NF; Martin, RR; Schenker, S, 2000) |
| "Mild cholestasis was present in four of the seven patients for whom data were available." | 1.30 | [RS3PE: a clinical diagnosis, a prognosis more simple than its name]. ( Azais, I; Becq-Giraudon, B; Paccalin, M; Ramassamy, A; Roblot, P; Zaim, A, 1998) |
| "POEMS syndrome is a rare synopsis of different multisystemic disorders (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammapathy, and skin lesions) associated with plasma cell dyscrasia." | 1.30 | POEMS syndrome, steroid-dependent diabetes mellitus, erythema elevatum diutinum, and rheumatoid arthritis as extramedullary manifestations of plasma cell dyscrasia. ( Albitar, S; Bourgeon, B; Genin, R; Jacquesson, M; Ribera, A; Riviere, JP; Serveaux, JP; Serveaux, MO, 1998) |
| "Iatrogenic osteoporosis is a very common secondary osteoporosis is found in patients treated with large dosage of glucocorticosteroid of long duration." | 1.29 | [Iatrogenic osteoporsis: six case reports]. ( Wang, JZ; Zheng, LM, 1994) |
| "Sacral insufficiency fractures developed in 4 of 386 patients." | 1.29 | Sacral insufficiency fractures in rheumatoid arthritis. ( Baker, MR; Place, HM; Troutner, JL; West, SG, 1994) |
| "We report a case of Temporal Arteritis, carrier of IgG anticardiolipin antibodies, who presented seronegative polyarthritis with AR criteria after 7 months." | 1.29 | [Acute ischemia of the lower limb in a patient with temporal arteritis and rheumatoid arthritis, carrier of anticardiolipin antibodies]. ( Fernández Domínguez, L; Jiménez, JL; López Barros, G; Margusino Framiñán, C; Rodríguez Gómez, M, 1995) |
| "Rheumatoid arthritis is a destructive systemic disorder characterized by remissions and exacerbations." | 1.28 | Rheumatoid arthritis of the larynx: the importance of early diagnosis and corticosteroid therapy. ( Abedi, E; Dockery, KM; Sismanis, A, 1991) |
| "Rheumatoid arthritis is not considered to be associated with recurrent thrombosis." | 1.28 | Rheumatoid arthritis and hypercoagulable state. ( Smith, RE; Theisen, AL, 1990) |
| "Flurbiprofen was better tolerated (p less than 0." | 1.27 | Steroid-sparing action of flurbiprofen and indomethacin in rheumatoid arthritis: a nine-week study. ( Benvenuti, C; Longoni, A; Viara, M, 1983) |
| " The mean dosage of azathioprin and prednisone in patients with SLE did not significantly differ from the non-SLE group." | 1.27 | [Reactivation of the alpha 1-fetoprotein synthesis in systemic lupus erythematosus]. ( Knopf, B; Schulze, M; Wollina, U, 1985) |
| "Deflazacort (DFC) is a new glucocorticoid which, when compared with prednisone (PDN), has similar anti-inflammatory actions, but lacks several unwanted side effects on mineral and carbohydrate metabolism." | 1.27 | Effects of a new heterocyclic glucocorticoid, deflazacort (DFC), on the functions of lymphocytes from patients with rheumatoid arthritis (RA). ( Imbimbo, B; Indiveri, F; Piccardo, C; Piovano, P; Scudeletti, M, 1987) |
| "The incidence of infections increased significantly with polymorphonuclear leukocyte (PMN) counts below 0." | 1.27 | Factors influencing the incidence of infections in Felty's syndrome. ( Breedveld, FC; Cats, A; Fibbe, WE; Hermans, J; van der Meer, JW, 1987) |
| "Gold-treated patients trended toward lower malignancy rates (11 versus 17 percent) than did those not treated with gold, and prednisone-treated patients had less malignancy (11 versus 20 percent) than did those not treated with prednisone." | 1.27 | Cancer in rheumatoid arthritis: a prospective long-term study of mortality. ( Bloch, D; Fries, JF; Mitchell, DM; Spitz, P, 1985) |
| "By contrast, in 39 patients with systemic lupus erythematosus (SLE), the mean colony number was 2,774 +/- 384, a value significantly less than controls (P less than 0." | 1.26 | Depressed T cell colony growth in systemic lupus erythematosus. ( Bernstein, ML; Dobson, SA; Winkelstein, A, 1980) |
| "Carpal tunnel syndrome was seen in four patients (10%)." | 1.26 | Skeletal manifestations of polymyalgia rheumatica. ( Miller, LD; Stevens, MB, 1978) |
| "While rheumatic fever is relatively uncommon except where there are poor and crowded living conditions, sporadic acute attacks continue to occur in a family or pediatric medical practice." | 1.25 | Acute rheumatic fever. ( Cumming, GR, 1974) |
| "Systemic lupus erythematosus is a polysystemic disease with a high incidence of associated glomerulonephritis." | 1.25 | Systemic lupus erythematosus. ( , 1969) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 514 (47.24) | 18.7374 |
| 1990's | 152 (13.97) | 18.2507 |
| 2000's | 154 (14.15) | 29.6817 |
| 2010's | 222 (20.40) | 24.3611 |
| 2020's | 46 (4.23) | 2.80 |
| Authors | Studies |
|---|---|
| BONATI, B | 1 |
| BERGAMINI, A | 1 |
| RANCATI, GB | 1 |
| TEDESCHI, B | 1 |
| Skalkou, A | 1 |
| Pelechas, E | 1 |
| Voulgari, PV | 3 |
| Drosos, AA | 4 |
| Ward, MM | 3 |
| Alba, MI | 1 |
| Metyas, S | 1 |
| Chen, C | 1 |
| Aung, T | 1 |
| Ballester, A | 1 |
| Cheav, S | 1 |
| Hazlewood, GS | 1 |
| Schieir, O | 1 |
| Bykerk, V | 1 |
| Mujaab, K | 1 |
| Tugwell, P | 2 |
| Wells, G | 2 |
| Richards, D | 1 |
| Proulx, L | 1 |
| Hull, PM | 1 |
| Bartlett, SJ | 1 |
| Batko, B | 1 |
| Jeka, S | 3 |
| Wiland, P | 1 |
| Brzosko, M | 1 |
| Samborski, W | 1 |
| Stajszczyk, M | 1 |
| Chudek, J | 1 |
| Żuber, Z | 1 |
| Luo, L | 1 |
| Li, X | 1 |
| Yan, R | 1 |
| Zhang, H | 1 |
| Li, C | 2 |
| Sakellariou, G | 2 |
| Scirè, CA | 4 |
| Rumi, F | 1 |
| Carrara, G | 2 |
| Zanetti, A | 2 |
| Cerra, C | 1 |
| Migliazza, S | 1 |
| Bugatti, S | 2 |
| Montecucco, C | 5 |
| de Steenwinkel, FDO | 2 |
| Dolhain, RJEM | 4 |
| Hazes, JMW | 4 |
| Hokken-Koelega, ACS | 2 |
| Chen, SL | 1 |
| Zheng, HJ | 1 |
| Zhang, LY | 1 |
| Xu, Q | 1 |
| Lin, CS | 1 |
| Dietzel, R | 1 |
| Wiegmann, S | 1 |
| Borucki, D | 1 |
| Detzer, C | 1 |
| Zeiner, KN | 1 |
| Schaumburg, D | 1 |
| Buehring, B | 1 |
| Buttgereit, F | 17 |
| Armbrecht, G | 1 |
| Owczarczyk-Saczonek, A | 1 |
| Kasprowicz-Furmańczyk, M | 1 |
| Kuna, J | 1 |
| Klimek, P | 1 |
| Krajewska-Włodarczyk, M | 1 |
| Pfeil, A | 1 |
| Heinz, M | 1 |
| Hoffmann, T | 1 |
| Weise, T | 1 |
| Renz, DM | 1 |
| Franz, M | 1 |
| Malich, A | 1 |
| Driesch, D | 1 |
| Oelzner, P | 2 |
| Wolf, G | 2 |
| Böttcher, J | 1 |
| Bergstra, SA | 8 |
| Sepriano, A | 3 |
| Kerschbaumer, A | 3 |
| van der Heijde, D | 6 |
| Caporali, R | 9 |
| Edwards, CJ | 3 |
| Verschueren, P | 7 |
| de Souza, S | 3 |
| Pope, JE | 4 |
| Takeuchi, T | 3 |
| Hyrich, KL | 4 |
| Winthrop, KL | 3 |
| Aletaha, D | 3 |
| Stamm, TA | 3 |
| Schoones, JW | 3 |
| Smolen, JS | 3 |
| Landewé, RBM | 5 |
| Zamora-Abrahan, GT | 1 |
| Salido, EO | 1 |
| Lichauco, JJT | 1 |
| Gutierrez-Rubio, AKM | 1 |
| Rivera-Go, ICT | 1 |
| Cortez, KJC | 1 |
| Suilan, KEA | 1 |
| Villo, JGB | 1 |
| Del Rosario, AG | 1 |
| Palmowski, A | 1 |
| Nielsen, SM | 1 |
| Boyadzhieva, Z | 1 |
| Schneider, A | 1 |
| Pankow, A | 1 |
| Hartman, L | 1 |
| Da Silva, JAP | 1 |
| Kirwan, J | 3 |
| Wassenberg, S | 1 |
| Dejaco, C | 1 |
| Christensen, R | 1 |
| Boers, M | 12 |
| Barbulescu, A | 1 |
| Sjölander, A | 1 |
| Delcoigne, B | 1 |
| Askling, J | 1 |
| Frisell, T | 1 |
| Karpouzas, GA | 2 |
| Papotti, B | 1 |
| Ormseth, SR | 2 |
| Palumbo, M | 1 |
| Hernandez, E | 1 |
| Adorni, MP | 1 |
| Zimetti, F | 1 |
| Budoff, MJ | 2 |
| Ronda, N | 1 |
| Crowson, LP | 1 |
| Davis, JM | 3 |
| Hanson, AC | 1 |
| Myasoedova, E | 1 |
| Kronzer, VL | 1 |
| Makol, A | 2 |
| Peterson, LS | 1 |
| Bekele, DI | 1 |
| Crowson, CS | 2 |
| Kalweit, M | 1 |
| Burden, AM | 1 |
| Boedecker, J | 1 |
| Hügle, T | 1 |
| Burkard, T | 1 |
| Sabounji, MM | 1 |
| Lissimo, H | 1 |
| Deme, A | 1 |
| Spinelli, FR | 1 |
| Garufi, C | 1 |
| Mancuso, S | 1 |
| Ceccarelli, F | 1 |
| Truglia, S | 1 |
| Conti, F | 1 |
| Scirocco, C | 1 |
| Ferrigno, S | 1 |
| Andreoli, L | 1 |
| Fredi, M | 1 |
| Lomater, C | 1 |
| Moroni, L | 1 |
| Mosca, M | 1 |
| Raffeiner, B | 1 |
| Landolfi, G | 1 |
| Rozza, D | 1 |
| Sebastiani, GD | 1 |
| Gaujoux-Viala, C | 1 |
| Bergmann, JF | 1 |
| Goguillot, M | 1 |
| Mélaine, A | 1 |
| Guérin, M | 1 |
| Edouard, A | 1 |
| Bénard, S | 1 |
| Fautrel, B | 2 |
| Driedger, M | 1 |
| Teo, I | 1 |
| Roth, V | 1 |
| Fakih, O | 1 |
| Verhoeven, F | 1 |
| Prati, C | 1 |
| Wendling, D | 3 |
| Zhuang, C | 1 |
| Zhou, J | 1 |
| Mo, H | 2 |
| Lin, D | 1 |
| Luo, X | 1 |
| Chen, RX | 1 |
| Cao, SS | 1 |
| Zhao, LD | 1 |
| Yang, HX | 1 |
| Değirmenci, C | 1 |
| Afrashi, F | 1 |
| Nalçacı, S | 1 |
| Çeper, SB | 1 |
| Manaï, M | 1 |
| van Middendorp, H | 1 |
| Veldhuijzen, DS | 1 |
| van der Pol, JA | 3 |
| Huizinga, TWJ | 8 |
| Evers, AWM | 1 |
| Chung, SW | 1 |
| Park, EH | 1 |
| Kang, EH | 1 |
| Lee, YJ | 1 |
| Ha, YJ | 1 |
| Ibraheim, MK | 1 |
| Govindu, RR | 1 |
| Zaichko, K | 1 |
| Stanislavchuk, M | 1 |
| Zaichko, N | 1 |
| Khomenko, V | 1 |
| van der Leeuw, MS | 1 |
| Welsing, PMJ | 3 |
| de Hair, MJH | 4 |
| Jacobs, JWG | 4 |
| Marijnissen, ACA | 1 |
| Linn-Rasker, SP | 2 |
| Fodili, F | 1 |
| Bos, R | 1 |
| Tekstra, J | 4 |
| van Laar, JM | 7 |
| Tomita, M | 1 |
| Oura, S | 1 |
| Nishiguchi, H | 1 |
| Makimoto, S | 1 |
| Riyazi, N | 2 |
| Goekoop-Ruiterman, YPM | 1 |
| Kerstens, PJSM | 1 |
| Lems, W | 1 |
| Allaart, CF | 34 |
| Gianfrancesco, M | 1 |
| Al-Adely, S | 1 |
| Carmona, L | 1 |
| Danila, MI | 1 |
| Gossec, L | 2 |
| Izadi, Z | 1 |
| Jacobsohn, L | 1 |
| Katz, P | 1 |
| Lawson-Tovey, S | 1 |
| Mateus, EF | 1 |
| Rush, S | 1 |
| Schmajuk, G | 1 |
| Simard, J | 1 |
| Strangfeld, A | 1 |
| Trupin, L | 1 |
| Wysham, KD | 1 |
| Bhana, S | 1 |
| Costello, W | 1 |
| Grainger, R | 1 |
| Hausmann, JS | 1 |
| Liew, JW | 1 |
| Sirotich, E | 1 |
| Sufka, P | 1 |
| Wallace, ZS | 1 |
| Yazdany, J | 1 |
| Machado, PM | 1 |
| Robinson, PC | 1 |
| Burmester, GR | 2 |
| Bernasconi, C | 1 |
| Álvaro-Gracia, JM | 1 |
| Castro, N | 1 |
| Dougados, M | 5 |
| Gabay, C | 2 |
| Nebesky, JM | 1 |
| Pethoe-Schramm, A | 2 |
| Salvarani, C | 2 |
| Donath, MY | 1 |
| John, MR | 1 |
| Jurgens, MS | 4 |
| Safy-Khan, M | 2 |
| Bijlsma, JWJ | 2 |
| Lafeber, FPJG | 1 |
| Sasso, EH | 1 |
| Roubille, C | 1 |
| Coffy, A | 1 |
| Rincheval, N | 1 |
| Flipo, RM | 2 |
| Daurès, JP | 1 |
| Combe, B | 2 |
| Conn, DL | 5 |
| Rezaeian, P | 1 |
| Hollan, I | 1 |
| Harada, T | 1 |
| Iwasaki, H | 1 |
| Muta, T | 1 |
| Urata, S | 1 |
| Sakamoto, A | 1 |
| Kohno, K | 1 |
| Takase, K | 1 |
| Miyamura, T | 1 |
| Sawabe, T | 1 |
| Asaoku, H | 1 |
| Oryoji, K | 1 |
| Fujisaki, T | 1 |
| Mori, Y | 1 |
| Yoshimoto, G | 1 |
| Ayano, M | 1 |
| Mitoma, H | 1 |
| Miyamoto, T | 1 |
| Niiro, H | 1 |
| Yamamoto, H | 3 |
| Oshiro, Y | 1 |
| Miyoshi, H | 1 |
| Ohshima, K | 1 |
| Takeshita, M | 1 |
| Akashi, K | 1 |
| Kato, K | 1 |
| Maassen, JM | 1 |
| Dos Santos Sobrín, R | 1 |
| Goekoop, R | 1 |
| Ocon, AJ | 1 |
| Reed, G | 4 |
| Pappas, DA | 2 |
| Curtis, JR | 5 |
| Kremer, JM | 8 |
| Wallace, BI | 1 |
| Moore, MN | 1 |
| Heisler, AC | 1 |
| Muhammad, LN | 1 |
| Song, J | 1 |
| Clauw, DJ | 1 |
| Bingham, CO | 1 |
| Bolster, MB | 1 |
| Marder, W | 1 |
| Neogi, T | 1 |
| Wohlfahrt, A | 1 |
| Dunlop, DD | 1 |
| Lee, YC | 1 |
| Stacy, JM | 1 |
| Greenmyer, JR | 1 |
| Beal, JR | 1 |
| Sahmoun, AE | 1 |
| Diri, E | 1 |
| Stock, T | 1 |
| Fleishaker, D | 1 |
| Wang, X | 2 |
| Mukherjee, A | 1 |
| Mebus, C | 1 |
| Ursini, F | 1 |
| Naty, S | 1 |
| Bruno, C | 1 |
| Grembiale, RD | 1 |
| Safy, M | 2 |
| Jacobs, J | 1 |
| IJff, ND | 2 |
| Bijlsma, J | 1 |
| de Hair, M | 1 |
| Li, Y | 1 |
| Ren, XY | 1 |
| Sun, F | 1 |
| Wang, P | 1 |
| Zhao, JL | 1 |
| Wu, QJ | 1 |
| Zeng, XF | 1 |
| Ramírez, J | 1 |
| Narváez, JA | 1 |
| Ruiz-Esquide, V | 2 |
| Hernández-Gañán, J | 1 |
| Cuervo, A | 1 |
| Inciarte-Mundo, J | 1 |
| Hernández, MV | 2 |
| Sampayo-Cordero, M | 1 |
| Pablos, JL | 1 |
| Sanmartí, R | 3 |
| Cañete, JD | 1 |
| Shoji, S | 1 |
| Suzuki, A | 1 |
| Conrado, DJ | 1 |
| Peterson, MC | 1 |
| Hey-Hadavi, J | 2 |
| McCabe, D | 2 |
| Rojo, R | 2 |
| Tammara, BK | 1 |
| Salehi, M | 1 |
| Miller, R | 1 |
| Khaing, M | 1 |
| Uchida, T | 1 |
| Inoue, M | 1 |
| Hua, J | 1 |
| Tajima, S | 1 |
| Ota, Y | 1 |
| Hagihara, M | 1 |
| Markusse, IM | 3 |
| Lems, WF | 12 |
| Maguire, SA | 1 |
| Sheehy, CM | 1 |
| Olivas, O | 1 |
| Akdemir, G | 3 |
| Collée, G | 4 |
| van Groenendael, JHLM | 2 |
| Heimans, L | 7 |
| Goekoop, RJ | 4 |
| van Oosterhout, M | 4 |
| Peeters, AJ | 6 |
| Steup-Beekman, GM | 3 |
| Lard, LR | 3 |
| de Sonnaville, PBJ | 1 |
| Grillet, BAM | 1 |
| Palmsten, K | 2 |
| Hulugalle, A | 1 |
| Bandoli, G | 1 |
| Kuo, GM | 1 |
| Ansari, S | 1 |
| Xu, R | 2 |
| Chambers, CD | 2 |
| Scherlinger, M | 1 |
| Schaeverbeke, T | 2 |
| Truchetet, ME | 1 |
| Weatherley, B | 1 |
| McFadyen, L | 1 |
| Tammara, B | 2 |
| Deng, W | 1 |
| Miao, C | 1 |
| Zhang, X | 2 |
| Tiliakos, A | 1 |
| Bao, G | 1 |
| Li, S | 1 |
| Easley, KA | 1 |
| Zheng, N | 1 |
| Guo, C | 1 |
| Wu, R | 1 |
| de Moel, EC | 2 |
| Derksen, VFAM | 2 |
| Stoeken, G | 1 |
| Trouw, LA | 2 |
| Bang, H | 2 |
| Speyer, I | 7 |
| Toes, REM | 2 |
| van der Woude, D | 2 |
| Rolland, M | 1 |
| Hebert, MF | 1 |
| Clowse, MEB | 1 |
| Schatz, M | 1 |
| Iriki, H | 1 |
| Ouchi, T | 1 |
| Ito, H | 1 |
| Sawada, M | 1 |
| Mukai, M | 1 |
| Nomura, H | 1 |
| Baba, Y | 1 |
| Adachi, T | 1 |
| Funakoshi, T | 1 |
| Amagai, M | 1 |
| Takahashi, H | 1 |
| Ivanova, R | 1 |
| Goremykina, M | 1 |
| Glushkova, N | 1 |
| Vento, S | 1 |
| Baker, JF | 4 |
| Sauer, B | 1 |
| Teng, CC | 2 |
| George, M | 1 |
| Cannon, GW | 5 |
| Ibrahim, S | 3 |
| Cannella, A | 2 |
| England, BR | 1 |
| Michaud, K | 5 |
| Caplan, L | 5 |
| Davis, LA | 1 |
| OʼDell, J | 1 |
| Mikuls, TR | 5 |
| Cao, QY | 1 |
| Wang, PY | 1 |
| Wang, QY | 1 |
| Zhao, F | 1 |
| Wang, KZ | 1 |
| Liu, JQ | 1 |
| Liu, TS | 1 |
| Wang, YF | 1 |
| Liu, YJ | 1 |
| Galmiche, S | 1 |
| Buob, D | 1 |
| Fellahi, S | 1 |
| Bastard, JP | 1 |
| Grateau, G | 1 |
| Georgin-Lavialle, S | 1 |
| Alten, R | 8 |
| Mischkewitz, M | 1 |
| Choy, E | 1 |
| Xavier, R | 1 |
| Bao, M | 1 |
| Devenport, J | 1 |
| Pethö-Schramm, A | 1 |
| Ramiro, S | 1 |
| Ince-Askan, H | 2 |
| van den Akker, ELT | 1 |
| de Rijke, YB | 1 |
| van Rossum, EFC | 1 |
| Malochet-Guinamand, S | 1 |
| Lambert, C | 1 |
| Soubrier, M | 1 |
| Petta, I | 1 |
| Peene, I | 1 |
| Elewaut, D | 1 |
| Vereecke, L | 1 |
| De Bosscher, K | 1 |
| Toyonaga, H | 1 |
| Fukushima, M | 1 |
| Shimeno, N | 1 |
| Inokuma, T | 1 |
| Burgers, LE | 1 |
| van der Helm-van Mil, AHM | 1 |
| Strand, V | 1 |
| Lee, EB | 1 |
| Simon-Campos, A | 1 |
| Genet, A | 1 |
| Ramirez, GA | 1 |
| Rovere-Querini, P | 1 |
| Blasi, M | 1 |
| Sartorelli, S | 1 |
| Di Chio, MC | 1 |
| Baldini, M | 1 |
| De Lorenzo, R | 1 |
| Bozzolo, EP | 1 |
| Leone, R | 1 |
| Mantovani, A | 1 |
| Manfredi, AA | 1 |
| Tombetti, E | 1 |
| Verhoeven, MM | 1 |
| de Hair, MJ | 1 |
| Bijlsma, JW | 16 |
| Borm, ME | 1 |
| Ter Borg, EJ | 1 |
| Teitsma, XM | 1 |
| Lafeber, FP | 6 |
| Jacobs, JW | 14 |
| Welsing, PM | 5 |
| Rodríguez-Jiménez, P | 1 |
| Chicharro, P | 1 |
| Reolid, A | 1 |
| Muñoz-Aceituno, E | 1 |
| Fraga, J | 1 |
| Llamas-Velasco, M | 1 |
| Stouten, V | 1 |
| Westhovens, R | 4 |
| Pazmino, S | 1 |
| De Cock, D | 3 |
| Van der Elst, K | 3 |
| Joly, J | 3 |
| Nambiar, PH | 1 |
| Katikaneni, M | 1 |
| Al Nahlawi, B | 1 |
| Hayat, SQ | 1 |
| Derendorf, H | 1 |
| Ruebsamen, K | 1 |
| Clarke, L | 2 |
| Schaeffler, A | 3 |
| Kirwan, JR | 6 |
| Piga, M | 1 |
| Gabba, A | 1 |
| Cauli, A | 1 |
| Garau, P | 1 |
| Vacca, A | 1 |
| Mathieu, A | 1 |
| Gibofsky, A | 2 |
| Malemba, JJ | 1 |
| Mbuyi Muamba, JM | 1 |
| Mukaya, J | 1 |
| Bossuyt, X | 1 |
| Li, LM | 1 |
| Tessier-Cloutier, B | 1 |
| Wang, Y | 2 |
| Bernatsky, S | 2 |
| Vinet, E | 1 |
| Ménard, HA | 1 |
| Panopalis, P | 1 |
| Hazel, E | 1 |
| Stein, M | 1 |
| Cohen, M | 1 |
| Starr, M | 1 |
| Pineau, C | 1 |
| Veilleux, MÈ | 1 |
| Colmegna, I | 1 |
| Clarke, LL | 1 |
| Wilson, S | 1 |
| Wevers-de Boer, KV | 5 |
| Visser, K | 7 |
| Harbers, JB | 3 |
| Bijkerk, C | 2 |
| de Buck, MP | 2 |
| de Sonnaville, PB | 6 |
| Grillet, BA | 6 |
| Huizinga, TW | 18 |
| Waimann, CA | 1 |
| Marengo, MF | 1 |
| de Achaval, S | 1 |
| Cox, VL | 1 |
| Garcia-Gonzalez, A | 1 |
| Reveille, JD | 1 |
| Richardson, MN | 1 |
| Suarez-Almazor, ME | 2 |
| Díaz Cuevas, Z | 1 |
| Rodríguez-Lozano, B | 1 |
| Campos Gutierrez, S | 1 |
| Lecuona Fernández, M | 1 |
| Ronday, HK | 9 |
| Giltay, EJ | 1 |
| van der Mast, RC | 1 |
| Naidu, A | 1 |
| Kessler, HP | 1 |
| Pavelka, MA | 1 |
| Henness, S | 1 |
| Yang, LP | 1 |
| Kälvesten, J | 1 |
| Steup-Beekman, M | 1 |
| Mercieca, C | 1 |
| Pouw, MF | 1 |
| Krieckaert, CL | 1 |
| Nurmohamed, MT | 3 |
| van der Kleij, D | 1 |
| Aarden, L | 1 |
| Rispens, T | 1 |
| Wolbink, G | 2 |
| Xuan, D | 1 |
| Yu, Y | 1 |
| Shao, L | 1 |
| Wang, J | 1 |
| Zhang, W | 2 |
| Zou, H | 1 |
| de Steenwinkel, FD | 3 |
| Hokken-Koelega, AC | 3 |
| Hazes, JM | 12 |
| Dolhain, RJ | 5 |
| Ternant, D | 1 |
| Ducourau, E | 1 |
| Perdriger, A | 1 |
| Corondan, A | 1 |
| Le Goff, B | 1 |
| Devauchelle-Pensec, V | 1 |
| Solau-Gervais, E | 2 |
| Watier, H | 1 |
| Goupille, P | 2 |
| Paintaud, G | 1 |
| Mulleman, D | 1 |
| Dominguez, AR | 1 |
| Goldman, SE | 1 |
| Velázquez Benito, A | 1 |
| Bellosta Diago, E | 1 |
| Santos Lasaosa, S | 1 |
| Pascual Millán, LF | 1 |
| Liu, SY | 1 |
| Yang, L | 1 |
| Zhang, L | 2 |
| He, YJ | 1 |
| del Rincón, I | 1 |
| Battafarano, DF | 1 |
| Restrepo, JF | 1 |
| Erikson, JM | 1 |
| Escalante, A | 1 |
| Koudijs, KK | 1 |
| Goekoop-Ruiterman, YP | 13 |
| Costedoat-Chalumeau, N | 1 |
| Le Guern, V | 1 |
| Piette, JC | 1 |
| de Ridder, MA | 1 |
| Topaloğlu, S | 1 |
| Çalık, A | 1 |
| Kalaycı, O | 1 |
| Çeşmecioğlu, E | 1 |
| Çobanoğlu, Ü | 1 |
| Uzun, Y | 1 |
| Chung, CG | 1 |
| Rosengrant, A | 1 |
| Helm, KF | 1 |
| Shupp, DL | 1 |
| Krasselt, M | 2 |
| Baerwald, C | 2 |
| Jo, D | 1 |
| Pompa, T | 1 |
| Khalil, A | 1 |
| Kong, F | 1 |
| Wetz, R | 1 |
| Goldstein, M | 2 |
| Kudoh, M | 1 |
| Harada, H | 1 |
| Matsumoto, K | 1 |
| Sato, Y | 1 |
| Omura, K | 1 |
| Ishii, Y | 1 |
| Brouwer, J | 1 |
| Laven, JS | 1 |
| Kolm, I | 1 |
| Aceto, L | 1 |
| Hombach, M | 1 |
| Kamarshev, J | 1 |
| Hafner, J | 1 |
| Urosevic-Maiwald, M | 1 |
| Rau, R | 1 |
| Bernauer, W | 2 |
| Pleisch, B | 1 |
| Brunner, M | 2 |
| Santosa, A | 1 |
| Ng, PS | 1 |
| Teng, GG | 1 |
| Wu, W | 1 |
| Lee, RA | 1 |
| Hata, T | 1 |
| Patel, R | 2 |
| Richards, JS | 1 |
| Kerr, G | 1 |
| Pincus, T | 12 |
| Cutolo, M | 6 |
| Fortunet, C | 2 |
| Pers, YM | 1 |
| Lambert, J | 1 |
| Godfrin-Valnet, M | 1 |
| Constant, E | 1 |
| Devilliers, H | 1 |
| Gaudin, P | 1 |
| Jorgensen, C | 1 |
| Prades, BP | 1 |
| Maillefert, JF | 3 |
| de Vries-Bouwstra, JK | 12 |
| Han, KH | 11 |
| van der Lubbe, PA | 4 |
| Schouffoer, AA | 2 |
| Kerstens, PJ | 17 |
| Corluy, L | 2 |
| Joos, R | 2 |
| Langenaken, C | 2 |
| Taelman, V | 2 |
| Raeman, F | 2 |
| Ravelingien, I | 2 |
| Vandevyvere, K | 2 |
| Lenaerts, J | 2 |
| Geens, E | 2 |
| Geusens, P | 3 |
| Vanhoof, J | 2 |
| Durnez, A | 2 |
| Remans, J | 2 |
| Vander Cruyssen, B | 2 |
| Van Essche, E | 2 |
| Sileghem, A | 2 |
| De Brabanter, G | 2 |
| Meyfroidt, S | 2 |
| Onuora, S | 1 |
| Wevers-deBoer, KV | 1 |
| Schroeder, LL | 1 |
| Tang, X | 1 |
| Wasko, MC | 2 |
| Bili, A | 1 |
| Besada, E | 1 |
| Molenaar, ET | 1 |
| van Groenendael, JH | 6 |
| van der Goes, MC | 2 |
| van der Veen, MJ | 3 |
| Lieberman, MR | 1 |
| Liebman, TN | 1 |
| Alapati, U | 1 |
| Khachemoune, A | 1 |
| Schuler, S | 1 |
| Saag, K | 2 |
| Grahn, A | 2 |
| Storey, D | 1 |
| Rice, P | 3 |
| Zhang, Y | 1 |
| Zheng, L | 1 |
| Lv, J | 1 |
| Zhao, H | 1 |
| Haroldsen, C | 1 |
| de Jong, TD | 1 |
| Vosslamber, S | 1 |
| Blits, M | 1 |
| van der Laken, CJ | 1 |
| Jansen, G | 1 |
| Voskuyl, AE | 2 |
| Verweij, CL | 1 |
| Solomon, DH | 3 |
| Greenberg, J | 1 |
| Liu, M | 1 |
| Farkouh, ME | 1 |
| Tsao, P | 1 |
| Etzel, CJ | 1 |
| Hooper, MM | 1 |
| Shan, Y | 1 |
| Wenkert, D | 1 |
| Greenberg, JD | 2 |
| Almodovar-Real, A | 1 |
| López-Delgado, D | 1 |
| Diaz-Martinez, MA | 1 |
| Fernández-Pugnaire, MA | 1 |
| Holt, R | 1 |
| Kent, J | 1 |
| Roginić, S | 1 |
| Jelić, A | 1 |
| Stipić-Marković, A | 1 |
| Marinko, A | 1 |
| Artuković, IN | 1 |
| Dušanka, MK | 1 |
| Pal, R | 1 |
| Chaudhary, MJ | 1 |
| Tiwari, PC | 1 |
| Babu, S | 1 |
| Pant, KK | 1 |
| Chester Wasko, M | 1 |
| Dasgupta, A | 1 |
| Ilse Sears, G | 1 |
| Fries, JF | 10 |
| Kent, JD | 1 |
| Holt, RJ | 1 |
| Grahn, AY | 1 |
| Yazici, Y | 3 |
| Tan, CZ | 1 |
| Novoa, R | 1 |
| Chen, JK | 1 |
| Rhoades, AC | 1 |
| Vernau, W | 1 |
| Kass, PH | 1 |
| Herrera, MA | 1 |
| Sykes, JE | 1 |
| Katsuragi, T | 1 |
| Iwashige, A | 1 |
| Tsukada, J | 1 |
| Franzen, D | 1 |
| Ciurea, A | 1 |
| Bratton, DJ | 1 |
| Clarenbach, CF | 1 |
| Latshang, TD | 1 |
| Russi, EW | 1 |
| Kyburz, D | 1 |
| Kohler, M | 1 |
| Sauer, BC | 1 |
| Jorgenson, E | 1 |
| Davis, L | 1 |
| Nair, SC | 1 |
| Bakker, MF | 4 |
| Jahangier, ZN | 2 |
| Amoruso, A | 1 |
| Sola, D | 1 |
| Rossi, L | 1 |
| Obeng, JA | 1 |
| Fresu, LG | 1 |
| Sainaghi, PP | 1 |
| Pirisi, M | 1 |
| Brunelleschi, S | 1 |
| Dirven, L | 3 |
| Molenaar, TH | 1 |
| Le Cessie, S | 1 |
| Stijnen, T | 1 |
| Ten Wolde, S | 1 |
| Xie, F | 1 |
| Yun, H | 1 |
| Balasubramanian, A | 1 |
| Wade, SW | 1 |
| Adler, RA | 1 |
| Lin, CJF | 1 |
| Maricic, M | 1 |
| O'Malley, CD | 1 |
| Oude Voshaar, MA | 1 |
| Schenk, O | 1 |
| Ten Klooster, PM | 1 |
| Vonkeman, HE | 1 |
| Bernelot Moens, HJ | 1 |
| van de Laar, MA | 2 |
| Zamora-Legoff, JA | 1 |
| Krause, ML | 1 |
| Ryu, JH | 3 |
| Matteson, EL | 4 |
| Sawahata, M | 1 |
| Sigiyama, Y | 1 |
| Yamasawa, H | 1 |
| Miki, A | 1 |
| Muto, S | 1 |
| Bando, M | 1 |
| Paudyal, S | 1 |
| Yang, FM | 1 |
| Rice, C | 1 |
| Chen, CC | 1 |
| Skelton, M | 1 |
| Bethel, M | 1 |
| Brown, S | 1 |
| Nahman, NS | 1 |
| Carbone, L | 1 |
| Salt, E | 1 |
| Wiggins, AT | 1 |
| Rayens, MK | 1 |
| Morris, BJ | 1 |
| Mannino, D | 1 |
| Hoellein, A | 1 |
| Donegan, RP | 1 |
| Crofford, LJ | 2 |
| Boccardi, V | 1 |
| Croce, MF | 1 |
| Ruggiero, C | 1 |
| Aisa, G | 1 |
| Tosti, A | 1 |
| Mecocci, P | 1 |
| Johnson, J | 1 |
| Yeter, K | 1 |
| Rajbhandary, R | 2 |
| Neal, R | 1 |
| Tian, Q | 1 |
| Jian, J | 1 |
| Fadle, N | 1 |
| Thurner, L | 1 |
| Liu, C | 1 |
| Stohl, W | 1 |
| Eguia, HA | 1 |
| Parodi Garcia, JF | 1 |
| Ramas Diez, C | 1 |
| Eguia A, EA | 1 |
| Truffaut, S | 1 |
| Bigaillon, C | 1 |
| Leroy, P | 1 |
| Bialé, L | 1 |
| Glanowski, C | 1 |
| Imbert, I | 1 |
| Lechevalier, D | 1 |
| Banal, F | 1 |
| Cuppen, BV | 1 |
| Pardali, K | 1 |
| Kraan, MC | 1 |
| Marijnissen, AC | 1 |
| Yrlid, L | 1 |
| Olsson, M | 1 |
| Fritsch-Stork, RD | 1 |
| Korsten, P | 1 |
| Bahlmann, D | 1 |
| Patschan, SA | 1 |
| Vacas, AS | 1 |
| Torre, AC | 1 |
| Bollea-Garlatti, ML | 1 |
| Warley, F | 1 |
| Galimberti, RL | 1 |
| Golda, N | 1 |
| Feldman, M | 1 |
| van der Kooij, SM | 7 |
| Güler-Yüksel, M | 4 |
| Zwinderman, AH | 5 |
| de Beus, WM | 2 |
| Breedveld, FC | 12 |
| Dijkmans, BA | 19 |
| Puri, PK | 1 |
| Lountzis, NI | 1 |
| Tyler, W | 1 |
| Ferringer, T | 1 |
| Pou, MA | 1 |
| Diaz-Torne, C | 1 |
| Vidal, S | 1 |
| Corchero, C | 1 |
| Narvaez, J | 2 |
| Nolla, JM | 2 |
| Diaz-Lopez, C | 1 |
| Swearingen, CJ | 2 |
| Bergman, M | 1 |
| Khellaf, M | 1 |
| Godeau, B | 1 |
| Luta, G | 1 |
| Sokka, T | 3 |
| Egnatios, G | 1 |
| Warthan, MM | 1 |
| Pariser, R | 1 |
| Hood, AF | 1 |
| Ewals, JA | 3 |
| van Zeben, D | 7 |
| Tang, Y | 1 |
| Leclair, SJ | 1 |
| Scarano, FJ | 1 |
| Parambil, JG | 1 |
| Yi, ES | 1 |
| van den Hout, WB | 1 |
| Hulsmans, HM | 2 |
| de Jonge-Bok, JM | 2 |
| Hachicha, I | 1 |
| Sellami, M | 1 |
| Fourati, H | 1 |
| Akrout, R | 1 |
| Hdiji, N | 1 |
| Baklouti, S | 1 |
| Serra-Bonett, N | 1 |
| Al Snih, S | 1 |
| Rodriguez, MA | 1 |
| Tindall, E | 1 |
| Kavanaugh, A | 1 |
| Zheng, C | 1 |
| Bishai, W | 1 |
| Hochberg, MC | 2 |
| Coulson, KA | 1 |
| Gilliam, BE | 1 |
| Pepmueller, PH | 1 |
| Gaylis, NB | 1 |
| Needell, SD | 1 |
| Burgos, RA | 1 |
| Hancke, JL | 1 |
| Bertoglio, JC | 1 |
| Aguirre, V | 1 |
| Arriagada, S | 1 |
| Calvo, M | 1 |
| Cáceres, DD | 1 |
| Kaufman, I | 1 |
| Moscovici, YB | 1 |
| Abudi, Y | 1 |
| Sofer, D | 1 |
| Mendelson, E | 1 |
| Balbir-Gurman, A | 1 |
| Caspi, D | 3 |
| Elkayam, O | 2 |
| Naik, S | 1 |
| Amchentsev, A | 1 |
| Saleh, A | 1 |
| Goldbach-Mansky, R | 1 |
| Wilson, M | 1 |
| Fleischmann, R | 1 |
| Olsen, N | 1 |
| Silverfield, J | 1 |
| Kempf, P | 1 |
| Kivitz, A | 1 |
| Sherrer, Y | 1 |
| Pucino, F | 1 |
| Csako, G | 1 |
| Costello, R | 1 |
| Pham, TH | 1 |
| Snyder, C | 1 |
| Tao, X | 1 |
| Wesley, R | 1 |
| Lipsky, PE | 1 |
| Serefhanoglu, S | 1 |
| Tapan, U | 1 |
| Ertenli, I | 1 |
| Kalyoncu, U | 1 |
| Uner, A | 1 |
| Moreno, D | 1 |
| Martínez, P | 1 |
| Berbegal, J | 1 |
| Femenia, M | 1 |
| Bakewell, C | 1 |
| Dugowson, C | 1 |
| Ali Ou Alla, S | 1 |
| Allali, F | 1 |
| Hajjaj-Hassouni, N | 3 |
| Shovman, O | 1 |
| Anouk, M | 1 |
| Vinnitsky, N | 1 |
| Arad, U | 1 |
| Paran, D | 1 |
| Litinsky, I | 1 |
| de Man, YA | 1 |
| van der Heide, H | 1 |
| Willemsen, SP | 1 |
| de Groot, CJ | 1 |
| Steegers, EA | 1 |
| Adenis-Lamarre, E | 1 |
| Kostrzewa, E | 1 |
| Texier-Maugein, J | 1 |
| Doutre, MS | 1 |
| Szerszen, A | 1 |
| Gupta, S | 2 |
| Seminara, D | 1 |
| Jarrett, M | 1 |
| Hong, BK | 1 |
| Kumar, C | 1 |
| Marottoli, RA | 1 |
| Papanikolaou, IC | 1 |
| Sharma, OP | 1 |
| Kim, EJ | 1 |
| Elicker, BM | 1 |
| Maldonado, F | 1 |
| Webb, WR | 1 |
| Van Uden, JH | 1 |
| Lee, JS | 1 |
| King, TE | 1 |
| Collard, HR | 1 |
| Noda, S | 1 |
| Asano, Y | 2 |
| Tamaki, Z | 1 |
| Takekoshi, T | 1 |
| Sugaya, M | 2 |
| Sato, S | 2 |
| Spies, CM | 1 |
| Villaggio, B | 2 |
| Pizzorni, C | 1 |
| Paolino, S | 2 |
| Moretti, S | 1 |
| Gallo, F | 1 |
| Bonassi, S | 1 |
| Sulli, A | 3 |
| Seriolo, B | 3 |
| Montagna, P | 2 |
| Soldano, S | 1 |
| Hunt, LP | 1 |
| Perry, MG | 1 |
| Straub, RH | 1 |
| Jessop, DS | 1 |
| Todoerti, M | 2 |
| Boffini, N | 1 |
| Imrich, R | 2 |
| Vlcek, M | 2 |
| Aldag, JC | 1 |
| Kerlik, J | 2 |
| Radikova, Z | 2 |
| Rovensky, J | 2 |
| Vigas, M | 1 |
| Masi, AT | 1 |
| Penn, SK | 1 |
| Kao, AH | 1 |
| Schott, LL | 1 |
| Elliott, JR | 1 |
| Toledo, FG | 1 |
| Kuller, L | 1 |
| Manzi, S | 1 |
| Catananti, C | 1 |
| Mastropaolo, S | 1 |
| Calabrese, C | 1 |
| Silveri, MC | 1 |
| Onder, G | 1 |
| Klarenbeek, NB | 5 |
| Huizinga, TJ | 1 |
| van Krugten, MV | 3 |
| Lin, H | 1 |
| Xiao, Y | 1 |
| Chen, G | 1 |
| Fu, D | 1 |
| Ye, Y | 1 |
| Liang, L | 1 |
| Fan, J | 1 |
| Yang, X | 1 |
| Sun, L | 1 |
| Xu, H | 2 |
| Gerards, AH | 4 |
| Seys, PE | 3 |
| Bonnet, N | 1 |
| Guis, S | 1 |
| Drancourt, M | 1 |
| Brouqui, P | 1 |
| Berbis, P | 1 |
| Doering, G | 2 |
| Witte, S | 4 |
| Sierakowski, S | 2 |
| Gromnica-Ihle, E | 3 |
| Krueger, K | 2 |
| Szechinski, J | 3 |
| Cavagna, L | 2 |
| Sepe, V | 1 |
| Bobbio-Pallavicini, F | 1 |
| Mangione, F | 1 |
| Gifre, L | 1 |
| Xaubet, A | 1 |
| Gómez-Puerta, JA | 1 |
| Kopec-Medrek, M | 2 |
| Widuchowska, M | 2 |
| Kotulska, A | 2 |
| Zycinska-Dębska, E | 1 |
| Kucharz, EJ | 2 |
| Sen, D | 1 |
| Carlino, A | 1 |
| Anderson, RJ | 2 |
| Schur, PH | 3 |
| Panush, RS | 2 |
| Döring, G | 1 |
| Straub, R | 1 |
| Kumar, D | 1 |
| Bouldin, TW | 1 |
| Berger, RG | 1 |
| Shmerling, RH | 1 |
| Housden, MM | 1 |
| Bell, G | 1 |
| Heycock, CR | 1 |
| Hamilton, J | 1 |
| Saravanan, V | 1 |
| Kelly, CA | 1 |
| Raza, SH | 1 |
| Pattanaik, D | 1 |
| Egerman, RS | 1 |
| El-Barbary, AM | 1 |
| Hussein, MS | 1 |
| Rageh, EM | 1 |
| Hamouda, HE | 1 |
| Wagih, AA | 1 |
| Ismail, RG | 1 |
| Rushing, EC | 1 |
| Hoschar, AP | 1 |
| McDonnell, JK | 1 |
| Billings, SD | 1 |
| Pawłowska, J | 1 |
| Smoleńska, Z | 1 |
| Daca, A | 1 |
| Witkowski, JM | 1 |
| Bryl, E | 1 |
| Taniguchi, T | 1 |
| Okada, A | 1 |
| Mendonça, JA | 1 |
| Marques-Neto, JF | 1 |
| Samara, AM | 1 |
| Appenzeller, S | 1 |
| Baccouche, K | 1 |
| Sellam, J | 1 |
| Guegan, S | 1 |
| Aractingi, S | 1 |
| Berenbaum, F | 1 |
| Nilsson, AC | 1 |
| Christensen, AF | 1 |
| Junker, P | 2 |
| Lindegaard, HM | 1 |
| Benbouazza, K | 2 |
| Rkain, H | 2 |
| Benchekroun, B | 2 |
| Amine, B | 2 |
| Bzami, F | 2 |
| Benbrahim, L | 2 |
| Atouf, O | 2 |
| Essakalli, M | 2 |
| Abouqal, R | 2 |
| Salesi, M | 1 |
| Farajzadegan, Z | 1 |
| Stephenson, SR | 1 |
| Campbell, SM | 1 |
| Drew, GS | 1 |
| Magro, CM | 1 |
| Roger, L | 3 |
| Pinto Valdivia, M | 1 |
| Ortiz Torres, M | 1 |
| Villena Chávez, J | 1 |
| Huys, AC | 1 |
| Guerne, PA | 1 |
| Horvath, J | 1 |
| Ezzedine, K | 1 |
| Belin, E | 1 |
| Guillet, S | 1 |
| D'Almeida, M | 1 |
| Droitcourt, C | 1 |
| Accocebery, I | 1 |
| Milpied, B | 1 |
| Jouary, T | 1 |
| Malvy, D | 1 |
| Taieb, A | 1 |
| Adamczak, M | 1 |
| Więcek, A | 1 |
| Hodkinson, B | 1 |
| Musenge, E | 1 |
| Ally, M | 1 |
| Meyer, PW | 1 |
| Anderson, R | 1 |
| Tikly, M | 1 |
| Du Pan, SM | 1 |
| Scherer, A | 1 |
| Finckh, A | 1 |
| Verstappen, SM | 2 |
| Ton, E | 1 |
| Geurts, MA | 1 |
| van der Werf, JH | 2 |
| van Albada-Kuipers, GA | 1 |
| Jahangier-de Veen, ZN | 1 |
| Verhoef, CM | 1 |
| McKeown, E | 1 |
| Bykerk, VP | 1 |
| De Leon, F | 1 |
| Bonner, A | 1 |
| Thorne, C | 1 |
| Hitchon, CA | 1 |
| Boire, G | 1 |
| Haraoui, B | 3 |
| Ferland, DS | 1 |
| Keystone, EC | 2 |
| Mehta, D | 1 |
| Alten, RE | 1 |
| Supronik, J | 1 |
| Szombati, I | 1 |
| Romer, U | 1 |
| Saag, KG | 3 |
| Fan, H | 1 |
| Yang, M | 1 |
| Che, X | 1 |
| Zhang, Z | 1 |
| Liu, K | 1 |
| Meng, Q | 1 |
| McGhie, T | 1 |
| Fader, R | 1 |
| Carpenter, J | 1 |
| Brown-Elliott, BA | 1 |
| Vasireddy, R | 1 |
| Wallace, RJ | 1 |
| Sokumbi, O | 1 |
| Wetter, DA | 1 |
| Warrington, KJ | 1 |
| Geenen, R | 1 |
| Bossema, ER | 1 |
| van Albada-Kuipers, IA | 1 |
| Ehrlich, JC | 1 |
| Castrejon, I | 3 |
| Protogerou, AD | 1 |
| Zampeli, E | 1 |
| Sfikakis, PP | 1 |
| Quax, RA | 1 |
| Koper, JW | 1 |
| de Jong, PH | 1 |
| van Heerebeek, R | 1 |
| Weel, AE | 1 |
| Huisman, AM | 1 |
| de Jong, FH | 1 |
| Lamberts, SW | 1 |
| Feelders, RA | 1 |
| Carter, JD | 1 |
| Zarabadi, SA | 1 |
| Ricca, LR | 1 |
| McNeil, A | 1 |
| Valeriano-Marcet, J | 1 |
| Vasey, FB | 2 |
| Sebba, AI | 1 |
| van den Broek, M | 1 |
| Kroon, HM | 1 |
| Seymour, MW | 1 |
| Kelly, S | 1 |
| Beals, CR | 1 |
| Malice, MP | 1 |
| Bolognese, JA | 1 |
| Dardzinski, BJ | 1 |
| Cheng, AS | 1 |
| Cummings, CE | 1 |
| Smugar, SS | 1 |
| McClinton, C | 1 |
| Fox, A | 1 |
| Dooley, WM | 1 |
| Pitzalis, C | 1 |
| Taylor, PC | 1 |
| Penesová, A | 1 |
| Lukáč, J | 1 |
| Pfeiffer, BM | 1 |
| Krenzer, S | 1 |
| Dockhorn, R | 1 |
| Schwenke, R | 1 |
| Schwenke, H | 1 |
| Waehrisch, J | 1 |
| Kraus, E | 1 |
| Lai, WS | 1 |
| Wang, CH | 1 |
| Shih, CP | 1 |
| Filippatos, TD | 1 |
| Derdemezis, CS | 1 |
| Tsimihodimos, V | 1 |
| Elisaf, MS | 1 |
| Tselepis, AD | 3 |
| Younis, S | 1 |
| Rosner, I | 2 |
| Rimar, D | 2 |
| Boulman, N | 2 |
| Rozenbaum, M | 2 |
| Odeh, M | 1 |
| Slobodin, G | 2 |
| Schrenk, KG | 1 |
| Krokowski, M | 1 |
| Feller, AC | 1 |
| Bernhard, V | 1 |
| Mügge, LO | 1 |
| Hochhaus, A | 1 |
| Neumann, T | 1 |
| Langen, ES | 1 |
| Chakravarty, EF | 2 |
| Liaquat, M | 1 |
| El-Sayed, YY | 1 |
| Druzin, ML | 1 |
| Shay, K | 1 |
| Kent, PD | 1 |
| Davis, MD | 1 |
| Fabris, M | 1 |
| Tolusso, B | 1 |
| Di Poi, E | 1 |
| Assaloni, R | 1 |
| Sinigaglia, L | 1 |
| Ferraccioli, G | 1 |
| Wolfe, F | 8 |
| Apple, R | 1 |
| Erlich, H | 1 |
| Bugawan, T | 1 |
| Holmes, T | 1 |
| Bruce, B | 1 |
| Bergholm, R | 1 |
| Leirisalo-Repo, M | 1 |
| Vehkavaara, S | 1 |
| Mäkimattila, S | 1 |
| Taskinen, MR | 1 |
| Yki-Järvinen, H | 1 |
| Lim, SS | 2 |
| Trethewey, P | 1 |
| Katz, JN | 2 |
| Jacobs, JP | 1 |
| La Tourette, AM | 1 |
| Coblyn, J | 1 |
| Gotzsche, PC | 2 |
| Johansen, HK | 2 |
| Markowitz, GS | 1 |
| Falkowitz, DC | 1 |
| Isom, R | 1 |
| Zaki, M | 1 |
| Imaizumi, S | 1 |
| Appel, GB | 1 |
| D'Agati, VD | 1 |
| Valleala, H | 1 |
| Mandelin, J | 1 |
| Laasonen, L | 1 |
| Koivula, MK | 1 |
| Risteli, J | 1 |
| Konttinen, YT | 1 |
| DEMARTINI, F | 1 |
| BOOTS, RH | 1 |
| SNYDER, AI | 1 |
| SANDSON, J | 1 |
| RAGAN, C | 1 |
| ROBECCHI, A | 2 |
| DANEO, V | 1 |
| MARRAZZI, G | 1 |
| VILLA, L | 1 |
| BALLABIO, CB | 1 |
| SALA, G | 1 |
| WARD, LE | 2 |
| HENCH, PS | 2 |
| BICKEL, G | 1 |
| SPIES, TD | 2 |
| STONE, RE | 2 |
| GARCIA LOPEZ, G | 1 |
| DIAZ TELLECHEA, CM | 1 |
| LOPEZ TOCA, R | 1 |
| REBOREDO, A | 1 |
| SUAREZ, RM | 1 |
| HART, FD | 3 |
| CLARK, CJ | 1 |
| GOLDING, JR | 1 |
| COHEN, A | 2 |
| TURNER, R | 1 |
| DUNSMORE, R | 1 |
| WYDLER-BAUMANN, A | 2 |
| RUIZ MORENO, A | 2 |
| BOLAND, EW | 6 |
| NEUSTADT, DH | 3 |
| MCCLENDON, R | 1 |
| OLASH, FA | 1 |
| BEST, M | 1 |
| TANCA MARENGO, J | 1 |
| ROSEN, PS | 1 |
| CARTER, AJ | 1 |
| DAUPHINEE, JA | 1 |
| GORNALL, AG | 1 |
| OGRYZLO, MA | 1 |
| KRECH, S | 1 |
| FENTRESS, V | 1 |
| FIRNSCHILD, P | 1 |
| REVENO, WS | 1 |
| MORGANO, G | 1 |
| DE CARLO, M | 1 |
| KUIPERS, RK | 4 |
| LAYANI, F | 1 |
| SENECA, H | 1 |
| LUCHERINI, T | 1 |
| NATALE, P | 1 |
| HANDRICK, HG | 2 |
| TARNOPOLSKY, S | 2 |
| PALLUCCHINI, M | 2 |
| GAYOTTO, F | 2 |
| NEBO, F | 6 |
| SPILBORGHS, G | 3 |
| Cayla, J | 2 |
| GJORUP, S | 5 |
| KILLMANN, SA | 2 |
| THAYSEN, JH | 5 |
| DE MATTEIS, F | 1 |
| SALOMONE, P | 1 |
| HELM, HH | 1 |
| HELM, H | 1 |
| GAULIER, R | 3 |
| CASS, LJ | 1 |
| FREDERIK, WS | 1 |
| DAIUTE, E | 1 |
| SCHERBEL, AL | 1 |
| BLACK, RL | 2 |
| YIELDING, KL | 1 |
| BUNIM, JJ | 2 |
| DAVISON, S | 2 |
| LARSEN, B | 1 |
| BENT-HANSEN, K | 1 |
| FRANCON, F | 1 |
| FRANCON, J | 1 |
| FINCH, CP | 1 |
| BONOMO, L | 2 |
| DORDICK, JR | 1 |
| GAMP, A | 4 |
| MOUZAS, GL | 1 |
| BRIGGS, JH | 1 |
| BOSCH, SJ | 2 |
| MITCHELL, H | 1 |
| PLATT, WD | 1 |
| STEINBERG, IH | 1 |
| BRANDT, H | 1 |
| NOAH, JW | 1 |
| BRAND, A | 1 |
| STOLZER, BL | 2 |
| BARR, JH | 2 |
| EISENBEIS, CH | 2 |
| WECHSLER, RL | 1 |
| MARGOLIS, HM | 2 |
| TURNER, RF | 1 |
| KANENSON, WL | 1 |
| GOLDMAN, J | 1 |
| DZIUBA, K | 1 |
| PAYNE, RW | 1 |
| SHETLAR, MR | 1 |
| HELLBAUM, AA | 1 |
| ISHMAEL, WK | 1 |
| SCHOEN, R | 2 |
| KRUSKEMPER, H | 2 |
| FRITZE, E | 1 |
| LAINE, V | 1 |
| SARIOLA, O | 1 |
| AHOLA, E | 1 |
| FEARNLEY, GR | 2 |
| BALMFORTH, GV | 1 |
| BLATCHLEY, R | 1 |
| SCHULTZE, H | 1 |
| HIRSCH, F | 1 |
| VERHULST, C | 1 |
| GEBALA, A | 1 |
| BARCELO, P | 3 |
| SANTAMARIA, A | 2 |
| SANSSOLA, L | 1 |
| MONTGOMERY, DA | 1 |
| HILBISH, TF | 1 |
| NASHELSKY, GM | 1 |
| SMYTH, CJ | 4 |
| MIZRAJI, M | 1 |
| CRESPO, DI | 1 |
| KOSSMANN, F | 1 |
| BROGLIE, M | 1 |
| BERG, EG | 1 |
| VOSS, G | 1 |
| EDGCOMB, JH | 1 |
| POLLEY, HF | 1 |
| POWER, MH | 1 |
| MASON, HL | 1 |
| SLOCUMB, CH | 1 |
| BARCZYK, W | 1 |
| ROTH, G | 1 |
| PELLET, AC | 1 |
| GEDDA, PO | 1 |
| MORITZ, U | 2 |
| TRAUT, EF | 1 |
| NUNES, CV | 1 |
| BROCHNER-MORTENSEN, K | 3 |
| McMAHON, M | 1 |
| MOLERES FERRANDIS, R | 1 |
| JOHNSON, RL | 1 |
| CLARK, GM | 1 |
| PIGUET, B | 1 |
| HARNAGEL, EE | 1 |
| MIEHLKE, K | 1 |
| THURIGEN, G | 1 |
| GIORDANO, M | 2 |
| ARA, M | 1 |
| TIRRI, G | 1 |
| KIRPILA, J | 1 |
| RIPATTI, N | 1 |
| KRAUS, KA | 1 |
| KOLL, JF | 1 |
| MATTHAEI, R | 1 |
| KLAES, H | 1 |
| FISHER, S | 1 |
| RANKIN, TJ | 1 |
| MARKHAM, S | 1 |
| JANKOWIAK, J | 1 |
| HASIK, J | 1 |
| KUJAWA, H | 1 |
| JELIASZEWICZ, J | 1 |
| SERRA PERALBA, A | 1 |
| OBACH BENA CH, J | 1 |
| SCHUSTER, E | 1 |
| GORDILLO, H | 1 |
| SAFFIE, F | 1 |
| BAHAMONDE, M | 1 |
| RIPA, R | 1 |
| SALVATORI TORRES, F | 1 |
| BOYE NIELSEN, J | 1 |
| DRIVSHOLM, A | 1 |
| FISCHER, F | 1 |
| COKE, H | 1 |
| KJELDSEN, K | 1 |
| HEMPEL-JORGENSEN, P | 1 |
| CONTRERAS, V | 1 |
| MUNOZ, A | 1 |
| LITVAK, J | 1 |
| JUENEMANN, C | 1 |
| PERALES, J | 2 |
| FIGUEROA, L | 2 |
| BARWIK-SCHRAM, A | 1 |
| SOKOLOWSKI, A | 1 |
| DIECKHOFF, J | 1 |
| SUNDMARK, E | 1 |
| YATES, DA | 2 |
| HEATHER, AJ | 1 |
| ARCANGELI, P | 1 |
| CORRADI, F | 1 |
| D AYALAVALVA, G | 1 |
| ROBINSON, HS | 1 |
| RUGGIERO, HA | 1 |
| ELIAS, H | 2 |
| ROTHSTEIN, A | 1 |
| GASCON, J | 2 |
| DIMATTEI, P | 1 |
| LUND, H | 1 |
| HILEMAN, WT | 1 |
| LABRAM, C | 1 |
| FOURNIE, A | 1 |
| CHAKRABARTI, R | 2 |
| HOCKING, ED | 2 |
| CARNEIRO, RA | 1 |
| FOWLER, WM | 1 |
| PEARSON, CM | 2 |
| FRANDSEN, E | 1 |
| SIEGENTHALER, W | 1 |
| SIEGENTHALER, G | 1 |
| BONER, A | 1 |
| SADIKARIO, A | 1 |
| MLADENOVSKI, B | 1 |
| KATONA, G | 1 |
| ROBLESGIL, J | 1 |
| HOLLEY, HL | 1 |
| HOGAN, RS | 1 |
| SILTZBACH, LE | 1 |
| SOKOLOVA-PONOMAREVA, OD | 1 |
| IAKOVLEVA, AA | 1 |
| IVANOVA, ED | 1 |
| FREYBERG, RH | 1 |
| EHRLICH, G | 1 |
| BIENENSTOCK, H | 1 |
| LITWIN, SD | 1 |
| LISTER, J | 1 |
| ROTSTEIN, J | 1 |
| GARRACHONAGUADO, J | 1 |
| RIVAS, R | 1 |
| VALLE, E | 1 |
| PIKIELNY, R | 1 |
| GARCIAMORTEO, O | 1 |
| FORESTIER, J | 1 |
| CERTONCINY, A | 1 |
| WILSON, H | 1 |
| SCHENKER, S | 2 |
| ROTHERMICH, NO | 1 |
| EVAIN, P | 1 |
| SERRE, H | 1 |
| SIMON, L | 2 |
| BARJON, MC | 1 |
| CAILLENS, JP | 1 |
| KENDALL, PH | 1 |
| SAUER, H | 1 |
| RAUSCH-STROOMANN, JG | 2 |
| MATHIES, H | 2 |
| HEINSIUS, M | 1 |
| RASPE, J | 1 |
| MICHOTTE, LJ | 1 |
| WAUTERS, M | 1 |
| TUBBS, OS | 1 |
| SLADE, PR | 1 |
| TURNER-WARWICK, M | 1 |
| HOEFER, W | 1 |
| FEARNLFY, GR | 1 |
| EMMRICH, R | 2 |
| ALKAN, WJ | 1 |
| LEWINSOHN, G | 1 |
| SWEETNAM, R | 1 |
| SCOTT, JT | 3 |
| TAUBNER, A | 1 |
| ROSEMAN, DL | 1 |
| ECONOMOU, SG | 1 |
| PALLIS, CA | 1 |
| GJEDDEBAEK, N | 1 |
| GRAUDAL, H | 1 |
| STOREY, G | 1 |
| BYWATERS, EG | 2 |
| RAO, SR | 1 |
| REDDY, BJ | 1 |
| ATWATER, EC | 1 |
| MONGAN, ES | 1 |
| WIECHE, DR | 1 |
| JACOX, RF | 1 |
| GRAY, JW | 1 |
| MERRICK, EZ | 1 |
| MARTZ, EW | 1 |
| BOLLET, AJ | 1 |
| BLACK, R | 1 |
| SPIES, HA | 1 |
| JUNEMANN, C | 1 |
| Frediani, B | 1 |
| Falsetti, P | 1 |
| Baldi, F | 1 |
| Acciai, C | 1 |
| Filippou, G | 1 |
| Marcolongo, R | 1 |
| Chung, CP | 1 |
| Russell, AS | 3 |
| Segami, MI | 1 |
| Ugarte, CA | 1 |
| Birlik, M | 2 |
| Akar, S | 2 |
| Onen, F | 2 |
| Ozcan, MA | 1 |
| Bacakoglu, A | 1 |
| Ozkal, S | 1 |
| Manisali, M | 1 |
| Akkoc, N | 2 |
| de Klerk, E | 2 |
| Landewé, R | 1 |
| van der Tempel, H | 1 |
| van der Linden, S | 1 |
| Guarnieri, MV | 1 |
| Rosenberg, L | 1 |
| Scheinberg, MA | 1 |
| Denko, CW | 1 |
| Malemud, CJ | 1 |
| Houtman, PM | 1 |
| van Everdingen, AA | 3 |
| Siewertsz van Reesema, DR | 2 |
| Dessein, PH | 1 |
| Joffe, BI | 1 |
| Stanwix, AE | 1 |
| Christian, BF | 1 |
| Veller, M | 1 |
| Marinella, MA | 1 |
| Arend, SM | 1 |
| Kuijper, EJ | 1 |
| Muller, WH | 2 |
| Van Dissel, JT | 1 |
| Arunkumar, P | 1 |
| Crook, T | 1 |
| Ballard, J | 1 |
| Habib, GS | 1 |
| Haj, S | 1 |
| Krishnan, E | 1 |
| Lingala, VB | 1 |
| Singh, G | 2 |
| Suponitskaia, EV | 1 |
| Smirnov, AV | 1 |
| Aleksandrova, EN | 1 |
| Novikov, AA | 1 |
| Nasonov, EL | 1 |
| Bremner, R | 1 |
| Simpson, E | 1 |
| White, CR | 1 |
| Morrison, L | 1 |
| Deodhar, A | 1 |
| Horton, MR | 1 |
| Hoshina, D | 1 |
| Shimizu, T | 1 |
| Abe, R | 1 |
| Murata, J | 1 |
| Tanaka, K | 1 |
| Shimizu, H | 2 |
| Fransen, J | 1 |
| Moens, HB | 1 |
| van Riel, PL | 7 |
| Kreuter, A | 1 |
| Rose, C | 1 |
| Zillikens, D | 1 |
| Altmeyer, P | 1 |
| Thaunat, O | 1 |
| Aaron, L | 1 |
| Desbene, C | 1 |
| Noël, LH | 1 |
| Karras, A | 1 |
| Lesavre, P | 1 |
| Alyanakian, MA | 1 |
| Fakhouri, F | 1 |
| Patiar, S | 1 |
| Ramsden, JD | 1 |
| Freeland, AP | 1 |
| Feldstein, AC | 1 |
| Elmer, PJ | 1 |
| Nichols, GA | 1 |
| Herson, M | 1 |
| Allan, JS | 1 |
| Donahue, DM | 1 |
| Garrity, JM | 1 |
| Anandacoomarasamy, A | 1 |
| Kannangara, S | 1 |
| Barnsley, L | 1 |
| Westedt, ML | 3 |
| Katikireddy, CK | 1 |
| Krishna, G | 1 |
| Berry, G | 1 |
| Faul, J | 1 |
| Kuschner, W | 1 |
| Ríos, G | 1 |
| Mitka, M | 1 |
| Lodder, MC | 1 |
| Lips, P | 1 |
| Schrameijer, N | 1 |
| van de Ven, CM | 1 |
| Yamauchi, PS | 1 |
| Turner, L | 1 |
| Lowe, NJ | 1 |
| Gindi, V | 1 |
| Jackson, JM | 1 |
| Acero, J | 1 |
| Navarro-Cuellar, C | 1 |
| Menarguez, J | 1 |
| Herencia, H | 1 |
| Navarro-Vila, C | 1 |
| Avery, JK | 1 |
| Aubin, F | 1 |
| Montecucco, CM | 1 |
| Capellino, S | 1 |
| Fazzuoli, L | 1 |
| Georgiadis, AN | 2 |
| Papavasiliou, EC | 1 |
| Lourida, ES | 1 |
| Alamanos, Y | 2 |
| Kostara, C | 1 |
| Ezell, J | 1 |
| Pawlik, A | 1 |
| Czerny, B | 1 |
| Dabrowska-Zamojcin, E | 1 |
| Górnik, W | 1 |
| Poziomkowska, I | 1 |
| Gawrońska-Szklarz, B | 1 |
| Herczyńska, M | 1 |
| San Miguel-Fraile, P | 1 |
| Vasallo, FJ | 1 |
| Rodríguez-Conde, I | 1 |
| Ortiz-Rey, JA | 1 |
| Shakiba, K | 1 |
| Falcone, T | 1 |
| Sari, I | 1 |
| Sis, B | 1 |
| Ferretti, V | 1 |
| Zisman, D | 1 |
| Eder, L | 1 |
| Feld, J | 1 |
| Montano-Loza, A | 1 |
| Czaja, AJ | 1 |
| Carpenter, HA | 1 |
| Piette, A | 1 |
| Murphy, D | 1 |
| Shums, Z | 1 |
| Burlingame, R | 1 |
| Norman, GL | 1 |
| Asada, Y | 1 |
| Isomoto, H | 1 |
| Shikuwa, S | 1 |
| Wen, CY | 1 |
| Fukuda, E | 1 |
| Miyazato, M | 1 |
| Okamoto, K | 1 |
| Nakamura, T | 1 |
| Nishiyama, H | 1 |
| Mizuta, Y | 1 |
| Migita, K | 1 |
| Ito, M | 1 |
| Kohno, S | 1 |
| Ahmed, M | 1 |
| Luggen, M | 1 |
| Herman, JH | 1 |
| Weiss, KL | 1 |
| Decourten-Myers, G | 1 |
| Quinlan, JG | 1 |
| Khanna, D | 1 |
| Cabral, D | 1 |
| Patrick, AR | 1 |
| Bukowski, JF | 1 |
| Coblyn, JS | 4 |
| Reitman, CA | 1 |
| Lidsky, MD | 2 |
| Heggeness, MH | 1 |
| Guzman-Clark, JR | 1 |
| Fang, MA | 1 |
| Sehl, ME | 1 |
| Traylor, L | 1 |
| Hahn, TJ | 2 |
| Tłustochowicz, W | 1 |
| Peters, MJ | 1 |
| Vis, M | 1 |
| van Halm, VP | 1 |
| Wolbink, GJ | 1 |
| Twisk, JW | 1 |
| de Koning, MH | 1 |
| van de Stadt, RJ | 1 |
| Mallée, C | 1 |
| Basoglu, A | 1 |
| Celik, B | 1 |
| Yetim, TD | 1 |
| Starosta, MA | 1 |
| Brandwein, SR | 1 |
| de Jager, MH | 1 |
| Fiehn, C | 1 |
| Jacki, S | 1 |
| Heilig, B | 1 |
| Lampe, M | 1 |
| Wiesmüller, G | 1 |
| Richter, C | 1 |
| Röther, E | 1 |
| Rochel, E | 1 |
| Gao, I | 1 |
| Chuang, E | 1 |
| Molitch, ME | 1 |
| Mohyuddin, T | 1 |
| Elyan, M | 1 |
| Kushner, I | 1 |
| Krishnamurthy, R | 1 |
| Dincer, HE | 1 |
| Whittemore, D | 1 |
| Wittig, Ch | 1 |
| Sanchez, E | 1 |
| Shirahama, J | 1 |
| Rüdt, R | 1 |
| van Ede, A | 1 |
| den Broeder, A | 1 |
| Wagenaar, M | 1 |
| van Riel, P | 1 |
| Creemers, MC | 1 |
| Swaneveld, FH | 1 |
| van Vugt, RM | 1 |
| de Boer, JP | 1 |
| Miranda, LA | 1 |
| Islabão, AG | 1 |
| Fischer, RG | 1 |
| Figueredo, CM | 1 |
| Oppermann, RV | 1 |
| Gustafsson, A | 1 |
| Wu, QF | 1 |
| Feng, XH | 1 |
| Zhang, JH | 1 |
| Wang, JP | 1 |
| Wang, HJ | 1 |
| Raczkiewicz-Papierska, A | 1 |
| Dudek, A | 1 |
| Bachta, A | 1 |
| Tłustochowicz, M | 1 |
| Zawadyl, B | 1 |
| Sułek, M | 1 |
| Liu, W | 1 |
| Liu, XY | 1 |
| Gill, JB | 1 |
| Brown, ES | 1 |
| Woolston, DJ | 1 |
| Frol, AB | 1 |
| Puéchal, X | 1 |
| Miceli-Richard, C | 1 |
| Mejjad, O | 1 |
| Lafforgue, P | 1 |
| Marcelli, C | 1 |
| Steinfeld, S | 1 |
| Villoutreix, C | 1 |
| Trèves, R | 2 |
| Mariette, X | 1 |
| Guillevin, L | 1 |
| Di Comite, G | 1 |
| Rossi, CM | 1 |
| Gadadhar, H | 1 |
| Hawkins, S | 1 |
| Huffstutter, JE | 1 |
| Panda, M | 1 |
| Argyropoulou, MI | 1 |
| Elisaf, M | 1 |
| Liu, XW | 1 |
| Zha, QL | 1 |
| He, YT | 1 |
| Coluccia, D | 1 |
| Wolf, OT | 1 |
| Kollias, S | 1 |
| Roozendaal, B | 1 |
| Forster, A | 1 |
| de Quervain, DJ | 1 |
| Vujasinovic-Stupar, N | 1 |
| Pejnovic, N | 1 |
| Markovic, O | 1 |
| Babic, G | 1 |
| Wijbrandts, CA | 1 |
| Klaasen, R | 1 |
| Dijkgraaf, MG | 1 |
| Gerlag, DM | 1 |
| van Eck-Smit, BL | 1 |
| Tak, PP | 1 |
| Belloli, L | 1 |
| Massarotti, M | 1 |
| Marasini, B | 1 |
| Moosbrugger, EA | 1 |
| Adams, BB | 1 |
| Kralovic, SM | 1 |
| Yackel, DB | 1 |
| Kempers, RD | 1 |
| McConahey, WM | 1 |
| Kantor, TG | 1 |
| Agus, H | 1 |
| Estrin, J | 1 |
| Duncan, H | 3 |
| McCarthy, JT | 1 |
| Torre, DP | 1 |
| Miller, JL | 1 |
| Sachs, P | 1 |
| Borman, MC | 1 |
| Pittelkow, RB | 1 |
| Lefebvre, J | 1 |
| Lerique, J | 1 |
| Chaumont, P | 1 |
| Hamonet, C | 1 |
| Bigot, B | 1 |
| Propp, RP | 1 |
| Stillman, JS | 1 |
| Neighbour, PA | 2 |
| Grayzel, AI | 2 |
| Miller, AE | 1 |
| Strober, S | 2 |
| Field, EM | 1 |
| Kotzin, BL | 2 |
| Hoppe, RT | 2 |
| Engleman, EC | 1 |
| Tanay, AS | 1 |
| Kaplan, HS | 2 |
| Ayulo, M | 1 |
| Aisner, SC | 1 |
| Margolis, K | 1 |
| Moravec, C | 1 |
| Depper, JM | 1 |
| Zvaifler, NJ | 1 |
| Bluestein, HG | 1 |
| Massey, EW | 1 |
| Mercado, U | 1 |
| Lockie, LM | 1 |
| Gomez, E | 1 |
| Smith, DM | 1 |
| Harris, ED | 3 |
| Emkey, RD | 2 |
| Nichols, JE | 1 |
| Newberg, A | 1 |
| Imbimbo, B | 3 |
| Tuzi, T | 1 |
| Porzio, F | 1 |
| Schiavetti, L | 1 |
| Zerwekh, JE | 1 |
| Bluestone, R | 4 |
| Engleman, EG | 1 |
| Calin, A | 1 |
| Kansas, GS | 1 |
| Terrell, CP | 1 |
| Als, OS | 1 |
| Christiansen, C | 1 |
| Hellesen, C | 1 |
| Mohan, M | 1 |
| Panda, A | 1 |
| Pattnaik, NK | 1 |
| Dada, VK | 1 |
| Stelling, CB | 1 |
| Keats, TE | 1 |
| Blum, M | 1 |
| Liron, M | 1 |
| Aviram, A | 1 |
| Drozd, C | 1 |
| Brahn, E | 1 |
| Helfgott, SM | 1 |
| Belli, JA | 1 |
| Reinherz, EL | 1 |
| Schlossman, SF | 1 |
| Austen, KF | 2 |
| Trentham, DE | 2 |
| Ward, JR | 1 |
| Clegg, DO | 2 |
| Samuelson, CO | 1 |
| Abbott, TM | 1 |
| Mautalen, C | 1 |
| Casco, C | 1 |
| González, D | 1 |
| Fromm, G | 1 |
| Romanowicz, A | 1 |
| Hofman, J | 1 |
| Di Giorgio, E | 1 |
| Maccagno, A | 1 |
| Viara, M | 1 |
| Benvenuti, C | 1 |
| Longoni, A | 1 |
| Gobernado, JM | 1 |
| Leiva, C | 1 |
| Rábano, J | 1 |
| Alvarez-Cermeño, JC | 1 |
| Fernández-Molina, A | 1 |
| McGuire, MJ | 1 |
| Ettinger, WH | 1 |
| Kickler, TS | 1 |
| Stevens, MB | 3 |
| Schlumpf, U | 1 |
| Bussmann, HU | 1 |
| Jerusalem, F | 1 |
| Persellin, RH | 1 |
| Cheng, CT | 1 |
| Goodman, BW | 1 |
| Shepard, FA | 1 |
| Pagonis, CP | 1 |
| Weinblatt, M | 1 |
| Holdsworth, D | 1 |
| Glass, D | 1 |
| Bernstein, ML | 1 |
| Winkelstein, A | 1 |
| Dobson, SA | 1 |
| Maggiolo, P | 1 |
| Pfau, J | 1 |
| Klinger, J | 1 |
| Harrist, TJ | 1 |
| Mihm, MC | 1 |
| Figueroa, JE | 1 |
| Waxman, J | 2 |
| Zinn, WM | 1 |
| Nehru, R | 1 |
| Barr, CC | 1 |
| Davis, H | 1 |
| Culbertson, WW | 1 |
| Gottlieb, NL | 2 |
| Penneys, NS | 1 |
| Hess, EV | 2 |
| Kammen, PL | 1 |
| Lane, NE | 1 |
| Mroczkowski, PJ | 1 |
| Dubois, T | 1 |
| Bisagni-Faure, A | 1 |
| Coste, J | 1 |
| Mavoungou, E | 1 |
| Menkes, CJ | 1 |
| Russo-Marie, F | 1 |
| Rothhut, B | 1 |
| Palmer, WE | 2 |
| Rosenthal, DI | 1 |
| Schoenberg, OI | 2 |
| Fischman, AJ | 1 |
| Simon, LS | 2 |
| Rubin, RH | 1 |
| Polisson, RP | 2 |
| Buckley, LM | 3 |
| Leib, ES | 3 |
| Cartularo, KS | 3 |
| Vacek, PM | 3 |
| Cooper, SM | 4 |
| Kaplan, S | 1 |
| McDonald, E | 1 |
| Marino, C | 1 |
| Petrillo, GF | 1 |
| Hamilton, RA | 1 |
| Zheng, LM | 1 |
| Wang, JZ | 1 |
| Markusse, HM | 2 |
| Hilkens, PH | 1 |
| van den Bent, MJ | 1 |
| Vecht, CJ | 1 |
| Fischman, A | 1 |
| Rubin, R | 1 |
| Rosenthal, D | 1 |
| van Gestel, AM | 1 |
| Laan, RF | 5 |
| Haagsma, CJ | 1 |
| van de Putte, LB | 5 |
| West, SG | 2 |
| Troutner, JL | 1 |
| Baker, MR | 1 |
| Place, HM | 1 |
| van Schaardenburg, D | 1 |
| Valkema, R | 1 |
| Papapoulos, S | 1 |
| Pauwels, EK | 1 |
| Taylor-Robinson, D | 1 |
| Gilroy, CB | 1 |
| Horowitz, S | 1 |
| Horowitz, J | 1 |
| Darling, TN | 1 |
| Sidhu-Malik, N | 1 |
| Corey, GR | 1 |
| Allen, NB | 1 |
| Kamino, H | 1 |
| Murray, JC | 1 |
| Ferraz, MB | 1 |
| Quaresma, MR | 1 |
| Goldsmith, CH | 1 |
| Bennett, K | 1 |
| Atra, E | 1 |
| Pérez, MC | 1 |
| Gómez Casares, MT | 1 |
| Mataix, R | 1 |
| Campo, C | 1 |
| Jiménez, S | 1 |
| Malcorra, JJ | 1 |
| Weinblatt, ME | 3 |
| Kaplan, H | 1 |
| Germain, BF | 2 |
| Block, S | 1 |
| Solomon, SD | 1 |
| Merriman, RC | 1 |
| Wall, B | 1 |
| Anderson, L | 1 |
| Gall, E | 1 |
| Chalmers, A | 1 |
| Scheifele, D | 1 |
| Patterson, C | 1 |
| Williams, D | 1 |
| Weber, J | 1 |
| Shuckett, R | 1 |
| Teufel, A | 1 |
| McDougall, R | 1 |
| Sibley, J | 1 |
| Haga, M | 1 |
| Russell, A | 1 |
| Martens, HF | 1 |
| Sheets, PK | 1 |
| Tenover, JS | 1 |
| Dugowson, CE | 1 |
| Bremner, WJ | 1 |
| Starkebaum, G | 1 |
| Tilley, BC | 1 |
| Alarcón, GS | 1 |
| Heyse, SP | 1 |
| Neuner, R | 1 |
| Kaplan, DA | 1 |
| Leisen, JC | 1 |
| Buckley, L | 1 |
| Pillemer, SR | 1 |
| Tuttleman, M | 1 |
| Fowler, SE | 1 |
| Eberhardt, R | 1 |
| Krüger, K | 1 |
| Reiter, W | 1 |
| Gross, W | 1 |
| Zwingers, T | 1 |
| Thonar, EJ | 1 |
| Martel-Pelletier, J | 3 |
| Goulet, JR | 1 |
| Raynauld, JP | 1 |
| Ouellet, M | 1 |
| Pelletier, JP | 3 |
| Dhodapkar, MV | 1 |
| Li, CY | 2 |
| Lust, JA | 1 |
| Tefferi, A | 2 |
| Phyliky, RL | 2 |
| Boerbooms, AM | 2 |
| Brummelkamp, EP | 1 |
| Callahan, LF | 2 |
| van Erning, LJ | 3 |
| van't Hof, MA | 1 |
| Lemmens, JA | 3 |
| Koehnke, R | 2 |
| Caldwell, JR | 1 |
| Brasington, R | 1 |
| Burmeister, LF | 1 |
| Zimmerman, B | 1 |
| Kohler, JA | 1 |
| Furst, DE | 4 |
| Romano, TJ | 1 |
| Ruiz-Calderón, AJ | 1 |
| Carrasco, F | 1 |
| Duro, R | 1 |
| Constantino, M | 1 |
| Criswell, LA | 4 |
| Redfearn, WJ | 1 |
| Laroche, M | 1 |
| Arlet, J | 1 |
| Wyss, E | 1 |
| Kuhn, M | 1 |
| Luzi, HP | 1 |
| Reinhart, WH | 1 |
| Rooney, TW | 1 |
| Burmeister, L | 1 |
| Ippolito, JA | 1 |
| Palmer, L | 1 |
| Spector, S | 1 |
| Kane, PB | 1 |
| Gorevic, PD | 1 |
| Ben-Chetrit, E | 1 |
| Rahav, G | 1 |
| Wilske, KR | 2 |
| Michel, BA | 3 |
| Bloch, DA | 4 |
| Scudeletti, M | 2 |
| Puppo, F | 1 |
| Lanza, L | 1 |
| Mantovani, L | 1 |
| Bosco, O | 1 |
| Iudice, A | 1 |
| Indiveri, F | 2 |
| Hawley, DJ | 1 |
| Cathey, MA | 1 |
| Bergman, B | 1 |
| Lindahl, G | 1 |
| Frierson, JH | 1 |
| May, CM | 1 |
| Williams, CA | 3 |
| Ramey, D | 1 |
| Buijs, WC | 1 |
| Corstens, FH | 1 |
| Ruijs, SH | 2 |
| Strosberg, JM | 1 |
| Damron, TA | 1 |
| Heiner, JP | 1 |
| Gennari, C | 1 |
| Rodríguez Gómez, M | 1 |
| López Barros, G | 1 |
| Fernández Domínguez, L | 1 |
| Margusino Framiñán, C | 1 |
| Jiménez, JL | 1 |
| Jifi-Bahlool, H | 1 |
| Saadeh, C | 1 |
| O'Connor, J | 1 |
| Henke, CJ | 1 |
| Hastier, P | 1 |
| Caroli-Bosc, FX | 1 |
| Bartel, HR | 1 |
| Harris, AG | 1 |
| Maes, B | 1 |
| Arpurt, JP | 1 |
| Taillan, B | 1 |
| Bodock, I | 1 |
| Dumas, R | 1 |
| Delmont, JP | 1 |
| Boiardi, L | 1 |
| Macchioni, P | 1 |
| Casadei Maldini, M | 1 |
| Mancini, R | 1 |
| Beltrandi, E | 1 |
| Portioli, I | 1 |
| Conti, A | 1 |
| Sartorio, A | 1 |
| Ferrero, S | 1 |
| Ferrario, S | 1 |
| Ambrosi, B | 1 |
| Chang, DJ | 1 |
| Lamothe, M | 1 |
| Stevens, RM | 1 |
| Sigal, LH | 1 |
| Roux, N | 1 |
| Cortet, B | 1 |
| Lafitte, JJ | 1 |
| Tonnel, AB | 1 |
| Duquesnoy, B | 1 |
| Delcambre, B | 1 |
| Uthman, I | 1 |
| Vázquez-Abad, D | 1 |
| Senécal, JL | 1 |
| Stage, DE | 1 |
| Sems, KM | 1 |
| Nettleman, MD | 1 |
| Kolluri, S | 1 |
| Alster, Y | 1 |
| Varssano, D | 1 |
| Loewenstein, A | 1 |
| Lazar, M | 1 |
| Liu, JD | 1 |
| Zhang, C | 1 |
| Li, WS | 1 |
| Lun, LD | 1 |
| Longworth, DL | 1 |
| Stoller, JK | 1 |
| Litaker, DG | 1 |
| Raymakers, JA | 1 |
| Ramey, DR | 1 |
| Lila, AM | 1 |
| Mazurov, VI | 1 |
| Novik, AA | 1 |
| Ramos-Remus, C | 1 |
| Verhoeven, AC | 3 |
| Liening, DA | 1 |
| Larouere, MJ | 1 |
| Lacki, JK | 3 |
| Mackiewicz, SH | 3 |
| Blanco, R | 1 |
| Martinez-Taboada, VM | 1 |
| Rodriguez-Valverde, V | 1 |
| Sanchez-Andrade, A | 1 |
| González-Gay, MA | 1 |
| Vernhes, JP | 1 |
| Fach, J | 1 |
| Lequen, L | 1 |
| Bannwarth, B | 1 |
| Dehais, J | 2 |
| Such, CL | 1 |
| Yelin, EH | 1 |
| Adachi, JD | 1 |
| Bell, MJ | 1 |
| Bensen, WG | 1 |
| Bianchi, F | 1 |
| Cividino, A | 1 |
| Sebaldt, RJ | 1 |
| Gordon, M | 1 |
| Ioannidis, G | 1 |
| Goldsmith, C | 1 |
| Maier, AL | 2 |
| Fraser, PA | 3 |
| Abbott, WG | 1 |
| Tan, PL | 1 |
| Geursen, A | 1 |
| Fraser, JD | 1 |
| Forbes, L | 1 |
| Simpson, IJ | 1 |
| Yuan, S | 1 |
| Skinner, MA | 1 |
| Marley, WP | 1 |
| Santilli, TF | 1 |
| Kelton, JG | 1 |
| Navarro, MA | 1 |
| Machuca, MI | 1 |
| González, A | 1 |
| Mateo, L | 1 |
| Bonnin, RM | 1 |
| Roig-Escofet, D | 1 |
| Bogomolski-Yahalom, V | 1 |
| Lossos, IS | 1 |
| Okun, E | 1 |
| Sherman, Y | 1 |
| Lossos, A | 1 |
| Polliack, A | 1 |
| Suazo-Barahona, J | 1 |
| Gallegos, J | 1 |
| Carmona-Sánchez, R | 1 |
| Martínez, R | 1 |
| Robles-Díaz, G | 1 |
| St Clair, EW | 1 |
| Moak, SA | 1 |
| Wilkinson, WE | 1 |
| Sanders, L | 1 |
| Lang, T | 1 |
| Greenwald, RA | 1 |
| Olsen, KE | 1 |
| Holland, EJ | 1 |
| Roblot, P | 1 |
| Zaim, A | 1 |
| Azais, I | 1 |
| Ramassamy, A | 1 |
| Paccalin, M | 1 |
| Becq-Giraudon, B | 1 |
| Fifield, J | 1 |
| Tennen, H | 1 |
| Reisine, S | 1 |
| McQuillan, J | 1 |
| Rodriguez-Moreno, J | 1 |
| Martinez-Aguilá, MD | 1 |
| Clavaguera, MT | 1 |
| Kotha, P | 1 |
| McGreevy, MJ | 1 |
| Kotha, A | 1 |
| Look, M | 1 |
| Weisman, MH | 1 |
| Albert, DA | 1 |
| Lozano, P | 1 |
| Gomez, FT | 1 |
| Julia, J | 1 |
| M-Rimbau, E | 1 |
| Garcia, F | 1 |
| Sutton, DA | 1 |
| Timm, WD | 1 |
| Morgan-Jones, G | 1 |
| Rinaldi, MG | 1 |
| Albitar, S | 1 |
| Bourgeon, B | 1 |
| Genin, R | 1 |
| Jacquesson, M | 1 |
| Riviere, JP | 1 |
| Serveaux, MO | 1 |
| Ribera, A | 1 |
| Serveaux, JP | 1 |
| Miyamoto, S | 1 |
| Kageyama, Y | 1 |
| Ozeki, T | 1 |
| Hiyoshi, M | 1 |
| Suzuki, M | 1 |
| Inoue, T | 1 |
| Pham, B | 1 |
| Cranney, A | 1 |
| Di Fazano, CS | 1 |
| Messica, O | 1 |
| Quennesson, S | 1 |
| Quennesson, ER | 1 |
| Inaoui, R | 1 |
| Vergne, P | 1 |
| Bonnet, C | 1 |
| Bertin, P | 1 |
| Cherasse, A | 1 |
| Henlin, JL | 1 |
| Chassard, D | 1 |
| Tavernier, C | 1 |
| Ho, YV | 1 |
| Briganti, EM | 1 |
| Duan, Y | 1 |
| Buchanan, R | 1 |
| Hall, S | 1 |
| Seeman, E | 1 |
| Larsen, CG | 1 |
| Hartelius, H | 1 |
| Sheon, RP | 3 |
| van der Tempel, H | 1 |
| van der Linden, S | 1 |
| Blaauw, AA | 1 |
| Fernandes, NF | 1 |
| Martin, RR | 1 |
| Lakatos, P | 1 |
| Nagy, Z | 1 |
| Kiss, L | 1 |
| Horvath, C | 1 |
| Takacs, I | 1 |
| Foldes, J | 1 |
| Speer, G | 1 |
| Bossanyi, A | 1 |
| Leszczyński, P | 1 |
| Paulus, HE | 2 |
| Di Primeo, D | 1 |
| Sanda, M | 1 |
| Lynch, JM | 1 |
| Schwartz, BA | 1 |
| Sharp, JT | 2 |
| Genant, HK | 1 |
| Weissman, BN | 2 |
| Westby, MD | 1 |
| Wade, JP | 2 |
| Rangno, KK | 1 |
| Berkowitz, J | 1 |
| Bruscas Izu, C | 1 |
| Medrano San Ildefonso, M | 1 |
| Biasi, D | 2 |
| Caramaschi, P | 2 |
| Carletto, A | 2 |
| Bambara, LM | 2 |
| Postlethwaite, AE | 1 |
| Baghai, M | 1 |
| Osmon, DR | 1 |
| Wolk, DM | 1 |
| Wold, LE | 1 |
| Haidukewych, GJ | 1 |
| Kroot, EJ | 1 |
| Nieuwenhuizen, MG | 1 |
| de Waal Malefijt, MC | 1 |
| Pasker-de Jong, PC | 1 |
| Go, RS | 1 |
| Lannes, F | 1 |
| Sailler, L | 1 |
| Ollier, S | 1 |
| Carreiro, M | 1 |
| Arlet, P | 1 |
| Kozora, E | 1 |
| Laudenslager, M | 1 |
| Lemieux, A | 1 |
| Stein, CM | 1 |
| Baron, BW | 1 |
| Martin, MS | 1 |
| Sucharetza, BS | 1 |
| Jeon, H | 1 |
| Baron, JM | 1 |
| Canestrini, S | 1 |
| Scambi, C | 1 |
| Scarperi, A | 1 |
| Mazzoleni, J | 1 |
| Soto, O | 1 |
| Takahashi, T | 1 |
| Kazama, Y | 1 |
| Yoshimoto, M | 1 |
| Tsujisaki, M | 1 |
| Imai, K | 1 |
| Duffy, J | 1 |
| Davis, JS | 1 |
| Person, DA | 1 |
| Hollinger, FB | 1 |
| Min, KW | 1 |
| Lee, P | 8 |
| Anderson, JA | 3 |
| Miller, J | 2 |
| Webb, J | 7 |
| Buchanan, WW | 6 |
| Goldman, JA | 1 |
| Casey, HL | 1 |
| McIlwain, H | 1 |
| Kirby, J | 1 |
| Wilson, CH | 1 |
| Miller, SB | 1 |
| Manthorpe, R | 1 |
| Hansen, TM | 1 |
| Lorenzen, I | 1 |
| Utne, HE | 1 |
| Fernández Miranda, C | 1 |
| Palacio Pérez-Medel, A | 1 |
| Calatayud Noguera, T | 1 |
| Díaz Rojas, F | 1 |
| Talal, N | 2 |
| Grey, HM | 1 |
| Zvaifler, N | 1 |
| Michalski, JP | 1 |
| Daniels, TE | 1 |
| Hohmeister, R | 1 |
| Waldburger, M | 1 |
| Hughes, GR | 3 |
| Smith, DC | 1 |
| Hirst, AE | 1 |
| McConkey, B | 4 |
| Davies, P | 2 |
| Crockson, RA | 3 |
| Crockson, AP | 3 |
| Butler, M | 1 |
| Constable, TJ | 1 |
| Amos, RS | 1 |
| Thorvaldsen, J | 1 |
| Kolanowski, J | 1 |
| Esselinckx, W | 1 |
| Nagant de Deuxchaisnes, C | 1 |
| Crabbe, J | 1 |
| Harth, M | 1 |
| Hickey, JP | 1 |
| Coulter, WK | 1 |
| Thompson, JM | 1 |
| Disney, TF | 1 |
| Klinefelter, HF | 1 |
| Winkenwerder, WL | 1 |
| Bledsoe, T | 1 |
| Fishbein, E | 1 |
| Ramos-Niembro, F | 1 |
| Alarcon-Segovia, D | 1 |
| Roux, H | 2 |
| Mercier, P | 1 |
| Jeandel, P | 1 |
| Brouillet-Gabriel, M | 1 |
| Serratrice, G | 2 |
| Rejholec, V | 2 |
| Vapaatalo, H | 1 |
| Tokola, O | 1 |
| Gothoni, G | 1 |
| Wilkenfeld, MJ | 1 |
| Sliwinski, AJ | 1 |
| Wallace, DJ | 1 |
| Goldfinger, D | 1 |
| Gatti, R | 1 |
| Lowe, C | 1 |
| Fan, P | 1 |
| Klinenberg, JR | 1 |
| Falck, HM | 1 |
| Törnroth, T | 1 |
| Skrifvars, B | 1 |
| Wegelius, O | 1 |
| Baron, EJ | 1 |
| Angevine, JM | 1 |
| Sundstrom, W | 1 |
| Walsh, L | 1 |
| Papp, GM | 1 |
| Lund, B | 1 |
| Andersen, RB | 1 |
| Friis, T | 1 |
| Hjorth, L | 1 |
| Jørgensen, FS | 1 |
| Norman, AW | 1 |
| Sørensen, OH | 1 |
| Guirgis, FK | 1 |
| Ghanem, MH | 1 |
| Zakaria, H | 1 |
| Fowles, JV | 1 |
| Kassab, MT | 1 |
| Younge, D | 1 |
| Prost, A | 1 |
| Hamelin, JP | 1 |
| Carlier, N | 1 |
| Boiteau, HL | 1 |
| Possel-Renac, F | 1 |
| Tanzer, FR | 1 |
| Lynfield, YL | 1 |
| Miller, LD | 1 |
| Pakuła, A | 1 |
| Kruszewski, S | 1 |
| Wirth, W | 1 |
| Diekmann, L | 1 |
| Klokenbusch, S | 1 |
| Meyer, E | 1 |
| Scharf, J | 1 |
| Miller, B | 1 |
| Zonis, S | 1 |
| Nahir, M | 1 |
| Delbarre, F | 1 |
| Le Gô, A | 1 |
| Kahan, A | 1 |
| McAdam, LP | 1 |
| O'Hanlan, MA | 1 |
| Krantz, SB | 1 |
| Sauerwein, HP | 1 |
| Halstead, LR | 1 |
| Haddad, JG | 1 |
| Gerber, DA | 2 |
| de Haas, WH | 1 |
| van Gool, J | 1 |
| Mathew, PK | 1 |
| Thorpe, P | 1 |
| MacGregor, RR | 1 |
| Cucher, BG | 1 |
| Goldman, AL | 1 |
| Grigor, RR | 1 |
| Prat, A | 1 |
| Bartholomew, BA | 1 |
| Mills, DM | 1 |
| Steigerwald, JC | 1 |
| Strong, SJ | 1 |
| Recart, S | 1 |
| Hastings, DE | 1 |
| Parker, SM | 1 |
| Epstein, WV | 1 |
| Watson, M | 1 |
| Anderson, J | 3 |
| Buchanan, W | 1 |
| Sponzilli, EE | 1 |
| Smith, JK | 1 |
| Malamud, N | 1 |
| McCulloch, JR | 1 |
| Ansell, BM | 1 |
| Maas, D | 1 |
| Schubothe, H | 1 |
| Schramm, A | 1 |
| Droese, M | 1 |
| Adelung, W | 1 |
| Winter, H | 1 |
| Buskila, D | 1 |
| Thomson, GT | 1 |
| Klein, M | 1 |
| Iglesias, A | 1 |
| Deulofeut, H | 1 |
| Dubey, DP | 1 |
| Salazar, M | 1 |
| Egea, E | 1 |
| Yunis, EJ | 1 |
| Marcum, SB | 1 |
| Caprotti, P | 1 |
| Caprotti, M | 1 |
| Notario, A | 1 |
| Cash, JM | 1 |
| Gallucci, WT | 1 |
| Sternberg, EM | 1 |
| Gold, PW | 1 |
| Chrousos, GP | 1 |
| Wilder, RL | 1 |
| Coulter, C | 1 |
| Walker, DG | 1 |
| Günsberg, M | 1 |
| Brown, IG | 1 |
| Bligh, JF | 1 |
| Prociv, P | 1 |
| Casoli, P | 1 |
| Tumiati, B | 1 |
| Messina, OD | 2 |
| Barreira, JC | 2 |
| Zanchetta, JR | 1 |
| Maldonado-Cocco, JA | 1 |
| Bogado, CE | 1 |
| Sebastián, ON | 1 |
| Flores, D | 1 |
| Riopedre, AM | 1 |
| Redondo, G | 1 |
| Lázaro, A | 1 |
| Stenberg, VI | 1 |
| Fiechtner, JJ | 1 |
| Rice, JR | 1 |
| Miller, DR | 1 |
| Johnson, LK | 1 |
| Glasser, DB | 1 |
| Bellor, J | 1 |
| Pignone, A | 1 |
| Matucci-Cerinic, M | 1 |
| Morfini, M | 1 |
| Lombardi, A | 1 |
| Rossi Ferrini, PL | 1 |
| Cagnoni, M | 1 |
| Caldwell, CW | 1 |
| Bridges, AJ | 2 |
| Walker, SE | 1 |
| Smarr, KL | 1 |
| Reichert, RJ | 1 |
| Anderson, SK | 1 |
| Hewett, JE | 1 |
| Parker, JC | 1 |
| Cracchiolo, A | 1 |
| Cimino, WR | 1 |
| Lian, G | 1 |
| Sambrook, P | 1 |
| Nguyen, T | 1 |
| Fernández Casares, M | 1 |
| Casas, HA | 1 |
| Leczycki, H | 1 |
| Holdsworth, DE | 1 |
| Falchuk, KR | 1 |
| Brick, JE | 2 |
| DiBartolomeo, AG | 1 |
| Leigh, JP | 1 |
| Sewell, KL | 1 |
| Kerr, LD | 1 |
| Spiera, H | 1 |
| Palacios, MF | 1 |
| Fondevilla, CG | 1 |
| Fernández, J | 1 |
| González, NH | 1 |
| Leboff, MS | 1 |
| Mackowiak, S | 1 |
| el-Hajj Fuleihan, G | 1 |
| Zangari, M | 1 |
| Liang, MH | 1 |
| Gruberg, L | 1 |
| Thaler, M | 1 |
| Rozenman, J | 1 |
| Bank, I | 1 |
| Pras, M | 1 |
| Felder, M | 1 |
| Rüegsegger, P | 1 |
| Tsuji, M | 1 |
| Douwaki, C | 1 |
| Yamada, A | 1 |
| Nakura, Y | 1 |
| Takahashi, S | 1 |
| Hatano, M | 1 |
| Sawada, S | 1 |
| Nishinarita, S | 1 |
| Ishikawa, H | 1 |
| Malone, DG | 1 |
| Jicinsky, J | 1 |
| Chen, M | 1 |
| Ory, P | 1 |
| Engber, W | 1 |
| Graziano, FM | 1 |
| Heurkens, AH | 1 |
| Dockery, KM | 1 |
| Sismanis, A | 1 |
| Abedi, E | 1 |
| Perhala, RS | 1 |
| Wilke, WS | 1 |
| Clough, JD | 1 |
| Segal, AM | 1 |
| Cloutier, JM | 2 |
| Faure, MP | 1 |
| Didry, C | 1 |
| Andary, M | 1 |
| Reme, T | 1 |
| Clot, J | 1 |
| Sany, J | 1 |
| Antonelli, MA | 1 |
| Moreland, LW | 1 |
| Gray, RE | 1 |
| Doherty, SM | 1 |
| Galloway, J | 1 |
| Coulton, L | 1 |
| de Broe, M | 1 |
| Kanis, JA | 1 |
| Healey, LA | 2 |
| Kriss, BD | 1 |
| Porter, JA | 1 |
| Slezak, FA | 1 |
| Vuong, TK | 1 |
| Laaban, JP | 1 |
| De Gennes, C | 1 |
| Rochemaure, J | 1 |
| Wolock, BD | 1 |
| Smith, RE | 1 |
| Theisen, AL | 1 |
| Wollina, U | 1 |
| Schulze, M | 1 |
| Knopf, B | 1 |
| van der Schee, AC | 1 |
| Dinkla, BA | 1 |
| Festen, JJ | 1 |
| Luggen, ME | 1 |
| Gartside, PS | 1 |
| Hsu, VM | 1 |
| Krey, PR | 1 |
| Schwartz, RA | 1 |
| Docken, WP | 1 |
| Sketchler, JJ | 1 |
| Sheldon, PJ | 1 |
| Piccardo, C | 1 |
| Piovano, P | 1 |
| Bergemer, AM | 1 |
| Fouquet, B | 1 |
| Charbonnier, B | 1 |
| Valat, JP | 1 |
| Baethge, BA | 1 |
| Wolf, RE | 1 |
| Weiner, SR | 1 |
| Noritake, DT | 1 |
| Danneskiold-Samsøe, B | 6 |
| Humad, S | 1 |
| Zarling, E | 1 |
| Clapper, M | 1 |
| Skosey, JL | 1 |
| Senior, J | 1 |
| Rubio, C | 1 |
| González Pares, E | 1 |
| Torres, EA | 1 |
| Iannuzzi, LP | 1 |
| Steen-Hansen, E | 1 |
| Hove, B | 1 |
| Andresen, J | 1 |
| Trnavský, K | 1 |
| Gates, S | 1 |
| Shary, J | 1 |
| Turner, RT | 1 |
| Wallach, S | 1 |
| Bell, NH | 1 |
| Schottstaedt, MW | 1 |
| Hurd, ER | 2 |
| Stone, MJ | 1 |
| Fibbe, WE | 1 |
| Hermans, J | 1 |
| van der Meer, JW | 1 |
| Cats, A | 1 |
| Slack, JD | 1 |
| Waller, B | 1 |
| Lee, JK | 1 |
| Espinoza, LR | 1 |
| Espinoza, CG | 1 |
| Grimby, G | 4 |
| Costabel, U | 1 |
| Schmitz-Schumann, M | 1 |
| Guzman, J | 1 |
| Stierle, H | 1 |
| Reinbold, WD | 1 |
| Matthys, H | 1 |
| Howell, DS | 1 |
| Kabadi, UM | 1 |
| Bourqui, M | 1 |
| Gerster, JC | 1 |
| Barton, JC | 1 |
| Prasthofer, EF | 1 |
| Egan, ML | 1 |
| Heck, LW | 1 |
| Koopman, WJ | 1 |
| Grossi, CE | 1 |
| Sarnat, RL | 1 |
| Jampol, LM | 1 |
| Westermann, CJ | 1 |
| Wagenaar, SS | 1 |
| Dinant, HJ | 1 |
| Bloch, D | 1 |
| Spitz, P | 1 |
| Mitchell, DM | 1 |
| Segal-Eiras, A | 1 |
| Segura, GM | 1 |
| Babini, JC | 1 |
| Arturi, AS | 1 |
| Fraguela, JM | 1 |
| Marcos, JC | 1 |
| Ryzen, E | 1 |
| Singer, FR | 1 |
| Hansen, RM | 1 |
| Csuka, ME | 1 |
| McCarty, DJ | 1 |
| Saryan, LA | 1 |
| Tishler, M | 1 |
| Yaron, M | 1 |
| Jorke, D | 2 |
| Schwela, G | 1 |
| Foad, BS | 1 |
| Kirsner, AB | 2 |
| Hoffmann-Blume, E | 1 |
| Kunze, M | 1 |
| Sittner, S | 1 |
| Solomon, L | 1 |
| Hay, JM | 1 |
| Testart, J | 1 |
| Oppermann, J | 1 |
| Geidel, H | 1 |
| Beickert, A | 1 |
| Barnett, EV | 1 |
| Brostoff, J | 2 |
| Freedman, A | 1 |
| Roitt, IM | 2 |
| Robitaille, P | 1 |
| Kulin, HE | 1 |
| Metzl, K | 1 |
| Peterson, R | 1 |
| Seidel, K | 2 |
| Eckstein, M | 1 |
| Kaiser, G | 1 |
| Brühl, W | 1 |
| Hamaty, D | 1 |
| Topp, JR | 1 |
| Hart, GD | 1 |
| Hicklin, JA | 1 |
| Wills, MR | 1 |
| de Sèze, S | 4 |
| Bedoiseau, M | 2 |
| Debeyre, N | 1 |
| Kahn, MF | 4 |
| Druet, P | 1 |
| Dryll, A | 1 |
| Ryckewaert, A | 2 |
| Mackay, JS | 1 |
| Sheridan, B | 1 |
| Weaver, JA | 1 |
| Galmiche, P | 1 |
| Fisher, DE | 1 |
| Bickel, WH | 1 |
| Jayson, MI | 1 |
| Jones, DE | 1 |
| Ebner, E | 2 |
| Ebner, S | 1 |
| Gifford, RH | 1 |
| Bitensky, L | 1 |
| Butcher, RG | 1 |
| Johnstone, JJ | 1 |
| Chayen, J | 1 |
| Wilkinson, AR | 1 |
| Cosh, JA | 1 |
| Dériaz, M | 1 |
| Junet, R | 1 |
| Burgoon, CF | 1 |
| Feinerman, LK | 1 |
| Eisen, AA | 1 |
| Norris, JW | 1 |
| Cumming, GR | 1 |
| Fenton, TR | 1 |
| Cobau, CD | 1 |
| Bartholomew, C | 1 |
| Howell, A | 1 |
| O'Donohue, WJ | 1 |
| Ahola, SJ | 1 |
| Grennan, D | 1 |
| Brooks, P | 1 |
| Gotoff, SP | 1 |
| Smith, RD | 1 |
| Sugar, O | 1 |
| Bethge, H | 1 |
| Abbona, C | 1 |
| Marugo, M | 1 |
| Berretti, A | 1 |
| Wiernik, PH | 1 |
| Dreiser, R | 1 |
| Josipović, DB | 1 |
| Stojanović, ID | 1 |
| van der Korst, JK | 1 |
| Jasin, HE | 1 |
| Andreis, M | 1 |
| Cheatum, DE | 1 |
| Giuliano, V | 1 |
| Smiley, JD | 1 |
| Bachanan, WW | 1 |
| Deren, B | 1 |
| Masi, R | 1 |
| Weksler, M | 1 |
| Nachman, RL | 1 |
| Etienne, JP | 1 |
| Labayle, D | 1 |
| Chaput, JC | 1 |
| Buffet, C | 1 |
| D'Elia, A | 1 |
| Colella, C | 1 |
| Contursi, R | 1 |
| Anderson, LG | 1 |
| Cummings, NA | 1 |
| Asofsky, R | 1 |
| Hylton, MB | 1 |
| Tarpley, TM | 1 |
| Tomasi, TB | 1 |
| Wolf, RO | 1 |
| Schall, GL | 1 |
| Meienberg, O | 1 |
| Bischoff, A | 1 |
| Regli, F | 1 |
| Ryffel, M | 1 |
| Callies, R | 1 |
| López, G | 1 |
| Martínez, MJ | 1 |
| Zimmermann-Górska, I | 1 |
| Routavaara, M | 1 |
| Martio, J | 1 |
| Canada, AT | 1 |
| Griswold, WR | 1 |
| McIntosh, RM | 1 |
| Cuddigan, JH | 1 |
| Henningsen, B | 1 |
| Maintz, J | 1 |
| Basedow, M | 1 |
| Harders, H | 1 |
| Bogdanikowa, B | 1 |
| Bernacka, K | 1 |
| Rudy, J | 1 |
| Stasiewicz, A | 1 |
| Tanner, E | 2 |
| Downie, WW | 1 |
| Dick, WC | 2 |
| Recordier, AM | 1 |
| Acquaviva, PC | 1 |
| Maestracci, D | 1 |
| D'Omezon, Y | 1 |
| Pollini, J | 1 |
| Albert, E | 1 |
| Duperrat, B | 1 |
| Jolly, G | 1 |
| Fourati, M | 1 |
| Ivey, KJ | 1 |
| Clifton, JA | 1 |
| Murray, HS | 1 |
| Strottman, MP | 1 |
| Cooke, AR | 1 |
| Philips, SF | 1 |
| Oldfather, T | 1 |
| Bizot, W | 1 |
| Kinnaird, D | 1 |
| Polk, HC | 1 |
| Iannotta, F | 1 |
| Fantini, F | 1 |
| Colombo, B | 1 |
| Boardman, PL | 1 |
| Cotzias, GC | 1 |
| Papavasiliou, PS | 1 |
| Hughes, ER | 1 |
| Tang, L | 1 |
| Borg, DC | 1 |
| Ridenhour, G | 1 |
| Stephenson, HE | 1 |
| Fearnley, ME | 2 |
| Franco, AE | 1 |
| Wilke, D | 1 |
| McKiddie, MT | 1 |
| Jasani, MK | 2 |
| Buchanan, KD | 1 |
| Boyle, JA | 2 |
| Wessel, G | 2 |
| Friedrich, H | 1 |
| Hesse, P | 1 |
| Schmied, P | 1 |
| Van Rossum, P | 1 |
| Fallet, GH | 1 |
| Cohen, SA | 1 |
| Christian, CL | 1 |
| Six, B | 1 |
| Le Goff, P | 1 |
| Saudan, Y | 1 |
| Chavannes, F | 1 |
| Strom, RL | 1 |
| Payson, R | 1 |
| Kitzmiller, G | 1 |
| Seidel, A | 1 |
| Renshaw, TS | 1 |
| Phelps, DB | 1 |
| Briggs, RC | 1 |
| Jezzi, B | 1 |
| Kvasnicka, I | 1 |
| Hledík, E | 1 |
| Flusser, J | 1 |
| Bohutová, J | 1 |
| Bossa, G | 1 |
| Kimball, CP | 1 |
| Van Rossum, PE | 1 |
| Jurist, JM | 1 |
| Taylor, RT | 1 |
| Huskisson, EC | 1 |
| Whitehouse, GH | 1 |
| Moldofsky, H | 1 |
| Rothman, AI | 1 |
| Hewitt, J | 1 |
| Lessana-Leibowitch, M | 1 |
| Benveniste, M | 1 |
| Saporta, L | 1 |
| David-Chaussé, J | 1 |
| David-Chaussé, F | 1 |
| Picot, C | 1 |
| Laporte, G | 1 |
| Lagoarde, J | 1 |
| Camus, JP | 1 |
| Bénichou, C | 1 |
| Guillien, P | 1 |
| Crouzet, J | 1 |
| Lièvre, JA | 1 |
| Geisert, J | 1 |
| Sacrez, R | 1 |
| Levy, JM | 1 |
| Berland, H | 1 |
| Liautaud, B | 1 |
| Santos, Oda R | 1 |
| Houli, J | 1 |
| Schilling, A | 1 |
| Jaffe, IA | 1 |
| Smith, RW | 1 |
| Herp, A | 1 |
| Fabianek, J | 1 |
| Calick, A | 1 |
| Pigman, W | 1 |
| Bruckner, I | 1 |
| Stroescu, O | 1 |
| Stroescu, V | 1 |
| Gheorghiu, M | 1 |
| Suţeanu, S | 1 |
| Ghelerter, L | 1 |
| Grozea, P | 1 |
| Bârnaş, M | 1 |
| Cruchaud, A | 1 |
| Wanebo, HJ | 1 |
| Rawson, RW | 1 |
| Bilka, PJ | 1 |
| Neumann, W | 1 |
| Unverricht, A | 1 |
| Correns, HJ | 1 |
| Peachey, RD | 1 |
| Wells, GC | 1 |
| Danielsen, L | 1 |
| Christensen, HE | 1 |
| Wanstrup, J | 1 |
| Bedi, SS | 1 |
| Ellis, W | 1 |
| Widomska-Czekajska, T | 1 |
| Miturzyńska-Stryjecka, H | 1 |
| Rupniewska, Z | 1 |
| Magora, A | 1 |
| Wolf, E | 1 |
| Gonen, B | 1 |
| Malodobry, T | 1 |
| Weigl, E | 1 |
| Benz, G | 1 |
| Steiger, U | 1 |
| Scheidegger, S | 1 |
| Huber, F | 1 |
| Siering, H | 1 |
| Eitner, K | 1 |
| Stroescu, I | 1 |
| Stoicescu, M | 1 |
| Dragomir, M | 1 |
| Burtea, A | 1 |
| Pintea, G | 1 |
| Stoia, I | 1 |
| Jones, FL | 1 |
| Blodgett, RC | 1 |
| Rautenstrauch, H | 1 |
| Fischer, P | 1 |
| Nostitz, HJ | 1 |
| Ruddy, S | 1 |
| Everson, LK | 1 |
| Emmanuel, JH | 1 |
| Montgomery, RD | 1 |
| Kindermann, G | 1 |
| Adelmann, G | 1 |
| Schwenk, D | 1 |
| Gaudlitz, G | 1 |
| Wille, T | 1 |
| Kapp, W | 1 |
| Klunker, W | 1 |
| Fellmann, N | 1 |
| Morris, HG | 1 |
| Jorgensen, JR | 1 |
| Elrick, H | 1 |
| Goldsmith, RE | 1 |
| Gerdes, H | 1 |
| Schmitz-Moormann, P | 1 |
| Stavem, P | 1 |
| Stromme, J | 1 |
| Bull, O | 1 |
| Block, SR | 1 |
| Gibbs, CB | 1 |
| Shulman, LE | 1 |
| Vignon, G | 1 |
| Bied, JC | 1 |
| Rubens-Duval, A | 1 |
| Villiaumey, J | 1 |
| Kaplan, G | 1 |
| Fedorová, O | 1 |
| Di Salvo, AF | 1 |
| Chew, WH | 1 |
| Christensen, MF | 1 |
| Iversen, TO | 1 |
| Digby, JW | 1 |
| Somer, T | 1 |
| Sievers, K | 1 |
| Groth, A | 1 |
| Groth, K | 1 |
| Mosbech, J | 1 |
| Wargocka-Kasińska, J | 1 |
| Siurala, M | 1 |
| Peltola, P | 1 |
| Varis, K | 1 |
| Gupta, MP | 1 |
| Bhargava, AN | 1 |
| Hausmann, A | 1 |
| Beckman, H | 1 |
| How, MJ | 1 |
| Long, VJ | 1 |
| Donner, L | 1 |
| Neuwirtová, R | 1 |
| Klener, P | 1 |
| Puylaert, CB | 1 |
| Hall, AP | 1 |
| Drogan, A | 1 |
| Schubart, AF | 1 |
| Ewald, RW | 1 |
| Schroeder, WC | 1 |
| Rothschild, HJ | 1 |
| Bhatavadekar, DN | 1 |
| Pullen, PK | 1 |
| Altava, V | 1 |
| Dupré, AL | 1 |
| Yasur, J | 1 |
| Gore, M | 1 |
| Leng-Lévy, J | 1 |
| Miller, WT | 1 |
| Restifo, RA | 1 |
| Masheter, HC | 1 |
| Murthy, AS | 1 |
| Elias, PM | 1 |
| Vetter, G | 1 |
| Heidelmann, G | 1 |
| Bergmann, E | 1 |
| Kaplan, D | 1 |
| Richter, J | 1 |
| Kurdow, N | 1 |
| Stocchi, F | 1 |
| Bossini, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica (ITTG PMR): An Open-label 52-week Randomized Controlled Trial[NCT06172361] | Phase 3 | 98 participants (Anticipated) | Interventional | 2024-01-15 | Not yet recruiting | ||
| Immunogenicity and Safety of the CoronaVac Vacccine in Patients With Autoimmune Rheumatic Diseases and People Living With HIV/AIDS[NCT04754698] | Phase 4 | 2,067 participants (Anticipated) | Interventional | 2021-02-09 | Active, not recruiting | ||
| Prospective, Multicentre, Placebo-controlled, Double-blind Interventional Study to Compare the Efficacy of Maintenance Treatment With Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Patients[NCT02573012] | Phase 4 | 314 participants (Actual) | Interventional | 2016-03-29 | Completed | ||
| An Impaired Functional Reserve of Adrenal Cortex May Associate With difficult-to Treat RA: Can a Disturbed Cortisol Circadian Rhythm Serve as a Predictor of Difficult-to-treat RA?[NCT05671627] | 50 participants (Anticipated) | Observational | 2022-02-02 | Recruiting | |||
| Etude et Suivi Des POlyarthrites Indifférenciées Récentes[NCT03666091] | 813 participants (Actual) | Observational | 2002-11-13 | Active, not recruiting | |||
| Secondary Event Prevention Using Population Risk Management After PCI[NCT02694185] | 5,269 participants (Actual) | Interventional | 2016-10-01 | Active, not recruiting | |||
| A MULTICENTER, OPEN LABEL STUDY TO EVALUATE EFFICACY AND SAFETY OF TOCILIZUMAB GIVEN SUBCUTANEOUSLY IN MONOTHERAPY AND IN COMBINATION WITH NON-BIOLOGIC DMARDS IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN LATIN AMERICA[NCT02011334] | Phase 3 | 285 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| An Open-Label Study to Evaluate Non-Progression Of Structural Joint Damage Of Subcutaneous Tocilizumab In Patients With Moderate To Severe Active Rheumatoid Arthritis (Ac-Cute)[NCT01951170] | Phase 3 | 52 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Tocilizumab SC in Patients With Active Rheumatoid Arthritis and Inadequate Response to DMARDs. A Single-Arm, Open-Label Study to Evaluate Safety, Tolerability and Efficacy. In a Subgroup of Patients Inflammation Will Be Measured by Ultrasound.[NCT02046616] | Phase 3 | 133 participants (Actual) | Interventional | 2014-05-28 | Completed | ||
| A National, Open-Label, Single-Arm, Phase IIIb Study to Evaluate the Efficacy of Weekly Tocilizumab Subcutaneous, Administered as Monotherapy or in Combination With Methotrexate and/or Other DMARDs in Rheumatoid Arthritis (RA) Patients[NCT01941940] | Phase 3 | 227 participants (Actual) | Interventional | 2013-09-05 | Completed | ||
| Open-Label, Phase IIIb Study to Evaluate the Efficacy and Safety of Subcutaneous (SC) Tocilizumab Monotherapy or Combination Therapy With Methotrexate (MTX) or Other Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Patients With Active Rheu[NCT02046603] | Phase 3 | 162 participants (Actual) | Interventional | 2014-03-04 | Completed | ||
| TOSCARA: An Open-label, Single Arm Study to Evaluate the Efficacy, Safety and Tolerability of Tocilizumab (TCZ) Subcutaneous in TCZ-naïve Patients With Active Rheumatoid Arthritis[NCT02031471] | Phase 3 | 57 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Multi-Center, Open Label, Single Arm Phase IIIB Study on Safety and Efficacy of Subcutaneous Tocilizumab in Monotherapy or in Combination With Methotrexate or Other Non-Biologic Disease Modifying Antirheumatic Drugs in Rheumatoid Arthritis Patients With a[NCT01987479] | Phase 3 | 150 participants (Actual) | Interventional | 2014-01-30 | Completed | ||
| A Multi-Center Open-Label Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Tocilizumab in Tocilizumab-Naive Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARD and/or Biologic Ther[NCT02001987] | Phase 3 | 139 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| A Phase IIIb Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous (SC) Tocilizumab (TCZ) Given as Monotherapy or in Combination With Methotrexate (MTX) or Other Non Biologics DMARDs in Subjects With Rheumatoid Arthritis[NCT01995201] | Phase 3 | 401 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| An Open-label, Multicenter Study to Evaluate Disease Activity and Safety of Treatment With Actemra (Tocilizumab) Administered as Subcutaneous Injection in Adult RA Patients.[NCT01988012] | Phase 3 | 100 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Multicenter, Open Label, Phase IIIb Study to Evaluate the Safety and Tolerability of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Methotrexate or Other Non-Biologic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Ar[NCT01941095] | Phase 3 | 100 participants (Actual) | Interventional | 2013-11-20 | Completed | ||
| A Phase 2, Randomized, Double Blind Assessment Of Efficacy And Safety Of Pf 04171327(1, 5, 10, 15 Mg Dose, Daily) Compared To 5 Mg And 10 Mg Prednisone Daily And Placebo Daily In Subjects With Rheumatoid Arthritis Over An 8 Week Period Followed By A 4 Wee[NCT01393639] | Phase 2 | 323 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A 2 Year Prospective Multicentre Randomised Controlled Trial Comparing Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.[NCT01172639] | Phase 4 | 400 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis and Candidates With a Biological Monotherapy[NCT02087696] | Phase 4 | 122 participants (Anticipated) | Interventional | 2014-05-31 | Recruiting | ||
| Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity: a Single Blind, Non-inferiority, Randomised Clinical Trial[NCT04222920] | Phase 4 | 78 participants (Actual) | Interventional | 2020-03-01 | Completed | ||
| Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring (ADDORA): Multi-centre Open Label Randomised Controlled Trail[NCT04194827] | Phase 4 | 267 participants (Anticipated) | Interventional | 2020-03-01 | Recruiting | ||
| Characterization of Immunogenicity of Tumor Necrosis Factor Inhibitors in Arthritis Patients With Poorer Treatment Response Due to Gender, Obesity and Smoking Status.[NCT04731831] | 120 participants (Anticipated) | Observational | 2020-08-01 | Recruiting | |||
| Pharmaco Kinetic and Pharmacokinetic-Pharmacodynamic Variability of Infliximab[NCT00840957] | 84 participants (Actual) | Observational | 2007-11-30 | Completed | |||
| The Effect of Prednisone on Atherogenesis as Studied in the Macrophage Foam Cell Formation Model System.[NCT03367663] | Early Phase 1 | 10 participants (Actual) | Interventional | 2018-01-17 | Completed | ||
| Effectiveness of a Combination of Methotrexate and a Step Down Glucocorticoid Regimen (COBRA-Slim) for Remission Induction in Patients With Early Rheumatoid Arthritis (RA), With or Without Fast Access to 24 Weeks of Tumor Necrosis Factor (TNF) Blockade in[NCT03649061] | Phase 4 | 284 participants (Actual) | Interventional | 2018-06-08 | Completed | ||
| Abatacept in T3: A Characterization of Abatacept's Efficacy and Outcomes From a Real-Word Clinical Practice Information Hub on Novel Patient Sub-Groups[NCT01555879] | 200 participants (Actual) | Observational | 2012-03-31 | Completed | |||
| Controlled, Randomized, Double-blind Clinical Trial, 24 Months Duration, to Compare the Efficacy, Safety and Tolerability of Andrographolide Versus Placebo in Patients With Progressive Forms of Multiple Sclerosis[NCT02273635] | Phase 1/Phase 2 | 68 participants (Anticipated) | Interventional | 2014-09-30 | Recruiting | ||
| Clinical Phase II Pilot Study of the Efficacy of FANG(30) to Treat Active Rheumatoid Arthritis in Adult Patients[NCT00749645] | Phase 2 | 60 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Randomized, Comparative, Double Blind Controlled Phase II Clinical Trial, to Evaluate the Efficacy of ApE in Patients With Multiple Sclerosis (MS).[NCT02280876] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| A Randomized, Controlled, Open-label Study to Assess the Efficacy of T2 Versus Azathioprine for the Maintenance of Clinical and Endoscopic Remission in Subjects With Crohn's Disease After Surgical Resection[NCT01015391] | 100 participants (Anticipated) | Interventional | 2009-11-30 | Recruiting | |||
| Phase 1/2 Study of Tripterygium Wilfordii Hook F (TwHF) Treatment for Evaluation the Efficacy and Safety in Immune Non-responders With HIV-1 Infection[NCT01666990] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2012-06-30 | Recruiting | ||
| PreConceptional Counselling in Active Rheumatoid Arthritis[NCT01345071] | 150 participants (Anticipated) | Observational | 2011-09-30 | Recruiting | |||
| A New Timed-Release Tablet Formulation of Prednisone Compared to Standard Prednisone in Patients With Rheumatoid Arthritis- A Randomized, Multi-Centre, Double-Blind, Active Controlled Study With Open Extension on the New Drug Only[NCT00146640] | Phase 3 | 288 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Comparison of the Efficacy and Safety of Two Different Starting Dosages of Prednisolone in Early Active Rheumatoid Arthritis: a Randomized, Placebo Controlled Trial[NCT02000336] | Phase 3 | 395 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| A Randomized Multi-Center, Double-Blind, Placebo-Controlled Study of a New Modified-Release Tablet Formulation of Prednisone (Lodotra®) in Patients With Rheumatoid Arthritis[NCT00650078] | Phase 3 | 350 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Access the Effects of Oral Prednisone on Clinical Efficacy and the Power Doppler Ultrasound Signal of Synovium in Patients With Rheumatoid Arthritis[NCT00746512] | Phase 1 | 45 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Effect of Specific Diet and Circuit-based Exercise on Weight and/or Fat Loss[NCT02325804] | 60 participants (Actual) | Interventional | 2014-12-31 | Completed | |||
| Non-interventional Study for Determining the Improvement in the Activity Status / Life Quality of Patients With Rheumatoid Arthritis Being Treated With the Tempus Tablet[NCT01075711] | 2,728 participants (Actual) | Observational | 2009-04-30 | Completed | |||
| Prognostic Factors of Efficacy in Corticoid and Anesthetic Joint Infiltration for the Treatment of Patients With Low Back Pain Secondary to Zygapophyseal Osteoarthritis: a Prospective Cohort Study[NCT03304730] | 147 participants (Anticipated) | Observational | 2017-09-01 | Recruiting | |||
| Observational Study to Determine the Effect of Wearing of White Coat on Patient Satisfaction in Indian Out Patient Department (OPD) Setting[NCT02669355] | 123 participants (Actual) | Observational | 2015-10-31 | Completed | |||
| Treat-to-target in RA: Collaboration To Improve adOption and adhereNce (TRACTION)[NCT02260778] | 11 participants (Actual) | Interventional | 2014-09-30 | Active, not recruiting | |||
| Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in Patients With Active Rheumatoid Arthritis (BACH)[NCT04985435] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-05-12 | Recruiting | ||
| Double Blind Randomized Comparison of a Subunit- and a Virosomal Influenza Vaccine in Immunocom-Promized Patients[NCT00783380] | Phase 4 | 304 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Methylprednisolone Taper to Treat Delayed Post-Operative Recovery After Total Knee Arthroplasty: a Double-Blind Randomized Controlled Trial[NCT05113901] | Phase 4 | 4 participants (Actual) | Interventional | 2022-03-03 | Terminated (stopped due to Extremely low participation, decided to focus on similar study instead) | ||
| Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial[NCT01400516] | Phase 4 | 26 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Open Label Multicenter Induction of CII Tolerance in Patients With Rheumatoid Arthritis[NCT00000401] | Phase 2 | 110 participants (Actual) | Interventional | 1999-07-31 | Completed | ||
| Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma[NCT00005675] | Phase 2 | 168 participants (Actual) | Interventional | 2000-04-30 | Completed | ||
| Patient Self-administration of Cortisol for Cortisol-responding Disorders in Men and Women Over the Age of 17, Demonstration of Double-blind Trial Results[NCT03558971] | Phase 4 | 2,430 participants (Actual) | Interventional | 2000-01-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index is calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter (cm) visual analog scale (VAS) + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 100 mm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores range from 0 to 76, with higher scores indicating increased disease activity. A positive change in score indicates worsening, and a negative change indicates improvement. (NCT02573012)
Timeframe: Baseline and Week 24
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | 2.663 |
| Tocilizumab+Prednisone (Constant Dose) | 0.321 |
The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint count, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100-millimeter (mm) visual analog scale (left end = no disease activity [symptom-free and no arthritis symptoms], right end = maximum disease activity [maximum arthritis disease activity]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A positive change in score indicates worsening, and a negative change indicates improvement. (NCT02573012)
Timeframe: Baseline to Week 24
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | 0.538 |
| Tocilizumab+Prednisone (Constant Dose) | -0.075 |
The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count based on a 28-joint assessment, patient and physician global assessment of disease activity according to 100-mm visual analog scale (VAS) and level of C-reactive protein in milligrams per deciliter (mg/dL, normal <1 mg/dl). The total SDAI score range is 0-86, where higher scores indicate increased disease activity. A positive change in score indicates worsening, and a negative change indicates improvement. (NCT02573012)
Timeframe: Randomization to Week 24
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | 2.511 |
| Tocilizumab+Prednisone (Constant Dose) | 0.248 |
Change from baseline in the acute phase reactant ESR (NCT02573012)
Timeframe: Baseline to Week 24
| Intervention | mm/hr (Mean) |
|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | 1.517 |
| Tocilizumab+Prednisone (Constant Dose) | -0.679 |
A measure of self-perceived disability containing 20 questions in eight categories and including additional section about aid from other people and devices needed to correct the disabilities. Scores range from 0 to 3, with higher scores indicating worse disability. (NCT02573012)
Timeframe: Baseline to Week 24
| Intervention | Score on a scale (Mean) |
|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | 0.167 |
| Tocilizumab+Prednisone (Constant Dose) | -0.087 |
Change from baseline in the acute phase reactant hsCRP (NCT02573012)
Timeframe: Baseline to Week 24
| Intervention | mg/dL (Mean) |
|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | -0.135 |
| Tocilizumab+Prednisone (Constant Dose) | -0.040 |
The ACR patient's assessment of pain is scored on a visual analog scale (VAS) from 0 (no pain) to 100 mm (unbearable pain). A positive change in score indicates worsening, and a negative change indicates improvement. (NCT02573012)
Timeframe: Baseline to Week 24
| Intervention | mm (Mean) |
|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | 4.648 |
| Tocilizumab+Prednisone (Constant Dose) | -8.010 |
The ACR patient's global assessment of disease activity is scored on a visual analog scale (VAS) from 0 (symptom-free and no arthritis symptoms) to 100 mm (maximum arthritis disease activity). A positive change in score indicates worsening, and a negative change indicates improvement. (NCT02573012)
Timeframe: Baseline to Week 24
| Intervention | cm (Mean) |
|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | 0.280 |
| Tocilizumab+Prednisone (Constant Dose) | -0.153 |
The ACR physician's global assessment of disease activity is scored on a visual analog scale (VAS) from 0 (symptom-free and no arthritis symptoms) to 100 mm (maximum arthritis disease activity). A positive change in score indicates worsening, and a negative change indicates improvement. (NCT02573012)
Timeframe: Baseline to Week 24
| Intervention | cm (Mean) |
|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | 0.345 |
| Tocilizumab+Prednisone (Constant Dose) | -0.248 |
Count of swollen joints based upon 66 assessed joints. (NCT02573012)
Timeframe: Baseline to Week 24
| Intervention | Swollen joints (Mean) |
|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | 0.129 |
| Tocilizumab+Prednisone (Constant Dose) | -0.107 |
Count of tender joints based on 68 assessed joints. (NCT02573012)
Timeframe: Baseline to Week 24
| Intervention | Tender joints (Mean) |
|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | 0.793 |
| Tocilizumab+Prednisone (Constant Dose) | -0.330 |
The RAID is a participant-completed questionnaire specific for RA consisting of a 0-10 rating for pain, functional disability, fatigue, sleep, physical well-being, emotional well-being and coping. Scores are weighted to produce a final numerical result. A positive change in score indicates worsening, and a negative change indicates improvement. (NCT02573012)
Timeframe: Baseline and Week 24
| Intervention | Score on a scale (Mean) |
|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | 0.469 |
| Tocilizumab+Prednisone (Constant Dose) | -0.220 |
Percentage of participants who permanently discontinue study treatment due to insufficient flare control (NCT02573012)
Timeframe: 24 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | 0 |
| Tocilizumab+Prednisone (Constant Dose) | 0.8 |
The proportion of participants with at least one administration of RA flare rescue medication. (NCT02573012)
Timeframe: Randomization to 24 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | 20.6 |
| Tocilizumab+Prednisone (Constant Dose) | 6.3 |
Percentage of participants with >=1 flare (NCT02573012)
Timeframe: 24 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | 26.0 |
| Tocilizumab+Prednisone (Constant Dose) | 10.9 |
Time of onset of first administration of RA flare rescue medication since randomization date (NCT02573012)
Timeframe: Randomization to 24 weeks
| Intervention | Weeks (Mean) |
|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | 13.59 |
| Tocilizumab+Prednisone (Constant Dose) | 8.76 |
The mean time of onset for the first RA flare since randomization. (NCT02573012)
Timeframe: Randomization to 24 weeks
| Intervention | Weeks (Mean) |
|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | 15.64 |
| Tocilizumab+Prednisone (Constant Dose) | 12.11 |
Treatment success was defined as the percentage of participants with stable low disease activity (LDA) (DAS28-ESR score ≤ 3.2) at Week 24 post-randomization, who did not suffer a flare due to RA and who showed no confirmed adrenal insufficiency that required replacement therapy. DAS28 has the following standardized cut-offs for disease activity and remission: DAS28 > 5.1 = high disease activity; DAS28 between 3.2 and 5.1 = moderate disease activity; DAS28 ≤ 3.2 = low disease activity; DAS28 ≤ 2.6 = remission. (NCT02573012)
Timeframe: Week 24
| Intervention | Percentage of Participants (Number) |
|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | 64.9 |
| Tocilizumab+Prednisone (Constant Dose) | 77.3 |
The WPAI:SHP is a 6-item questionnaire to measure performance impairment of work and regular daily activity and yields 4 types of scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (WI) (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). Total score and each score range from 0 (not affected/no impairment) to 100 (completely affected/impaired). Higher scores indicate greater impairment and less productivity. A positive change in score indicates impairment, and a negative change indicates improvement. (NCT02573012)
Timeframe: Baseline and Week 24
| Intervention | Score on a scale (Mean) | |||
|---|---|---|---|---|
| Percent work time missed due to problem | Percent impairment while working due to problem | Percent overall work impairment due to problem | Percent activity impairment due to problem | |
| Tocilizumab+Prednisone (Constant Dose) | 0.572 | -5.584 | -6.191 | -4.190 |
| Tocilizumab+Prednisone (Tapering Dose) | 4.535 | -0.851 | 6.219 | 3.398 |
"In Post-randomization prednisone arm, Cumulative dose = (number of capsules taken during week 1 to 4 * 1 mg) + (3/4 * number of capsules taken during week 5 to 8 * 1 mg) + (1/2 * number of capsules taken during week 9 to 12 * 1 mg) + (1/4 * number of capsules taken during week 13 to 16 * 1 mg). In continued arm, cumulative dose = (1/4 * number of capsule taken * 5 mg).~Cumulative prednisone dose is defined as cumulative blinded prednisone + cumulative flare rescue prednisone." (NCT02573012)
Timeframe: Randomization to 24 weeks
| Intervention | mg (Mean) | ||
|---|---|---|---|
| Cumulative blinded prednisone dose | Cumulative flare rescue prednisone dose | Cumulative prednisone dose | |
| Tocilizumab+Prednisone (Constant Dose) | 769.459 | 121.875 | 777.136 |
| Tocilizumab+Prednisone (Tapering Dose) | 267.099 | 98.519 | 287.405 |
Proportion of participants who received courses of RA flare rescue medication by number of courses received. (NCT02573012)
Timeframe: Randomization to 24 weeks
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| 0 courses | 1 course | 2 courses | 3 courses | >3 courses | |
| Tocilizumab+Prednisone (Constant Dose) | 93.8 | 3.9 | 1.6 | 0.8 | 0 |
| Tocilizumab+Prednisone (Tapering Dose) | 79.4 | 15.3 | 4.6 | 0 | 0.8 |
"The proportion of participants who maintained LDA and the proportion of participants who maintained the baseline disease activity level at Week 24.~LDA was defined as DAS28 ESR score <= 3.2. Remission was defined as DAS28 ESR score <= 2.6. Participants who maintained the baseline activity was defined as DAS28-ESR at Week 24 <= DAS28-ESR at baseline." (NCT02573012)
Timeframe: Randomization to Week 24
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| LDA at baseline | LDA at Week 24 | Baseline DAS28-ESR ≤ 2.6 | Remission at Week 24 | Maintained baseline activity at Week 24 | |
| Tocilizumab+Prednisone (Constant Dose) | 96.9 | 83.1 | 76.6 | 81.6 | 54.7 |
| Tocilizumab+Prednisone (Tapering Dose) | 97.7 | 73.4 | 78.6 | 61.2 | 36.6 |
(NCT02573012)
Timeframe: Randomization to 24 weeks
| Intervention | Percentage of visits with flares (Number) | |||
|---|---|---|---|---|
| 1 Visit | 2 Visits | 3 Visits | >3 Visits | |
| Tocilizumab+Prednisone (Constant Dose) | 7.0 | 3.9 | 0 | 0 |
| Tocilizumab+Prednisone (Tapering Dose) | 16.0 | 6.9 | 2.3 | 0.8 |
Cardiovascular Events (CVEs) such as mortality, myocardial infarction, stroke, or repeat revascularization among IHD patients at 12 months post-PCI and progressive erosive disease demonstrated in patients with rheumatic disease will be monitored. CVEs will be monitored to determine if there is a reduction in the occurrence of those events as a result of the intervention. (NCT02694185)
Timeframe: 1 year
| Intervention | Cardiovascular events (Mean) |
|---|---|
| Experimental Group | 15.2 |
| Control Group | 14.3 |
To establish the cost to implement and maintain the intervention, above the cost of usual care. Incremental Cost Effectiveness (ICE) is the cost to achieve a 10% improvement in PDC, and the cost of CVE prevented. (NCT02694185)
Timeframe: through study completion, an average of 1 year
| Intervention | dollars per patient (Median) |
|---|---|
| Experimental Group | 821.45 |
| Control Group | 893.55 |
Proportion of Days Covered (PDC) is measured by looking at the number of doses of medication a patient has versus days in the month (if a patient has 20 days of medication for a 30 day period their PDC is 20/30, 2/3, or 66.7%). Used to assess the effectiveness of the intervention, PDC will be tested among IHD patients in the year after PCI and among rheumatology clinic patients chronically prescribed DMARDs. (NCT02694185)
Timeframe: 1 year
| Intervention | percentage of days covered (Mean) | ||
|---|---|---|---|
| Anti-platelet | Beta-Blocker | Statin | |
| Control Group | 75.6 | 73.3 | 71.2 |
| Experimental Group | 82.6 | 78.4 | 78.8 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count of 28 joints (TJC28), swollen joint count of 28 joints (SJC28), patient's global assessment of disease activity visual analog scale (PGA VAS) with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to 10. Higher scores represent higher disease activity. DAS28-ESR remission is defined as a score < 2.6. (NCT01951170)
Timeframe: At Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Tocilizumab | 76.60 |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT01951170)
Timeframe: Up to Week 32 (end of follow up: 8 weeks after end of treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| Tocilizumab | 92.31 |
The CDAI is a combined index for measuring disease activity in rheumatoid arthritis and calculated as CDAI = TJC28 + SJC28 + PGA VAS (in mm) + Physician Global Assessment of Disease Activity VAS (in mm) with a total CDAI score ranging from 0-76. Higher scores indicate greater disease activity. The SDAI scale is divided into the following categories: Clinical remission = score ≤ 2.8; Low disease activity = score > 2.8 and ≤ 10.0; Moderate disease activity = score > 10.0 and ≤ 22.0; Severe disease = score > 22.0. A negative change from baseline indicates improvement. (NCT01951170)
Timeframe: From baseline to Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (n=51) | Change from baseline at Week 24 (n=46) | |
| Tocilizumab | 36.91 | -30.0 |
The FACIT measurement system is a collection of health-related quality of life questionnaires targeted to the management of chronic illness and includes questions on physical well-being, social/family well-being, emotional well-being and functional well-being. The FACIT-F Scale measures an individual's level of fatigue during their usual daily activities. Total scores range from 0 to 52 with lower scores representing greater fatigue, and scores below 30 representing severe fatigue. A positive change from baseline indicates improvement. (NCT01951170)
Timeframe: From baseline to Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (n=52) | Change from baseline at Week 24 (n=47) | |
| Tocilizumab | 27.42 | 12.62 |
The mTSS is a measure of joint damage that combines scores for bone erosion and joint-space narrowing (JNS). Erosion score: A total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=normal to 3.5=very severe erosion. JNS score: A total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=normal to 4.0=definite ankylosis (stiffness or fixation of a joint). mTSS scores ranged from 0 (normal) to 292 (worst possible total score). Change from baseline = mTSS score at Week 24 minus score at baseline. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement. (NCT01951170)
Timeframe: From baseline to Week 24
| Intervention | units on a scale (Median) | |
|---|---|---|
| Baseline | Change from baseline at Week 24 | |
| Tocilizumab | 7.00 | 0 |
HAQ-DI is the participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. A negative change from baseline indicates improvement. (NCT01951170)
Timeframe: From baseline to Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (n=52) | Change from baseline at Week 24 (n=47) | |
| Tocilizumab | 1.36 | -0.78 |
"PGA VAS is the participant's overall assessment of their current disease activity. The disease activity is displayed on a 100-mm horizontal VAS. The left-hand extreme (0 mm) of the line is described as no disease activity (symptom free and no arthritis symptoms) and the right-hand extreme (100 mm) is described as maximum disease activity (maximum arthritis disease activity). The change in PGA VAS is determined as the difference in values from baseline. A negative change from baseline indicates improvement." (NCT01951170)
Timeframe: From baseline to Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (n=52) | Change from baseline at Week 24 (n=47) | |
| Tocilizumab | 67.26 | -48.6 |
"The PGA pain VAS is the participant's overall assessment of pain. Pain is displayed on a 100-mm horizontal VAS. The left-hand extreme (0 mm) of the line is described as no pain and the right-hand extreme (100 mm) is described as unbearable pain. The change in PGA VAS is determined as the difference in values from baseline. A negative change from baseline indicates improvement." (NCT01951170)
Timeframe: From baseline to Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (n=52) | Change from baseline at Week 24 (n=47) | |
| Tocilizumab | 59.55 | -41.9 |
"The Physician Global Assessment of Disease Activity is the investigator's overall assessment of the participant's current disease activity. The disease activity is displayed on a 100-mm horizontal VAS. The left-hand extreme (0 mm) of the line is described as no disease activity (symptom free and no arthritis symptoms) and the right-hand extreme (100 mm) is described as maximum disease activity (maximum arthritis disease activity). The change in Physician Global Assessment of Disease Activity is determined as the difference in values from baseline. A negative change from baseline indicates improvement." (NCT01951170)
Timeframe: From baseline to Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (n=51) | Change from baseline at Week 24 (n=46) | |
| Tocilizumab | 64.63 | -48.8 |
Cartilage loss was assessed by MRI at baseline and Week 24. Scans of 25 joints were read and scored in pairs for each participant by 2 assessors. Scores for each location ranged 0-4 on a 9-point scale, with 0= no cartilage loss and 4= complete cartilage loss. Total score was the sum of the 25 individual scores and ranged 0-100 with 0= no cartilage loss and 100= most severe cartilage loss. A negative change from baseline indicates improvement. (NCT01951170)
Timeframe: From baseline to Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at Week 24 | |
| Tocilizumab | 6.29 | 0.12 |
Osteitis (bone inflammation) was assessed by MRI at baseline and Week 24. Scans of 25 bone locations were read and scored in pairs for each participant by 2 assessors. Scores for each location ranged 0-3 on a 4-point scale, with 0= no osteitis, 1= 1-33% involvement of original articular bone, 2= 34-67% involvement of original articular bone and 3= 68-100% involvement of original articular bone. Total score was the sum of the 25 individual scores and ranged 0-75 with 0= no osteitis and 75= most severe osteitis. A negative change from baseline indicates improvement. (NCT01951170)
Timeframe: From baseline to Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at Week 24 | |
| Tocilizumab | 6.63 | -4 |
Synovitis (synovial membrane inflammation) was assessed by MRI at baseline and Week 24. Scans of 8 joint locations were read and scored in pairs for each participant by 2 assessors. Scores for each location ranged 0-3 on a 4-point scale, with 0= no synovitis, 1= 1-33% volume enhancement, 2= 34-67% volume enhancement and 3= 68-100% volume enhancement. Total score was the sum of the 8 individual scores and ranged 0-24 with 0= no synovitis and 24= most severe synovitis. A negative change from baseline indicates improvement. (NCT01951170)
Timeframe: From baseline to Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at Week 24 | |
| Tocilizumab | 4.5 | -1.7 |
Bone erosions were assessed by magnetic resonance imaging (MRI) at baseline and Week 24. Scans of 25 bone locations were read and scored in pairs for each participant by 2 assessors. Scores for each location ranged 0-10 on an 11-point scale with 0= no erosion, 1= 1-10% erosion, 2= 11-20% erosion, and up to 10= 91-100% erosion. Total score was the sum of the 25 individual scores and ranged 0-250 with 0= no erosion and 250= most severe erosion. A negative change from baseline indicates improvement. (NCT01951170)
Timeframe: From baseline to Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at Week 24 | |
| Tocilizumab | 8.88 | 0.9 |
The SDAI is a combined index for measuring disease activity in rheumatoid arthritis and calculated as SDAI = TJC28 + SJC28 + PGA VAS (in mm) + Physician Global Assessment of Disease Activity VAS (in mm) + C reactive protein (CRP) in milligrams/deciliter (mg/dL) with a total SDAI score ranging from 0 to 86. Higher scores indicate greater disease activity. The SDAI scale is divided into the following categories: Clinical remission = score ≤ 3.3; Low disease activity = score > 3.3 and ≤ 11.0; Moderate disease activity = score > 11.0 and ≤ 26.0; Severe disease = score > 26.0. A negative change from baseline indicates improvement. (NCT01951170)
Timeframe: From baseline to Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (n=50) | Change from baseline at Week 24 (n=45) | |
| Tocilizumab | 38.65 | -31.6 |
SJC was counted based on 66 joints (SJC66) and based on 28 joints (SJC28). A negative change from baseline indicates improvement. (NCT01951170)
Timeframe: From baseline to Week 24
| Intervention | swollen joints (Mean) | |||
|---|---|---|---|---|
| SJC66: Baseline (n=52) | SJC66: Change from baseline at Week 24 (n=47) | SJC28: Baseline (n=52) | SJC28: Change from baseline at Week 24 (n=47) | |
| Tocilizumab | 17.00 | -13.0 | 10.71 | -8.77 |
TJC was counted based on 68 joints (TJC68) and based on 28 joints (TJC28). A negative change from baseline indicates improvement. (NCT01951170)
Timeframe: From baseline to Week 24
| Intervention | tender joints (Mean) | |||
|---|---|---|---|---|
| TJC68: Baseline (n=52) | TJC68: Change from baseline at Week 24 (n=47) | TJC28: Baseline (n=52) | TJC28: Change from Baseline at Week 24 (n=47) | |
| Tocilizumab | 24.27 | -20.8 | 13.19 | -11.1 |
EULAR response was calculated as the difference between DAS28-ESR scores at baseline and Week 24, and reported as the percentage of participants with good, moderate, or no response. Good responders = decrease from baseline >1.2 with a DAS28 score of ≤3.2; moderate responders = decrease from baseline >1.2 with a DAS28 score of >3.2, or decrease from baseline >0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders = decrease from baseline ≤0.6 or decrease from baseline >0.6 and ≤1.2 with a DAS28 score of >5.1. (NCT01951170)
Timeframe: From baseline to Week 24
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| No Response | Moderate | Good | |
| Tocilizumab | 2.13 | 17.02 | 80.85 |
A positive ACR20 response requires at least 20% improvement compared to baseline in SJC (66 joints) and TJC (68 joints) as well as at least 20% improvement in 3 of the following 5 assessments: 1) PGA pain VAS, 2) PGA VAS; 3) physician's global assessment of disease activity VAS, 4) Health Assessment Questionnaire-Disability Index (HAQ-DI) with 20 questions consisting of 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do; and 5) acute phase reactant (C-reactive protein [CRP] - if not available, ESR was used). ACR50 and ACR70 responses are defined in a similar way except that they required a 50% and 70% improvement from baseline, respectively. VAS range for all assessments was 0=no disease activity to 100=maximum disease activity. (NCT01951170)
Timeframe: From baseline to Week 24
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| ACR20 | ACR50 | ACR70 | |
| Tocilizumab | 91.49 | 76.60 | 53.19 |
(NCT01951170)
Timeframe: Up to Week 32 (end of follow up: 8 weeks after end of treatment)
| Intervention | adverse events (Number) | |
|---|---|---|
| Leading to withdrawal of study treatment | Leading to dose modification | |
| Tocilizumab | 2 | 3 |
A tocilizumab antibody screen was performed at baseline and at the end of follow up (8 weeks after end of treatment at Week 32). A confirmatory anti-tocilizumab antibody test was performed on positive screen samples. A confirmed positive test indicates the presence of tocilizumab antibodies. (NCT01951170)
Timeframe: At baseline, Week 32 (end of follow up: 8 weeks after end of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Baseline | Week 32 | |
| Tocilizumab | 0 | 0 |
Participants were provided with diary cards to record home injections. Compliance with treatment was calculated individually for each participant as the actual number of injections as a percentage of the planned number of injections (up to the point of discontinuation for those who discontinued study treatment prematurely) and then averaged among all participants. (NCT02046616)
Timeframe: Baseline up to Week 24
| Intervention | percentage of injections (Mean) |
|---|---|
| Tocilizumab Alone or Combined With Methotrexate or Other DMARD | 86.78 |
Participants were evaluated for the presence of anti-tocilizumab antibodies. Confirmatory assays were performed in the case of a positive screen assay result. (NCT02046616)
Timeframe: Baseline to FU Week 8 (up to 32 weeks overall)
| Intervention | participants (Number) |
|---|---|
| Tocilizumab Alone or Combined With Methotrexate or Other DMARD | 1 |
CDAI was derived as the sum of the following: TJC, SJC, PGA of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 mm and rounded to the nearest cm on a VAS, where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity. (NCT02046616)
Timeframe: Baseline and Weeks 2, 4, 8, 16, 20, 24
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 16 | Change at Week 20 | Change at Week 24 | |
| Tocilizumab Alone or Combined With Methotrexate or Other DMARD | -6.2 | -10.5 | -15.7 | -18.8 | -18.9 | -19.0 |
CDAI was derived as the sum of the following: tender joint count (TJC), swollen joint count (SJC), participant global assessment (PGA) of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 millimeters (mm) and rounded to the nearest centimeter (cm) on a visual analog scale (VAS), where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity. (NCT02046616)
Timeframe: Baseline, Week 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Week 12 | |
| Tocilizumab Alone or Combined With Methotrexate or Other DMARD | 24.9 | -16.6 |
DAS28-ESR was based on TJC, SJC, PGA of disease activity, and laboratory-derived ESR. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA of disease activity was scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity. The total DAS28-ESR score was transformed to a single score range of 0-10, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity. (NCT02046616)
Timeframe: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | |
| Tocilizumab Alone or Combined With Methotrexate or Other DMARD | 5.0 | -1.4 | -2.1 | -2.8 | -2.9 | -3.2 | -3.3 | -3.3 |
"FACIT-F consisted of 40 questions/statements assessing chronic illness therapy with special emphasis on fatigue over the past 7 days, with each item rated 0 (not at all) to 4 (very much). During score calculations, negatively-worded item scales (e.g., I have a lack of energy) were reversed so that higher scores indicated more favorable conditions. The total FACIT-F score was the sum of all item scores and ranged 0-160, and the brief FACIT-F score was the sum of 13 item scores and ranged 0-52, where higher scores indicate greater well-being. Change from baseline was averaged among all participants. Positive values indicate improvement in well-being." (NCT02046616)
Timeframe: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
| Intervention | units on a scale (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brief Score, Baseline (n=133) | Brief Score, Change at Week 2 | Brief Score, Change at Week 4 | Brief Score, Change at Week 8 | Brief Score, Change at Week 12 | Brief Score, Change at Week 16 | Brief Score, Change at Week 20 | Brief Score, Change at Week 24 | Total Score, Baseline | Total Score, Change at Week 2 | Total Score, Change at Week 4 | Total Score, Change at Week 8 | Total Score, Change at Week 12 | Total Score, Change at Week 16 | Total Score, Change at Week 20 | Total Score, Change at Week 24 | |
| Tocilizumab Alone or Combined With Methotrexate or Other DMARD | 32.9 | 3.4 | 5.7 | 6.6 | 7.6 | 7.9 | 8.0 | 8.4 | 106.8 | 6.9 | 13.0 | 15.1 | 17.1 | 18.0 | 18.6 | 20.1 |
HAQ-DI consisted of 20 questions assessing ADLs in 8 domains (dress/groom, arise, eat, walk, reach, grip, hygiene) with each item rated 0 (no difficulty) to 3 (unable to do). The highest score recorded for any question in a domain determined the score for that domain, unless assistance was required. The total HAQ-DI score was the sum of domain scores divided by the number of domains answered/scored, for a single score range of 0-3, where higher scores indicate increased functional disability. Change from baseline was averaged among all participants. Negative values indicate improvement in ability to perform ADLs. (NCT02046616)
Timeframe: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (n=133) | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | |
| Tocilizumab Alone or Combined With Methotrexate or Other DMARD | 1.2 | -0.1 | -0.3 | -0.5 | -0.5 | -0.6 | -0.6 | -0.6 |
PGA of disease activity was scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity. (NCT02046616)
Timeframe: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
| Intervention | mm (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | |
| Tocilizumab Alone or Combined With Methotrexate or Other DMARD | 53.2 | -6.8 | -20.3 | -24.6 | -30.3 | -32.3 | -32.2 | -34.3 |
PGA of RA-related pain was scored 0-100 mm on a VAS, where higher scores indicate greater perceived pain. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA-related pain. (NCT02046616)
Timeframe: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
| Intervention | mm (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 (n=128) | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | |
| Tocilizumab Alone or Combined With Methotrexate or Other DMARD | 54.8 | -9.1 | -22.5 | -28.9 | -32.8 | -35.6 | -35.0 | -37.8 |
SDAI was derived as the sum of the following: TJC, SJC, PGA of disease activity, physician assessment of disease activity, and laboratory-derived C-reactive protein level. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 mm and rounded to the nearest cm on a VAS, where higher scores indicate greater perceived disease activity. The total SDAI score range was 0-86, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity. (NCT02046616)
Timeframe: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | |
| Tocilizumab Alone or Combined With Methotrexate or Other DMARD | 35.76 | -15.37 | -20.32 | -25.89 | -26.19 | -29.03 | -28.47 | -28.93 |
SJC was taken as the number of swollen joints out of 28 assessed joints. (NCT02046616)
Timeframe: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
| Intervention | swollen joints (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | |
| Tocilizumab Alone or Combined With Methotrexate or Other DMARD | 6.8 | -2.3 | -3.1 | -4.8 | -5.3 | -5.9 | -6.0 | -5.4 |
TJC was taken as the number of tender joints out of 28 assessed joints. (NCT02046616)
Timeframe: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
| Intervention | tender joints (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | |
| Tocilizumab Alone or Combined With Methotrexate or Other DMARD | 8.8 | -2.1 | -3.5 | -5.8 | -5.5 | -6.7 | -6.7 | -7.1 |
ACR response was assessed on the basis of percent improvement (20% for ACR20, 50% for ACR50, 70% for ACR70) in both TJC and SJC as well as at least three of the following: physician assessment of disease activity, PGA of disease activity, PGA of pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), and either ESR or C-reactive protein level. TJC and SJC were taken as the number of tender and swollen joints, out of 68 and 66 assessed joints, respectively. PGA and physician assessments were scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity or pain. HAQ-DI was scored using participant responses to 20 questions assessing activities of daily living (ADLs), with total score scale of 0-3, where higher scores indicate increased functional disability. The percentage of participants meeting criteria for each level of ACR response was reported. (NCT02046616)
Timeframe: Weeks 2, 4, 8, 12, 16, 20, 24
| Intervention | percentage of participants (Number) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACR20, Week 2 | ACR20, Week 4 | ACR20, Week 8 | ACR20, Week 12 | ACR20, Week 16 | ACR20, Week 20 | ACR20, Week 24 | ACR50, Week 2 | ACR50, Week 4 | ACR50, Week 8 | ACR50, Week 12 (n=120) | ACR50, Week 16 | ACR50, Week 20 | ACR50, Week 24 | ACR70, Week 2 | ACR70, Week 4 | ACR70, Week 8 | ACR70, Week 12 | ACR70, Week 16 | ACR70, Week 20 | ACR70, Week 24 | |
| Tocilizumab Alone or Combined With Methotrexate or Other DMARD | 25.2 | 51.5 | 70.4 | 70.8 | 82.5 | 77.2 | 78.1 | 8.7 | 22.3 | 46.4 | 51.7 | 65.8 | 64.9 | 63.2 | 0.8 | 8.5 | 24.0 | 30.0 | 44.2 | 42.1 | 47.4 |
The percentage of participants with at least one adverse event leading to dose/frequency reduction or temporary dose hold was reported. (NCT02046616)
Timeframe: Baseline up to Week 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Dose/Frequency Reduced Due to Adverse Event | Dose Held Due to Adverse Event | |
| Tocilizumab Alone or Combined With Methotrexate or Other DMARD | 18.80 | 27.07 |
EULAR response was assessed by change from baseline and absolute DAS28-ESR score. EULAR response classification was as follows: Good (change >1.2 with absolute score 1.2 with absolute score >3.2 or change >0.6 with absolute score 5.1). DAS28-ESR was based on TJC, SJC, and PGA of disease activity, and laboratory-derived ESR. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA of disease activity was scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity. The total DAS28-ESR score was transformed to a single score range of 0-10, where higher scores indicate increased disease activity. The percentage of participants meeting criteria for each level of EULAR response was reported. (NCT02046616)
Timeframe: Weeks 2, 4, 8, 12, 16, 20, 24
| Intervention | percentage of participants (Number) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2, Good | Week 2, Moderate | Week 2, None | Week 4, Good | Week 4, Moderate | Week 4, None | Week 8, Good | Week 8, Moderate (n=125) | Week 8, None | Week 12, Good (n=119) | Week 12, Moderate | Week 12, None | Week 16, Good | Week 16, Moderate | Week 16, None | Week 20, Good | Week 20, Moderate | Week 20, None | Week 24, Good | Week 24, Moderate | Week 24, None | |
| Tocilizumab Alone or Combined With Methotrexate or Other DMARD | 29.1 | 47.2 | 23.6 | 51.2 | 39.5 | 9.3 | 78.4 | 16.8 | 4.8 | 78.2 | 16.0 | 5.9 | 87.5 | 9.2 | 3.3 | 86.7 | 8.8 | 4.4 | 87.7 | 9.6 | 2.6 |
sIL-6R concentration was determined, averaged among all participants, and expressed in nanograms per milliliter (ng/mL). (NCT02046616)
Timeframe: Predose (30 minutes) at baseline; Weeks 12, 24; and FU Week 8 (up to 32 weeks overall)
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| Baseline | Week 12 | Week 24 | FU Week 8 | |
| Tocilizumab Alone or Combined With Methotrexate or Other DMARD | 37.0 | 509.4 | 520.2 | 166.0 |
Tocilizumab concentration was determined, averaged among all participants, and expressed in micrograms per milliliter (mcg/mL). (NCT02046616)
Timeframe: Predose (30 minutes) at baseline; Weeks 12, 24; and FU Week 8 (up to 32 weeks overall)
| Intervention | mcg/mL (Mean) | |||
|---|---|---|---|---|
| Baseline | Week 12 | Week 24 | FU Week 8 | |
| Tocilizumab Alone or Combined With Methotrexate or Other DMARD | 0.6 | 47.4 | 48.0 | 32.8 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score 2.8 to 10 indicates low disease activity, >10 to 22 indicates moderate disease activity, and >22 indicates high disease activity. (NCT01941940)
Timeframe: Baseline, Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab | -19.1 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score 2.8 to 10 indicates low disease activity, >10 to 22 indicates moderate disease activity, and >22 indicates high disease activity. (NCT01941940)
Timeframe: Baseline, Week 16
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab | -20.2 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score 2.8 to 10 indicates low disease activity, >10 to 22 indicates moderate disease activity, and >22 indicates high disease activity. (NCT01941940)
Timeframe: Baseline, Week 2
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab | -9.1 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score 2.8 to 10 indicates low disease activity, >10 to 22 indicates moderate disease activity, and >22 indicates high disease activity. (NCT01941940)
Timeframe: Baseline, Week 20
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab | -21.3 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score 2.8 to 10 indicates low disease activity, >10 to 22 indicates moderate disease activity, and >22 indicates high disease activity. (NCT01941940)
Timeframe: Baseline, Week 4
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab | -14.0 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score 2.8 to 10 indicates low disease activity, >10 to 22 indicates moderate disease activity, and >22 indicates high disease activity. (NCT01941940)
Timeframe: Baseline, Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab | -17.7 |
The CDAI is a numerical sum of 4 outcome parameters: tender joint count (TJC) and swollen joint count (SJC) based on a 28-joint assessment, patient's global assessment of disease activity (PtGDA) and physician global assessment of disease activity (PGDA) assessed on 0-10 centimeters (cm) visual analogue scale (VAS). Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score less than or equal to () 2.8 to 10 indicates low disease activity, >10 to 22 indicates moderate disease activity, and >22 indicates high disease activity. (NCT01941940)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab | -21.6 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score NCT01941940)
Timeframe: Baseline up to Week 52 (Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 38, and 52)
| Intervention | participants (Number) |
|---|---|
| Tocilizumab | 10 |
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs are AEs occurring between the first dose of study drug and up to 28 days after the last dose that were absent before treatment or that worsened relative to pre-treatment state. Following AEs were considered as AEs of special interest: anaphylactic reaction, hypersensitivity, stress cardiomyopathy, Gilbert's syndrome, gastrointestinal perforation, injection site erythema, injection site hypersensitivity, injection site irritation, injection site pruritus, arthritis bacterial, cellulitis, klebsiella infection, oral candidiasis, pneumonia, skin infection, vulvovaginal candidiasis, alanine aminotransferase increased, hepatic enzyme increased, brain neoplasm malignant, and urticaria. (NCT01941940)
Timeframe: Baseline up to 95 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tocilizumab | 7.5 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. EULAR response criteria (based on DAS28 score): Good responders (change from baseline >1.2 with DAS28 1.2 with DAS28 >3.2 to 0.6 to 0.6 and 5.1). Regression coefficient for relationship between CDAI and EULAR Good response at different time points is reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship. (NCT01941940)
Timeframe: Weeks 2, 24, 52
| Intervention | regression coefficient (Number) | ||
|---|---|---|---|
| Week 2: CDAI and EULAR (n=220) | Week 24: CDAI and EULAR (n=186) | Week 52: CDAI and EULAR (n=32) | |
| Tocilizumab | -10.97686 | -7.03184 | -9.46563 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. The ACR 20, 50, and 70 responses: >/=20%, 50%, and 70% improvement in TJC and SJC, and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit. Regression coefficients for relationship between CDAI and ACR responses (ACR20, ACR50, and ACR70) at different time points are reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship. (NCT01941940)
Timeframe: Weeks 2, 24, 52
| Intervention | regression coefficient (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 2: CDAI and ACR20 (n=220) | Week 2: CDAI and ACR50 (n=220) | Week 2: CDAI and ACR70 (n=220) | Week 24: CDAI and ACR20 (n=186) | Week 24: CDAI and ACR50 (n=186) | Week 24: CDAI and ACR70 (n=186) | Week 52: CDAI and ACR20 (n=32) | Week 52: CDAI and ACR50 (n=32) | Week 52: CDAI and ACR70 (n=32) | |
| Tocilizumab | -9.65473 | -10.67389 | -13.38810 | -13.18433 | -11.95933 | -11.18299 | -18.94643 | -18.94643 | -18.94643 |
DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. EULAR response criteria (based on DAS28 score): Good responders (change from baseline >1.2 with DAS28 1.2 with DAS28 >3.2 to 0.6 to 0.6 and 5.1). Regression coefficient for relationship between DAS28-ESR and EULAR Good response at different time points is reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship. (NCT01941940)
Timeframe: Weeks 2, 24, 52
| Intervention | regression coefficient (Number) | ||
|---|---|---|---|
| Week 2: DAS28-ESR and EULAR (n=213) | Week 24: DAS28-ESR and EULAR (n=182) | Week 52: DAS28-ESR and EULAR (n=32) | |
| Tocilizumab | -1.62883 | -1.36226 | -1.47781 |
DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. The ACR 20, 50, and 70 responses: >/=20%, 50%, and 70% improvement in TJC and SJC, and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit. Regression coefficients for relationship between DAS28-ESR and ACR responses (ACR20, ACR50, and ACR70) at different time points are reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship. (NCT01941940)
Timeframe: Weeks 2, 24, 52
| Intervention | regression coefficient (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 2: DAS28-ESR and ACR20 (n=213) | Week 2: DAS28-ESR and ACR50 (n=213) | Week 2: DAS28-ESR and ACR70 (n=213) | Week 24: DAS28-ESR and ACR20 (n=182) | Week 24: DAS28-ESR and ACR50 (n=182) | Week 24: DAS28-ESR and ACR70 (n=182) | Week 52: DAS28-ESR and ACR20 (n=32) | Week 52: DAS28-ESR and ACR50 (n=32) | Week 52: DAS28-ESR and ACR70 (n=32) | |
| Tocilizumab | -1.02676 | -1.31737 | -1.50400 | -1.71191 | -1.54281 | -1.43977 | -2.05036 | -2.05036 | -2.05036 |
The SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. EULAR response criteria (based on DAS28 score): Good responders (change from baseline >1.2 with DAS28 1.2 with DAS28 >3.2 to 0.6 to 0.6 and 5.1). Regression coefficient for relationship between SDAI and EULAR Good response at different time points is reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship. (NCT01941940)
Timeframe: Weeks 2, 24, 52
| Intervention | regression coefficient (Number) | ||
|---|---|---|---|
| Week 2: SDAI and EULAR (n=213) | Week 24: SDAI and EULAR (n=185) | Week 52: SDAI and EULAR (n=31) | |
| Tocilizumab | -11.73463 | -7.32435 | -9.64146 |
SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. The ACR 20, 50, and 70 responses: >/=20%, 50%, and 70% improvement in TJC and SJC, and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit. Regression coefficients for relationship between SDAI and ACR responses (ACR20, ACR50, and ACR70) at different time points are reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship. (NCT01941940)
Timeframe: Weeks 2, 24, 52
| Intervention | regression coefficient (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 2: SDAI and ACR20 (n=213) | Week 2: SDAI and ACR50 (n=213) | Week 2: SDAI and ACR70 (n=213) | Week 24: SDAI and ACR20 (n=185) | Week 24: SDAI and ACR50 (n=185) | Week 24: SDAI and ACR70 (n=185) | Week 52: SDAI and ACR20 (n=31) | Week 52: SDAI and ACR50 (n=31) | Week 52: SDAI and ACR70 (n=31) | |
| Tocilizumab | -9.44923 | -10.74230 | -13.31421 | -14.19790 | -12.65454 | -11.78067 | -22.83519 | -22.83519 | -22.83519 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. Higher scores represent greater affectation due to disease activity. SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. Higher scores indicate greater affectation due to disease activity. Correlation coefficient for relationship between CDAI and SDAI at different time points is reported. Correlation coefficient value range= -1 to 1. Higher positive value indicates greater positive relationship and higher negative value indicates greater negative relationship. (NCT01941940)
Timeframe: Weeks 2, 24, 52
| Intervention | correlation coefficient (Number) | ||
|---|---|---|---|
| Week 2 (n=213) | Week 24 (n=185) | Week 52 (n=31) | |
| Tocilizumab | 0.98602 | 0.97515 | 0.97389 |
DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. Higher scores indicate greater affectation due to disease activity. The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. Higher scores represent greater affectation due to disease activity. Correlation coefficient for relationship between DAS28-ESR and CDAI at different time points is reported. Correlation coefficient value range= -1 to 1. Higher positive value indicates greater positive relationship and higher negative value indicates greater negative relationship. (NCT01941940)
Timeframe: Weeks 2, 24, 52
| Intervention | correlation coefficient (Number) | ||
|---|---|---|---|
| Week 2 (n=213) | Week 24 (n=182) | Week 52 (n=32) | |
| Tocilizumab | 0.86514 | 0.86944 | 0.87301 |
DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. Higher scores indicate greater affectation due to disease activity. SDAI is a numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. Higher scores indicate greater affectation due to disease activity. Correlation coefficient for relationship between DAS28-ESR and SDAI at different time points is reported. Correlation coefficient value range= -1 to 1. Higher positive value indicates greater positive relationship and higher negative value indicates greater negative relationship. (NCT01941940)
Timeframe: Weeks 2, 24, 52
| Intervention | correlation coefficient (Number) | ||
|---|---|---|---|
| Week 2 (n=213) | Week 24 (n=182) | Week 52 (n=31) | |
| Tocilizumab | 0.88118 | 0.87060 | 0.81995 |
DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hour) and PtGDA assessed on 0-10 cm VAS. Higher scores indicate greater affectation due to disease activity. DAS28-ESR total score= 0-9.4. DAS28-ESR 3.2 to 5.1 indicates moderate to high disease activity, and DAS28-ESR NCT01941940)
Timeframe: Baseline, Weeks 2, 24, and 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline (n=216) | Change at Week 2 (n=208) | Change at Week 24 (n=174) | Change at Week 52 (n=31) | |
| Tocilizumab | 5.81 | -1.5 | -3.2 | -3.6 |
FACIT total score is sum of Functional Assessment of Cancer Therapy-General (FACT-G) score and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F; additional concerns) score. FACT-G is a core questionnaire that evaluates quality of life (QoL) in cancer population. FACT-G consists of 27 questions grouped in 4 domains of general health-related QoL: physical well-being, social/family well-being, emotional well-being, and functional well-being; each item ranges from 0 (not at all) to 4 (very much). FACT-G score ranges between 0-108. FACIT-F is a 13-item questionnaire that evaluates self-reported fatigue and its impact upon daily activities. Each item ranges from 0 (Not at all) to 4 (Very much). The sum of all responses result in the FACIT total score with a total possible range of 0 (better score) to 160 (worse score). Negative change from baseline represents a better QoL. (NCT01941940)
Timeframe: Baseline, Weeks 2, 24, and 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline (n=207) | Change at Week 2 (n=196) | Change at Week 24 (n=165) | Change at Week 52 (n=60) | |
| Tocilizumab | 72.41 | -5.8 | -11.1 | -43.8 |
HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. (NCT01941940)
Timeframe: Baseline, Weeks 2, 24, and 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline (n=223) | Change at Week 2 (n=215) | Change at Week 24 (n=183) | Change at Week 52 (n=31) | |
| Tocilizumab | 1.04 | -0.2 | -0.4 | -0.5 |
The physician assessed participant's current disease activity on a 0-100 mm VAS, where 0 mm = no disease activity and 100 mm = maximum disease activity. (NCT01941940)
Timeframe: Baseline, Weeks 2, 24, and 52
| Intervention | mm (Mean) | |||
|---|---|---|---|---|
| Baseline (n=226) | Change at Week 2 (n=220) | Change at Week 24 (n=186) | Change at Week 52 (n=32) | |
| Tocilizumab | 57.36 | -15.3 | -38.0 | -43.9 |
PSQI is a questionnaire with 18 questions to assess sleep quality. The 18 questions are distributed to 7 elements (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction). A participant indicates how frequently each item was experienced on a scale from 0 to 3. The global score is the sum score of all 7 elements and ranges from 0-21 with higher values indicating worse sleep quality. A score of >/=5 indicates poor sleepers. (NCT01941940)
Timeframe: Baseline, Weeks 24 and 52
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline (n=103) | Change at Week 24 (n=73) | Change at Week 52 (n=16) | |
| Tocilizumab | 11.00 | -0.7 | -0.9 |
"Participants answered the following question: Considering all the ways your arthritis affects you, how are you feeling today. Participants responded by using a 0 - 100 millimeter (mm) VAS, where 0 mm = very well and 100 mm = very poorly." (NCT01941940)
Timeframe: Baseline, Weeks 2, 24, and 52
| Intervention | mm (Mean) | |||
|---|---|---|---|---|
| Baseline (n=226) | Change at Week 2 (n=220) | Change at Week 24 (n=186) | Change at Week 52 (n=32) | |
| Tocilizumab | 61.31 | -10.6 | -28.4 | -38.4 |
SDAI is a numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and C-reactive protein (CRP) in milligrams per deciliter (mg/dL). Higher scores indicate greater affectation due to disease activity. SDAI total score = 0-86. SDAI 3.4 to 11 indicates low disease activity, >11 to 26 indicates moderate disease activity, and >26 indicates high disease activity. (NCT01941940)
Timeframe: Baseline, Weeks 2, 24, and 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline (n=215) | Change at Week 2 (n=203) | Change at Week 24 (n=176) | Change at Week 52 (n=29) | |
| Tocilizumab | 48.70 | -26.5 | -38.9 | -39.3 |
SJC was defined as the total number of swollen joints based on 66-joint assessment (SJC-66) and 28-joint assessment (SJC-28). (NCT01941940)
Timeframe: Baseline, Weeks 2, 24, and 52
| Intervention | swollen joints (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| SJC-66, Baseline (n=223) | SJC-66, Change at Week 2 (n=218) | SJC-66, Change at Week 24 (n=188) | SJC-66, Change at Week 52 (n=69) | SJC-28, Baseline (n=224) | SJC-28, Change at Week 2 (n=219) | SJC-28, Change at Week 24 (n=189) | SJC-28, Change at Week 52 (n=70) | |
| Tocilizumab | 9.53 | -3.7 | -8.3 | -9.1 | 7.90 | -2.9 | -6.7 | -7.6 |
TJC was defined as the total number of painful joints based on 68-joint assessment (TJC-68) and 28-joint assessment (TJC-28). (NCT01941940)
Timeframe: Baseline, Weeks 2, 24, and 52
| Intervention | tender joints (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| TJC-68, Baseline (n=223) | TJC-68, Change at Week 2 (n=218) | TJC-68, Change at Week 24 (n=188) | TJC-68, Change at Week 52 (n=69) | TJC-28, Baseline (n=224) | TJC-28, Change at Week 2 (n=219) | TJC-28, Change at Week 24 (n=189) | TJC-28, Change at Week 52 (n=70) | |
| Tocilizumab | 16.91 | -5.4 | -12.9 | -16.5 | 11.32 | -3.7 | -8.6 | -11.0 |
(NCT01941940)
Timeframe: Baseline, Weeks 12, 24, 38, 52, at early withdrawal (up to Week 52), at Follow-up Visit 2 (Week 76)
| Intervention | nanograms per milliliter (ng/mL) (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline (n=213) | Week 12 (n=189) | Week 24 (n=181) | Week 38 (n=171) | Week 52 (n=168) | Early Withdrawal (up to Week 52) (n=32) | Follow-up Visit 2 (Week 76) (n=18) | |
| Tocilizumab | 43.6 | 543.9 | 536.3 | 557.8 | 539.4 | 329.1 | 523.4 |
(NCT01941940)
Timeframe: Baseline, Weeks 12, 24, 38, 52, at early withdrawal (up to Week 52), at Follow-up Visit 2 (Week 76)
| Intervention | micrograms per milliliter (mcg/mL) (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline (n=2) | Week 12 (n=186) | Week 24 (n=177) | Week 38 (n=169) | Week 52 (n=165) | Early Withdrawal (up to Week 52) (n=19) | Follow-up Visit 2 (Week 76) (n=17) | |
| Tocilizumab | 35.6 | 46.4 | 52.6 | 55.2 | 54.0 | 24.8 | 49.2 |
The SF-HLQ assessed productivity losses related to health problems in individuals with paid or unpaid work and consisted of three modules (absenteeism from paid work, production losses without absenteeism from paid work and hindrance in the performance of paid and unpaid work). Any missed working days or number of worked days with reduced efficiency during the last month were reported. (NCT01941940)
Timeframe: Weeks 24 and 52
| Intervention | days (Mean) | |
|---|---|---|
| Week 24 (n=69) | Week 52 (n=7) | |
| Tocilizumab | 6.4 | 0.3 |
Participants assessed their pain using a 0-100 mm VAS. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain. (NCT01941940)
Timeframe: Weeks 2, 24, and 52
| Intervention | mm (Mean) | |||
|---|---|---|---|---|
| Baseline (n=226) | Change at Week 2 (n=220) | Change at Week 24 (n=186) | Change at Week 52 (n=32) | |
| Tocilizumab | 58.21 | -11.4 | -26.5 | -36.0 |
Percentage of DMARDs dose reduction and/or discontinuation (Red/Dis) events is reported by different reasons. (NCT01941940)
Timeframe: Baseline up to Week 52
| Intervention | percentage of events (Number) | ||||
|---|---|---|---|---|---|
| Safety | Discomfort | Lack of Efficacy | Other Than Above | Unknown | |
| Tocilizumab | 27.7 | 9.5 | 29.7 | 31.1 | 2.0 |
Percentage of Non-DMARDs dose reduction and/or discontinuation (Red/Dis) events is reported by different reasons. (NCT01941940)
Timeframe: Baseline up to Week 52
| Intervention | percentage of events (Number) | ||||
|---|---|---|---|---|---|
| Safety | Discomfort | Lack of Efficacy | Other Than Above | Unknown | |
| Tocilizumab | 9.5 | 1.3 | 8.8 | 73.7 | 6.8 |
The ACR 20, 50, and 70 responses: greater than or equal to (>/=) 20 percent (%), 50%, and 70% improvement in TJC and SJC (28 assessed joints), and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP or ESR at each visit. (NCT01941940)
Timeframe: Weeks 2, 24, and 52
| Intervention | percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 2: ACR 20 (n=222) | Week 2: ACR 50 (n=222) | Week 2: ACR 70 (n=222) | Week 24: ACR 20 (n=192) | Week 24: ACR 50 (n=192) | Week 24: ACR 70 (n=192) | Week 52: ACR 20 (n=70) | Week 52: ACR 50 (n=70) | Week 52: ACR 70 (n=70) | |
| Tocilizumab | 18.5 | 6.3 | 11.7 | 8.3 | 4.7 | 65.6 | 0.0 | 0.0 | 40.0 |
Percentage of participants with positive results for ATA against tocilizumab at different time points is reported. (NCT01941940)
Timeframe: Baseline, Weeks 12, 24, 38, 52, at 8 weeks after last dose (up to Week 60), at early withdrawal (up to Week 52), at Follow-up Visits 1 (Week 64), 2 (Week 76), and 3 (Week 88)
| Intervention | percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=227) | Week 12 (n=6) | Week 24 (n=179) | Week 38 (n=6) | Week 52 (n=161) | 8 Weeks After Last Dose (up to Week 60) (n=41) | Early Withdrawal (up to Week 52) (n=31) | Follow-up Visit 1 (Week 64) (n=16) | Follow-up Visit 2 (Week 76) (n=11) | Follow-up Visit 3 (Week 88) (n=3) | |
| Tocilizumab | 2.6 | 100.0 | 1.7 | 33.3 | 1.2 | 2.4 | 6.5 | 100.0 | 100.0 | 100.0 |
The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline >1.2 with DAS28 1.2 with DAS28 >3.2 to 0.6 to 0.6 and 5.1. (NCT01941940)
Timeframe: Baseline, Weeks 2, 24, and 52
| Intervention | percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 2: No Response (n=222) | Week 2: Moderate Response (n=222) | Week 2: Good Response (n=222) | Week 24: No Response (n=192) | Week 24: Moderate Response (n=192) | Week 24: Good Response (n=192) | Week 52: No Response (n=70) | Week 52: Moderate Response (n=70) | Week 52: Good Response (n=70) | |
| Tocilizumab | 32.4 | 50.5 | 17.1 | 13.5 | 25.0 | 61.5 | 55.7 | 8.6 | 35.7 |
Treatment Compliance was calculated as (total actual doses taken for the period) / (total planned or prescribed dose for the period) x 100. (NCT01941940)
Timeframe: Weeks 24 and 52
| Intervention | percentage of planned dose (Mean) | |
|---|---|---|
| Week 24 (n=221) | Week 52 (n=222) | |
| Tocilizumab | 94.9 | 94.7 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, >3.2 to ≤5.1 implied moderate disease activity, >5.1 implied high/severe disease, and <2.6 implied clinical remission. (NCT02046603)
Timeframe: Baseline, early withdrawal (up to Week 52)
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab Monotherapy | -2.88 |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | -1.63 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, >3.2 to ≤5.1 implied moderate disease activity, >5.1 implied high/severe disease, and <2.6 implied clinical remission. (NCT02046603)
Timeframe: Baseline, Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab Monotherapy | -2.33 |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | -2.99 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, >3.2 to ≤5.1 implied moderate disease activity, >5.1 implied high/severe disease, and <2.6 implied clinical remission. (NCT02046603)
Timeframe: Baseline, Week 16
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab Monotherapy | -2.93 |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | -3.07 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, >3.2 to ≤5.1 implied moderate disease activity, >5.1 implied high/severe disease, and <2.6 implied clinical remission. (NCT02046603)
Timeframe: Baseline, Week 20
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab Monotherapy | -3.17 |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | -3.13 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, >3.2 to ≤5.1 implied moderate disease activity, >5.1 implied high/severe disease, and <2.6 implied clinical remission. (NCT02046603)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab Monotherapy | -3.28 |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | -3.33 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, >3.2 to ≤5.1 implied moderate disease activity, >5.1 implied high/severe disease, and <2.6 implied clinical remission. (NCT02046603)
Timeframe: Baseline, Week 28
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab Monotherapy | -3.54 |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | -3.32 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, >3.2 to ≤5.1 implied moderate disease activity, >5.1 implied high/severe disease, and <2.6 implied clinical remission. (NCT02046603)
Timeframe: Baseline, Week 32
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab Monotherapy | -3.19 |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | -3.54 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, >3.2 to ≤5.1 implied moderate disease activity, >5.1 implied high/severe disease, and <2.6 implied clinical remission. (NCT02046603)
Timeframe: Baseline, Week 36
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab Monotherapy | -3.57 |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | -3.55 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, >3.2 to ≤5.1 implied moderate disease activity, >5.1 implied high/severe disease, and <2.6 implied clinical remission. (NCT02046603)
Timeframe: Baseline, Week 4
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab Monotherapy | -1.86 |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | -2.11 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, >3.2 to ≤5.1 implied moderate disease activity, >5.1 implied high/severe disease, and <2.6 implied clinical remission. (NCT02046603)
Timeframe: Baseline, Week 40
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab Monotherapy | -3.82 |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | -3.64 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, >3.2 to ≤5.1 implied moderate disease activity, >5.1 implied high/severe disease, and <2.6 implied clinical remission. (NCT02046603)
Timeframe: Baseline, Week 44
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab Monotherapy | -3.61 |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | -3.65 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, >3.2 to ≤5.1 implied moderate disease activity, >5.1 implied high/severe disease, and <2.6 implied clinical remission. (NCT02046603)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab Monotherapy | -3.54 |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | -3.65 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, >3.2 to ≤5.1 implied moderate disease activity, >5.1 implied high/severe disease, and <2.6 implied clinical remission. (NCT02046603)
Timeframe: Baseline, Week 52
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab Monotherapy | -3.75 |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | -3.67 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, >3.2 to ≤5.1 implied moderate disease activity, >5.1 implied high/severe disease, and <2.6 implied clinical remission. (NCT02046603)
Timeframe: Baseline, Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Tocilizumab Monotherapy | -2.42 |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | -2.62 |
Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 66. A reduction in number of swollen joints compared to baseline indicates improvement. The outcome is reported as the percent change from baseline to end of treatment (52 weeks). (NCT02046603)
Timeframe: Baseline, Week 52
| Intervention | percent change (Mean) |
|---|---|
| Tocilizumab Monotherapy | -89.31 |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | -74.77 |
Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 68. A reduction in number of tender joints compared to baseline indicates improvement. The outcome is reported as the percent change from baseline to end of treatment (52 weeks). (NCT02046603)
Timeframe: Baseline, Week 52
| Intervention | percent change (Mean) |
|---|---|
| Tocilizumab Monotherapy | -83.12 |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | -80.44 |
The CDAI is the numerical sum of four outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician's global assessment of disease activity assessed on 0-10 cm VAS (0 cm= no disease activity and 10 cm= worst disease activity). CDAI total score = 0-76. CDAI ≤2.8 indicates clinical remission, >2.8 to 10 = low disease activity, >10 to 22 = moderate disease activity, and >22 = high (or severe) disease activity. (NCT02046603)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
| Intervention | units on a scale (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | Change at Week 28 | Change at Week 32 | Change at Week 36 | Change at Week 40 | Change at Week 44 | Change at Week 48 | Change at Week 52 | Change at early withdrawal | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 30.88 | -5.16 | -12.26 | -15.63 | -18.66 | -19.51 | -19.23 | -21.96 | -21.48 | -23.20 | -23.10 | -24.01 | -24.42 | -24.59 | -24.42 | -8.68 |
| Tocilizumab Monotherapy | 29.69 | -8.35 | -11.87 | -17.74 | -15.39 | -20.70 | -22.19 | -22.88 | -23.43 | -21.55 | -24.86 | -25.74 | -25.42 | -25.36 | -25.48 | -17.78 |
DAS28 was calculated from swollen joint count (SJC) and tender joint count (TJC) using 28 joints count, erythrocyte sedimentation rate (ESR; millimeters per hour [mm/hour]), and patient's global assessment of disease activity (measured on a 0 to 100 mm Visual Analog Scale [VAS] where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR greater than or equal to (≥) 2.6 to less than or equal to (≤) 3.2 implied low disease activity, greater than (>) 3.2 to ≤5.1 implied moderate disease activity, >5.1 implied high/severe disease, and less than (<) 2.6 implied clinical remission. (NCT02046603)
Timeframe: Baseline, Week 2
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Week 2 | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 5.53 | -1.22 |
| Tocilizumab Monotherapy | 5.52 | -1.41 |
The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician global assessment of disease activity assessed on 0-10 centimeter (cm) VAS (0 cm= no disease activity and 10 cm= worst disease activity), and CRP in milligrams per liter (mg/L). SDAI total score = 0-86. SDAI ≤3.3 indicates clinical remission, >3.3 to 11 = low disease activity, >11 to 26 = moderate disease activity, and >26 = high (or severe) disease activity. (NCT02046603)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
| Intervention | units on a scale (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | Change at Week 28 | Change at Week 32 | Change at Week 36 | Change at Week 40 | Change at Week 44 | Change at Week 48 | Change at Week 52 | Change at early withdrawal | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 32.33 | -6.94 | -13.92 | -17.21 | -20.26 | -21.16 | -20.50 | -23.48 | -23.26 | -24.94 | -24.65 | -25.46 | -26.08 | -26.13 | -26.15 | -9.45 |
| Tocilizumab Monotherapy | 31.23 | -9.80 | -12.64 | -19.75 | -14.65 | -19.48 | -23.67 | -24.31 | -24.87 | -22.98 | -26.32 | -27.29 | -27.71 | -26.83 | -27.45 | -18.94 |
Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28. A reduction in number of swollen joints compared to baseline indicates improvement. (NCT02046603)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
| Intervention | swollen joints (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | Change at Week 28 | Change at Week 32 | Change at Week 36 | Change at Week 40 | Change at Week 44 | Change at Week 48 | Change at Week 52 | Change at early withdrawal | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 5.6 | -0.8 | -2.5 | -3.2 | -3.8 | -3.9 | -4.2 | -4.7 | -4.4 | -4.8 | -4.9 | -5.0 | -5.2 | -5.0 | -5.1 | -1.7 |
| Tocilizumab Monotherapy | 7.0 | -2.5 | -4.2 | -4.8 | -4.2 | -5.3 | -5.6 | -5.9 | -6.4 | -5.4 | -6.5 | -6.6 | -6.6 | -6.4 | -6.3 | -5.8 |
Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28. A reduction in number of tender joints compared to baseline indicates improvement. (NCT02046603)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
| Intervention | tender joints (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | Change at Week 28 | Change at Week 32 | Change at Week 36 | Change at Week 40 | Change at Week 44 | Change at Week 48 | Change at Week 52 | Change at early withdrawal | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 12.9 | -2.4 | -5.4 | -6.4 | -8.0 | -8.2 | -8.3 | -9.3 | -9.2 | -10.1 | -9.7 | -10.3 | -10.4 | -10.5 | -10.4 | -3.3 |
| Tocilizumab Monotherapy | 10.4 | -3.4 | -3.9 | -6.6 | -6.0 | -7.9 | -8.5 | -8.3 | -8.7 | -7.6 | -9.4 | -10.1 | -9.7 | -9.6 | -9.4 | -7.0 |
The FACIT-F score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-F score for a total possible score of 0 (worse score) to 52 (better score). (NCT02046603)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
| Intervention | units on a scale (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | Early withdrawal | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 24.3 | 27.9 | 30.7 | 32.8 | 33.7 | 34.0 | 34.1 | 35.3 | 35.5 | 36.2 | 36.8 | 37.1 | 37.2 | 37.9 | 38.1 | 24.5 |
| Tocilizumab Monotherapy | 18.4 | 23.1 | 25.1 | 30.2 | 28.4 | 31.3 | 33.2 | 33.8 | 32.9 | 34.1 | 30.3 | 31.7 | 31.0 | 31.6 | 33.4 | 31.3 |
The HAQ-DI questionnaire measures functional status (disability) and health-related quality of life. It measures the participant's ability to perform everyday tasks. The index consists of 20 questions regarding the function of the upper and lower extremities. These questions are summarized in 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common activities over past week. Each question is evaluated according to the degree of severity on a 4-point scale. Total score for HAQ-DI was the average of all questions and ranges from 0 = without any difficulty to 3 = unable to do. (NCT02046603)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
| Intervention | units on a scale (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | Early withdrawal | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 1.738 | 1.659 | 1.546 | 1.404 | 1.333 | 1.312 | 1.318 | 1.261 | 1.221 | 1.232 | 1.170 | 1.199 | 1.130 | 1.114 | 1.154 | 1.756 |
| Tocilizumab Monotherapy | 1.806 | 1.558 | 1.616 | 1.508 | 1.488 | 1.351 | 1.409 | 1.330 | 1.330 | 1.351 | 1.432 | 1.479 | 1.442 | 1.361 | 1.338 | 1.252 |
A participant had an ACR50 response if there was at least a 50% improvement, ie, reduction from Baseline, in TJC (68 joints) and SJC (66 joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity [VAS: 0 mm=no disease activity to 100 mm=maximum disease activity]; 2) Patient's Global Assessment of Disease Activity [VAS: 0 mm=no disease activity to 100 mm=maximum disease activity]; 3) Patient's Assessment of Pain [VAS: 0 mm=no pain to 100 mm=unbearable pain]; 4) Health Assessment Questionnaire [20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, averaged to 0=without difficulty to 3=unable to do] and 5) an acute-phase reactant (either CRP or ESR). (NCT02046603)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
| Intervention | participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | Early withdrawal | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 5 | 20 | 43 | 54 | 62 | 61 | 64 | 68 | 69 | 74 | 71 | 72 | 73 | 73 | 4 |
| Tocilizumab Monotherapy | 0 | 3 | 6 | 8 | 7 | 9 | 9 | 13 | 8 | 9 | 9 | 10 | 11 | 8 | 2 |
A participant had an ACR70 response if there was at least a 70% improvement, ie, reduction from Baseline, in TJC (68 joints) and SJC (66 joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity [VAS: 0 mm=no disease activity to 100 mm=maximum disease activity]; 2) Patient's Global Assessment of Disease Activity [VAS: 0 mm=no disease activity to 100 mm=maximum disease activity]; 3) Patient's Assessment of Pain [VAS: 0 mm=no pain to 100 mm=unbearable pain]; 4) Health Assessment Questionnaire [20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, averaged to 0=without difficulty to 3=unable to do] and 5) an acute-phase reactant (either CRP or ESR). (NCT02046603)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
| Intervention | participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | Early withdrawal | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 0 | 9 | 19 | 30 | 32 | 37 | 38 | 44 | 47 | 48 | 49 | 53 | 56 | 54 | 1 |
| Tocilizumab Monotherapy | 0 | 1 | 4 | 3 | 3 | 7 | 5 | 6 | 6 | 7 | 8 | 6 | 8 | 7 | 2 |
A participant had an ACR20 response if there was at least a 20 percent (%) improvement, ie, reduction from Baseline, in TJC (68 joints) and SJC (66 joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity [VAS: 0 mm=no disease activity to 100 mm=maximum disease activity]; 2) Patient's Global Assessment of Disease Activity [VAS: 0 mm=no disease activity to 100 mm=maximum disease activity]; 3) Patient's Assessment of Pain [VAS: 0 mm=no pain to 100 mm=unbearable pain]; 4) Health Assessment Questionnaire [20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, averaged to 0=without difficulty to 3=unable to do] and 5) an acute-phase reactant (either C-reactive protein [CRP] or ESR). (NCT02046603)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
| Intervention | participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | Early withdrawal | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 23 | 68 | 69 | 83 | 83 | 86 | 90 | 87 | 89 | 92 | 91 | 88 | 87 | 88 | 10 |
| Tocilizumab Monotherapy | 6 | 6 | 11 | 10 | 13 | 15 | 15 | 14 | 13 | 12 | 13 | 12 | 12 | 12 | 3 |
A diary card was provided to participants to record home injections. Participants were asked to return all empty drug supply boxes, unused pre-filled syringe, and diary cards to the clinic at each visit as a measure of drug accountability and participant compliance. A participant was considered compliant if the participant correctly administered all scheduled doses of SC tocilizumab during the assessment period. (NCT02046603)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | Early withdrawal | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 137 | 126 | 132 | 124 | 121 | 120 | 114 | 107 | 112 | 111 | 105 | 104 | 102 | 107 | 98 | 27 |
| Tocilizumab Monotherapy | 21 | 20 | 20 | 18 | 18 | 19 | 18 | 16 | 19 | 17 | 17 | 16 | 16 | 13 | 16 | 4 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity. (NCT02046603)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | Early withdrawal | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 5 | 18 | 30 | 25 | 23 | 20 | 15 | 15 | 15 | 14 | 14 | 14 | 10 | 12 | 11 | 4 |
| Tocilizumab Monotherapy | 0 | 7 | 9 | 3 | 6 | 3 | 3 | 2 | 4 | 5 | 1 | 3 | 5 | 3 | 0 | 2 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR <2.6 implied clinical remission. (NCT02046603)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | Early withdrawal | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 3 | 15 | 34 | 53 | 66 | 72 | 75 | 76 | 73 | 80 | 80 | 81 | 80 | 78 | 80 | 7 |
| Tocilizumab Monotherapy | 0 | 1 | 2 | 5 | 6 | 10 | 11 | 14 | 14 | 12 | 14 | 13 | 10 | 11 | 12 | 3 |
(NCT02046603)
Timeframe: Baseline, Weeks 12 and 24, at early withdrawal (up to Week 52), and follow-up visit (8 weeks after last dose of tocilizumab, up to 60 weeks)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Baseline | Week 24 | Early withdrawal | Follow-up visit | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 6 | 2 | 0 | 0 |
(NCT02046603)
Timeframe: Baseline, Weeks 12 and 24, at early withdrawal (up to Week 52), and follow-up visit (8 weeks after last dose of tocilizumab, up to 60 weeks)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Baseline | Week 12 | Week 24 | Early withdrawal | Follow-up visit | |
| Tocilizumab Monotherapy | 3 | 0 | 0 | 0 | 0 |
DAS28-ESR was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (VAS: 0 mm=no disease activity to 100 mm=maximum disease activity). DAS28-ESR scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. The DAS28-ESR based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline >1.2 with a DAS28 score ≤3.2; moderate responders had a change from baseline >1.2 with a DAS28 score >3.2 or a change from baseline >0.6 to ≤1.2 with a DAS28 score ≤5.1. Participants with change from baseline >0.6 to ≤1.2 with a DAS28 score >5.1, or any score with change from baseline ≤0.6, were assessed as non-responders. (NCT02046603)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2: No response | Week 2: Moderate response | Week 2: Good response | Week 4: No response | Week 4: Moderate response | Week 4: Good response | Week 8: No response | Week 8: Moderate response | Week 8: Good response | Week 12: No response | Week 12: Moderate response | Week 12: Good response | Week 16: No response | Week 16: Moderate response | Week 16: Good response | Week 20: No response | Week 20: Moderate response | Week 20: Good response | Week 24: No response | Week 24: Moderate response | Week 24: Good response | Week 28: No response | Week 28: Moderate response | Week 28: Good response | Week 32: No response | Week 32: Moderate response | Week 32: Good response | Week 36: No response | Week 36: Moderate response | Week 36: Good response | Week 40: No response | Week 40: Moderate response | Week 40: Good response | Week 44: No response | Week 44: Moderate response | Week 44: Good response | Week 48: No response | Week 48: Moderate response | Week 48: Good response | Week 52: No response | Week 52: Moderate response | Week 52: Good response | Early Withdrawal: No response | Early Withdrawal: Moderate response | Early Withdrawal: Good response | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 56 | 56 | 25 | 22 | 58 | 57 | 11 | 48 | 72 | 11 | 34 | 83 | 9 | 30 | 86 | 9 | 27 | 85 | 7 | 21 | 89 | 5 | 24 | 86 | 3 | 21 | 91 | 4 | 19 | 91 | 2 | 15 | 94 | 5 | 15 | 87 | 4 | 13 | 90 | 5 | 12 | 90 | 11 | 8 | 9 |
| Tocilizumab Monotherapy | 4 | 10 | 7 | 3 | 7 | 11 | 1 | 9 | 8 | 4 | 3 | 12 | 1 | 4 | 13 | 0 | 5 | 14 | 1 | 2 | 16 | 1 | 0 | 18 | 1 | 2 | 16 | 0 | 3 | 15 | 0 | 1 | 16 | 0 | 2 | 15 | 0 | 2 | 14 | 0 | 3 | 12 | 0 | 1 | 4 |
Results are reported for number of participants who had non-biologic DMARD/corticosteroid dose reductions and/or discontinuation by reasons for dose reductions or discontinuation (safety reasons, discomfort, lack of efficacy, other reasons, and unknown reasons). Participants may be included under more than one reason. (NCT02046603)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, at early withdrawal (up to Week 52), follow-up Week 4 (up to Week 56), and follow-up Week 8 (up to Week 60)
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: Safety | Baseline: Discomfort | Baseline: Lack of efficacy | Baseline: Other | Baseline: Unknown | Week 2: Safety | Week 2: Discomfort | Week 2: Lack of efficacy | Week 2: Other | Week 2: Unknown | Week 4: Safety | Week 4: Discomfort | Week 4: Lack of efficacy | Week 4: Other | Week 4: Unknown | Week 8: Safety | Week 8: Discomfort | Week 8: Lack of efficacy | Week 8: Other | Week 8: Unknown | Week 12: Safety | Week 12: Discomfort 8 | Week 12: Lack of efficacy | Week 12: Other | Week 12: Unknown | Week 16: Safety | Week 16: Discomfort | Week 16: Lack of efficacy | Week 16: Other | Week 16: Unknown | Week 20: Safety | Week 20: Discomfort | Week 20: Lack of efficacy | Week 20: Other | Week 20: Unknown | Week 24: Safety | Week 24:Discomfort | Week 24: Lack of efficacy | Week 24: Other | Week 24: Unknown | Week 28: Safety | Week 28: Discomfort | Week 28: Lack of efficacy | Week 28: Other | Week 28: Unknown | Week 32: Safety | Week 32: Discomfort | Week 32: Lack of efficacy | Week 32: Other | Week 32: Unknown | Week 36: Safety | Week 36: Discomfort | Week 36: Lack of efficacy | Week 36: Other | Week 36: Unknown | Week 40: Safety | Week 40: Discomfort | Week 40: Lack of efficacy | Week 40: Other | Week 40: Unknown | Week 44: Safety | Week 44: Discomfort | Week 44: Lack of efficacy | Week 44: Other | Week 44: Unknown | Week 48: Safety | Week 48: Discomfort | Week 48: Lack of efficacy | Week 48: Other | Week 48: Unknown | Week 52: Safety | Week 52: Discomfort | Week 52: Lack of efficacy | Week 52: Other | Week 52: Unknown | Early withdrawal: Safety | Early withdrawal: Discomfort | Early withdrawal: Lack of efficacy | Early withdrawal: Other | Early withdrawal: Unknown | Follow-up Week 4: Safety | Follow-up Week 4: Discomfort | Follow-up Week 4: Lack of efficacy | Follow-up Week 4: Other | Follow-up Week 4: Unknown | Follow-up Week 8: Safety | Follow-up Week 8: Discomfort | Follow-up Week 8: Lack of efficacy | Follow-up Week 8: Other | Follow-up Week 8: Unknown | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 1 | 0 | 1 | 2 | 0 | 4 | 0 | 0 | 7 | 0 | 6 | 0 | 1 | 9 | 1 | 8 | 0 | 0 | 13 | 1 | 6 | 2 | 0 | 14 | 0 | 7 | 0 | 1 | 13 | 0 | 6 | 0 | 0 | 9 | 1 | 5 | 0 | 0 | 13 | 1 | 3 | 0 | 1 | 7 | 0 | 4 | 0 | 2 | 11 | 0 | 3 | 1 | 0 | 3 | 0 | 4 | 1 | 1 | 1 | 0 | 3 | 0 | 0 | 7 | 0 | 3 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Tocilizumab Monotherapy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Patient global assessment of disease activity was measured on a 0 to 100 mm horizontal VAS where 0 mm=no disease activity and 100 mm=maximum disease activity. (NCT02046603)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
| Intervention | mm (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | Early withdrawal | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 62.3 | 54.5 | 42.3 | 36.2 | 32.1 | 29.2 | 29.9 | 26.6 | 26.7 | 24.3 | 22.3 | 21.4 | 22.0 | 18.9 | 21.4 | 52.4 |
| Tocilizumab Monotherapy | 59.6 | 50.3 | 46.4 | 35.8 | 41.3 | 29.6 | 25.7 | 23.8 | 23.2 | 24.0 | 24.1 | 22.5 | 22.7 | 22.9 | 20.6 | 30.8 |
This assessment represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS where 0 mm= no pain to 100 mm= unbearable pain. (NCT02046603)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
| Intervention | mm (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | Early withdrawal | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 57.5 | 51.1 | 42.4 | 35.3 | 30.8 | 26.8 | 28.6 | 25.2 | 25.6 | 22.6 | 22.1 | 20.9 | 20.0 | 17.6 | 19.0 | 51.6 |
| Tocilizumab Monotherapy | 50.5 | 46.1 | 47.0 | 37.8 | 40.9 | 29.7 | 27.6 | 29.9 | 24.8 | 25.1 | 29.6 | 27.6 | 26.7 | 28.6 | 22.4 | 30.4 |
Methotrexate adherence was determined from responses to the question 'Over the last 3 months you were prescribed 12 doses of methotrexate, how many (approximately) have you taken?' Adherence (%) was calculated as: (Approximate number of doses taken/12)*100. (NCT02046603)
Timeframe: Baseline, Weeks 12, 24, 36, 52, and at early withdrawal (up to Week 52)
| Intervention | percentage of methotrexate adherence (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Week 12 | Week 24 | Week 36 | Week 52 | Early withdrawal | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 96.82 | 92.92 | 91.54 | 90.14 | 95.28 | 90.69 |
(NCT02046603)
Timeframe: Baseline, Weeks 12 and 24, at early withdrawal (up to Week 52), and follow-up visit (8 weeks after last dose of tocilizumab, up to 60 weeks)
| Intervention | nanograms per milliliter (ng/mL) (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 12 | Week 24 | Early withdrawal | Follow-up visit | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 42.40 | 548.70 | 521.07 | 327.95 | 125.07 |
| Tocilizumab Monotherapy | 43.63 | 577.42 | 602.25 | 639.75 | 132.23 |
(NCT02046603)
Timeframe: Baseline, Weeks 12 and 24, at early withdrawal (up to Week 52), and follow-up visit (8 weeks after last dose of tocilizumab, up to 60 weeks)
| Intervention | micrograms per milliliter (mcg/mL) (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 12 | Week 24 | Early withdrawal | Follow-up visit | |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | 0.0082 | 40.2529 | 43.9047 | 17.6160 | 2.3123 |
| Tocilizumab Monotherapy | 0.0000 | 35.3953 | 53.0416 | 44.7160 | 0.0597 |
(NCT02031471)
Timeframe: Up to Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Tocilizumab | 50.0 |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT02031471)
Timeframe: Up to 52 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tocilizumab | 96.5 |
A negative change from baseline in CRP level indicates an improvement. (NCT02031471)
Timeframe: From Baseline to Week 2, Week 24 and Week 52
| Intervention | milligrams per liter (mg/L) (Mean) | |||
|---|---|---|---|---|
| Baseline (n=55) | Change at Week 2 (n=54) | Change at Week 24 (n=42) | Change at Week 52 (n=8) | |
| Tocilizumab | 13.79 | -13.19 | -10.12 | -25.07 |
A negative change from baseline in ESR indicates an improvement. (NCT02031471)
Timeframe: From Baseline to Week 2, Week 24 and Week 52
| Intervention | millimeters per hour (mm/hr) (Mean) | |||
|---|---|---|---|---|
| Baseline (n=56) | Change at Week 2 (n=55) | Change at Week 24 (n=44) | Change at Week 52 (n=9) | |
| Tocilizumab | 33.75 | -19.95 | -22.80 | -27.78 |
The AIMS-SF is a reduced version of the validated AIMS2 questionnaire. The Short Form has been developed using a comprehensive expert-based approach and supported by psychometric testing. The AIMS-SF is a self-administered questionnaire to measure changes in global health, pain, mobility and social function in adult patients with arthritis and reports scores for physical, symptoms, affect, social and work assessments. Scores range from 0 to 10, higher scores indicating higher impact of arthritis on the assessments. A negative change from baseline indicates an improvement. (NCT02031471)
Timeframe: From Baseline to Week 4, Week 24 and Week 52
| Intervention | Units on a scale (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: Physical (n= 49) | Change at Week 4: Physical (n= 47) | Change at Week 24: Physical (n=38) | Change at Week 52: Physical (n=3) | Baseline: Symptom (50) | Change at Week 4: Symptom (n= 48) | Change at Week 24: Symptom (n=40) | Change at Week 52: Symptom (n=3) | Baseline: Affect (n=50) | Change at Week 4: Affect (n= 48) | Change at Week 24: Affect (n=40) | Change at Week 52: Affect (n=3) | Baseline: Social (n=50) | Change at Week 4: Social (n= 48) | Change at Week 24: Social (n=40) | Change at Week 52: Social (n=3) | Baseline: Work (n=26) | Change at Week 4: Work (n= 23) | Change at Week 24: Work (n=21) | Change at Week 52: Work (n=1) | |
| Tocilizumab | 3.57 | -0.57 | -1.41 | -3.62 | 6.33 | -1.15 | -2.69 | -3.89 | 5.07 | -0.66 | -1.74 | -4.50 | 5.36 | 0.18 | -0.56 | -1.46 | 3.17 | -0.92 | -0.65 | 3.75 |
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint count of 28 joints (TJC28), swollen joint count of 28 joints (SJC28), patient's global assessment of disease activity visual analog scale (PGA VAS) with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate [ESR] or C-reactive protein [CRP]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56*√[TJC28]) + (0.28*√[SJC28]) + (0.70*ln[ESR]) + (0.014*VAS). Higher scores represent higher disease activity. A negative change from baseline indicates an improvement. (NCT02031471)
Timeframe: From baseline to Week 24
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline (n=56) | Change at Week 24 (n=42) | |
| Tocilizumab | 5.55 | -3.24 |
The DAS28 score is a measure of the participant's disease activity calculated using the TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS and acute phase reactant (ESR or CRP) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56*√[TJC28]) + (0.28*√[SJC28]) + (0.70*ln[ESR]) + (0.014*VAS). Higher scores represent higher disease activity. A negative change from baseline indicates an improvement. (NCT02031471)
Timeframe: From baseline to Week 24
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline (n= 27) | Change at Week 24 (n= 20) | |
| Tocilizumab | 5.73 | -3.21 |
The symptom-specific measure FACIT-F was developed to assess chronic illness therapy with special emphasis on fatigue in the past 7 days. In this study, only the FACIT-F short questionnaire, which is a shorter version of the initial FACIT-F questionnaire, was used. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions. The 13 items included in the FACIT-F short can be used to calculate the brief score for FACIT-F scale (score range: 0-52). A positive change from baseline indicates an improvement. (NCT02031471)
Timeframe: From Baseline to Week 2, Week 24 and Week 52
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline (n=57) | Change at Week 2 (n=57) | Change at Week 24 (n=45) | Change at Week 52 (n=9) | |
| Tocilizumab | 26.09 | 2.32 | 10.53 | 20.89 |
The Stanford HAQ-DI is a patient-oriented outcome assessment questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities. Each category contains multiple questions, which were answered using a 4-point scale from 0 to 3. The overall index score was an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. A negative change from baseline indicates an improvement. (NCT02031471)
Timeframe: From Baseline to Week 2, Week 24 and Week 52
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline (n=57) | Change at Week 2 (n=57) | Change at Week 24 (n=46) | Change at Week 52 (n=9) | |
| Tocilizumab | 1.44 | -0.08 | -0.54 | -1.33 |
"The Patient Fatigue VAS assessment represents the participant's assessment of his/her current level of fatigue on a 100 mm horizontal VAS. The extreme left end of the line represents 0=no fatigue and the extreme right end 100=extreme fatigue. A negative change from baseline indicates an improvement." (NCT02031471)
Timeframe: From Baseline to Week 2, Week 24 and Week 52
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline (n=57) | Change at Week 2 (n=57) | Change at Week 24 (n=46) | Change at Week 52 (n=9) | |
| Tocilizumab | 60.19 | -3.74 | -21.48 | -50.89 |
"The Patient Quality of Sleep VAS assessment represents the participant's assessment of his/her current quality of sleep on a 100 mm horizontal VAS. The extreme left end of the line represents 0=no difficulty to sleep and the extreme right end 100=extreme sleeping difficulties. A negative change from baseline indicates an improvement." (NCT02031471)
Timeframe: From Baseline to Week 2, Week 24 and Week 52
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline (n=57) | Change at Week 2 (n=57) | Change at Week 24 (n=46) | Change at Week 52 (n=9) | |
| Tocilizumab | 54.95 | -8.40 | -21.93 | -34.22 |
"The Patient Satisfaction VAS assessment represents the participant's assessment of his/her current satisfaction with treatment on a 100 mm horizontal VAS. The extreme left end of the line represents 0=no satisfaction and the extreme right end 100=extremely satisfied. A positive change from baseline indicates an improvement." (NCT02031471)
Timeframe: From Baseline to Week 2, Week 24 and Week 52
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline (n=53) | Change at Week 2 (n=53) | Change at Week 24 (n=43) | Change at Week 52 (n=8) | |
| Tocilizumab | 39.66 | 9.49 | 33.07 | 49.38 |
"Patient's Assessment of Pain VAS represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line represents 0=no pain and the extreme right end 100=unbearable pain. A negative change from baseline indicates an improvement." (NCT02031471)
Timeframe: From Baseline to Week 2 and Week 24
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline (n=57) | Change at Week 2 (n=57) | Change at Week 24 (n=46) | Change at Week 52 (n=9) | |
| Tocilizumab | 66.77 | -11.32 | -35.37 | -49.33 |
"PGA VAS represents the participant's overall assessment of their current disease activity on a 100 mm horizontal VAS. The extreme left end of the line represents 0= no disease activity (symptom-free and no arthritis symptoms) and the extreme right end 100=maximum disease activity (maximum arthritis disease activity). A negative change from baseline indicates an improvement." (NCT02031471)
Timeframe: From Baseline to Week 2, Week 24 and Week 52
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline (n=57) | Change at Week 2 (n=57) | Change at Week 24 (n=46) | Change at Week 52 (n=9) | |
| Tocilizumab | 67.28 | -11.82 | -36.02 | -44.78 |
"Physician's Global Assessment of disease activity VAS represents the physician's assessment of the participant's current disease activity on a 100 mm horizontal VAS. The extreme left end of the line represents 0= no disease activity (symptom-free and no arthritis symptoms) and the extreme right end 100= maximum disease activity. This was completed by the Treating Physician (or designee). A negative change from baseline indicates an improvement." (NCT02031471)
Timeframe: From Baseline to Week 2, Week 24 and Week 52
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline (n=56) | Change at Week 2 (n=56) | Change at Week 24 (n=45) | Change at Week 52 (n=9) | |
| Tocilizumab | 64.93 | -16.34 | -48.93 | -57.44 |
"The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over 1-month time interval. Nineteen individual items generate seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The participant self-rates each of these seven areas of sleep. Scoring of answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. Global scores range from 0 to 21 and a global sum of 5 or greater indicates a poor sleeper. Although there are several questions that request the evaluation of the participant's bed mate or roommate, these are not scored. A negative change from baseline indicates an improvement." (NCT02031471)
Timeframe: From Baseline to Week 4, Week 24 and Week 52
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline (n=57) | Change at Week 4 (n=54) | Change at Week 24 (n=46) | Change at Week 52 (n=9) | |
| Tocilizumab | 8.81 | -1.24 | -2.63 | -4.56 |
SDAI is a similar index to DAS28 but has the advantage of not needing a complicated mathematical formula for its determination, but a simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS, and CRP concentration in mg/L. CDAI does not incorporate an acute response, therefore it can be used to evaluate disease activity in the absence of laboratory testing of CRP and ESR. VAS range for all assessments was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. SDAI scores ranged from 0 to 86, CDAI from 0 to 76 with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement. (NCT02031471)
Timeframe: From Baseline to Week 2, Week 24 and Week 52
| Intervention | Units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (n=53) | Change at Week 2: SDAI (n=52) | Change at Week 24: SDAI (n=38) | Change at Week 52: SDAI (n=7) | Baseline: CDAI (n= 55) | Change at Week 2: CDAI (n=55) | Change at Week 24: CDAI (n=42) | Change at Week 52: CDAI (n=8) | |
| Tocilizumab | 33.26 | -9.00 | -25.33 | -34.04 | 31.86 | -7.61 | -23.55 | -29.99 |
The 23-item RA-WIS is a simple, validated screening tool for work instability, i.e., the consequences of a mismatch between an individual's functional ability and their work tasks. This self-administered questionnaire covers a broad range of specific work-related issues and enables monitoring the risk of work disability in rheumatoid arthritis patients. The RA-WIS is scored by summing responses from all 23 scale items. The scale ranges from 0 to 23. Cut points have been established to differentiate levels of work instability: low < 10, moderate 10-17 and high > 17. A negative change from baseline indicates an improvement. (NCT02031471)
Timeframe: From Baseline to Week 24
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline (n=26) | Change at Week 24 (n=22) | |
| Tocilizumab | 13.15 | -3.55 |
An assessment of 66 joints for swelling and 68 joints for tenderness was made. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints were not taken into consideration for swelling or tenderness. A negative change from baseline indicates an improvement. (NCT02031471)
Timeframe: From Baseline to Week 2, Week 24 and Week 52
| Intervention | Joint Counts (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline: TJC (n=53) | Change at Week 2: TJC (n=53) | Change at Week 24: TJC (n=41) | Change at Week 52: TJC (n=8) | Baseline: SJC (n=55) | Change at Week 2: SJC (n=55) | Change at Week 24: SJC (n=42) | Change at Week 52: SJC (n=8) | |
| Tocilizumab | 16.02 | -3.58 | -12.10 | -17.25 | 10.20 | -3.93 | -9.81 | -11.75 |
The DAS28 score is a measure of the participant's disease activity calculated using TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate [ESR] or C-reactive protein [CRP]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56*√[TJC28]) + (0.28*√[SJC28]) + (0.70*ln[ESR]) + (0.014*VAS). Higher scores represent higher disease activity. DAS28 Clinically Significant Improvement was defined as a DAS28 score reduction of at least 1.2 units from Baseline. (NCT02031471)
Timeframe: From Baseline to Week 2, Week 24 and Week 52
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Week 2 (n=56) | Week 24 (n=42) | Week 52 (n=8) | |
| Tocilizumab | 66.1 | 90.5 | 100 |
CDAI is calculated by simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS. VAS range was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Total CDAI score ranges from 0 to 76 with higher scores indicating increased disease activity. Clinical remission = score ≤ 2.8; Low disease activity = score > 2.8 and ≤ 10.0; Moderate disease activity = score > 10.0 and ≤ 22.0; High disease activity = score > 22.0. (NCT02031471)
Timeframe: Baseline to Week 2, Week 24 and Week 52
| Intervention | percentage of participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: Clinical remission (n=55) | Week 2: Clinical remission (n=56) | Week 24: Clinical remission (n=43) | Week 52: Clinical remission (n=8) | Baseline: Low disease activity (n=55) | Week 2: Low disease activity (n=56) | Week 24: Low disease activity (n=43) | Week 52: Low disease activity (n=8) | Baseline: Moderate disease activity (n=55) | Week 2: Moderate disease activity (n=56) | Week 24: Moderate disease activity (n=43) | Week 52: Moderate disease activity (n=8) | Baseline: High disease activity (n=55) | Week 2: High disease activity (n=56) | Week 24: High disease activity (n=43) | Week 52: High disease activity (n=8) | |
| Tocilizumab | 0 | 1.8 | 30.2 | 37.5 | 0 | 7.1 | 34.9 | 25.0 | 21.8 | 48.2 | 30.2 | 37.5 | 78.2 | 42.9 | 4.7 | 0 |
The DAS28 score is a measure of the participant's disease activity calculated using TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate [ESR] or C-reactive protein [CRP]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56*√[TJC28]) + (0.28*√[SJC28]) + (0.70*ln[ESR]) + (0.014*VAS). Higher scores represent higher disease activity. Clinical remission = score <2.6; Low disease activity = score ≥2.6 and ≤3.2; Moderate disease activity = score > 3.2 and ≤5.1; High disease activity = score >5.1. (NCT02031471)
Timeframe: From Baseline to Week 2, Week 24 and Week 52
| Intervention | percentage of participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: Clinical remission (n=56) | Week 2: Clinical remission (n=56) | Week 24: Clinical remission (n=42) | Week 52: Clinical remission (n=8) | Baseline: Low disease activity (n=56) | Week 2: Low disease activity (n=56) | Week 24: Low disease activity (n=42) | Week 52: Low disease activity (n=8) | Baseline: Moderate disease activity (n=56) | Week 2: Moderate disease activity (n=56) | Week 24: Moderate disease activity (n=42) | Week 52: Moderate disease activity (n=8) | Baseline: High disease activity (n=56) | Week 2: High disease activity (n=56) | Week 24: High disease activity (n=42) | Week 52: High disease activity (n=8) | |
| Tocilizumab | 0 | 7.1 | 64.3 | 87.5 | 1.8 | 16.1 | 16.7 | 0 | 35.7 | 53.6 | 19.0 | 12.5 | 62.5 | 23.2 | 0 | 0 |
SDAI is calculated by simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS, and CRP concentration in mg/L. VAS range was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Total SDAI score ranges from 0 to 86 with higher scores indicating increased disease activity. Clinical remission = score ≤ 3.3; Low disease activity = score > 3.3 and ≤ 11.0; Moderate disease activity = score > 11.0 and ≤ 26.0; high disease activity = score > 26.0. (NCT02031471)
Timeframe: From Baseline to Week 2, Week 24 and Week 52
| Intervention | percentage of participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: Clinical remission (n=53) | Week 2: Clinical remission (n=55) | Week 24: Clinical remission (n=40) | Week 52: Clinical remission (n=7) | Baseline: Low disease activity (n=53) | Week 2: Low disease activity (n=55) | Week 24: Low disease activity (n=40) | Week 52: Low disease activity (n=7) | Baseline: Moderate disease activity (n=53) | Week 2: Moderate disease activity (n=55) | Week 24: Moderate disease activity (n=40) | Week 52: Moderate disease activity (n=7) | Baseline: High disease activity (n=53) | Week 2: High disease activity (n=55) | Week 24: High disease activity (n=40) | Week 52: High disease activity (n=7) | |
| Tocilizumab | 0 | 1.8 | 30.0 | 42.9 | 0 | 7.3 | 40.0 | 14.3 | 30.2 | 54.5 | 25.0 | 42.9 | 69.8 | 36.4 | 5.0 | 0 |
The ACR core set of outcome measures and their definition of improvement includes a >= 20% improvement (ACR20) compared to Baseline in both SJC and TJC as well as in three out of five additional parameters: Physician's Global Assessment of disease activity VAS, PGA VAS, patient's assessment of pain VAS, Health Assessment Questionnaire-Disability Index (HAQ-DI), and acute phase reactant (CRP or ESR). VAS range for all assessments was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Achievement of an ACR50 requires a >= 50% improvement in the same parameters and an ACR70 requires a >= 70% improvement. (NCT02031471)
Timeframe: From Baseline to Week 2, Week 24, and Week 52
| Intervention | percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: ACR 20 (n=55) | Week 2: ACR 20 (n=51) | Week 24: ACR 20 (n=39) | Week 52: ACR 20 (n=8) | Baseline: ACR 50 (n=55) | Week 2: ACR 50 (n=52) | Week 24: ACR 50 (n=39) | Week 52: ACR 50 (n=8) | Baseline: ACR 70 (n=55) | Week 2: ACR 70 (n=52) | Week 24: ACR 70 (n=39) | Week 52: ACR 70 (n=8) | |
| Tocilizumab | 0 | 21.6 | 84.6 | 100 | 0 | 1.9 | 66.7 | 62.5 | 0 | 0 | 38.5 | 25.0 |
EULAR response was calculated as the difference between DAS28-ESR scores at baseline and Week 24, and reported as the percentage of participants with good, moderate, or no response. Good responders = decrease from baseline >1.2 with a DAS28 score of <=3.2; moderate responders = decrease from baseline >1.2 with a DAS28 score of >3.2, or decrease from baseline >0.6 to <=1.2 with a DAS28 score of <=5.1; non-responders = decrease from baseline <=0.6 or decrease from baseline >0.6 and <=1.2 with a DAS28 score of >5.1. (NCT02031471)
Timeframe: From Baseline to Week 2, Week 24
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 2: Good response (n=56) | Week 24: Good response (n=42) | Week 2: Moderate response (n=56) | Week 24: Moderate response (n=42) | Week 2: No response (n=56) | Week 24: No response (n=42) | |
| Tocilizumab | 17.9 | 76.2 | 50.0 | 19.0 | 32.1 | 4.8 |
(NCT02031471)
Timeframe: Baseline, Week 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Baseline (n= 55) | Week 24 (n= 43) | |
| Tocilizumab | 0 | 1.7 |
The abbreviated 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) derived from the TSQM Version 1.4 but without the five items of the side effects domain, is a reliable and valid measure to assess participants' satisfaction with treatment. The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain. Domains included are effectiveness, convenience and global satisfaction. (NCT02031471)
Timeframe: Week 24
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Effectiveness (n=46) | Convenience (n=46) | Global Satisfaction (n=46) | |
| Tocilizumab | 66.7 | 76.09 | 65.06 |
An adverse event was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Adverse events included serious as well as non-serious adverse events. (NCT01987479)
Timeframe: Baseline up to Week 32
| Intervention | percentage of participants (Number) |
|---|---|
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 91.3 |
Time to discontinuation or first dose reduction of corticosteroids or NSAIDs (weeks) = (Date of the first dose reduction or end date of corticosteroids or NSAIDs treatment - date of first drug intake of this study) + 1. Time to discontinuation or first dose reduction was based on the first occurring event (corticosteroid discontinuation or corticosteroid first dose reduction or NSAIDs discontinuation or NSAIDs first dose reduction, whichever occurred first). (NCT01987479)
Timeframe: Baseline up to Week 32
| Intervention | weeks (Median) |
|---|---|
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 25.3 |
The CDAI is the numerical sum of four outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician's global assessment of disease activity assessed on 0-10 cm VAS (0 cm= no disease activity and 10 cm= worst disease activity). CDAI total score = 0-76. CDAI <= 2.8 indicates clinical remission, >2.8 to 10 = low disease activity, >10 to 22 = moderate disease activity, and >22 = high (or severe) disease activity. (NCT01987479)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=150) | Change at Week 2 (n=148) | Change at Week 4 (n=144) | Change at Week 8 (n=135) | Change at Week 12 (n=132) | Change at Week 16 (n=129) | Change at Week 20 (n=122) | Change at Week 24 (n=121) | Change at early withdrawal visit (n=27) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 24.32 | -4.7 | -9.4 | -13.4 | -15.4 | -16.7 | -17.8 | -18.3 | -6.4 |
DAS28 was calculated from swollen joint count (SJC) and tender joint count (TJC) using 28 joints count, erythrocyte sedimentation rate (ESR; millimeters per hour [mm/hour]), and patient's global assessment of disease activity (measured on a 0 to 100 mm Visual Analog Scale [VAS] where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR less than or equal to (≤) 3.2 implied low disease activity and greater than (>) 3.2 to 5.1 implied moderate to high disease activity, and DAS28-ESR less than (<) 2.6 implied clinical remission. (NCT01987479)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=150) | Change at Week 2 (n=148) | Change at Week 4 (n=144) | Change at Week 8 (n=136) | Change at Week 12 (n=133) | Change at Week 16 (n=128) | Change at Week 20 (n=122) | Change at Week 24 (n=121) | Change at early withdrawal visit (n=27) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 4.8 | 1.337 | 2.037 | 2.635 | 2.908 | 3.014 | 3.169 | 3.232 | 1.653 |
The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician global assessment of disease activity assessed on 0-10 centimeter (cm) VAS (0 cm= no disease activity and 10 cm= worst disease activity), and CRP in milligrams per liter (mg/L). SDAI total score = 0-86. SDAI <=3.3 indicates clinical remission, >3.4 to 11 = low disease activity, >11 to 26 = moderate disease activity, and >26 = high (or severe) disease activity . (NCT01987479)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=145) | Change at Week 2 (n=97) | Change at Week 4 (n=78) | Change at Week 8 (n=64) | Change at Week 12 (n=63) | Change at Week 16 (n=67) | Change at Week 20 (n=57) | Change at Week 24 (n=56) | Change at early withdrawal visit (n=18) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 26.03 | -6.2 | -11.3 | -14.4 | -17.2 | -18.5 | -19.7 | -19.9 | -8.0 |
Number of swollen joints was determined by examination of 28 joints for SJC28 and 66 joints for SJC66 and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28 for a SJC28 and 66 for a SJC66. A reduction in number of swollen joints compared to baseline indicates improvement. (NCT01987479)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
| Intervention | swollen joints (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SJC28: Baseline (n=150) | SJC28: Change at Week 2 (n=148) | SJC28: Change at Week 4 (n=144) | SJC28: Change at Week 8 (n=136) | SJC28: Change at Week 12 (n=133) | SJC28: Change at Week 16 (n=130) | SJC28: Change at Week 20 (n=123) | SJC28: Change at Week 24 (n=121) | SJC28: Change at early withdrawal visit (n=27) | SJC66: Baseline (n=150) | SJC66: Change at Week 2 (n=148) | SJC66: Change at Week 4 (n=144) | SJC66: Change at Week 8 (n=136) | SJC66: Change at Week 12 (n=133) | SJC66: Change at Week 16 (n=130) | SJC66: Change at Week 20 (n=123) | SJC66: Change at Week 24 (n=121) | SJC66: Change at early withdrawal visit (n=27) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 6.2 | -1.18 | -2.44 | -3.62 | -4.24 | -4.61 | -4.92 | -5.23 | -1.33 | 9.1 | -1.84 | -3.94 | -5.61 | -6.50 | -6.78 | -7.52 | -7.80 | -2.33 |
Number of tender joints was determined by examining 28 joints for TJC28 and 68 joints for TJC68, and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28 for a TJC28 and 68 for a TJC68. A reduction in number of tender joints compared to baseline indicates improvement. (NCT01987479)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
| Intervention | tender joints (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TJC28: Baseline (n=150) | TJC28: Change at Week 2 (n=148) | TJC28: Change at Week 4 (n=144) | TJC28: Change at Week 8 (n=136) | TJC28: Change at Week 12 (n=133) | TJC28: Change at Week 16 (n=130) | TJC28: Change at Week 20 (n=123) | TJC28: Change at Week 24 (n=121) | TJC28: Change at early withdrawal visit (n=27) | TJC68: Baseline (n=150) | TJC68: Change at Week 2 (n=148) | TJC68: Change at Week 4 (n=144) | TJC68: Change at Week 8 (n=136) | TJC68: Change at Week 12 (n=133) | TJC68: Change at Week 16 (n=130) | TJC68: Change at Week 20 (n=123) | TJC68: Change at Week 24 (n=121) | TJC68: Change at early withdrawal visit (n=27) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 7.7 | -1.38 | -2.94 | -4.33 | -4.68 | -5.36 | -5.79 | -5.96 | -1.07 | 13.2 | -2.40 | -5.15 | -7.19 | -7.98 | -9.45 | -9.86 | -10.02 | -1.93 |
The FACIT-F score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). (NCT01987479)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and early withdrawal (up to Week 24)
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=133) | Week 2 (n=134) | Week 4 (n=133) | Week 8 (n=126) | Week 12 (n=126) | Week 16 (n=122) | Week 20 (n=118) | Week 24 (n=114) | Early withdrawal (n=27) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 29.84 | 33.07 | 35.10 | 37.34 | 37.89 | 37.93 | 39.65 | 39.93 | 33.48 |
The HAQ-DI questionnaire measures functional status (disability) and health-related quality of life. It measures the participant's ability to perform everyday tasks. The index consists of 20 questions regarding the function of the upper and lower extremities. These questions are summarized in 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common activities over past week. Each question is evaluated according to the degree of severity on a 4-point scale. Total score for HAQ-DI was the average of all questions and ranges from 0 = without any difficulty to 3 = unable to do. (NCT01987479)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and early withdrawal (up to Week 24)
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=147) | Week 2 (n=147) | Week 4 (n=143) | Week 8 (n=134) | Week 12 (n=131) | Week 16 (n=129) | Week 20 (n=122) | Week 24 (n=119) | Early withdrawal (n=27) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 1.2329 | 1.0978 | 0.9673 | 0.8249 | 0.7460 | 0.6996 | 0.6620 | 0.6681 | 1.2315 |
Patient global assessment of disease activity was measured on a 0 to 100 mm horizontal VAS where 0 mm=no disease activity and 100 mm=maximum disease activity. (NCT01987479)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and Early withdrawal (up to Week 24)
| Intervention | mm (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=150) | Week 2 (n=148) | Week 4 (n=144) | Week 8 (n=136) | Week 12 (n=133) | Week 16 (n=129) | Week 20 (n=123) | Week 24 (n=121) | Early withdrawal (n=27) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 54.8 | 43.6 | 35.5 | 27.2 | 22.2 | 21.3 | 19.2 | 18.8 | 40.4 |
This assessment represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS where 0 mm= no pain to 100 mm= unbearable pain. (NCT01987479)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and Early withdrawal (up to Week 24)
| Intervention | mm (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=150) | Week 2 (n=148) | Week 4 (n=144) | Week 8 (n=136) | Week 12 (n=133) | Week 16 (n=129) | Week 20 (n=123) | Week 24 (n=121) | Early withdrawal (n=27) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 52.5 | 44.4 | 35.8 | 27.6 | 21.7 | 20.9 | 19.5 | 19.6 | 42.8 |
A participant had an ACR50 response if there was at least a 50% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity [VAS: 0 mm=no disease activity to 100 mm=maximum disease activity]; 2) Patient's Global Assessment of Disease Activity [VAS: 0 mm=no disease activity to 100 mm=maximum disease activity]; 3) Patient's Assessment of Pain [VAS: 0 mm=no pain to 100 mm=unbearable pain]; 4) Health Assessment Questionnaire [20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do] and 5) an acute-phase reactant (either CRP or ESR). (NCT01987479)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 2 (n=148) | Week 4 (n=144) | Week 8 (n=136) | Week 12 (n=133) | Week 16 (n=130) | Week 20 (n=123) | Week 24 (n=121) | Early withdrawal visit (n=27) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 6.1 | 18.1 | 33.1 | 43.6 | 52.3 | 54.5 | 62.0 | 18.5 |
A participant had an ACR70 response if there was at least a 70% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity [VAS: 0 mm=no disease activity to 100 mm=maximum disease activity]; 2) Patient's Global Assessment of Disease Activity [VAS: 0 mm=no disease activity to 100 mm=maximum disease activity]; 3) Patient's Assessment of Pain [VAS: 0 mm=no pain to 100 mm=unbearable pain]; 4) Health Assessment Questionnaire [20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do] and 5) an acute-phase reactant (either CRP or ESR). (NCT01987479)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 2 (n=148) | Week 4 (n=144) | Week 8 (n=136) | Week 12 (n=133) | Week 16 (n=130) | Week 20 (n=123) | Week 24 (n=121) | Early withdrawal visit (n=27) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 1.4 | 6.9 | 14.0 | 21.1 | 29.2 | 38.2 | 35.5 | 14.8 |
A participant had an ACR90 response if there was at least a 90% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity [VAS: 0 mm=no disease activity to 100 mm=maximum disease activity]; 2) Patient's Global Assessment of Disease Activity [VAS: 0 mm=no disease activity to 100 mm=maximum disease activity]; 3) Patient's Assessment of Pain [VAS: 0 mm=no pain to 100 mm=unbearable pain]; 4) Health Assessment Questionnaire [20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do] and 5) an acute-phase reactant (either CRP or ESR). (NCT01987479)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 2 (n=148) | Week 4 (n=144) | Week 8 (n=136) | Week 12 (n=133) | Week 16 (n=130) | Week 20 (n=123) | Week 24 (n=121) | Early withdrawal visit (n=27) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 0.0 | 1.4 | 2.9 | 6.8 | 9.2 | 11.4 | 15.7 | 3.7 |
A participant had an ACR20 response if there was at least a 20 percent (%) improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity [VAS: 0 mm=no disease activity to 100 mm=maximum disease activity]; 2) Patient's Global Assessment of Disease Activity [VAS: 0 mm=no disease activity to 100 mm=maximum disease activity]; 3) Patient's Assessment of Pain [VAS: 0 mm=no pain to 100 mm=unbearable pain]; 4) Health Assessment Questionnaire [20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do] and 5) an acute-phase reactant (either C-reactive protein [CRP] or ESR). (NCT01987479)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 2 (n=148) | Week 4 (n=144) | Week 8 (n=136) | Week 12 (n=133) | Week 16 (n=130) | Week 20 (n=123) | Week 24 (n=121) | Early withdrawal visit (n=27) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 20.3 | 40.3 | 58.1 | 69.9 | 71.5 | 78.9 | 82.6 | 37.0 |
A diary card was provided to participants to record home injections. Participants were asked to return all empty drug supply boxes, unused pre-filled syringe, and diary cards to the clinic at each visit as a measure of drug accountability and participant compliance. A participant was considered compliant if the participant correctly administered all scheduled doses of SC tocilizumab during the assessment period. (NCT01987479)
Timeframe: Weeks 2, 4, 8, 12, 16, 20, 24, and early withdrawal (up to Week 24)
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 2 (n=148) | Week 4 (n=144) | Week 8 (n=136) | Week 12 (n=133) | Week 16 (n=130) | Week 20 (n=123) | Week 24 (n=121) | Early withdrawal (n=27) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 90.5 | 95.8 | 91.9 | 97.7 | 93.8 | 95.1 | 92.6 | 88.9 |
(NCT01987479)
Timeframe: Baseline, Weeks 12 and 24, early withdrawal (up to Week 24), follow-up visit (8 weeks after last dose of tocilizumab, up to 32 weeks)
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Baseline (n=147) | Week 12 (n=5) | Week 24 (n=121) | Early withdrawal (n=22) | Follow-up visit (n=26) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 6.1 | 40.0 | 7.4 | 9.1 | 11.5 |
Results are reported for percentage of participants who had corticosteroid dose reductions or discontinuation by reasons for dose reductions or discontinuation (unknown reasons, safety reasons, other reasons, lack of efficacy, and discomfort). (NCT01987479)
Timeframe: From Week 16 and before Week 20; From Week 20 and before Week 24
| Intervention | percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Unknown reasons (Week 16 to Week 20) | Safety reasons (Week 16 to Week 20) | Other reasons (Week 16 to Week 20) | Lack of efficacy (Week 16 to Week 20) | Discomfort (Week 16 to Week 20) | Unknown reasons (Week 20 to Week 24) | Safety reasons (Week 20 to Week 24) | Other reasons (Week 20 to Week 24) | Lack of efficacy (Week 20 to Week 24) | Discomfort (Week 20 to Week 24) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 0.0 | 1.3 | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 0.7 | 0.0 |
DAS28-ESR was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (VAS: 0 mm=no disease activity to 100 mm=maximum disease activity). DAS28-ESR scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. The DAS28-ESR based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline >1.2 with a DAS28 score ≤3.2; moderate responders had a change from baseline >1.2 with a DAS28 score >3.2 or a change from baseline >0.6 to ≤1.2 with a DAS28 score ≤5.1. Participants with change from baseline >0.6 to ≤1.2 with a DAS28 score >5.1, or any score with change from baseline ≤0.6, were assessed as non-responders. (NCT01987479)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
| Intervention | percentage of participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2: Good response (n=148) | Week 2: Moderate response (n=148) | Week 2: No response (n=148) | Week 4: Good response (n=144) | Week 4: Moderate response (n=144) | Week 4: No response (n=144) | Week 8: Good response (n=136) | Week 8: Moderate response (n=136) | Week 8: No response (n=136) | Week 12: Good response (n=133) | Week 12: Moderate response (n=133) | Week 12: No response (n=133) | Week 16: Good response (n=128) | Week 16: Moderate response (n=128) | Week 16: No response (n=128) | Week 20: Good response (n=122) | Week 20: Moderate response (n=122) | Week 20: No response (n=122) | Week 24: Good response (n=121) | Week 24: Moderate response (n=121) | Week 24: No response (n=121) | Early withdrawal visit: Good response (n=27) | Early withdrawal visit: Moderate response (n=27) | Early withdrawal visit: No response (n=27) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 34.5 | 41.9 | 23.6 | 59.7 | 34.0 | 6.3 | 78.7 | 17.6 | 3.7 | 85.0 | 12.0 | 3.0 | 89.1 | 7.0 | 3.9 | 91.8 | 5.7 | 2.5 | 92.6 | 5.0 | 2.5 | 44.4 | 29.6 | 25.9 |
Results are reported for percentage of participants who had NSAIDs dose reductions or discontinuation by reasons for dose reductions or discontinuation (unknown reasons, safety reasons, other reasons, lack of efficacy, and discomfort). (NCT01987479)
Timeframe: From Week 16 and before Week 20; From Week 20 and before Week 24
| Intervention | percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Unknown reasons (Week 16 to Week 20) | Safety reasons (Week 16 to Week 20) | Other reasons (Week 16 to Week 20) | Lack of efficacy (Week 16 to Week 20) | Discomfort (Week 16 to Week 20) | Unknown reasons (Week 20 to Week 24) | Safety reasons (Week 20 to Week 24) | Other reasons (Week 20 to Week 24) | Lack of efficacy (Week 20 to Week 24) | Discomfort (Week 20 to Week 24) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 0.0 | 0.7 | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
(NCT01987479)
Timeframe: Baseline, Weeks 12 and 24, Early Withdrawal (up to Week 24), Follow-up Visit (8 weeks after last dose of tocilizumab, up to 32 weeks)
| Intervention | nanograms per milliliter (ng/mL) (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (n=139) | Week 12 (n=126) | Week 24 (n=115) | Early withdrawal (n=21) | Follow-up visit (n=26) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 38.3 | 516.6 | 536.5 | 380.4 | 117.5 |
(NCT01987479)
Timeframe: Baseline, Weeks 12 and 24, Early Withdrawal (up to Week 24), Follow-up Visit (8 weeks after last dose of tocilizumab, up to 32 weeks)
| Intervention | micrograms per milliliter (mcg/mL) (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (n=4) | Week 12 (n=123) | Week 24 (n=112) | Early withdrawal (n=17) | Follow-up visit (n=3) | |
| Tocilizumab Alone or in Combination With Methotrexate or DMARD | 0.5 | 42.3 | 46.5 | 16.8 | 60.9 |
Percentage of participants with a positive response to anti-therapeutic antibodies against tocilizumab by confirmatory assays at any time during the study is reported. (NCT02001987)
Timeframe: Baseline up to 8 weeks after last study drug administration (up to Week 84)
| Intervention | percentage of participants (Number) |
|---|---|
| TCZ - All Participants | 3.6 |
Time to first temporary discontinuation in corticosteroid dosage during core study period is reported. Participants who temporarily discontinued corticosteroids at any time during core study period were only included in the analysis. (NCT02001987)
Timeframe: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
| Intervention | days (Median) |
|---|---|
| TCZ MONO - Core Study Period | 50 |
| TCZ COMBO - Core Study Period | 105 |
Time to first temporary discontinuation in corticosteroid dosage during study is reported. Participants who temporarily discontinued corticosteroids at any time during entire study were only included in the analysis. (NCT02001987)
Timeframe: Screening up to 8 weeks after last dose (overall up to 88 weeks)
| Intervention | days (Median) |
|---|---|
| TCZ - All Participants | 147 |
Time to permanent discontinuation in corticosteroid dosage during core study period is reported. Participants who permanently discontinued corticosteroids at any time during core study period were only included in the analysis. (NCT02001987)
Timeframe: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
| Intervention | days (Median) |
|---|---|
| TCZ MONO - Core Study Period | 24 |
| TCZ COMBO - Core Study Period | 96 |
Time to permanent discontinuation in corticosteroid dosage during study is reported. Participants who permanently discontinued corticosteroids at any time during entire study were only included in the analysis. (NCT02001987)
Timeframe: Screening up to 8 weeks after last dose (overall up to 88 weeks)
| Intervention | days (Median) |
|---|---|
| TCZ - All Participants | 202 |
Treatment compliance from Baseline up to Week 24 was assessed using following formula: (number of actual injection received / number of theoretical injection which should be received at week 24) * 100. (NCT02001987)
Timeframe: Baseline up to Week 24
| Intervention | percentage of injections (Mean) |
|---|---|
| TCZ - All Participants - Core Study Period | 91.19 |
BRAF-NRS are 3 standardized NRS (range = 0-10) for disease related fatigue domains (severity of fatigue, fatigue effect, and coping with fatigue). Higher values reflect greater problems for severity/level fatigue and effect fatigue NRS, but lower scores reflect greater problems for copped fatigue NRS. (NCT02001987)
Timeframe: Baseline, Weeks 24 and 52
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline, Level Fatigue NRS | Baseline, Effect Fatigue NRS | Baseline, Copped Fatigue NRS | Change at Week 24, Level Fatigue NRS | Change at Week 24, Effect Fatigue NRS | Change at Week 24, Copped Fatigue NRS | Change at Week 52, Level Fatigue NRS | Change at Week 52, Effect Fatigue NRS | Change at Week 52, Copped Fatigue NRS | |
| TCZ - All Participants | 6.14 | 5.87 | 5.48 | -2.41 | -2.44 | -0.47 | -3.75 | -3.83 | -1.33 |
BRAF-MDQ assessed the overall experience and impact of disease related fatigue, using four dimensions (physical fatigue [4 items], living with fatigue [7 items], cognitive fatigue [5 items], and emotional fatigue [4 items]). A total fatigue score (range 0 to 70) was obtained by summing the 20 item scores ranging from 0 to 3, except for item 1 (0-10), item 2 (0-7) and item 3 (0-2). Higher scores reflect greater fatigue. If only 1 domain was missing it was replaced by the mean of the others; otherwise, the total score was not calculated. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better quality of life. (NCT02001987)
Timeframe: Baseline, Weeks 24 and 52
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Change at Week 24 | Change at Week 52 | |
| TCZ - All Participants | 35.50 | -13.18 | -20.09 |
CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score 22 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity. (NCT02001987)
Timeframe: Baseline, Week 24, last assessment (up to Week 76)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change at Week 24 | Change at Last Assessment | |
| TCZ - All Participants | -20.85 | -21.74 |
CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score 22 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity. (NCT02001987)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | |
| TCZ COMBO - Core Study Period | 29.34 | -7.15 | -12.65 | -15.75 | -18.17 | -19.25 | -19.29 | -18.40 |
| TCZ MONO - Core Study Period | 32.17 | -5.57 | -11.17 | -17.32 | -20.25 | -20.24 | -21.27 | -19.45 |
The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-millimeter (mm) VAS. DAS28-ESR scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity. (NCT02001987)
Timeframe: Baseline, Week 24, last assessment (up to Week 76)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Change at Week 24 | Change at Last Assessment | |
| TCZ - All Participants | 5.90 | -3.30 | -3.41 |
The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-mm VAS. DAS28-ESR scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity. (NCT02001987)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | |
| TCZ COMBO - Core Study Period | 5.67 | -1.41 | -2.21 | -2.74 | -3.02 | -3.08 | -3.21 | -3.10 |
| TCZ MONO - Core Study Period | 6.08 | -1.19 | -2.16 | -2.70 | -3.16 | -3.20 | -3.27 | -3.01 |
The DAS28-ESR was derived from assessments of erythrocyte sedimentation rate (ESR), tender joint count (TJC), swollen joint count (SJC), and Patient Global Assessment of disease activity (PGA) according to 100-millimeter (mm) Visual Analog Scale (VAS). DAS28-ESR scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in millimeters per hour (mm/h). DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. The change from Baseline to Week 24 was averaged among all participants, where negative changes indicated an improvement in disease activity. (NCT02001987)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Week 24 | |
| TCZ - All Participants - Core Study Period | 5.80 | -3.07 |
FLARE is a 13-item questionnaire assessed disease flares between two medical consultations. Each item score ranged from 0 (completely untrue) to 10 (absolutely true) on a 6-step scale. The FLARE questionnaire global score (range = 0-10) is a mean score of 11 of the 13 items [items 6 ('doses of pain killers or anti-inflammatory medication') and 13 ('need for help') not taken into account], with the highest score corresponding to the highest disease activity. The global score was computed if at least the scores of 6 items were available. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome. (NCT02001987)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 40, 52, and 64
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | Change at Week 28 | Change at Week 40 | Change at Week 52 | Change at Week 64 | |
| TCZ - All Participants | 5.61 | -1.35 | -2.38 | -2.94 | -3.41 | -3.10 | -3.30 | -3.41 | -3.31 | -3.44 | -4.16 | -7.55 |
FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated questions), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). The changes from Baseline to any time point were averaged among all participants, where negative changes indicated an increase in fatigue. (NCT02001987)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
| Intervention | units on a scale (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | Change at Week 28 | Change at Week 32 | Change at Week 36 | Change at Week 40 | Change at Week 44 | Change at Week 48 | Change at Week 52 | Change at Week 56 | Change at Week 60 | Change at Week 64 | |
| TCZ - All Participants | 25.44 | 3.71 | 6.08 | 7.98 | 9.43 | 9.19 | 8.84 | 9.26 | 11.54 | 9.87 | 8.63 | 10.41 | 10.30 | 11.50 | 12.25 | 14.83 | 17.00 | 20.00 |
MOS sleep scale comprised of 6-item with each item score ranged from 0 to 100. The total score was the average of scores sum (range 0-100), with highest values reflecting biggest participant's sleeping problems. If more than 3 items were missing the index was not calculated. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome. (NCT02001987)
Timeframe: Baseline, Weeks 12, 24, 28, 40, 52, and 64
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 12 | Change at Week 24 | Change at Week 28 | Change at Week 40 | Change at Week 52 | Change at Week 64 | |
| TCZ - All Participants | 47.09 | -7.21 | -5.44 | -8.48 | -5.56 | -8.33 | -27.08 |
Participant-assessed pain was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of pain (0 mm=none; 100 mm=very severe). The change from Baseline to any time point was averaged among all participants, where negative change indicated a decrease in participant-assessed pain. (NCT02001987)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
| Intervention | mm (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | Change at Week 28 | Change at Week 32 | Change at Week 36 | Change at Week 40 | Change at Week 44 | Change at Week 48 | Change at Week 52 | Change at Week 56 | Change at Week 60 | Change at Week 64 | |
| TCZ - All Participants | 57.57 | -7.50 | -15.28 | -22.58 | -28.29 | -29.50 | -30.55 | -31.85 | -33.29 | -32.67 | -34.51 | -34.36 | -32.30 | -35.56 | -36.42 | -39.50 | -42.00 | -40.00 |
Participant-assessed disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of disease activity (0 mm=none; 100 mm=very severe). The change from Baseline to any time point was averaged among all participants, where negative change indicated a decrease in participant-assessed disease activity. (NCT02001987)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
| Intervention | mm (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | Change at Week 28 | Change at Week 32 | Change at Week 36 | Change at Week 40 | Change at Week 44 | Change at Week 48 | Change at Week 52 | Change at Week 56 | Change at Week 60 | Change at Week 64 | |
| TCZ - All Participants | 59.88 | -8.11 | -17.19 | -24.49 | -29.62 | -31.61 | -31.80 | -33.79 | -37.90 | -33.96 | -34.10 | -37.74 | -36.55 | -37.63 | -37.50 | -41.00 | -46.00 | -42.50 |
Physician-assessed disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the physician's evaluation of disease activity (0 mm=none; 100 mm=very severe). The change from Baseline to any time point was averaged among all participants, where negative change indicated a decrease in physician-assessed disease activity. (NCT02001987)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
| Intervention | mm (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | |
| TCZ - All Participants | 62.08 | -11.38 | -22.10 | -29.67 | -35.25 | -35.69 | -37.80 | -34.98 |
RAID assessed the impact of rheumatoid arthritis on participant's quality of life. It comprised 7 domains: pain, function, fatigue, physical and psychological well-being, sleep disturbance and coping. Each domain was a single question scored from 0 (best) to 10 (worst) on a continuous numerical rating scale (NRS). Each domain also had a specific weight assigned by a participant survey and RAID total score ranged from 0 (best) to 10 (worst). If only 1 domain was missing it was replaced by the mean of the others; otherwise, RAID score was not calculated. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better quality of life. (NCT02001987)
Timeframe: Baseline, Weeks 12, 24, 28, 40, 52, and 64
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 12 | Change at Week 24 | Change at Week 28 | Change at Week 40 | Change at Week 52 | Change at Week 64 | |
| TCZ - All Participants | 5.94 | -2.74 | -2.94 | -2.99 | -3.21 | -3.27 | -5.59 |
RAPID-3 is a combined index derived from the Multidimensional Health Assessment Questionnaire that includes physical function score, pain VAS, and PGA VAS. The total RAPID-3 score ranges from 0 to 10 where higher scores represent worse outcomes. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome. (NCT02001987)
Timeframe: Baseline, Weeks 2, 4, 12, 24, 28, 40, 52, and 64
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 12 | Change at Week 24 | Change at Week 28 | Change at Week 40 | Change at Week 52 | Change at Week 64 | |
| TCZ - All Participants | 15.41 | -1.72 | -4.18 | -7.07 | -7.68 | -8.16 | -8.86 | -8.91 | -9.00 |
SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg/dL. Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI 26 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity. (NCT02001987)
Timeframe: Baseline, Week 24, last assessment (up to Week 76)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change at Week 24 | Change at Last Assessment | |
| TCZ - All Participants | -23.29 | -24.36 |
SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg per deciliter (dL). Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI 26 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity. (NCT02001987)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | |
| TCZ COMBO - Core Study Period | 31.47 | -9.20 | -14.62 | -17.47 | -20.33 | -21.39 | -21.93 | -20.31 |
| TCZ MONO - Core Study Period | 35.42 | -8.54 | -14.23 | -20.20 | -23.09 | -24.31 | -24.41 | -22.45 |
A total of 28 joints were assessed for swelling. The number of swollen joints at could range from 0 to 28, where higher values represented more swollen joints. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity. (NCT02001987)
Timeframe: Baseline, Week 24, last assessment (up to Week 76)
| Intervention | swollen joints (Median) | |
|---|---|---|
| Change at Week 24 | Change at Last Assessment | |
| TCZ - All Participants | -6.0 | -6.5 |
A total of 28 joints were assessed for swelling. The number of swollen joints at could range from 0 to 28, where higher values represented more swollen joints. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity. (NCT02001987)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
| Intervention | swollen joints (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | |
| TCZ COMBO - Core Study Period | 7.0 | -2.0 | -3.0 | -4.0 | -5.0 | -5.0 | -5.0 | -5.0 |
| TCZ MONO - Core Study Period | 6.0 | -1.0 | -3.0 | -3.5 | -4.0 | -5.0 | -4.0 | -5.0 |
"Synovitis was assessed by ultrasonographic evaluation (B-mode ultrasound) and scored from 0 to 3 for each 7 paired joints (wrists on both sides, 2nd and 3rd metacarpo-phalangeal [MCP 2/3] on both sides, 2nd and 3rd proximal inter-phalangeal [PIP 2/3] on both sides, 2nd and 5th metatarsophalangeal [MTP 2/5] on both sides). Synovitis total score was calculated by adding the sum of scores for each joint for a total score ranging from 0 to 42. A score of 0 indicated no damage and a score of 42 indicated most severe damage. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome." (NCT02001987)
Timeframe: Baseline, Weeks 24
| Intervention | units on a scale (Median) | |
|---|---|---|
| Baseline | Change at Week 24 | |
| TCZ - All Participants | 14.0 | -8.0 |
"Synovitis was assessed by ultrasonographic evaluation (Power-Doppler-mode ultrasound) and scored from 0 to 3 for each 7 paired joints (wrists on both sides, 2nd and 3rd metacarpo-phalangeal [MCP 2/3] on both sides, 2nd and 3rd proximal inter-phalangeal [PIP 2/3] on both sides, 2nd and 5th metatarsophalangeal [MTP 2/5] on both sides). Synovitis total score was calculated by adding the sum of scores for each joint for a total score ranging from 0 to 42. A score of 0 indicated no damage and a score of 42 indicated most severe damage. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome." (NCT02001987)
Timeframe: Baseline, Weeks 24
| Intervention | units on a scale (Median) | |
|---|---|---|
| Baseline | Change at Week 24 | |
| TCZ - All Participants | 5.0 | -4.0 |
A total of 28 joints were assessed for tenderness. The number of tender joints at could range from 0 to 28, where higher values represented more tender joints. The change from Baseline to any time points was averaged among all participants, where negative changes indicated an improvement in disease activity. (NCT02001987)
Timeframe: Baseline, Week 24, last assessment (up to Week 76)
| Intervention | tender joints (Median) | |
|---|---|---|
| Change at Week 24 | Change at Last Assessment | |
| TCZ - All Participants | -6.5 | -6.0 |
A total of 28 joints were assessed for tenderness. The number of tender joints at could range from 0 to 28, where higher values represented more tender joints. The change from Baseline to any time points was averaged among all participants, where negative changes indicated an improvement in disease activity. (NCT02001987)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
| Intervention | tender joints (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | |
| TCZ COMBO - Core Study Period | 8.0 | -2.0 | -3.0 | -5.0 | -5.0 | -5.5 | -5.0 | -5.0 |
| TCZ MONO - Core Study Period | 12.0 | -1.0 | -2.5 | -6.5 | -8.0 | -8.0 | -8.0 | -8.0 |
Number of participants according to reasons for a change in corticosteroid dosage during core study period compared to Baseline is reported. The change included either an initiation/ increase (>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (NCT02001987)
Timeframe: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Initiation/ Increase, Lack of Efficacy | Initiation/ Increase, End of Treatment Planned | Initiation/ Increase, Other Reason | Decrease, Adverse Event | Decrease, Lack of Efficacy | Decrease, End of Treatment Planned | Decrease, Other Reason | |
| TCZ COMBO - Core Study Period | 1 | 1 | 1 | 0 | 1 | 3 | 5 |
| TCZ MONO - Core Study Period | 0 | 0 | 0 | 1 | 0 | 2 | 3 |
Number of participants according to reasons for a change in corticosteroid dosage during study compared to Baseline is reported. The change included either an initiation/ increase (>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (NCT02001987)
Timeframe: Screening up to 8 weeks after last dose (overall up to 88 weeks)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Initiation/ Increase, Lack of Efficacy | Initiation/ Increase, Other Reason | Decrease, Lack of Efficacy | Decrease, End of Treatment Planned | Decrease, Other Reason | |
| TCZ - All Participants | 1 | 1 | 1 | 4 | 9 |
Number of participants according to reasons for changes in csDMARDs treatment during core study period is reported. The changes included Increase of dose (the dose increase had to be greater than the highest dose received within the 4 weeks on or before baseline); Addition of another csDMARD (without suppression of the first one); Switch (add and suppression) of a csDMARD for another reason than intolerance to the csDMARD suppressed; Modification of the administration route of MTX (with increase or maintenance of the dose): per oral route to intravenous (IV)/ intramuscular (IM)/ SC. Participants with a change in csDMARDs treatment during core study period were only included in the analysis. (NCT02001987)
Timeframe: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Adverse Event | End of Treatment Planned | Lack of Efficacy | Poor Treatment Compliance | Other Reason | |
| TCZ - All Participants - Core Study Period | 19 | 2 | 1 | 1 | 6 |
Number of participants according to reasons for changes in csDMARDs treatment during study is reported. The changes included Increase of dose (the dose increase had to be greater than the highest dose received within the 4 weeks on or before baseline); Addition of another csDMARD (without suppression of the first one); Switch (add and suppression) of a csDMARD for another reason than intolerance to the csDMARD suppressed; Modification of the administration route of MTX (with increase or maintenance of the dose): per oral route to IV/IM/SC. Participants with a change in csDMARDs treatment during entire study were only included in the analysis. (NCT02001987)
Timeframe: Screening up to 8 weeks after last dose (overall up to 88 weeks)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Adverse Event | End of Treatment Planned | Lack of Efficacy | Poor Treatment Compliance | Other Reason | |
| TCZ - All Participants | 5 | 1 | 2 | 1 | 3 |
"Participants were asked: If you were to remain in the same condition for the next few months as you have been over the last 8 days, would this be 1) acceptable, 2) Inacceptable? The number of participants who responded acceptable or Inacceptable at each time point is presented." (NCT02001987)
Timeframe: Baseline, Weeks 24, 52, and last assessment (up to Week 76)
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline, Acceptable | Baseline, Inacceptable | Week 24, Acceptable | Week 24, Incceptable | Week 52, Acceptable | Week 52, Inacceptable | Last Assessment, Acceptable | Last Assessment, Inacceptable | |
| TCZ - All Participants | 31 | 101 | 78 | 27 | 8 | 3 | 83 | 35 |
The ACR 20, 50, and 70 responses at any time is defined as >/=20%, 50%, and 70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 20%, 50%, 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) PGA according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/L). Percentage of participants with ACR 20, 50, and 70 responses at Week 24 and at last assessment is reported. (NCT02001987)
Timeframe: Baseline, Week 24, last assessment (up to Week 76)
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 24, ACR20 | Week 24, ACR50 | Week 24, ACR70 | Last Assessment, ACR20 | Last Assessment, ACR50 | Last Assessment, ACR70 | |
| TCZ - All Participants | 76.6 | 51.6 | 35.9 | 76.6 | 56.3 | 37.5 |
The ACR 20, 50, and 70 responses at any time was defined as greater than or equal to (>/=) 20%, 50%, and 70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 20%, 50%, 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) PGA according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via a Health Assessment Questionnaire-Disability Index (HAQ-DI), and 5) Acute phase reactant (ESR in mm/h or C-Reactive Protein [CRP] in milligrams per liter [mg/L]). Percentage of participants with ACR 20, 50, and 70 responses at Week 24 is reported. 95% CI was determined using Clopper-Pearson method. (NCT02001987)
Timeframe: Baseline, Week 24
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| ACR20 | ACR50 | ACR70 | |
| TCZ COMBO - Core Study Period | 73.8 | 52.4 | 28.6 |
| TCZ MONO - Core Study Period | 69.7 | 54.5 | 33.3 |
CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score 22 indicates high disease activity. Percentage of participants with CDAI LDA and remission at Week 24 is reported. 95% CI was determined using Clopper-Pearson method. (NCT02001987)
Timeframe: Week 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| LDA | Remission | |
| TCZ COMBO - Core Study Period | 60.4 | 16.7 |
| TCZ MONO - Core Study Period | 44.2 | 16.3 |
CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score 22 indicates high disease activity. Percentage of participants with CDAI LDA and remission at Week 24 and at last assessment is reported. (NCT02001987)
Timeframe: Week 24, last assessment (up to Week 76)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 24, LDA | Week 24, Remission | Last Assessment, LDA | Last Assessment, Remission | |
| TCZ - All Participants | 57.8 | 17.2 | 60.9 | 23.4 |
Percentage of participants with a change in corticosteroid dosage during core study period compared to Baseline is reported. The change included either an initiation/ increase (>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (NCT02001987)
Timeframe: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Initiation/ Increase | Decrease | |
| TCZ COMBO - Core Study Period | 3.1 | 9.4 |
| TCZ MONO - Core Study Period | 0.0 | 14.0 |
Percentage of participants with a change in corticosteroid dosage during study compared to Baseline is reported. The change included either an initiation/ increase (>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (NCT02001987)
Timeframe: Screening up to 8 weeks after last dose (overall up to 88 weeks)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Initiation/ Increase | Decrease | |
| TCZ - All Participants | 3.1 | 21.9 |
The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-mm VAS. DAS28-ESR scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. DAS28-ESR score 3.2 indicates moderate to high disease activity, and DAS28-ESR <2.6 indicates remission. Percentage of participants with DAS28-ESR LDA and remission at Week 24 and at last assessment is reported. (NCT02001987)
Timeframe: Week 24, last assessment (up to Week 76)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 24, LDA | Week 24, Remission | Last Assessment, LDA | Last Assessment, Remission | |
| TCZ - All Participants | 71.9 | 54.7 | 71.9 | 53.1 |
The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-mm VAS. DAS28-ESR scores were calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. DAS28-ESR score less than or equal to () 3.2 indicates moderate to high disease activity, and DAS28-ESR less than (<) 2.6 indicates remission. Percentage of participants with DAS28-ESR LDA and remission at Week 24 is reported. 95 percent (%) confidence interval (CI) was determined using Clopper-Pearson method. (NCT02001987)
Timeframe: Week 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| LDA | Remission | |
| TCZ COMBO - Core Study Period | 70.8 | 55.2 |
| TCZ MONO - Core Study Period | 67.4 | 41.9 |
Percentage of participants with a discontinuation in corticosteroid dosage during core study period is reported. The discontinuations were categorized as either permanent or temporary. Participants with temporary discontinuation first followed by permanent discontinuation were counted in both categories. Participants who were receiving corticosteroids at Baseline were only included in the analysis. (NCT02001987)
Timeframe: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Permanent Discontinuation | Temporary Discontinuation | |
| TCZ COMBO - Core Study Period | 7.3 | 7.3 |
| TCZ MONO - Core Study Period | 8.3 | 16.7 |
Percentage of participants with a discontinuation in corticosteroid dosage during study is reported. The discontinuations were categorized as either permanent or temporary. Participants with temporary discontinuation first followed by permanent discontinuation were counted in both categories. Participants who were receiving corticosteroids at Baseline were only included in the analysis. (NCT02001987)
Timeframe: Screening up to 8 weeks after last dose (overall up to 88 weeks)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Permanent Discontinuation | Temporary Discontinuation | |
| TCZ - All Participants | 10.0 | 15.0 |
The DAS28-ESR-based EULAR response criteria were used to measure individual response as 'Good', 'Moderate', and 'No Response', depending upon DAS28-ESR absolute scores at Week 24 and the DAS28-ESR reduction from Baseline to Week 24. Good Response: change from baseline >1.2 with DAS28-ESR score 1.2 with DAS28-ESR score >3.2 to 0.6 to 0.6 and 5.1. Percentage of participants with EULAR responses at Week 24 and at last assessment is reported. (NCT02001987)
Timeframe: Baseline, Week 24, last assessment (up to Week 76)
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 24, Good Response | Week 24, Moderate Response | Week 24, No Response | Last Assessment, Good Response | Last Assessment, Moderate Response | Last Assessment, No Response | |
| TCZ - All Participants | 68.8 | 26.6 | 4.7 | 65.6 | 31.3 | 3.1 |
The DAS28-ESR-based EULAR response criteria were used to measure individual response as 'Good', 'Moderate', and 'No Response', depending upon DAS28-ESR absolute scores at Week 24 and the DAS28-ESR reduction from Baseline to Week 24. Good Response: change from baseline >1.2 with DAS28-ESR score 1.2 with DAS28-ESR score >3.2 to 0.6 to 0.6 and 5.1. Percentage of participants with EULAR responses at Week 24 is reported. 95% CI was determined using Clopper-Pearson method. (NCT02001987)
Timeframe: Baseline, Week 24
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Good Response | Moderate Response | No Response | |
| TCZ COMBO - Core Study Period | 60.4 | 19.8 | 19.8 |
| TCZ MONO - Core Study Period | 58.1 | 14.0 | 27.9 |
HAQ-DI assessed 20 items in 8 functional activity domains including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item was scored on a scale of 0 to 3, where 0 represented activities performed without difficulty and 3 represented inability to perform activities alone. The total score (range = 0-3) was calculated as an average of all item scores. Percentage of participants with HAQ-DI clinically meaningful improvement (reduction in HAQ-DI score from baseline >/=0.22) at each time point is reported. (NCT02001987)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
| Intervention | percentage of participants (Number) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | Week 56 | Week 60 | Week 64 | |
| TCZ - All Participants | 42.5 | 55.3 | 62.1 | 71.6 | 75.0 | 67.6 | 73.6 | 76.8 | 72.0 | 64.9 | 73.9 | 65.0 | 62.5 | 50.0 | 66.7 | 100.0 | 50.0 |
HAQ-DI assessed 20 items in 8 functional activity domains including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item was scored on a scale of 0 to 3, where 0 represented activities performed without difficulty and 3 represented inability to perform activities alone. The total score (range = 0-3) was calculated as an average of all item scores. Percentage of participants with HAQ-DI remission (HAQ-DI score <0.5) at each time point is reported. (NCT02001987)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
| Intervention | percentage of participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | Week 56 | Week 60 | Week 64 | |
| TCZ - All Participants | 6.0 | 8.4 | 12.6 | 23.3 | 31.7 | 35.9 | 31.3 | 30.3 | 37.3 | 32.1 | 25.0 | 30.4 | 30.0 | 25.0 | 33.3 | 33.3 | 50.0 | 50.0 |
SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg/dL. Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI 26 indicates high disease activity. Percentage of participants with SDAI LDA and remission at Week 24 is reported. 95% CI was determined using Clopper-Pearson method. (NCT02001987)
Timeframe: Week 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| LDA | Remission | |
| TCZ COMBO - Core Study Period | 59.4 | 19.8 |
| TCZ MONO - Core Study Period | 46.5 | 18.6 |
SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg/dL. Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI 26 indicates high disease activity. Percentage of participants with SDAI LDA and remission at Week 24 and at last assessment is reported. (NCT02001987)
Timeframe: Week 24, last assessment (up to Week 76)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 24, LDA | Week 24, Remission | Last Assessment, LDA | Last Assessment, Remission | |
| TCZ - All Participants | 57.8 | 20.3 | 64.1 | 25.0 |
Time to first change in corticosteroid dosage during core study period compared to Baseline is reported. The change included either an initiation/ increase (>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (NCT02001987)
Timeframe: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
| Intervention | days (Median) |
|---|---|
| Decrease | |
| TCZ MONO - Core Study Period | 98 |
Time to first change in corticosteroid dosage during core study period compared to Baseline is reported. The change included either an initiation/ increase (>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (NCT02001987)
Timeframe: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
| Intervention | days (Median) | |
|---|---|---|
| Initiation/ Increase | Decrease | |
| TCZ COMBO - Core Study Period | 38 | 107 |
Time to first change in corticosteroid dosage during study compared to Baseline is reported. The change included either an initiation/ increase (>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (NCT02001987)
Timeframe: Screening up to 8 weeks after last dose (overall up to 88 weeks)
| Intervention | days (Median) | |
|---|---|---|
| Initiation/ Increase | Decrease | |
| TCZ - All Participants | 44 | 210 |
The DAS 28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP) and general health status. For this study ESR was used to calculate the DAS 28 score. (NCT01995201)
Timeframe: Week 20 and Week 24
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase 1: Tocilizumab Monotherapy | 48.4 |
| Phase 1: Combination Therapy | 52.9 |
"This patient reported outcome assessment represents the patient's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line should be described as no pain and the extreme right end as unbearable pain." (NCT01995201)
Timeframe: From baseline to Week 24
| Intervention | Millimeters (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | LOCF visit | |
| Phase 1: Combination Therapy | 58.59 | 47.46 | 42.88 | 34.28 | 31.07 | 30.18 | 28.26 | 26.43 | 29.78 |
| Phase 1: Tocilizumab Monotherapy | 66.38 | 53.20 | 43.11 | 35.95 | 29.44 | 32.17 | 26.58 | 23.56 | 27.34 |
"This patient reported outcome assessment represents the patient's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line should be described as no pain and the extreme right end as unbearable pain." (NCT01995201)
Timeframe: Baseline, from week 28 until week 48
| Intervention | Millimeters (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | LOCF visit | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 55.73 | 17.33 | 17.08 | 18.81 | 16.96 | 15.05 | 11.90 | 12.74 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 56.00 | 15.67 | 17.27 | 14.36 | 17.07 | 16.27 | 16.31 | 16.41 |
The symptom-specific measure FACIT-F assesses chronic illness therapy with special emphasis on fatigue in the past 7 days and consists of 5 dimensions: 1) physical well- being, 2) social/family well-being, 3) emotional well-being, 4) functional well-being, and 5) additional concerns. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much for a total possible FACIT-F score of 0 to 160. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions. (NCT01995201)
Timeframe: From baseline to Week 24
| Intervention | FACIT-F score (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | LOCF visit | |
| Phase 1: Combination Therapy | 89.16 | 95.82 | 99.54 | 103.46 | 104.08 | 105.51 | 104.91 | 107.01 | 104.65 |
| Phase 1: Tocilizumab Monotherapy | 81.72 | 86.64 | 92.26 | 96.45 | 98.29 | 98.41 | 102.46 | 104.36 | 101.38 |
The symptom-specific measure FACIT-F assesses chronic illness therapy with special emphasis on fatigue in the past 7 days and consists of 5 dimensions: 1) physical well- being, 2) social/family well-being, 3) emotional well-being, 4) functional well-being, and 5) additional concerns. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much for a total possible FACIT-F score of 0 to 160. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions. (NCT01995201)
Timeframe: Baseline, from week 28 until week 48
| Intervention | FACIT-F score (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | LOCF visit | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 17.36 | 23.50 | 23.62 | 23.23 | 23.39 | 23.48 | 23.95 | 23.69 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 17.13 | 23.12 | 22.98 | 22.90 | 23.02 | 23.13 | 22.87 | 22.88 |
"The Stanford HAQ-DI is a patient-oriented outcome assessment questionnaire specific for RA. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.~To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3." (NCT01995201)
Timeframe: From baseline to Week 24
| Intervention | HAQ-DI score (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | LOCF visit | |
| Phase 1: Combination Therapy | 1.36 | 1.18 | 1.05 | 0.95 | 0.91 | 0.87 | 0.83 | 0.82 | 0.88 |
| Phase 1: Tocilizumab Monotherapy | 1.49 | 1.39 | 1.20 | 1.10 | 0.99 | 0.99 | 0.88 | 0.85 | 0.97 |
"The Stanford HAQ-DI is a patient-oriented outcome assessment questionnaire specific for RA. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.~To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3." (NCT01995201)
Timeframe: Baseline, from week 28 until week 48
| Intervention | HAQ-DI score (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | LOCF visit | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 1.21 | 0.58 | 0.55 | 0.60 | 0.55 | 0.53 | 0.53 | 0.55 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 1.20 | 0.57 | 0.57 | 0.56 | 0.61 | 0.58 | 0.57 | 0.56 |
Number of patients resulting positive to anti-tocilizumab antibodies test are reported. (NCT01995201)
Timeframe: From baseline to Week 24
| Intervention | Number of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Screen - Baseline | Screen - Week 12 | Screen - Week 24 | Confirmatory - Baseline | Confirmatory - Week 12 | Confirmatory - Week 24 | |
| Phase 1: Combination Therapy | 13 | 2 | 9 | 5 | 0 | 3 |
| Phase 1: Tocilizumab Monotherapy | 6 | 1 | 3 | 4 | 1 | 1 |
Number of patients resulting positive to anti-tocilizumab antibodies test are reported. (NCT01995201)
Timeframe: From week 24 until week 48
| Intervention | Number of participants (Number) | |||
|---|---|---|---|---|
| Screen - Week 36 | Screen - Week 48 | Confirmatory - Week 36 | Confirmatory - Week 48 | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 0 | 1 | 0 | 0 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 0 | 3 | 0 | 0 |
| Phase 2 Arm B: Participants With Low Disease Activity | 0 | 2 | 0 | 0 |
| Phase 2 Arm C: Moderate EULAR Response at Week 24 | 2 | 3 | 1 | 1 |
Mean concentration of SIL-6R in patients' blood are reported. (NCT01995201)
Timeframe: Baseline, Week 36 and Early Withdrawal Visit
| Intervention | mcg/ml (Mean) | |
|---|---|---|
| Baseline | Early withdrawal visit | |
| Phase 2 Arm D: Non Responders | 37.30 | 513.00 |
Mean concentration of SIL-6R in patients' blood are reported. (NCT01995201)
Timeframe: Baseline, Week 36 and Early Withdrawal Visit
| Intervention | mcg/ml (Mean) | ||
|---|---|---|---|
| Baseline | Week 36 | Early withdrawal visit | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 39.87 | 539.89 | 412.53 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 39.70 | 476.28 | 643.00 |
| Phase 2 Arm B: Participants With Low Disease Activity | 39.39 | 542.99 | 338.38 |
| Phase 2 Arm C: Moderate EULAR Response at Week 24 | 43.11 | 552.65 | 217.74 |
Mean concentration of SIL-6R in patients' blood are reported. (NCT01995201)
Timeframe: From baseline to Week 24
| Intervention | mcg/ml (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Week 24 | |
| Phase 1: Combination Therapy | 39.29 | 570.34 | 565.34 |
| Phase 1: Tocilizumab Monotherapy | 42.85 | 566.47 | 570.49 |
Mean concentrations of TCZ in patients' blood are reported. (NCT01995201)
Timeframe: week 36 and early withdrawal visit
| Intervention | mcg/ml (Mean) |
|---|---|
| Early withdrawal visit | |
| Phase 2 Arm D: Non Responders | 1.78 |
Mean concentrations of TCZ in patients' blood are reported. (NCT01995201)
Timeframe: week 36 and early withdrawal visit
| Intervention | mcg/ml (Mean) | |
|---|---|---|
| Week 36 | Early withdrawal visit | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 48.47 | 36.45 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 16.77 | 19.20 |
| Phase 2 Arm B: Participants With Low Disease Activity | 41.89 | 24.43 |
| Phase 2 Arm C: Moderate EULAR Response at Week 24 | 48.33 | 13.75 |
Mean concentrations of TCZ in patients' blood are reported. (NCT01995201)
Timeframe: From baseline to Week 24
| Intervention | mcg/ml (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Week 24 | |
| Phase 1: Combination Therapy | 0.67 | 41.23 | 46.87 |
| Phase 1: Tocilizumab Monotherapy | 0.49 | 37.97 | 46.42 |
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter [cm] Visual Analog Scale [VAS] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement. (NCT01995201)
Timeframe: From week 24 until week 48
| Intervention | CDAI score (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline values | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | LOCF visit | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 29.27 | -25.54 | -24.75 | -24.56 | -23.90 | -25.16 | -25.45 | -26.44 | -25.74 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 29.64 | -25.34 | -24.01 | -25.12 | -25.45 | -25.45 | -25.26 | -25.13 | -24.87 |
TCJ is a clinical assessment of 68 joints which are classified as tender/not tender by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints are not be taken into consideration. (NCT01995201)
Timeframe: From baseline to Week 24
| Intervention | TJC (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline visit | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | LOCF visit | |
| Phase 1: Combination Therapy | 19.12 | -5.00 | -7.96 | -10.90 | -12.01 | -13.09 | -13.70 | -14.20 | -13.19 |
| Phase 1: Tocilizumab Monotherapy | 18.05 | -4.31 | -7.04 | -9.81 | -12.27 | -13.43 | -13.65 | -15.47 | -14.36 |
TCJ is a clinical assessment of 68 joints which are classified as tender/not tender by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints are not be taken into consideration. (NCT01995201)
Timeframe: From week 24 until week 48
| Intervention | TJC (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline values | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | LOCF visit | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 15.42 | -13.66 | -13.40 | -13.13 | -14.06 | -14.32 | -14.40 | -13.96 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 15.97 | -12.88 | -13.88 | -13.78 | -14.49 | -13.93 | -13.43 | -13.27 |
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter [cm] Visual Analog Scale [VAS] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement. (NCT01995201)
Timeframe: From baseline to Week 24
| Intervention | CDAI score (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline values | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | LOCF visit | |
| Phase 1: Combination Therapy | 32.06 | -8.62 | -13.23 | -18.46 | -20.60 | -21.79 | -22.88 | -23.43 | -21.58 |
| Phase 1: Tocilizumab Monotherapy | 33.06 | -7.54 | -13.03 | -18.06 | -21.56 | -23.01 | -24.07 | -25.80 | -24.42 |
The DAS 28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP) and general health status. For this study ESR was used to calculate the DAS 28 score. (NCT01995201)
Timeframe: From week 24 up to week 48
| Intervention | mm/hr (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | -4.07 | -3.94 | -3.97 | -3.82 | -3.95 | -4.05 | -4.14 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | -4.01 | -3.78 | -3.77 | -3.90 | -3.84 | -3.76 | -3.68 |
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =< 3.3 indicates disease remission, > 3.4 to 11 indicates low disease activity, > 11 to 26 indicates moderate disease activity, and > 26 indicates high disease activity. (NCT01995201)
Timeframe: From baseline to Week 24
| Intervention | SDAI score (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline values | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | LOCF visit | |
| Phase 1: Combination Therapy | 44.40 | -19.50 | -24.34 | -29.34 | -30.95 | -32.66 | -33.95 | -34.80 | -32.73 |
| Phase 1: Tocilizumab Monotherapy | 48.66 | -20.45 | -27.86 | -32.61 | -36.23 | -37.82 | -36.79 | -41.38 | -39.15 |
Simplified Disease Activity Index (SDAI) which is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =< 3.3 indicates disease remission, > 3.4 to 11 indicates low disease activity, > 11 to 26 indicates moderate disease activity, and > 26 indicates high disease activity. (NCT01995201)
Timeframe: From week 24 until week 48
| Intervention | SDAI score (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline values | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | LOCF visit | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 41.45 | -37.02 | -35.15 | -35.60 | -35.29 | -37.26 | -37.09 | -37.93 | -36.93 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 40.92 | -35.88 | -34.50 | -34.88 | -35.35 | -35.70 | -35.06 | -35.02 | -34.69 |
SJC is a clinical assessment of 66 joints classified as swollen/not swollen by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints will not be taken into consideration for swelling. (NCT01995201)
Timeframe: From baseline to Week 24
| Intervention | SJC (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline values | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | LOCF visit | |
| Phase 1: Combination Therapy | 9.76 | -3.42 | -5.46 | -6.81 | -7.60 | -8.01 | -8.37 | -8.38 | -7.71 |
| Phase 1: Tocilizumab Monotherapy | 10.05 | -3.22 | -5.07 | -7.38 | -7.93 | -8.35 | -8.72 | -9.13 | -8.47 |
SJC is a clinical assessment of 66 joints classified as swollen/not swollen by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints will not be taken into consideration for swelling. (NCT01995201)
Timeframe: From week 24 until week 48
| Intervention | SJC (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline values | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | LOCF visit | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 9.28 | -8.64 | -8.54 | -8.48 | -8.85 | -8.73 | -9.06 | -8.82 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 9.23 | -8.14 | -8.62 | -8.38 | -8.51 | -8.62 | -8.72 | -8.64 |
DAS28-based EULAR response criteria were used to measure individual response as good or moderate depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline >1.2 with DAS28 ≤3.2; moderate responders: change from baseline >1.2 with DAS28 >3.2 to ≤5.1 or change from baseline >0.6 to =<1.2 with DAS28 ≤5.1. (NCT01995201)
Timeframe: From week 28 until week 48
| Intervention | Number of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Good response - week 28 | Moderate response - week 28 | Good response - week 32 | Moderate response - week 32 | Good response - week 36 | Moderate response - week 36 | Good response - week 40 | Moderate response - week 40 | Good response - week 44 | Moderate response - week 44 | Good response - week 48 | Moderate response - week 48 | Good response - LOCF visit | Moderate response - LOCF visit | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 82 | 5 | 79 | 6 | 75 | 9 | 75 | 9 | 78 | 4 | 78 | 4 | 84 | 5 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 77 | 10 | 81 | 9 | 80 | 8 | 81 | 7 | 75 | 13 | 73 | 15 | 74 | 16 |
DAS28-based EULAR response criteria were used to measure individual response as good or moderate depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline >1.2 with DAS28 ≤3.2; moderate responders: change from baseline >1.2 with DAS28 >3.2 to ≤5.1 or change from baseline >0.6 to =<1.2 with DAS28 ≤5.1. (NCT01995201)
Timeframe: From week 2 until week 24
| Intervention | Number of participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Good response - week 2 | Moderate response - week 2 | Good response - week 4 | Moderate response - week 4 | Good response - week 8 | Moderate response - week 8 | Good response - week 12 | Moderate response - week 12 | Good response - week 16 | Moderate response - week 16 | Good response - week 20 | Moderate response - week 20 | Good response - week 24 | Moderate response - week 24 | Good response - LOCF visit | Moderate response - LOCF visit | |
| Phase 1: Combination Therapy | 61 | 196 | 109 | 175 | 162 | 121 | 194 | 95 | 209 | 76 | 221 | 56 | 225 | 53 | 247 | 73 |
| Phase 1: Tocilizumab Monotherapy | 14 | 36 | 18 | 49 | 37 | 32 | 41 | 27 | 45 | 22 | 45 | 18 | 48 | 16 | 54 | 19 |
"This patient reported outcome assessment represents the patient's overall assessment of their current disease activity on a 100 mm horizontal VAS. The extreme left end of the line should be described as no disease activity (symptom-free and no arthritis symptoms) and the extreme right end as maximum disease activity (maximum arthritis disease activity). The line was marked by the participant and the distance from the left edge was recorded and the mean values are reported." (NCT01995201)
Timeframe: From baseline to Week 24
| Intervention | Millimeters (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | LOCF visit | |
| Phase 1: Combination Therapy | 59.40 | 44.16 | 35.19 | 26.04 | 22.24 | 20.71 | 18.79 | 19.00 | 22.23 |
| Phase 1: Tocilizumab Monotherapy | 65.26 | 49.53 | 38.21 | 30.03 | 22.71 | 19.28 | 16.80 | 16.63 | 20.36 |
"This patient reported outcome assessment represents the patient's overall assessment of their current disease activity on a 100 mm horizontal VAS. The extreme left end of the line should be described as no disease activity (symptom-free and no arthritis symptoms) and the extreme right end as maximum disease activity (maximum arthritis disease activity). The line was marked by the participant and the distance from the left edge was recorded and the mean values are reported." (NCT01995201)
Timeframe: Baseline, from week 28 until week 48
| Intervention | Millimeters (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | LOCF visit | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 58.97 | 11.97 | 10.78 | 11.99 | 10.62 | 9.50 | 8.13 | 8.97 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 60.96 | 12.74 | 10.80 | 10.30 | 10.94 | 10.06 | 9.99 | 10.21 |
The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR will be used to calculate the DAS28 score. (NCT01995201)
Timeframe: From week 28 up to week 48
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 88.5 | 87.2 | 80.2 | 82.1 | 89.0 | 91.5 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 84.1 | 81.1 | 86.4 | 80.7 | 78.4 | 73.9 |
The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR will be used to calculate the DAS28 score. (NCT01995201)
Timeframe: From week 28 up to week 48
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 96.6 | 96.5 | 93.0 | 98.8 | 98.8 | 100.0 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 96.6 | 95.6 | 97.7 | 98.9 | 95.5 | 95.5 |
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter [cm] Visual Analog Scale [VAS] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement. (NCT01995201)
Timeframe: From baseline to Week 24
| Intervention | Percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | LOCF visit | |
| Phase 1: Combination Therapy | 16.9 | 26.9 | 47.5 | 52.4 | 60.7 | 65.1 | 66.9 | 61.2 |
| Phase 1: Tocilizumab Monotherapy | 13.5 | 24.7 | 41.1 | 57.1 | 62.3 | 66.2 | 71.9 | 66.2 |
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter [cm] Visual Analog Scale [VAS] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement. (NCT01995201)
Timeframe: From week 28 until week 48
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | LOCF Visit | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 86.4 | 89.7 | 80.2 | 86.9 | 89.0 | 92.8 | 91.0 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 85.4 | 86.7 | 89.8 | 88.6 | 85.4 | 87.6 | 87.8 |
The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR is used to calculate the DAS28 score. (NCT01995201)
Timeframe: From baseline to Week 24
| Intervention | Percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | LOCF visit | |
| Phase 1: Combination Therapy | 21.5 | 36.8 | 55.4 | 67.7 | 72.4 | 78.2 | 81.1 | 74.0 |
| Phase 1: Tocilizumab Monotherapy | 21.6 | 26.0 | 50.7 | 58.6 | 66.7 | 67.7 | 75.0 | 73.0 |
The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR was used to calculate the DAS28 score. (NCT01995201)
Timeframe: From week 28 until week 48
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | LOCF Visit | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 95.4 | 91.9 | 87.2 | 89.3 | 96.3 | 95.1 | 94.4 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 88.6 | 92.2 | 92.0 | 92.0 | 87.5 | 86.4 | 85.6 |
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =< 3.3 indicates disease remission, > 3.4 to 11 indicates low disease activity, > 11 to 26 indicates moderate disease activity, and > 26 indicates high disease activity. (NCT01995201)
Timeframe: From baseline to Week 24
| Intervention | Percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | LOCF visit | |
| Phase 1: Combination Therapy | 17.6 | 28.3 | 48.1 | 55.6 | 62.5 | 66.3 | 67.3 | 56.9 |
| Phase 1: Tocilizumab Monotherapy | 16.7 | 27.1 | 41.7 | 58.6 | 63.8 | 65.6 | 74.6 | 63.5 |
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =< 3.3 indicates disease remission, > 3.4 to 11 indicates low disease activity, > 11 to 26 indicates moderate disease activity, and > 26 indicates high disease activity. (NCT01995201)
Timeframe: From week 28 until week 48
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | LOCF Visit | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 84.9 | 89.5 | 79.1 | 86.7 | 91.5 | 93.9 | 91.0 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 83.89 | 85.6 | 87.5 | 86.4 | 82.0 | 81.8 | 81.1 |
The definition of improvement of ACR core set of outcome measures includes an improvement equal or higher to the 20%, 50%, 70%, 90% compared to Baseline in both Swollen Joint Count (SJC) and Tender Joint Count (TJC) as well as in three out of five additional parameters: Physician's Global Assessment of disease activity VAS, patient's Global Assessment of disease activity VAS, patient's assessment of pain VAS, HAQ-DI, and acute phase reactant (either CRP or erythrocyte sedimentation rate [ESR]). (NCT01995201)
Timeframe: From week 2 until week 24
| Intervention | Percentage of participants (Number) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACR20 - Week 2 | ACR20 - Week 4 | ACR20 - Week 8 | ACR20 - Week 12 | ACR20 - Week 16 | ACR20 - Week 20 | ACR20 - Week 24 | ACR20 - LOCF visit | ACR50 - week 2 | ACR50 - week 4 | ACR50 - week 8 | ACR50 - week 12 | ACR50 - week 16 | ACR50 - week 20 | ACR50 - week 24 | ACR50 - LOCF visit | ACR70 - week 2 | ACR70 - week 4 | ACR70 - week 8 | ACR70 - week 12 | ACR70 - week 16 | ACR70 - week 20 | ACR70 - week 24 | ACR70 - LOCF visit | ACR90 - week 2 | ACR90 - week 4 | ACR90 - week 8 | ACR90 - week 12 | ACR90 - week 16 | ACR90 - week 20 | ACR90 - week 24 | ACR90 - LOCF visit | |
| Phase 1: Combination Therapy | 31.7 | 49.7 | 67.0 | 74.7 | 75.7 | 81.0 | 83.3 | 79.0 | 13.2 | 25.3 | 41.3 | 52.7 | 52.4 | 58.5 | 58.7 | 54.2 | 2.8 | 10.6 | 22.7 | 27.0 | 32.2 | 36.6 | 37.7 | 33.9 | 0.9 | 1.6 | 7.3 | 8.8 | 12.0 | 13.7 | 16.7 | 15.0 |
| Phase 1: Tocilizumab Monotherapy | 27.0 | 50.7 | 67.1 | 80.0 | 79.7 | 73.8 | 79.7 | 77.0 | 9.5 | 20.5 | 37.0 | 51.4 | 53.6 | 58.5 | 59.4 | 55.4 | 5.4 | 12.3 | 17.8 | 32.9 | 29.0 | 33.8 | 40.6 | 37.8 | 1.4 | 2.7 | 6.8 | 12.9 | 13.0 | 13.8 | 23.4 | 20.3 |
The definition of improvement of ACR core set of outcome measures includes an improvement equal or higher to the 20%, 50%, 70%, 90% compared to Baseline in both Swollen Joint Count (SJC) and Tender Joint Count (TJC) as well as in three out of five additional parameters: Physician's Global Assessment of disease activity VAS, patient's Global Assessment of disease activity VAS, patient's assessment of pain VAS, HAQ-DI, and acute phase reactant (either CRP or erythrocyte sedimentation rate [ESR]). (NCT01995201)
Timeframe: From week 28 until week 48
| Intervention | Percentage of participants (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACR20 - Week 28 | ACR20 - Week 32 | ACR20 - Week 36 | ACR20 - Week 40 | ACR20 - Week 44 | ACR20 - Week 48 | ACR20 - LOCF visit | ACR50 - Week 28 | ACR50 - Week 32 | ACR50 - Week 36 | ACR50 - Week 40 | ACR50 - Week 44 | ACR50 - Week 48 | ACR50 - LOCF visit | ACR70 - Week 28 | ACR70 - Week 32 | ACR70 - Week 36 | ACR70 - Week 40 | ACR70 - Week 44 | ACR70 - Week 48 | ACR70 - LOCF visit | ACR90 - Week 28 | ACR90 - Week 32 | ACR90 - Week 36 | ACR90 - Week 40 | ACR90 - Week 44 | ACR90 - Week 48 | ACR90 - LOCF visit | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 90.0 | 93.1 | 84.9 | 88.1 | 91.5 | 96.4 | 95.5 | 79.5 | 85.1 | 74.4 | 79.8 | 80.5 | 88.1 | 84.3 | 59.1 | 65.5 | 61.6 | 65.5 | 67.1 | 71.4 | 68.5 | 27.3 | 35.6 | 33.7 | 41.7 | 34.1 | 45.2 | 42.7 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 92.2 | 94.4 | 91.0 | 93.2 | 91.0 | 88.8 | 87.8 | 81.1 | 83.3 | 83.1 | 81.8 | 78.7 | 79.8 | 78.9 | 57.8 | 54.4 | 62.9 | 59.1 | 59.6 | 65.2 | 64.4 | 32.2 | 31.1 | 30.3 | 29.5 | 27.0 | 32.6 | 32.2 |
The DAS 28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP) and general health status. For this study ESR was used to calculate the DAS 28 score. (NCT01995201)
Timeframe: Week 48
| Intervention | Percentage of participants (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | LOCF Visit | |
| Phase 2 Arm A1 - Monotherapy - qw | 82.6 | 81.8 | 90.5 | 85.0 | 94.7 | 100 | 91.3 |
| Phase 2 Arm A1- Combination Therapy - qw | 90.6 | 89.1 | 76.9 | 81.3 | 87.3 | 89.1 | 89.4 |
| Phase 2 Arm A2 - Combination Therapy - q2w | 83.1 | 82.1 | 86.4 | 81.8 | 78.8 | 72.7 | 73.1 |
| Phase 2 Arm A2 - Monotherapy - q2w | 87.0 | 78.3 | 86.4 | 77.3 | 77.3 | 77.3 | 73.9 |
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter [cm] Visual Analog Scale [VAS] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement. (NCT01995201)
Timeframe: From baseline to Week 24
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline visit | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | LOCF visit | |
| Phase 1: Combination Therapy | 0 | 1.6 | 5.1 | 14.4 | 19.3 | 22.8 | 26.8 | 30.2 | 29.4 |
| Phase 1: Tocilizumab Monotherapy | 0 | 2.7 | 2.7 | 11.0 | 15.7 | 18.8 | 27.7 | 29.7 | 29.7 |
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter [cm] Visual Analog Scale [VAS] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement. (NCT01995201)
Timeframe: From week 28 until week 48
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | LOCF Visit | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 46.6 | 48.3 | 52.3 | 52.4 | 50.0 | 59.0 | 57.8 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 48.3 | 45.6 | 46.6 | 45.5 | 50.6 | 53.9 | 60.3 |
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =< 3.3 indicates disease remission, > 3.4 to 11 indicates low disease activity, > 11 to 26 indicates moderate disease activity, and > 26 indicates high disease activity. (NCT01995201)
Timeframe: From baseline to Week 24
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline visit | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | LOCF visit | |
| Phase 1: Combination Therapy | 0 | 1.9 | 4.8 | 14.6 | 18.8 | 22.2 | 25.8 | 28.8 | 25.4 |
| Phase 1: Tocilizumab Monotherapy | 0 | 1.4 | 2.9 | 11.1 | 14.3 | 17.4 | 28.1 | 31.7 | 28.4 |
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =< 3.3 indicates disease remission, > 3.4 to 11 indicates low disease activity, > 11 to 26 indicates moderate disease activity, and > 26 indicates high disease activity. (NCT01995201)
Timeframe: From week 28 until week 48
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | LOCF Visit | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 50.0 | 48.8 | 53.5 | 55.4 | 50.0 | 52.4 | 51.7 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 46.0 | 45.6 | 47.7 | 44.3 | 47.2 | 47.7 | 47.8 |
Number of patients reporting any treatment emergent adverse event (TEAE), at least one TEAE of special interest, at least one serious TEAE, at least one TEAE leading to dose modification, at least one TEAE leading to discontinuation up to week 24 (NCT01995201)
Timeframe: From baseline to Week 24
| Intervention | Number of participants (Number) | ||||
|---|---|---|---|---|---|
| Any treatment emergent adverse event (TEAE) | At least one TEAE of special interest | At least one serious TEAE | At least one TEAE leading to dose modification | At least one TEAE leading to discontinuation | |
| Phase 1: Combination Therapy | 254 | 13 | 10 | 103 | 21 |
| Phase 1: Tocilizumab Monotherapy | 52 | 2 | 3 | 24 | 4 |
Number of patients reporting any treatment emergent adverse event (TEAE), at least one TEAE of special interest, at least one serious TEAE, at least one TEAE leading to dose modification, at least one TEAE leading to discontinuation up to week 48 (NCT01995201)
Timeframe: From week 24 until week 48
| Intervention | Number of participants (Number) | ||||
|---|---|---|---|---|---|
| Any TEAE | At least one TEAE of special interest | At least one serious TEAE | At least one TEAE leading to dose modification | At least one TEAE leading to discontinuation | |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 50 | 1 | 2 | 15 | 0 |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 63 | 2 | 1 | 23 | 0 |
| Phase 2 Arm B: Participants With Low Disease Activity | 68 | 2 | 2 | 23 | 0 |
| Phase 2 Arm C: Moderate EULAR Response at Week 24 | 46 | 4 | 5 | 21 | 2 |
| Phase 2 Arm D: Non Responders | 1 | 0 | 1 | 1 | 0 |
Response was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from the reference visit. Participants with a score lesser than or equal to () 1.2 points were assessed as having a 'good' response. Participants with a score >3.2 with reduction of >1.2 points, or a score <=5.1 with reduction of >0.6 to <=1.2 points, were assessed as having a 'moderate' response. Participants with a score >5.1 with reduction of >0.6 to <=1.2 points, or any score with reduction <=0.6 points, were assessed as non-responders with response recorded as 'none.' (NCT01988012)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Tocilizumab | 96.4 |
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter [cm] Visual Analog Scale [VAS] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement. (NCT01988012)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Week 24 | |
| Tocilizumab | 31.89 | -18.29 |
The DAS28-ESR score is a measure of the patient's disease activity calculated using the tender joint count on 28 joints (TJC28), swollen joint count on 28 joints (SJC28), patient's global assessment (PGA) of disease activity based on visual analog scale (VAS) and the erythrocyte sedimentation rate (ESR) in millimeter/hour (mm/hr). VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total possible score ranged from 0 to 10. Higher scores represent higher disease activity. A negative change from baseline indicates an improvement. (NCT01988012)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Week 24 | |
| Tocilizumab | 4.98 | -2.47 |
The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities and 20 questions. Each category contains multiple questions, which were answered using a 4-point scale from 0 (without any difficulty) to 3 (unable to do). The overall index score was an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. A negative change from baseline indicates an improvement. (NCT01988012)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Week 24 | |
| Tocilizumab | 1.55 | -0.34 |
The symptom-specific measure FACIT-F assesses chronic illness therapy with special emphasis on fatigue in the past 7 days and consists of 5 dimensions: 1) physical well- being, 2) social/family well-being, 3) emotional well-being, 4) functional well-being, and 5) additional concerns. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much for a total possible FACIT-F score of 0 to 52. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions. A positive change from baseline indicates an improvement. (NCT01988012)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Week 24 | |
| Tocilizumab | 23.46 | 6.95 |
PGA VAS represents the participant's overall assessment of their current disease activity on a 100 millimeter (mm) horizontal VAS scale from 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates an improvement. (NCT01988012)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Week 24 | |
| Tocilizumab | 69.73 | -31.22 |
Patient Pain VAS represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS scale from 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates an improvement. (NCT01988012)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Week 24 | |
| Tocilizumab | 64.82 | -29.11 |
Participants were either on tocilizumab monotherapy or tocilizumab plus non-biologic disease modifying anti-rheumatic drugs (DMARDs). Reported here is the percentage of participants on tocilizumab monotherapy at baseline and the change from baseline at Week 24. A positive change from baseline at Week 24 indicates the percentage of participants, who discontinued DMARDs during the study. (NCT01988012)
Timeframe: Baseline, Week 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Baseline | Change from Baseline at Week 24 | |
| Tocilizumab | 26 | 12 |
Simplified Disease Activity Index (SDAI) was an index for measuring disease activity in RA and had a good correlation with the DAS28. The index was calculated using the following formula: SDAI: SJC28 + TJC28 + PGA (10 cm VAS) + PhGA (10 cm VAS + C-Reactive Protein (CRP) in mg/L. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. A negative change from baseline indicates an improvement. (NCT01988012)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Week 24 | |
| Tocilizumab | 33.73 | -21.41 |
The number of tender joints (based on 68 joints) and swollen joints (based on 66 joints) were counted at each visit. TJC was determined by identifying the joints that were painful under pressure or to passive motion; no tenderness =0, tenderness =1. SJC was determined by identifying swelling; no swelling =0, swelling =1. A negative change from baseline indicates an improvement. (NCT01988012)
Timeframe: Baseline, Week 24
| Intervention | joint count (Mean) | |||
|---|---|---|---|---|
| TJC at Baseline | TJC Change from Baseline at Week 24 | SJC at Baseline | SJC Change from Baseline at Week 24 | |
| Tocilizumab | 21.42 | -11.91 | 10.30 | -7.54 |
A positive change from Week 1 indicates an increase in sIL-6R levels. (NCT01988012)
Timeframe: Week 1, Week 12, Week 24, Follow-up Week 32 and Early Withdrawal
| Intervention | nanograms/milliliter (ng/mL) (Mean) | ||||
|---|---|---|---|---|---|
| Week 1 | Change from Week 1 at Week 12 | Change from Week 1 at Week 24 | Change from Week 1 at Follow-up at Week 32 | Change from Week 1 at Early withdrawal | |
| Tocilizumab | 38.33 | 475.79 | 503.67 | 382.26 | 309.91 |
Reported is the percentage of participants positive for anti-tocilizumab antibodies in the confirmatory anti-tocilizumab antibody assay, which followed an initial anti-tocilizumab screen. Participants, who withdrew from the study (NCT01988012)
Timeframe: Baseline, Week 24, Follow-up Week 32 and Early Withdrawal
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Baseline | Week 24 | Follow-up Visit Week 32 | Early Withdrawal | |
| Tocilizumab | 1.0 | 0 | 0 | 0 |
(NCT01988012)
Timeframe: Week 12, Week 24, Follow-up Week 32 and Early Withdrawal
| Intervention | microgram/milliliter (mcg/mL) (Mean) | |||
|---|---|---|---|---|
| Week 12 | Week 24 | Follow-up Week 32 | Early withdrawal | |
| Tocilizumab | 35.49 | 41.63 | 39.53 | 19.04 |
An ACR20 response requires at least 20% improvement compared to baseline in SJC (based on 66 joints) and TJC (based on 68 joints) as well as at least 20% improvement in 3 of the following 5 assessments: 1) PGA pain VAS, 2) PGA VAS; 3) physician's global assessment of disease activity VAS, 4) Health Assessment Questionnaire-Disability Index (HAQ-DI) with 20 questions consisting of 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do; and 5) CRP in mg/L or ESR in mm/hr. ACR50 and ACR70 responses are defined in a similar way except that they required a 50% and 70% improvement from baseline, respectively. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). (NCT01988012)
Timeframe: Week 24
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| ACR20 | ACR50 | ACR70 | |
| Tocilizumab | 62.4 | 37.6 | 20.0 |
(NCT01988012)
Timeframe: Up to Week 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| % of Particpants with Dose Modifications | % of Participants Who Discontinued Study | |
| Tocilizumab | 16 | 5 |
An AE is any untoward medical occurrence in a participant administered a drug and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug, whether or not considered related to the drug. Preexisting conditions which worsen during a study are also considered as AEs. AESIs are AEs that occur in categories of special interest with regard to the benefit-risk profile and overall safety of a drug. The following nine categories of AESIs were identified for tocilizumab: 1) serious and/or medically significant infections, 2) myocardial infarction/acute coronary syndrome, 3) gastrointestinal perforations, 4) malignancies, 5) anaphylaxis/hypersensitivity reactions, 6) demyelinating disorders, 7) stroke, 8) serious and/or medically significant bleeding events, and 9) serious and/or medically significant hepatic events. (NCT01988012)
Timeframe: Up to Follow-up Week 32
| Intervention | percentage of participants (Number) | |
|---|---|---|
| AEs | AESIs | |
| Tocilizumab | 70.0 | 7.0 |
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter [cm] Visual Analog Scale [VAS] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. Remission is defined as CDAI ≤2.8 and Low Disease Activity (LDA) is defined as 2.8< CDAI ≤10. (NCT01988012)
Timeframe: Week 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| CDAI Remission | CDAI LDA | |
| Tocilizumab | 16.5 | 34.1 |
Simplified Disease Activity Index (SDAI) was an index for measuring disease activity in RA and had a good correlation with the DAS28. The index was calculated using the following formula: SDAI: SJC28 + TJC28 + PGA (10 cm VAS) + PhGA (10 cm VAS + C-Reactive Protein (CRP) in milligram/liter (mg/L). VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. An SDAI score of ≤ 3.3 represents clinical remission, a score of ≤ 11.0 represents low disease activity. (NCT01988012)
Timeframe: Week 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| SDAI Remission | SDAI LDA | |
| Tocilizumab | 19.2 | 38.5 |
The HDRS is a clinician-administered depression assessment and consists of 17 items with a total score range from 0 to 54. A higher score indicates a worse outcome. HAS is a clinician-administered assessment to measure the severity of anxiety symptoms and consists of 14 items with a total score range from 0 to 56. A higher score indicates a worse outcome. (NCT01988012)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| HDRS at Baseline | HDRS at Week 24 | HAS at Baseline | HAS at Week 24 | |
| Tocilizumab | 7.87 | 4.94 | 8.56 | 5.93 |
DAS28-ESR score is a measure of participant's disease activity calculated using tender joint count in 28 joints (TJC28), swollen joint count in 28 joints (SJC28), patient global assessment of disease activity (PGA) (general health [GH]) using visual analog scale (VAS): 0 millimeter (mm)=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in millimeters per hour [mm/hr]). The score is calculated using the following formula: DAS28-ESR = [0.56 multiplied by (*) square root (√) of TJC28] plus (+) [0.28*√SJC28]+[0.70*the natural logarithm (ln) ESR]+[0.014*GH]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. DAS28-ESR score of less than (<) 2.6 represents DAS28-ESR remission. (NCT01941095)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Tocilizumab | 40 |
(NCT01941095)
Timeframe: From Baseline up to Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Tocilizumab | 48.6 |
DAS28-ESR score is a measure of participant's disease activity calculated using TJC28, SJC28, PGA using VAS 0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in mm/hr) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28-ESR = [0.56 * √TJC28 + [0.28*√SJC28]+[0.70*ln ESR]+[0.014*GH]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. A negative change from baseline indicates an improvement. (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
| Intervention | units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | Change at Week 28 | Change at Week 32 | Change at Week 36 | Change at Week 40 | Change at Week 44 | Change at Week 48 | Change at Week 52 | |
| Tocilizumab | -0.99 | -1.70 | -2.20 | -2.56 | -2.59 | -2.93 | -3.14 | -3.22 | -3.34 | -3.32 | -3.40 | -3.45 | -3.42 | -3.40 |
SDAI is an index for measuring disease activity. SDAI is the numerical sum of five outcome parameters: TJC28 and SJC28, PGA and physician global assessment of disease activity assessed on VAS (0 centimeter [cm]-10 cm); 0 cm= no disease activity and 10 cm= worst disease activity, and CRP (in milligrams per deciliter [mg/dL]). SDAI total score ranges from 0 to 86, with higher scores indicating increased (or severe) disease activity. SDAI score 3.4 to 11 = low disease activity, >11 to 26 = moderate disease activity, and >26 = high (or severe) disease activity. (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
| Intervention | units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | Change at Week 28 | Change at Week 32 | Change at Week 36 | Change at Week 40 | Change at Week 44 | Change at Week 48 | Change at Week 52 | |
| Tocilizumab | -3.41 | -6.54 | -8.72 | -11.07 | -13.47 | -13.88 | -14.08 | -15.37 | -16.09 | -15.61 | -14.86 | -16.31 | -16.47 | -17.35 |
28 joints were assessed for swelling and joints were classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 28. A negative change from baseline indicated improvement. (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
| Intervention | swollen joints (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | Change at Week 28 | Change at Week 32 | Change at Week 36 | Change at Week 40 | Change at Week 44 | Change at Week 48 | Change at Week 52 | |
| Tocilizumab | -1.82 | -3.08 | -4.71 | -5.24 | -5.79 | -6.06 | -6.60 | -6.65 | -6.73 | -6.76 | -6.91 | -6.82 | -6.63 | -6.98 |
28 joints were assessed for tenderness and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 28. A negative change from baseline indicated improvement. (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
| Intervention | tender joints (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | Change at Week 28 | Change at Week 32 | Change at Week 36 | Change at Week 40 | Change at Week 44 | Change at Week 48 | Change at Week 52 | |
| Tocilizumab | -1.30 | -3.26 | -4.97 | -5.82 | -6.39 | -7.03 | -7.72 | -7.91 | -8.38 | -8.28 | -8.22 | -8.63 | -8.26 | -8.75 |
FACIT-Fatigue total score is sum of FACIT-General subscale score and FACIT-Fatigue (additional concerns) subscale score. FACT-General consists of 27 questions grouped in 4 domains of general health-related quality of life: physical well-being, social/family well-being, emotional well-being, and functional well-being; each item ranges from 0 (not at all) to 4 (very much). FACT-General score ranges between 0-108. FACIT-Fatigue subscale is a 13-item questionnaire that evaluates self-reported fatigue and its impact upon daily activities. Each item ranges from 0 (Not at all) to 4 (Very much). For all items, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue subscale score for a total possible score of 0 (worse score) to 52 (better score). FACIT-Fatigue total score (FACT-G plus FACT-F subscale scores) ranges from 0 (better score) to 160 (worse score). (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
| Intervention | units on a scale (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | |
| Tocilizumab | 89.68 | 91.83 | 100.38 | 103.16 | 106.39 | 110.17 | 112.60 | 114.21 | 114.85 | 117.01 | 116.50 | 116.59 | 119.67 | 119.83 | 121.82 |
"The Stanford HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Responses in each component set were scored from 0 (without any difficulty) to 3 (unable to do). The highest score recorded for any question in a category determines the score for the category, unless aids, devices, or help from another person was required. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, giving a possible range of scores from 0 to 3. Scores of 0 to 1 are generally considered to represent mild to moderate difficulty, 1 to 2 as moderate to severe disability, and 2 to 3 as severe to very severe disability." (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
| Intervention | units on a scale (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | |
| Tocilizumab | 1.31 | 1.22 | 1.09 | 0.91 | 0.82 | 0.72 | 0.68 | 0.66 | 0.66 | 0.59 | 0.63 | 0.60 | 0.59 | 0.56 | 0.54 |
Reasons for corticosteroid dose reduction included: Safety Reasons (including elevated liver function test results, respiratory infections, infections and infestations, gastrointestinal disorders etc.); Other Reasons (disease remission, improvement etc.); and Unknown Reasons (including no reason). Number of participants by reasons (Safety, Other, Unknown) for corticosteroid dose reduction or discontinuation were reported. (NCT01941095)
Timeframe: From Baseline up to Week 52
| Intervention | participants (Number) | ||
|---|---|---|---|
| Safety | Other | Unknown | |
| Tocilizumab | 6 | 10 | 2 |
ACR20 response was defined as >/=20% improvement from baseline in both TJC28 and SJC28 as well as in 3 out of 5 additional parameters: Separate patient and physician's global assessment of disease activity on VAS (0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS), patient's assessment of pain on VAS (0 mm=no pain to 100 mm=unbearable pain, displayed on the 100 mm horizontal VAS), Health Assessment Questionnaire - Disability Index (HAQ-DI) (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without any difficulty to 3=unable to do), and acute phase response (ESR in mm/hr, for a total possible score of 0 to 10). (NCT01941095)
Timeframe: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
| Intervention | participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | |
| Tocilizumab | 19 | 19 | 23 | 9 | 13 | 16 | 9 | 13 | 10 | 11 | 10 | 12 | 13 | 15 |
All samples were tested using a screening assay and, if positive, by a confirmation assay to determine specificity and a neutralizing assay to test for the ability to inhibit the activity of tocilizumab. Number of participants with a positive assay result for screening assay (ATA - Screen), confirmatory assay (ATA - Confirmatory), and neutralizing assay (ATA - Neutralizing) was reported separately. (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 12, 24, 36, 52, and 8 weeks after Week 52 dose (Week 60)
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1: ATA - Screen | Week 1: ATA - Confirmatory | Week 1: ATA - Neutralizing | Week 12: ATA - Screen | Week 12: ATA - Confirmatory | Week 12: ATA - Neutralizing | Week 24: ATA - Screen | Week 24: ATA - Confirmatory | Week 24: ATA - Neutralizing | Week 36: ATA - Screen | Week 36: ATA - Confirmatory | Week 36: ATA - Neutralizing | Week 52: ATA - Screen | Week 52: ATA - Confirmatory | Week 52: ATA - Neutralizing | Week 60: ATA - Screen | Week 60: ATA - Confirmatory | Week 60: ATA - Neutralizing | |
| Tocilizumab | 7 | 4 | 0 | 3 | 0 | 0 | 3 | 1 | 1 | 2 | 0 | 0 | 2 | 0 | 0 | 1 | 1 | 0 |
"The participant's level of pain was assessed on a 0 to 100 mm horizontal VAS. The extreme left end of the line = 0 mm, and was described as no pain and the extreme right end = 100 mm, and was described as unbearable pain. Higher values correspond to worst state of participant (higher level of pain)." (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
| Intervention | mm (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | |
| Tocilizumab | 46.40 | 52.04 | 49.87 | 42.72 | 37.21 | 34.24 | 31.00 | 29.57 | 29.63 | 25.50 | 26.78 | 27.50 | 26.88 | 23.61 | 23.98 |
DAS28-ESR score is a measure of participant's disease activity calculated using TJC28, SJC28, PGA using VAS 0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in mm/hr) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28-ESR = [0.56 * √TJC28 + [0.28*√SJC28]+[0.70*ln ESR]+[0.014*GH]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. DAS28-ESR score <2.6 represents DAS28-ESR remission. DAS28-ESR score greater than or equal to (>/=) 2.6 and <3.2 represents LDA. (NCT01941095)
Timeframe: Weeks 28, 32, 36, 40, 44, 48, 52
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 28: Remission | Week 32: Remission | Week 36: Remission | Week 40: Remission | Week 44: Remission | Week 48: Remission | Week 52: Remission | Week 28: LDA | Week 32: LDA | Week 36: LDA | Week 40: LDA | Week 44: LDA | Week 48: LDA | Week 52: LDA | |
| Tocilizumab | 5.1 | 8.1 | 4.1 | 9.5 | 6.9 | 8.5 | 6 | 7.6 | 1.4 | 6.8 | 6.8 | 6.9 | 4.2 | 9 |
DAS28-ESR score is a measure of participant's disease activity calculated using TJC28, SJC28, PGA using VAS 0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in mm/hr) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28-ESR = [0.56 * √TJC28 + [0.28*√SJC28]+[0.70*ln ESR]+[0.014*GH]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. DAS28-ESR score <2.6 represents DAS28-ESR remission. The percentage reported for Week 24 is based on confirmation on switching to SC tocilizumab monotherapy. (NCT01941095)
Timeframe: Weeks 24, 28, 32, 36, 40, 44, 48, 52
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | |
| Tocilizumab | 38.7 | 34.2 | 36.5 | 36.5 | 36.5 | 35.2 | 35.7 | 38.8 |
Compliance (in terms of percentage of participants who received all planned study medication) was assessed on the basis of participant diary cards and return records. (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
| Intervention | percentage of participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | |
| Tocilizumab | 66 | 97.9 | 100 | 100 | 98.9 | 97.6 | 98.8 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Response to treatment was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from the baseline visit. Participants with a score lesser than or equal to () 1.2 points were assessed as having a 'good' response. Participants with a score >3.2 with reduction of >1.2 points, or a score 0.6 to 5.1 with reduction of >0.6 to NCT01941095)
Timeframe: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
| Intervention | percentage of participants (Number) | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2: Good response | Week 2: Moderate response | Week 2: No response | Week 4: Good response | Week 4: Moderate response | Week 4: No response | Week 8: Good response | Week 8: Moderate response | Week 8: No response | Week 12: Good response | Week 12: Moderate response | Week 12: No response | Week 16: Good response | Week 16: Moderate response | Week 16: No response | Week 20: Good response | Week 20: Moderate response | Week 20: No response | Week 24: Good response | Week 24: Moderate response | Week 24: No response | Week 28: Good response | Week 28: Moderate response | Week 28: No response | Week 32: Good response | Week 32: Moderate response | Week 32: No response | Week 36: Good response | Week 36: Moderate response | Week 36: No response | Week 40: Good response | Week 40: Moderate response | Week 40: No response | Week 44: Good response | Week 44: Moderate response | Week 44: No response | Week 48: Good response | Week 48: Moderate response | Week 48: No response | Week 52: Good response | Week 52: Moderate response | Week 52: No response | |
| Tocilizumab | 9.4 | 44.8 | 45.8 | 9.5 | 38.9 | 51.6 | 10.8 | 23.6 | 65.6 | 9.2 | 20.7 | 70.1 | 5.9 | 15.3 | 78.8 | 6.1 | 26.8 | 67.1 | 6.2 | 21.2 | 72.6 | 6.3 | 11.4 | 82.3 | 0 | 18.9 | 81.1 | 1.3 | 14.9 | 83.8 | 5.4 | 17.6 | 77 | 2.8 | 13.9 | 83.3 | 5.7 | 11.4 | 82.9 | 94 | 6 | 0 |
"PGA was assessed on a 0 to 100 mm horizontal VAS. The extreme left end of the line = 0 mm, and was described as no disease activity (symptom-free and no arthritis symptoms) and the extreme right end = 100 mm, and was described as maximum disease activity (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity)." (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
| Intervention | mm (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | |
| Tocilizumab | 28.26 | 27.57 | 28.36 | 32.28 | 28.73 | 24.40 | 28.15 | 32.63 | 26.02 | 27.08 | 30.79 | 30.50 | 25.79 | 23.86 | 23.08 |
(NCT01941095)
Timeframe: Baseline (Week 1), Weeks 12, 24, 36, 52, and 8 weeks after Week 52 dose (Week 60)
| Intervention | nanograms per milliliter (ng/mL) (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 1 | Week 12 | Week 24 | Week 36 | Week 52 | Week 60 | |
| Tocilizumab | 39450 | 553.43 | 572.03 | 570.78 | 537.73 | 42850 |
(NCT01941095)
Timeframe: Baseline (Week 1), Weeks 12, 24, 36, 52, and 8 weeks after Week 52 dose (Week 60)
| Intervention | microgrms per milliliter (mcg/mL) (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 1 | Week 12 | Week 24 | Week 36 | Week 52 | Week 60 | |
| Tocilizumab | 0.38 | 41.98 | 44.67 | 47.90 | 45.37 | 6.46 |
"Number of patients with a change of > 0.22 in the Health Assessment Questionnaire (HAQ) score over the period between baseline and week 104.~A change of > 0.22 in this score is considered as clinical relevant for rheumatoid arthritis patients." (NCT01172639)
Timeframe: Baseline-week104
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 71 |
| CoBRA Slim High Risk Group | 62 |
| CoBRA Avant-garde High Risk Group | 64 |
| CoBRA Slim Low Risk Group | 25 |
| Tight Step Up Low Risk Group | 26 |
"Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 104. (co-primary endpoints)~DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).~A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity." (NCT01172639)
Timeframe: week 104
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 64 |
| CoBRA Slim High Risk Group | 71 |
| CoBRA Avant-garde High Risk Group | 69 |
| CoBRA Slim Low Risk Group | 29 |
| Tight Step Up Low Risk Group | 34 |
"Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 16.~DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).~A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity." (NCT01172639)
Timeframe: week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 69 |
| CoBRA Slim High Risk Group | 72 |
| CoBRA Avant-garde High Risk Group | 61 |
| CoBRA Slim Low Risk Group | 25 |
| Tight Step Up Low Risk Group | 23 |
"Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 52. (co-primary end point)~DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).~A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity." (NCT01172639)
Timeframe: week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 63 |
| CoBRA Slim High Risk Group | 57 |
| CoBRA Avant-garde High Risk Group | 57 |
| CoBRA Slim Low Risk Group | 29 |
| Tight Step Up Low Risk Group | 29 |
"Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 16.~SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.~A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity." (NCT01172639)
Timeframe: week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 42 |
| CoBRA Slim High Risk Group | 33 |
| CoBRA Avant-garde High Risk Group | 44 |
| CoBRA Slim Low Risk Group | 12 |
| Tight Step Up Low Risk Group | 12 |
"Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 104.~SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.~A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity." (NCT01172639)
Timeframe: week 104
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 31 |
| CoBRA Slim High Risk Group | 28 |
| CoBRA Avant-garde High Risk Group | 41 |
| CoBRA Slim Low Risk Group | 20 |
| Tight Step Up Low Risk Group | 13 |
"Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 52.~SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.~A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity." (NCT01172639)
Timeframe: week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 36 |
| CoBRA Slim High Risk Group | 27 |
| CoBRA Avant-garde High Risk Group | 39 |
| CoBRA Slim Low Risk Group | 20 |
| Tight Step Up Low Risk Group | 15 |
Participants recorded the status of recurrence of joint stiffness (Yes/No) in diary data. Percentage of participants who selected Yes for recurrence of joint stiffness, are reported. (NCT00146640)
Timeframe: Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| MR Prednisone | 47 |
| IR Prednisone | 43 |
DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). Total DAS28 score range from 0 to approximately 10. DAS28 less than or equal to (≤) 3.2 = low disease activity, DAS28 greater than (>) 3.2 to 5.1 = moderate to high disease activity, and DAS28 >5.1 = severe disease activity. Relative (percent) change = ([value at Week 12 minus value at Baseline] divided by [value at baseline]) multiplied by 100. (NCT00146640)
Timeframe: Baseline, Week 12
| Intervention | percent change (Mean) |
|---|---|
| MR Prednisone | -9.03 |
| IR Prednisone | -12.30 |
Duration of morning stiffness was defined as the time elapsed (in minutes) between the time of usual awakening (even if not in the morning) and the time the participant was able to resume normal activities without stiffness. Relative (percent) change = ([value at Week 12 minus value at Baseline] divided by [value at baseline]) multiplied by 100. (NCT00146640)
Timeframe: Baseline, Week 12
| Intervention | percent change (Mean) |
|---|---|
| MR Prednisone | -22.7 |
| IR Prednisone | -0.4 |
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. Relative (percent) change = ([value at Week 12 minus value at Baseline] divided by [value at baseline]) multiplied by 100. (NCT00146640)
Timeframe: Baseline, Week 12
| Intervention | percent change (Mean) |
|---|---|
| MR Prednisone | 0.07 |
| IR Prednisone | -4.7 |
Participants assessed pain intensity on a 100 millimeter (mm) visual analog scale (VAS), where 0 mm = no pain, 100 mm = worst pain. Relative (percent) change = ([value at Week 12 minus value at Baseline] divided by [value at baseline]) multiplied by 100. (NCT00146640)
Timeframe: Baseline, Week 12
| Intervention | percent change (Mean) |
|---|---|
| MR Prednisone | -8.57 |
| IR Prednisone | -6.53 |
Participants assessed quality of sleep on a 100 mm VAS, where 0 mm = very good, 100 mm = very bad. Relative (percent) change = ([value at Week 12 minus value at Baseline] divided by [value at baseline]) multiplied by 100. (NCT00146640)
Timeframe: Baseline, Week 12
| Intervention | percent change (Mean) |
|---|---|
| MR Prednisone | 4.63 |
| IR Prednisone | 0.13 |
SF-36 is a standardized survey evaluating 8 aspects of functional health and wellbeing: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a domain was an average of the individual question scores, which were scaled 0-100 (100=highest level of functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100=highest level of physical functioning). Relative (percent) change = ([value at Week 12 minus value at Baseline] divided by [value at baseline]) multiplied by 100. (NCT00146640)
Timeframe: Baseline, Week 12
| Intervention | percent change (Mean) |
|---|---|
| MR Prednisone | 19.43 |
| IR Prednisone | 21.0 |
SF-36 is a standardized survey evaluating 8 domains of functional health and wellbeing: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a domain was an average of the individual question scores, which were scaled 0-100 (100=highest level of functioning). Score from mental health, role emotional, social functioning, and vitality domains were averaged to calculate MCS. Total score range for MCS was 0-100 (100=highest level of mental functioning). Relative (percent) change = ([value at Week 12 minus value at Baseline] divided by [value at baseline]) multiplied by 100. (NCT00146640)
Timeframe: Baseline, Week 12
| Intervention | percent change (Mean) |
|---|---|
| MR Prednisone | 10.63 |
| IR Prednisone | 18.08 |
"Responders were defined as patients whose improvement from baseline to Visit 4 (Week 12) fulfilled all 3 of the following criteria:~> 20% reduction in the tender joint count (0-28)~> 20% reduction in the swollen joint count (0-28)~> 20% reduction in 3 out of the 5 following additional measures:~Patient's assessment of pain~Patient's global assessment of disease activity~Physician's global assessment of disease activity~Functional Disability Index of the Health Assessment Questionnaire~C-reactive protein or erythrocyte sedimentation rate" (NCT00650078)
Timeframe: Week 12
| Intervention | participants (Number) |
|---|---|
| NP01 | 108 |
| Placebo | 34 |
Data for the duration of morning stiffness were obtained from patient diaries. Duration of morning stiffness was the difference between the time of resolution of morning stiffness and the time of wake-up. Duration of morning stiffness is the average of the morning stiffness duration (minutes) over the last 7 days prior to visit day (including day of visit). If more than 4 assessments were missing, then the duration was set to missing. Baseline was the value recorded at Week -1 (Visit 0). (NCT00650078)
Timeframe: Week 12
| Intervention | Relative Change from Baseline (%) (Median) |
|---|---|
| NP01 | -55.22 |
| Placebo | -34.62 |
"The DAS28(CRP) is a measure of disease activity with components which include the tender joint count (TJC) & swollen joint count (SJC) (each out of 28 joints counted), a Global Health (GH) index (100 mm visual analog scale [VAS]), and the CRP (in mg/L measured from lab test). The scoring formula was:~DAS28(CRP) = 0.56*SQR(TJC28) + 0.28*SQR(SJC28) + 0.36*ln(CRP+1) + 0.014*GH(VAS) + 0.96.~Where SQR is square root and ln is natural log.~The formula produces a score from 0 to 10: >5.1 means high disease activity; <3.2 means low disease activity, <2.6 is generally considered remission." (NCT00746512)
Timeframe: Baseline and Day 14
| Intervention | score on scale (Mean) | ||
|---|---|---|---|
| Baseline | Day 14 | Change from Baseline at Day 14 | |
| Placebo 15 mg | 5.45 | 5.04 | -0.41 |
| Placebo 7.5 mg | 5.62 | 5.38 | -0.23 |
| Prednisone 15 mg | 5.17 | 3.57 | -1.61 |
| Prednisone 7.5 mg | 5.31 | 4.57 | -0.74 |
Synovial Blood Flow was measured as the 2-dimensional quantitative Transverse Power Doppler Area summed over each of the 10 metacarpophalangeal joints (10MCP 2D Trans PDA). The PDA is a count of the number of pixels with power Doppler signal, uncorrected by pixel intensity, within an expert drawn region of interest encompassing the synovium and excluding digital vessels in a standardized 2D transverse image of the joint. A higher pixel count relates to greater synovial blood flow. A decrease in pixel count relates to a reduction in synovial blood flow. (NCT00746512)
Timeframe: Baseline and Day 14
| Intervention | pixel count (Mean) | ||
|---|---|---|---|
| Baseline | Day 14 | Change from Baseline at Day 14 | |
| Placebo 15 mg | 10.55 | 13.37 | 2.82 |
| Placebo 7.5 mg | 9.78 | 9.15 | -0.64 |
| Prednisone 15 mg | 9.48 | 6.52 | -2.96 |
| Prednisone 7.5 mg | 8.31 | 4.44 | -3.88 |
Adverse outcomes including infection, avascular necrosis, and 90-day readmission rates (NCT05113901)
Timeframe: within 90 days after initial total knee arthroplasty
| Intervention | Participants (Count of Participants) |
|---|---|
| Methylprednisolone Taper | 0 |
| Placebo Taper | 0 |
Manipulations under anesthesia (MUAs) following total knee arthroplasty surgery and treatment (NCT05113901)
Timeframe: within 90 days after initial total knee arthroplasty
| Intervention | Participants (Count of Participants) |
|---|---|
| Methylprednisolone Taper | 0 |
| Placebo Taper | 0 |
Single Assessment Numeric Evaluation (SANE), a single-question patient rating of 0-100, scoring their function to the area being treated. Zero represents a poor functional knee and 100 is the best functioning. (NCT05113901)
Timeframe: 6 weeks after treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Methylprednisolone Taper | 89.5 |
UCLA activity score, on a scale of 1 to 10 where 10 is the most active patient with examples of activities (NCT05113901)
Timeframe: 6 weeks after treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Methylprednisolone Taper | 5.25 |
VR-12: Assesses physical functioning, physical/ mental limitations. Scored as summary of mental and physical, measure in standard deviations. The scale range is 0 to 100, where a score of 100 represents the best physical and mental health and zero is the worst outcome. (NCT05113901)
Timeframe: 6 weeks after treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Methylprednisolone Taper | 50.28 |
Forgotten Joint Score (FJS) is a survey scored ranging from 0 to 100, where a high score indicates a high degree of a forgetting they have an artificial joint, which is an ideal outcome. (NCT05113901)
Timeframe: 6 weeks after treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Methylprednisolone Taper | 57.82 |
Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS JR), a survey given to patients standard of care containing 7 questions. The score ranges from 0 to 100 where zero represents total disability and 100 represents a perfect knee health. (NCT05113901)
Timeframe: 6 weeks after treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Methylprednisolone Taper | 72.12 |
Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS JR), a survey given to patients standard of care containing 7 questions. The score ranges from 0 to 100 where zero represents total disability and 100 represents a perfect knee health. (NCT05113901)
Timeframe: pre treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Methylprednisolone Taper | 50.04 |
Single Assessment Numeric Evaluation (SANE), a single-question patient rating of 0-100, scoring their function to the area being treated. Zero represents a poor functional knee and 100 is the best functioning. (NCT05113901)
Timeframe: pre treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Methylprednisolone Taper | 29.5 |
Veterans Rand 12-Item Health Survey (VR-12), a survey of 12 questions to measure health relating to patient's quality of life. Scored as summary of mental and physical, measure in standard deviations. The scale range is 0 to 100, where a score of 100 represents the best physical and mental health and zero is the worst outcome. (NCT05113901)
Timeframe: pre treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Methylprednisolone Taper | 38.73 |
Forgotten Joint Score (FJS) is a survey scored ranging from 0 to 100, where a high score indicates a high degree of a forgetting they have an artificial joint, which is an ideal outcome. (NCT05113901)
Timeframe: pre treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Methylprednisolone Taper | 91.67 |
UCLA activity score, on a scale of 1 to 10 where 10 is the most active patient with examples of activities (NCT05113901)
Timeframe: pre treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Methylprednisolone Taper | 4.25 |
"Knee society score (KSS); done standard of care on a scale of 0-100, where 100 means a more functional knee.~**Please note, the study was terminated early, only 4 subjects were enrolled and none were randomized to the placebo group. At 3 weeks post treatment, only 3 of the 4 subjects enrolled were still part of the study." (NCT05113901)
Timeframe: 3 weeks post treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Methylprednisolone Taper | 68.33 |
"Knee society score (KSS); done standard of care on a scale of 0-100, where 100 means a more functional knee.~**Please note, the study was terminated early, only 4 subjects were enrolled and none were randomized to the placebo group. This is a standard of care survey available on all subjects." (NCT05113901)
Timeframe: 6 weeks post treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Methylprednisolone Taper | 78.75 |
"Using daily defense and veterans pain rating scale (DVPRS) on a scale of 1 to 10, 10 being the worst.~Please note, only one patient made it to the 6 week post treatment mark of the 4 enrolled. The study was terminated and none of the patients were randomized to the placebo group. All other patients followed up but were not interested in continuing. No range could be provided given only one subject answered and completed this visit" (NCT05113901)
Timeframe: 6 weeks post treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Methylprednisolone Taper | 1.93 |
"Knee society score (KSS); done standard of care on a scale of 0-100, where 100 means a more functional knee~**Please note, the study was terminated early, only 4 subjects were enrolled and none were randomized to the placebo group." (NCT05113901)
Timeframe: pre treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Methylprednisolone Taper | 66.25 |
"Using Daily Visual Analogue Scale (VAS) pain score, which measures intensity of pain on a scale of 0 (no pain) to 10 (worst pain possible).~**Please note, this study was terminated early, only enrolling 4 patients, none were randomized to the placebo group." (NCT05113901)
Timeframe: Days 1 through 6 following treatment
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | |
| Methylprednisolone Taper | 2.33 | 3 | 1.33 | 1.33 | 1.67 | 2.3 |
"Range of motion (ROM) from pre-treatment to six weeks following treatment. Patients started treatment after total knee replacement surgery and presented to clinic with at least one inclusion criteria to be enrolled. Range of motion in degrees is taken at each visit by a clinician (standard of care), starting at zero degrees (straight leg) to about 135 degrees. The ROM was documented as part of consenting and enrollment into study. Subjects returned to the office at 6 weeks post treatment where ROM was performed in a clinic setting once again and documented. ROM is done using a goniometer by a clinician in each clinic.~This study was terminated early, therefore of the 4 enrolled, zero were randomized to the placebo group. Only 1 of the four subjects completed the 6 weeks, however, ROM was captured on all as standard of care." (NCT05113901)
Timeframe: Baseline, Week 6 Following Treatment
| Intervention | Range of Motion in Degrees (Mean) | |
|---|---|---|
| Pre treatment | Post treatment | |
| Methylprednisolone Taper | 82.5 | 112 |
BMD was measured at the lumbosacral spine antero-posterior and at the femoral neck using a densitometer. A positive change from Baseline (increased bone density) indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12
| Intervention | grams/centimeters squared (g/cm^2) (Mean) | |||
|---|---|---|---|---|
| Spine, Baseline | Spine, Change from Baseline at Month12 | Femoral neck, Baseline | Femoral neck, Change from Baseline at Month 12 | |
| Control Arm | 0.93 | -0.002 | 0.73 | -0.03 |
| Teriparatide | 0.91 | 0.06 | 0.68 | 0.03 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and C-Reactive Protein (CRP) for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Month 12 | |
| Control Arm | 2.73 | -0.50 |
| Teriparatide | 2.66 | 0.42 |
Both hands were scanned using a CT scanner. A semi-automated software tool was used to segment the erosion margins in 3D. A board certified radiologist identified the individual erosions in six sub-regions: radius, ulna, proximal carpals, distal carpals, metacarpophalangeal (MCP) joints and proximal interphalangeal (PIP) joints. The average total in a single hand/wrist was calculated. A negative change from Baseline(less joint erosions) indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12
| Intervention | cubic millimeter (mm^3) (Median) | |
|---|---|---|
| Baseline | Change from Baseline at Month 12 | |
| Control Arm | 571.4 | 9.1 |
| Teriparatide | 369.8 | -0.4 |
76 reviews available for prednisone and Arthritis, Rheumatoid
| Article | Year |
|---|---|
TNF-induced Lupus. A Case-Based Review.
Topics: Adalimumab; Antibodies, Antinuclear; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheuma | 2022 |
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Glucocorticoids; Humans; Pre | 2023 |
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Glucocorticoids; Humans; Pre | 2023 |
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Glucocorticoids; Humans; Pre | 2023 |
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Glucocorticoids; Humans; Pre | 2023 |
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Glucocorticoids; Humans; Pre | 2023 |
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Glucocorticoids; Humans; Pre | 2023 |
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Glucocorticoids; Humans; Pre | 2023 |
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Glucocorticoids; Humans; Pre | 2023 |
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Glucocorticoids; Humans; Pre | 2023 |
Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis.
Topics: Arthritis, Rheumatoid; Glucocorticoids; Humans; Prednisone; Randomized Controlled Trials as Topic | 2023 |
Diffuse large B-cell lymphoma involving the left sternoclavicular joint mimicking rheumatoid arthritis flare: a case-based review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Cyclophosphamide; Diagn | 2020 |
The Story Behind the Use of Glucocorticoids in the Treatment of Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Glucocorticoids; Humans; Prednisone; Rheumatology | 2021 |
Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Delayed-Action Preparations; Drug Administration Sc | 2017 |
New concepts to reduce glucocorticoid toxicity.
Topics: Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related | 2019 |
Risks and benefits of corticosteroids in arthritic diseases in the clinic.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Humans; Prednisone | 2019 |
Delayed-release prednisone - a new approach to an old therapy.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Delayed-Action Preparations; Glucocorticoids; Human | 2013 |
Epstein-Barr virus-positive oral ulceration simulating Hodgkin lymphoma in a patient treated with methotrexate: case report and review of the literature.
Topics: Aged, 80 and over; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Diagnosis, | 2014 |
Modified-release prednisone: in patients with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Humans; Observational Studies as Topic; Prednisone; | 2013 |
The intelligent use of systemic glucocorticoids in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Delayed-Action Preparations; Glucocorticoids; Humans; Prednisone | 2014 |
Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Arthritis, Rheumatoid; Azathioprine; Cohort Studies; Derm | 2014 |
Rheumatoid myositis leading to acute lower extremity compartment syndrome: a case-based review.
Topics: Arthritis, Rheumatoid; Biopsy; Blood Sedimentation; Compartment Syndromes; Creatine Kinase; Edema; F | 2015 |
Cervicofacial actinomycosis: a long forgotten infectious complication of immunosuppression - report of a case and review of the literature.
Topics: Actinomycosis, Cervicofacial; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Arth | 2014 |
Glucocorticoid treatment in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Glucoco | 2014 |
TNF-inhibitor induced lupus in a patient treated with adalimumab for rheumatoid arthritis.
Topics: Adalimumab; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Clobetasol; Diagnosis, Differential; | 2014 |
Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Humans; Prednisone | 2016 |
Primary thyroid marginal zone B-cell lymphoma MALT-type in a patient with rheumatoid arthritis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arthritis, R | 2010 |
[Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab: a case description and literature review].
Topics: Adalimumab; Aged; Animals; Animals, Domestic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humani | 2010 |
Pharmacology of glucocorticoids in rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Delayed-Action Preparations; Evidence-Based Me | 2010 |
Treatment strategies in recent onset rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Therapy, Combination; Hu | 2011 |
Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Circadian Clocks; Delayed-Action Preparations; Drug | 2012 |
Symptom control with low-dose glucocorticoid therapy for rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Circadian Rhythm; Dose-Response Relationship, Drug; Glucocorticoids; Humans; | 2012 |
Lessons for the use of non-biologic anchor treatments for rheumatoid arthritis in the era of biologic therapies.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Glucoco | 2012 |
My treatment approach to rheumatoid arthritis.
Topics: Abatacept; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Muri | 2012 |
A fresh look at glucocorticoids how to use an old ally more effectively.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chronotherapy; Glucocorticoids; Humans; Prednisone; Tre | 2012 |
The use of low-dose prednisone in the management of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug A | 2001 |
Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; In | 2003 |
New role for an old friend: prednisone is a disease-modifying agent in early rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 2003 |
[TREATMENT OF KIDNEY DISEASES, CARDIAC AND VASCULAR DISORDERS AS WELL AS COLLAGENOSES WITH CORTISONES].
Topics: Adams-Stokes Syndrome; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis, Rheumatoid; | 1964 |
Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; In | 2004 |
Rheumatoid arthritis associated interstitial lung disease.
Topics: Arthritis, Rheumatoid; Cough; Dyspnea; Female; Humans; Lung Diseases, Interstitial; Male; Middle Age | 2004 |
B-cell lymphoma of the larynx in a patient with rheumatoid arthritis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Arthritis, Rheumatoid; C | 2005 |
The specificity and clinical usefulness of the lupus band test.
Topics: Antibodies, Antinuclear; Antigen-Antibody Complex; Arthritis, Rheumatoid; Basement Membrane; Blood V | 1980 |
Prevention and management of glucocorticoid-induced osteoporosis.
Topics: Arthritis, Rheumatoid; Asthma; Bone Density; Female; Glucocorticoids; Humans; Male; Middle Aged; Ost | 1995 |
[Should long-term corticosteroid treatment be given in rheumatoid arthritis?].
Topics: Arthritis, Rheumatoid; Glucocorticoids; Humans; Long-Term Care; Prednisolone; Prednisone | 1993 |
[Fatal outcome of pneumocystis-carinii pneumonia under low-dose methotrexate and prednisone therapy for chronic rheumatoid arthritis. Case report and literature review].
Topics: Aged; Arthritis, Rheumatoid; Candida; Candidiasis; Fatal Outcome; Female; Humans; Immunosuppressive | 1994 |
Bronchiolitis obliterans organizing pneumonia and rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Bronchiolitis Obliterans; Female; Humans; Pneumonia; Prednisone; Radiog | 1993 |
Rapidly progressive protrusio acetabuli in patients with rheumatoid arthritis.
Topics: Acetabulum; Adult; Aged; Anthropometry; Arthritis, Rheumatoid; Bone Diseases, Metabolic; Diagnosis, | 1993 |
Pyoderma gangrenosum with hepatopancreatic manifestations in a patient with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Female; Humans; Liver Diseases; Middle Aged; Pancreatic Diseases; Prednisone; | 1996 |
Dapsone in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trial | 1996 |
Pneumocystis carinii pneumonia in rheumatoid arthritis patients treated with methotrexate. A report of two cases.
Topics: Anti-Infective Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Bronchoalveolar Lavage; Drug The | 1996 |
Low-dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; C | 1996 |
[Rheumatoid arthritis and multiple myeloma--the risk of a combination of the 2 diseases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Cyclophosphamide; Dexam | 1997 |
Dangers of low-dose corticosteroid therapy in rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Humans; Prednisone; Time F | 1997 |
Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases.
Topics: Arthritis, Rheumatoid; Bone Density; Cohort Studies; Female; Femur Neck; Glucocorticoids; Humans; Lu | 1997 |
Chronic immunity-driven polyarthritis in hairy cell leukemia. Report of a case and review of the literature.
Topics: Aged; Aged, 80 and over; Antibodies, Antinuclear; Antineoplastic Agents; Arthritis, Rheumatoid; B-Ly | 1997 |
Early deaths with thrombolytic therapy for acute myocardial infarction in corticosteroid-dependent rheumatoid arthritis.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Death, Sudden, Cardiac; Fatal Outcome; Female | 1998 |
Recurrent embolism caused by floating thrombus in the thoracic aorta.
Topics: Anti-Inflammatory Agents; Aorta, Thoracic; Aortic Diseases; Arthritis, Rheumatoid; Echocardiography, | 1998 |
Aggressive treatment of early rheumatoid arthritis to prevent joint damage.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Manage | 1998 |
[Pharmacotherapy of patients with (early) rheumatoid arthritis].
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Bo | 2000 |
Can we induce tolerance in rheumatoid arthritis?
Topics: Abortifacient Agents, Nonsteroidal; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Ste | 2001 |
Can we induce tolerance in rheumatoid arthritis?
Topics: Abortifacient Agents, Nonsteroidal; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Ste | 2001 |
Can we induce tolerance in rheumatoid arthritis?
Topics: Abortifacient Agents, Nonsteroidal; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Ste | 2001 |
Can we induce tolerance in rheumatoid arthritis?
Topics: Abortifacient Agents, Nonsteroidal; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Ste | 2001 |
Four patients with both thrombotic thrombocytopenic purpura and autoimmune thrombocytopenic purpura: the concept of a mixed immune thrombocytopenia syndrome and indications for plasma exchange.
Topics: Adult; Arthritis, Rheumatoid; Aspirin; Autoimmune Diseases; Blood Platelets; Combined Modality Thera | 2001 |
Rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 2002 |
[Disseminated lupus erythematosus: an analysis of organ involvement].
Topics: Abortion, Spontaneous; Adolescent; Adult; Alopecia; Antibodies, Antinuclear; Arthritis, Rheumatoid; | 1978 |
Relapsing polychondritis: prospective study of 23 patients and a review of the literature.
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Cartilage; Cartilage, A | 1976 |
Diagnosis and treatment of pure red cell aplasia.
Topics: Acute Kidney Injury; Anemia, Aplastic; Antilymphocyte Serum; Arthritis, Rheumatoid; Blood Cell Count | 1976 |
Rheumatoid arthritis, corticosteroid therapy and Kaposi's sarcoma: a coincidence? A case and review of literature.
Topics: Adrenal Cortex Hormones; Aged; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Female; Huma | 1992 |
Rethinking the therapeutic pyramid for rheumatoid arthritis. When are NSAIDs alone not enough?
Topics: Arthritis, Rheumatoid; Gold; Humans; Immunosuppressive Agents; Penicillamine; Prednisone | 1992 |
Low-dose prednisone therapy.
Topics: Acute Disease; Arthritis, Rheumatoid; Humans; Polymyalgia Rheumatica; Prednisone | 1989 |
Late-onset rheumatoid arthritis vs polymyalgia rheumatica: making the diagnosis.
Topics: Age Factors; Arthritis, Rheumatoid; Blood Sedimentation; Diagnosis, Differential; Humans; Middle Age | 1988 |
[Myocarditis in Still's disease in adults].
Topics: Adult; Arthritis, Rheumatoid; Follow-Up Studies; Humans; Male; Myocarditis; Prednisone; Rheumatic He | 1988 |
Oral steroids in rheumatoid arthritis. Helpful but not remittive.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Arthritis, Rheumatoid; Aspirin; Clinical Trial | 1987 |
Longterm methotrexate therapy in rheumatoid arthritis: a review.
Topics: Arthritis, Rheumatoid; Biopsy; Chemical and Drug Induced Liver Injury; Drug Resistance; Gold; Humans | 1985 |
Systemic lupus erythematosus.
Topics: Antibodies, Antinuclear; Arthritis, Rheumatoid; Female; Hepatitis; Humans; Hydralazine; Immunoglobul | 1973 |
[Drug therapy in collagen diseases].
Topics: Adenosine Triphosphatases; Administration, Oral; Adrenal Cortex Hormones; Antimalarials; Antineoplas | 1971 |
Corticosteroid therapy for rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis, Rheumatoid; Atrophy; Betamethasone; | 1973 |
Adrenal steroid therapy in neurological disease. Part I.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Animals; Arteritis; Arthritis, Rheumatoid; Col | 1969 |
Osteoporosis in rheumatoid arthritis and corticosteroid induced osteoporosis.
Topics: Animals; Arthritis, Juvenile; Arthritis, Rheumatoid; Bone Regeneration; Cervical Vertebrae; Child, P | 1972 |
Amyloid joint disease.
Topics: Adult; Alkylating Agents; Amyloidosis; Arthritis; Arthritis, Rheumatoid; Bence Jones Protein; Blood | 1972 |
Rheumatoid arthritis.
Topics: Antigen-Antibody Reactions; Arthritis, Juvenile; Arthritis, Rheumatoid; Aspirin; Biopsy; Chloroquine | 1973 |
The 1972 annual meeting of the American Rheumatism Association.
Topics: Arthritis, Juvenile; Arthritis, Rheumatoid; Biopsy; Cartilage; Cathepsins; Complement System Protein | 1972 |
Advances in the treatment of rheumatic disorders.
Topics: Alkylating Agents; Allopurinol; Analgesics; Anti-Inflammatory Agents; Antimalarials; Antimetabolites | 1968 |
Rheumatoid arthritis. Medical management.
Topics: Arthritis, Rheumatoid; Aspirin; Diet; Gold; Humans; Hydrocortisone; Immunosuppressive Agents; Indome | 1970 |
[The conservative treatment of chronic inflammatory rheumatism].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Analgesics; Anti-Inflammatory Agents; Antimalarials; Art | 1969 |
141 trials available for prednisone and Arthritis, Rheumatoid
| Article | Year |
|---|---|
Pharmacological conditioning in the treatment of recent-onset rheumatoid arthritis: a randomized controlled trial study protocol.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Conditioning, Psychological; Dose-Response Relat | 2020 |
Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; | 2020 |
Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Administration S | 2020 |
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; A | 2020 |
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; A | 2020 |
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; A | 2020 |
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; A | 2020 |
The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Disease Progression; Drug Therapy, Combinat | 2020 |
Current Smoking Negatively Affects the Response to Methotrexate in Rheumatoid Arthritis in a Dose-responsive Way, Independently of Concomitant Prednisone Use.
Topics: Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Prednisone; Smoking; Treatme | 2021 |
Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Disability | 2017 |
Dissociated Agonist of Glucocorticoid Receptor or Prednisone for Active Rheumatoid Arthritis: Effects on P1NP and Osteocalcin Pharmacodynamics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Biomark | 2017 |
What have we learned from BeSt?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Infliximab; Predniso | 2018 |
Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Administration S | 2017 |
Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study.
Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Disease Progression | 2018 |
Population Pharmacokinetics of Fosdagrocorat (PF-04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid Arthritis.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Area Under Curve; Arthritis, Rheu | 2018 |
Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Drug T | 2018 |
In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; | 2019 |
Evaluation of the Implementation of Guidelines on the Treatment of Osteoporosis in Patients with Rheumatoid Arthritis.
Topics: Aged; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Cross-Sectional Studies | 2020 |
Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; | 2019 |
Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Administration S | 2019 |
Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cross-Over Studies; Delayed-Action Preparati | 2013 |
Rituximab treatment for 'rhupus syndrome': clinical and power-Doppler ultrasonographic monitoring of response. A longitudinal pilot study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Do | 2013 |
A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Belgium; Cost Savings; Cost-Benefit Analys | 2013 |
Using actigraphy to measure sleep patterns in rheumatoid arthritis: a pilot study in patients taking night-time prednisone.
Topics: Actigraphy; Aged; Arthritis, Rheumatoid; Circadian Rhythm; Female; Glucocorticoids; Humans; Male; Mi | 2013 |
A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic | 2014 |
The relationship between disease activity and depressive symptoms severity and optimism--results from the IMPROVED study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Attitude; Depression; Female; Humans; Infl | 2013 |
Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study.
Topics: Absorptiometry, Photon; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Disease Progressi | 2015 |
Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; | 2014 |
Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; | 2014 |
Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; | 2014 |
Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; | 2014 |
Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Adm | 2013 |
Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Dise | 2014 |
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Early Medical I | 2015 |
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Early Medical I | 2015 |
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Early Medical I | 2015 |
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Early Medical I | 2015 |
Can we prevent rapid radiological progression in patients with early rheumatoid arthritis?
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Foot Joints; | 2015 |
Alternative Ways to Quantify Sustained Remission: Applying the Continuity Rewarded Score and Patient Vector Graph.
Topics: Adult; Aged; Arthritis, Rheumatoid; Data Display; Data Interpretation, Statistical; Drug Therapy, Co | 2015 |
What Is the Relationship Between Morning Symptoms and Measures of Disease Activity in Patients With Rheumatoid Arthritis?
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Circadian Rhythm; Female; Humans; Male; Middl | 2015 |
Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Biomarkers; Circadian Rhythm; Delayed-Action Prepar | 2015 |
Improvement Thresholds for Morning Stiffness Duration in Patients Receiving Delayed- Versus Immediate-Release Prednisone for Rheumatoid Arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Circadian Rhythm; Delayed-Action Preparati | 2015 |
Comparison of the efficacy of prednisone and cyclosporine for treatment of dogs with primary immune-mediated polyarthritis.
Topics: Administration, Oral; Analgesics, Opioid; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agent | 2016 |
Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment: A Randomized Trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Thera | 2016 |
Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-la
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Drug Therapy, Combinat | 2017 |
Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-la
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Drug Therapy, Combinat | 2017 |
Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-la
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Drug Therapy, Combinat | 2017 |
Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-la
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Drug Therapy, Combinat | 2017 |
Further Simplification of the Simple Erosion Narrowing Score With Item Response Theory Methodology.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Humans; | 2016 |
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.
Topics: Acute Disease; Aged; Analysis of Variance; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, | 2009 |
Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Meth | 2009 |
Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluat | 2009 |
Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analy | 2009 |
Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Andrographis; Arsenicals; Arthralgia; Arthritis, Rheumatoid; Chloroquine; D | 2009 |
Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Andrographis; Arsenicals; Arthralgia; Arthritis, Rheumatoid; Chloroquine; D | 2009 |
Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Andrographis; Arsenicals; Arthralgia; Arthritis, Rheumatoid; Chloroquine; D | 2009 |
Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Andrographis; Arsenicals; Arthralgia; Arthritis, Rheumatoid; Chloroquine; D | 2009 |
Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Andrographis; Arsenicals; Arthralgia; Arthritis, Rheumatoid; Chloroquine; D | 2009 |
Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Andrographis; Arsenicals; Arthralgia; Arthritis, Rheumatoid; Chloroquine; D | 2009 |
Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Andrographis; Arsenicals; Arthralgia; Arthritis, Rheumatoid; Chloroquine; D | 2009 |
Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Andrographis; Arsenicals; Arthralgia; Arthritis, Rheumatoid; Chloroquine; D | 2009 |
Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Andrographis; Arsenicals; Arthralgia; Arthritis, Rheumatoid; Chloroquine; D | 2009 |
Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2009 |
Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2009 |
Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2009 |
Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2009 |
Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2010 |
Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Pressure; Body Mass Index | 2010 |
Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis.
Topics: Absorptiometry, Photon; Adult; Aged; Antibodies, Monoclonal; Arthritis, Rheumatoid; Bone Density; Di | 2010 |
A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; C-Reactive Prot | 2010 |
Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Circadian Rhythm; Delayed-Action Preparati | 2010 |
Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Circadian Rhythm; Color Therapy; Corticotropi | 2010 |
Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis.
Topics: Adiponectin; Adult; Aged; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvas | 2011 |
Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Bi | 2011 |
The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progressio | 2011 |
Remission in early rheumatoid arthritis treated with conventional DMARDs. Results of a two-year follow-up study of El Ayachi Moroccan cohort.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Drug Therapy, Combination; | 2012 |
Efficacy of vitamin D in patients with active rheumatoid arthritis receiving methotrexate therapy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Double-Blind Method; Drug The | 2012 |
Profile and course of early rheumatoid arthritis in Morocco: a two-year follow-up study.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disease Progre | 2011 |
Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combina | 2012 |
Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2).
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoi | 2013 |
Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Female; Humans; Male; M | 2012 |
Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: side effect of the prednisone or better control of disease activity?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; Double-Blind Method; Drug Therapy, Com | 2013 |
In vitro glucocorticoid sensitivity is associated with clinical glucocorticoid therapy outcome in rheumatoid arthritis.
Topics: Administration, Oral; Adult; Aged; Arthritis, Rheumatoid; Cohort Studies; Female; Glucocorticoids; H | 2012 |
Large-joint damage in patients with early rheumatoid arthritis and its association with treatment strategy and damage of the small joints.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Cluster Analysis; | 2012 |
Ultrasound of metacarpophalangeal joints is a sensitive and reliable endpoint for drug therapies in rheumatoid arthritis: results of a randomized, two-center placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-Reactive | 2012 |
Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?
Topics: Absorptiometry, Photon; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Bone | 2013 |
Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Arthrography; Collagen Type I; Disease Progression; Dose-Respons | 2003 |
Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound.
Topics: Absorptiometry, Photon; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Arthrit | 2003 |
The serum growth hormone to somatostatin ratio is skewed upward in rheumatoid arthritis patients.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Female; Human Growth Hormone; Humans; Insulin-Like | 2004 |
The clinical effect of glucocorticoids in patients with rheumatoid arthritis may be masked by decreased use of additional therapies.
Topics: Activities of Daily Living; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Di | 2004 |
Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; | 2005 |
[Effect of small-dose glucocorticoids on the course of early rheumatic arthritis].
Topics: Adolescent; Adult; Age Factors; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoi | 2004 |
Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial.
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthri | 2005 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2005 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2005 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2005 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2005 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2005 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2005 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2005 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2005 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2005 |
Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Topics: Absorptiometry, Photon; Alendronate; Alkaline Phosphatase; Analysis of Variance; Arthritis, Rheumato | 2006 |
[The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone].
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Genetic Predisposition to Disease; | 2005 |
Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Bone Density; Drug Therapy, Combination; Female; Humans; Methotrexate; | 2006 |
Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthr | 2007 |
Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug | 2007 |
Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial).
Topics: Aged; Analysis of Variance; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Dru | 2007 |
Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug The | 2007 |
[Clinical study on effect of total panax notoginseng saponins on immune related inner environment imbalance in rheumatoid arthritis patients].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthriti | 2007 |
[Leflunomide as a second choice treatment in patients with rheumatoid arthritis].
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combinati | 2007 |
[Effect of chinese herbs in enhancing prednisone for treatment of refractory rheumatoid arthritis].
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Synergism; Drug Therapy, Combinat | 2007 |
[Comparative study on characteristics of Chinese and Western medicine for treatment of rheumatoid arthritis regarding cartilage erosion related blood biochemical and immunological factors].
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cartilage, Articular; Drugs, Chinese Herbal; Ery | 2007 |
Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial.
Topics: Arthritis, Rheumatoid; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedul | 2008 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Fema | 2008 |
Glucocorticoid therapy-induced memory deficits: acute versus chronic effects.
Topics: Adult; Aged; Analysis of Variance; Arthritis, Rheumatoid; Cross-Over Studies; Double-Blind Method; F | 2008 |
Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Ag | 2009 |
Low dose prednisone therapy in rheumatoid arthritis: a double blind study.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Double-Blind Method; Femal | 1983 |
Clinical equivalence of a new glucocorticoid, deflazacort and prednisone in rheumatoid arthritis and S.L.E. patients.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Clinical Trials as Topic; Double-Blind Method; Female; Hum | 1984 |
Low-dose prednisone therapy in rheumatoid arthritis: effect on vitamin D metabolism.
Topics: 24,25-Dihydroxyvitamin D 3; Arthritis, Rheumatoid; Calcifediol; Calcitriol; Clinical Trials as Topic | 1984 |
Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis.
Topics: Absorptiometry, Photon; Arthritis, Rheumatoid; Bone Density; Cross-Sectional Studies; Dose-Response | 1995 |
Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cohort Studies | 1995 |
Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial.
Topics: Administration, Oral; Adult; Arthritis, Rheumatoid; Aurothioglucose; Double-Blind Method; Drug Thera | 1995 |
Prednisone treatment of elderly-onset rheumatoid arthritis. Disease activity and bone mass in comparison with chloroquine treatment.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Bone Density; Bone Remodeling; Chloroquine; Elbow In | 1995 |
Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Female; Follow-Up Studies; Humans; Male; Meth | 1994 |
Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity.
Topics: Arthritis, Rheumatoid; Hemagglutination Inhibition Tests; Humans; Immunization; Immunosuppressive Ag | 1994 |
Decreased testosterone levels in men with rheumatoid arthritis: effect of low dose prednisone therapy.
Topics: Adult; Aged; Arthritis, Rheumatoid; Follicle Stimulating Hormone; Humans; Male; Middle Aged; Prednis | 1994 |
Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; D | 1995 |
Long-term therapy with the new glucocorticosteroid deflazacort in rheumatoid arthritis. Double-blind controlled randomized 12-months study against prednisone.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Body Weight; Cushing Syndrome; Double- | 1994 |
Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study.
Topics: Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Double-Blind Method | 1993 |
Aspirin is not associated with more toxicity than other nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis treated with methotrexate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheu | 1993 |
Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases.
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; CD4-CD8 Ratio; Double-Blind Method; Humans; | 1993 |
The relative toxicity of disease-modifying antirheumatic drugs.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Azathiopri | 1993 |
Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Arthritis, Rheumatoid; Bone Density; Calcium Carbonate; Cholecalciferol; Double-Blind M | 1996 |
Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Art | 1997 |
[The effect of immunosuppressive drugs on expression of surface antigens of lymphocytes in patients with rheumatoid arthritis].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Surface; Arthritis, Rheumatoid; B-Ly | 1997 |
Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Anticardiolipin; Arthrit | 1997 |
Fluoride therapy in prevention of rheumatoid arthritis induced bone loss.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; B | 1997 |
[The effect of low dose methotrexate on the course of rheumatoid arthritis--four years of observation].
Topics: Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents | 1997 |
Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy.
Topics: Arthritis, Rheumatoid; Biopsy; Cross-Over Studies; Drug Therapy, Combination; Humans; Liver; Longitu | 1998 |
Effects of glucocorticoids on bone mineral density in rheumatoid arthritis patients. A longitudinal study.
Topics: Absorptiometry, Photon; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthrit | 1999 |
Prevention of corticosteroid-induced osteoporosis by alfacalcidol.
Topics: Adjuvants, Immunologic; Adult; Arthritis, Rheumatoid; Asthma; Bone Density; Calcium; Dose-Response R | 2000 |
[Glucocorticosteroid induced osteoporosis in patients with rheumatoid arthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Bone Density; Female; Glucocorticoids; Humans; Middle Aged; Oste | 2000 |
Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Arthrography; Disease Progression; Dose-Response Rel | 2000 |
A randomized controlled trial to evaluate the effectiveness of an exercise program in women with rheumatoid arthritis taking low dose prednisone.
Topics: Arthritis, Rheumatoid; Bone Density; Disease Progression; Dose-Response Relationship, Drug; Exercise | 2000 |
Unsuccessful treatment with fludarabine in four cases of refractory rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Disease Progression; Female; Humans; Immunosuppressive Agents; Lymphocyte Cou | 2000 |
Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Disease Progression; F | 2002 |
Summaries for patients. Prednisone for rheumatoid arthritis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Disease Progression; F | 2002 |
Evaluation of analgesic action and efficacy of antirheumatic drugs. Study of 10 drugs in 684 patients with rheumatoid arthritis.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Clinical Tri | 1976 |
[Cellular immunity in rheumatoid arthritis. Effect of therapy].
Topics: Antimalarials; Arthritis, Rheumatoid; B-Lymphocytes; Clinical Trials as Topic; Fluorescent Antibody | 1977 |
Tolfenamic acid in the treatment of rheumatoid arthritis.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; A | 1979 |
Cyclophosphamide therapy for rheumatoid arthritis.
Topics: Administration, Oral; Alopecia; Arthritis, Rheumatoid; Blood Sedimentation; Clinical Trials as Topic | 1975 |
[Comparative evaluation of the therapeutic efficiency of flurbiprofene in rheumatoid polyarthritis].
Topics: Acetaminophen; Arthritis, Rheumatoid; Aspirin; Biphenyl Compounds; Chemical Phenomena; Chemistry; Cl | 1975 |
Therapeutic effectiveness of paracetamol in rheumatoid arthritis.
Topics: Acetaminophen; Analysis of Variance; Arthritis, Rheumatoid; Aspirin; Drug Evaluation; Female; Humans | 1975 |
Effect of low doses of deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Density; Dose-Response | 1992 |
Endocrine control of inflammation: rheumatoid arthritis double-blind, crossover clinical trial.
Topics: Adult; Aged; Analysis of Variance; Arthritis, Rheumatoid; Double-Blind Method; Female; Humans; Male; | 1992 |
Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update.
Topics: Aged; Arthritis, Rheumatoid; Biopsy; Drug Administration Schedule; Humans; Liver; Liver Cirrhosis; M | 1992 |
Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis.
Topics: Aged; Arthritis, Rheumatoid; Azathioprine; Drug Therapy, Combination; Female; Humans; Male; Predniso | 1991 |
A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders.
Topics: Analysis of Variance; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone and Bones; Calcium; Chro | 1991 |
Oral steroids in rheumatoid arthritis. Helpful but not remittive.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Arthritis, Rheumatoid; Aspirin; Clinical Trial | 1987 |
[Possibilities of intermittent therapy of progressive chronic polyarthritis].
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Arthritis, Rheumatoid; Ascorbic Acid; Female; Fructo | 1971 |
[Therapeutic value of the combination of a corticosteroid (prednisone) with a gastroprotective substance (xylamide)].
Topics: Adult; Aged; Amides; Arthritis, Rheumatoid; Bronchitis; Clinical Trials as Topic; Drug Combinations; | 1972 |
[Study of triacetyloleandomycin in rheumatoid polyarthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Middle Aged; Placebos; Prednis | 1972 |
Method for assessing therapeutic potential of anti-inflammatory antirheumatic drugs in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Humans; Methods; | 1973 |
Proceedings: Technique for assessing the potential effectiveness of antirheumatic drugs.
Topics: Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Drug Evaluation; Ethics, Medical; Humans; | 1974 |
Evaluation of the therapeutic potential of ketoprofen in rheumatoid arthritis.
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Benzophenones; | 1974 |
[Controlled clinical trial a gastroprotective steroid (prednisone + xylamide)].
Topics: Amides; Arthritis, Rheumatoid; Asthma; Benzoates; Bronchitis; Chronic Disease; Drug Combinations; Ev | 1972 |
Evaluation of digital joint circumference measurements in rheumatoid arthritis.
Topics: Anthropometry; Arthritis, Rheumatoid; Aspirin; Blood Sedimentation; Circadian Rhythm; Finger Joint; | 1973 |
Effect of several drugs on gastric potential difference in man.
Topics: Adult; Arthritis, Rheumatoid; Aspirin; Drug Combinations; Drug Synergism; Ethanol; Female; Gastric M | 1974 |
Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis.
Topics: Acetaminophen; Anthropometry; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Placebos; Pre | 1967 |
Slow turnover of manganese in active rheumatoid arthritis accelerated by prednisone.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Hepatolenticular Degeneration; Humans; Hydralazine; | 1968 |
An investigation of possible synergism between flufenamic acid and prednisone.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Synergism; Flufenami | 1966 |
872 other studies available for prednisone and Arthritis, Rheumatoid
| Article | Year |
|---|---|
[Various metabolic, functional and clinical aspects of deltacortene therapy].
Topics: Arthritis; Arthritis, Rheumatoid; Blood; Blood Coagulation; Humans; Kidney Function Tests; Lipoprote | 1955 |
Estimates of minimal clinically important improvments vary with the responsiveness of the sample.
Topics: Arthritis, Rheumatoid; Humans; Longitudinal Studies; Prednisone; Prospective Studies; Severity of Il | 2022 |
Rheumatologic Manifestations of Post SARS-CoV-2 Infection: A Case Series.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Reactive; Arthritis, Rheum | 2022 |
Frequency of Symptomatic Adverse Events in Rheumatoid Arthritis: An Exploratory Online Survey.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Predni | 2022 |
Deep dive into achieving the therapeutic target: results from a prospective, 6‑month, observational study nested in routine rheumatoid arthritis care.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Prednisone; Prospective Studies; Quality of Lif | 2022 |
Risk factors for adverse pregnancy outcomes in women with rheumatoid arthritis and follow-up of their offspring.
Topics: Abortion, Spontaneous; Adolescent; Antibodies, Antinuclear; Arthritis, Rheumatoid; Child; Child, Pre | 2022 |
Influence of initial glucocorticoid co-medication on mortality and hospitalization in early inflammatory arthritis: an investigation by record linkage of clinical and administrative databases.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Glucocorticoids; Hospitalization; Humans; Middle Aged; | 2022 |
Does prednisone use in pregnant women with rheumatoid arthritis induce insulin resistance in the offspring?
Topics: Adiponectin; Arthritis, Rheumatoid; Birth Weight; Child; Female; Glucocorticoids; Humans; Insulin; I | 2023 |
Case report: Joint deformity associated with systemic lupus erythematosus.
Topics: Adult; Antibodies, Antinuclear; Antigens, Nuclear; Arthritis, Rheumatoid; C-Reactive Protein; Celeco | 2022 |
Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition.
Topics: Aged; Arthritis, Rheumatoid; C-Reactive Protein; Cross-Sectional Studies; Glucocorticoids; Humans; N | 2022 |
Aseptic Abscess Syndrome in Rheumatoid Arthritis Patient.
Topics: Abscess; Adalimumab; Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Arthritis, Rheumatoid; CO | 2022 |
The relationship between structural analysis of the hand and clinical characteristics in psoriatic arthritis.
Topics: Absorptiometry, Photon; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Bone Dens | 2022 |
Outcomes of Filipinos with inflammatory rheumatic diseases developing COVID-19 prior to vaccinations and new variants: a historical perspective.
Topics: Adult; Arthritis, Rheumatoid; COVID-19; Female; Heart Diseases; Humans; Hypertension; Lupus Erythema | 2023 |
Glucocorticoid exposure and the risk of serious infections in rheumatoid arthritis: a marginal structural model application.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Glucocorticoids; Humans; Prednisone; Prospective Studie | 2023 |
ATP-binding cassette G1 membrane transporter-mediated cholesterol efflux capacity influences coronary atherosclerosis and cardiovascular risk in Rheumatoid Arthritis.
Topics: Adenosine Triphosphate; Animals; Arthritis, Rheumatoid; Cardiovascular Diseases; CHO Cells; Choleste | 2023 |
Time Trends in Glucocorticoid Use in Rheumatoid Arthritis During the Biologics Era: 1999-2018.
Topics: Arthritis, Rheumatoid; Biological Products; Female; Glucocorticoids; Humans; Incidence; Male; Predni | 2023 |
Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Deep Learning; Female; | 2023 |
Viewpoint: Glucocorticoids in the treatment of rheumatoid arthritis: points to (re)consider.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Glucocorticoids; Humans; Prednisone | 2023 |
Childhood-onset rheumatoid arthritis at a tertiary hospital in Senegal, West Africa.
Topics: Adolescent; Adult; Africa, Western; Arthritis, Juvenile; Arthritis, Rheumatoid; Child; Cohort Studie | 2023 |
Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib.
Topics: Aged; Arthritis, Rheumatoid; Glucocorticoids; Humans; Middle Aged; Pilot Projects; Prednisone | 2023 |
COVID-19 prognosis in systemic lupus erythematosus compared with rheumatoid arthritis and spondyloarthritis: results from the CONTROL-19 Study by the Italian Society for Rheumatology.
Topics: Aged; Arthritis, Rheumatoid; COVID-19; Female; Humans; Hypertension; Lupus Erythematosus, Systemic; | 2023 |
Suboptimal management of rheumatoid arthritis in France: a real-world study based on data from the French National Health Data System.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Longitudinal Studies; Prednisone; Retrospective | 2023 |
Leprosy with type 1 reaction in a patient from Ontario, Canada without recent travel misdiagnosed as vasculitic neuropathy: a case report.
Topics: Aged, 80 and over; Arthritis, Rheumatoid; Delayed Diagnosis; Diagnostic Errors; Exanthema; Humans; L | 2023 |
Paradoxical Löfgren's syndrome in a patient treated with rituximab: interferon is not the key.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Follow-Up Studies; Humans; | 2020 |
Effectiveness of methotrexate in combination therapy in a rat collagen-induced arthritis model.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Collagen; Combined Mo | 2019 |
Obstructive uropathy associated with rheumatoid arthritis successfully treated with steroids and immunosuppressive therapy: A case report.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Disease Progression; Female; Hematuria; Humans; Hyd | 2019 |
Atypical Presentation of Choroidal Folds: Steroid-induced Central Serous Chorioretinopathy-like Maculopathy
Topics: Aged; Arthritis, Rheumatoid; Central Serous Chorioretinopathy; Choroid Diseases; Drug Therapy, Combi | 2019 |
Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Topics: Arthritis, Rheumatoid; Azathioprine; Dyspnea; Hand; Humans; Lung; Lung Diseases, Interstitial; Male; | 2020 |
ASSOCIATIONS BETWEEN EFFICACY OF THE THERAPY AND CIRCADIAN FLUCTUATIONS OF ENDOTHELIAL NITRIC OXIDE SYNTHASE WITH TOLL-LIKE RECEPTORS 2 EXPRESSION, AND NOS3 POLYMORPHISM IN FEMALES WITH RHEUMATOID ARTHRITIS.
Topics: Adult; Arthritis, Rheumatoid; Circadian Rhythm; Drug Therapy, Combination; Female; Humans; Male; Met | 2020 |
A case of bilateral methotrexate-associated diffuse large B-cell lymphomas of the breasts with unique clinical presentation and outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; | 2020 |
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Antirheumatic Agent | 2020 |
Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Blood Sedimentation; Cardiovascular Diseases; Female; Fractures, Bone; | 2021 |
Epicardial Adipose Tissue Volume As a Marker of Subclinical Coronary Atherosclerosis in Rheumatoid Arthritis.
Topics: Adipose Tissue; Arthritis, Rheumatoid; Atherosclerosis; Biomarkers; C-Reactive Protein; Case-Control | 2021 |
Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents | 2021 |
Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Deprescriptions; Female; Glucocorticoids; | 2021 |
Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis.
Topics: Acute Coronary Syndrome; Adult; Aged; Angina, Unstable; Antirheumatic Agents; Arrhythmias, Cardiac; | 2021 |
Fibromyalgianess and glucocorticoid persistence among patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Fibromyalgia; Glucocorticoids; Humans; Prednisone | 2022 |
The efficacy of low dose short-term prednisone therapy for remission induction in newly diagnosed rheumatoid arthritis patients.
Topics: Arthritis, Rheumatoid; Glucocorticoids; Humans; Prednisone; Remission Induction; Retrospective Studi | 2021 |
Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Drug Therapy, C | 2017 |
[The 456th case: polyarthritis, dry cough, dyspnea on exertion].
Topics: Arthralgia; Arthritis, Rheumatoid; Autoantibodies; Blood Sedimentation; C-Reactive Protein; Cough; D | 2017 |
Does prednisone use or disease activity in pregnant women with rheumatoid arthritis influence the body composition of their offspring?
Topics: Adult; Arthritis, Rheumatoid; Body Composition; Child; Female; Glucocorticoids; Humans; Infant, Newb | 2017 |
Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; Disease Progression; E | 2017 |
Methotrexate-induced Hypersensitivity Pneumonitis appearing after 30 years of use: a case report.
Topics: Administration, Oral; Aged; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents; Antirheumatic | 2017 |
Iatrogenic immunodeficiency-associated Epstein-Barr virus (EBV) -negative natural killer cell lymphoproliferative disorder in a patient undergoing rheumatoid arthritis therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Cyclophosphamide; Doxor | 2017 |
Discussion of Methotrexate Dosage.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Follow-Up Studies; Humans; Methotrexate; Prednisone | 2018 |
Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; | 2017 |
Agreement Between Maternal Report and Medical Records During Pregnancy: Medications for Rheumatoid Arthritis and Asthma.
Topics: Adult; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Asthma; Et | 2018 |
Serum sickness-like disease after switching to biosimilar infliximab.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biosimilar Pharmaceuticals; Drug Substitution; Drug The | 2017 |
Response to eLetter: 'Discussion of methotrexate dosage' by Maguire
Topics: Arthritis, Rheumatoid; Follow-Up Studies; Humans; Methotrexate; Prednisone | 2018 |
Abrupt generalized pustules in patients with rheumatoid arthritis and interstitial lung disease.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Arthritis, Rheumatoid; Biopsy; Chromones; Cyclosp | 2018 |
Effect of daily low dose prednisone, divided or single daily dose, in the treatment of African Americans with early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Black or African American; Disease Progres | 2018 |
Iguratimod is effective in refractory rheumatoid arthritis patients with inadequate response to methotrexate-cyclosporin A-hydroxychloroquine-prednisone.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Cyclosporine; Drug Therapy, Combinati | 2018 |
Patterns of prednisone use during pregnancy in women with rheumatoid arthritis: Daily and cumulative dose.
Topics: Administration, Oral; Adult; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Female; Gestat | 2018 |
Case of lamotrigine-induced drug adverse reaction under tocilizumab treatment with clinical and virological features of drug-induced hypersensitivity syndrome.
Topics: Adult; Antibodies, Monoclonal, Humanized; Anticonvulsants; Arthritis, Rheumatoid; Biopsy; C-Reactive | 2018 |
Successful Use of a Reduced Dose Regimen of Rituximab in a Case of Rheumatoid Arthritis with Raynaud's Syndrome.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Immunologic Tests; Male; Methotrexate; P | 2018 |
Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Pressure; Female; | 2018 |
[Effects of Tongbi capsule on joint lesions in rabbits with rheumatoid arthritis].
Topics: Animals; Arthritis, Rheumatoid; Cartilage, Articular; Drugs, Chinese Herbal; Interleukin-1; Joints; | 2018 |
Rheumatoid arthritis revealed by polyadenopathy, diarrhea and digestive AA amyloidosis.
Topics: Amyloidosis; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Biopsy, Needle; Diagnosis, Di | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2019 |
Associations between antenatal prednisone exposure and long-term cortisol and cortisone concentrations in children born to women with rheumatoid arthritis: results from a nationwide prospective cohort study.
Topics: Anthropometry; Arthritis, Rheumatoid; Biomarkers; Child; Cortisone; Female; Humans; Maternal Exposur | 2019 |
Methotrexate-associated lymphoproliferative disorder in the stomach and duodenum: a case report.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antirh | 2019 |
Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; | 2019 |
PTX3 Intercepts Vascular Inflammation in Systemic Immune-Mediated Diseases.
Topics: Acute-Phase Proteins; Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Arthr | 2019 |
Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-I
Topics: Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Cluster Analy | 2019 |
Sequential appearance of small vessel vasculitis and neutrophilic panniculitis in a patient with rheumatoid arthritis: further insight into the mechanism of this infrequent panniculitis.
Topics: Arthritis, Rheumatoid; Biopsy; Female; Humans; Middle Aged; Neutrophils; Panniculitis; Prednisone; S | 2019 |
Leprosy after interleukin 6 inhibitor therapy in a patient with rheumatoid arthritis.
Topics: Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Dapsone; Exanthema; Female; Humans; Lepros | 2019 |
Treatment of rheumatoid arthritis with methotrexate in Congolese patients.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Democratic Republic of the Congo; Disease | 2013 |
Assessing process of care in rheumatoid arthritis at McGill University hospitals.
Topics: Absorptiometry, Photon; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive | 2013 |
Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Stud | 2013 |
[Nodular skin lesions in a patient with rheumatoid arthritis under therapy with anti-tumor necrosis factor-α].
Topics: Antibodies, Monoclonal; Arthritis, Rheumatoid; Azathioprine; Biological Products; Clarithromycin; Dr | 2014 |
Key findings towards optimising adalimumab treatment: the concentration-effect curve.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic | 2015 |
Key findings towards optimising adalimumab treatment: the concentration-effect curve.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic | 2015 |
Key findings towards optimising adalimumab treatment: the concentration-effect curve.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic | 2015 |
Key findings towards optimising adalimumab treatment: the concentration-effect curve.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic | 2015 |
Key findings towards optimising adalimumab treatment: the concentration-effect curve.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic | 2015 |
Key findings towards optimising adalimumab treatment: the concentration-effect curve.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic | 2015 |
Key findings towards optimising adalimumab treatment: the concentration-effect curve.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic | 2015 |
Key findings towards optimising adalimumab treatment: the concentration-effect curve.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic | 2015 |
Key findings towards optimising adalimumab treatment: the concentration-effect curve.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic | 2015 |
The influence of foetal prednisone exposure on the cortisol levels in the offspring.
Topics: Adult; Area Under Curve; Arthritis, Rheumatoid; Blood Pressure; Female; Glucocorticoids; Humans; Hyd | 2014 |
Nonuremic calciphylaxis in a patient with rheumatoid arthritis and osteoporosis treated with teriparatide.
Topics: Arthritis, Rheumatoid; Bone Density Conservation Agents; Calciphylaxis; Diagnosis, Differential; Dru | 2014 |
[Acute sensory-motor axonal neuropathy (Guillain-Barre syndrome) following vertebroplasty].
Topics: Accidental Falls; Arthritis, Rheumatoid; Female; Guillain-Barre Syndrome; Humans; Immunocompromised | 2014 |
[The short-term efficacy and safety of methotrexate plus low dose prednisone in patients with rheumatoid arthritis].
Topics: Adult; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle | 2013 |
Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; Glu | 2014 |
Brief report: does medication use or disease activity during pregnancy in patients with rheumatoid arthritis affect bone density in their prepubertal offspring?
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Child; Child, Preschool; Female; H | 2014 |
Reply: To PMID 23728826.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Monitoring, Physiol | 2014 |
Determining adherence to therapeutic regimens in patients with chronic illness: comment on the article by Waimann et Al.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Monitoring, Physiol | 2014 |
Rheumatoid arthritis during pregnancy and postnatal catch-up growth in the offspring.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Birth Weight; Child Development; Child, Preschoo | 2014 |
Fibrosing cholestatic hepatitis after methotrexate and prednisone therapy for rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Chemical and Drug Induced Liver Injury; Cholest | 2014 |
Glucocorticoids in the treatment of rheumatoid arthritis: still used after 65 years.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Therapy, Combination; Gl | 2014 |
Necrobiosis lipoidica occurring in a patient with rheumatoid arthritis on concurrent tumor necrosis factor-α inhibitor therapy.
Topics: Adalimumab; Arthritis, Rheumatoid; Female; Humans; Immunosuppressive Agents; Leg Dermatoses; Methotr | 2015 |
The current relevance and use of prednisone in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Glucocorticoids; | 2014 |
Are glucocorticoids harmful to bone in early rheumatoid arthritis?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Density; Glucocorticoids; Humans; | 2014 |
Methotrexate-associated lymphoproliferative disorder arising in the retromolar triangle and lung of a patient with rheumatoid arthritis.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antirh | 2014 |
Fertility in women with rheumatoid arthritis: influence of disease activity and medication.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response Relationship, D | 2015 |
Five-year outcome in immune-mediated scleritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Autoantibodies; Autoantigens; Female; Follow-Up Studies; Glucoco | 2014 |
Traditional Chinese medication for rheumatoid arthritis: more than what meets the eye.
Topics: Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Female; Humans; Hydrochloro | 2015 |
The use of sirolimus to treat Kaposi's sarcoma in an HIV-negative rheumatoid arthritis patient on disease-modifying drug therapies.
Topics: Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Arthritis, Rheumatoid; HIV Seronegativity; Hu | 2015 |
Disease characteristics and treatment patterns in veterans with rheumatoid arthritis and concomitant hepatitis C infection.
Topics: Aged; Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; Comorbidity; Female; Hepatitis | 2015 |
Clinical trials documenting the efficacy of low-dose glucocorticoids in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Glucocort | 2015 |
Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthr | 2015 |
Rheumatoid arthritis: Methotrexate and bridging glucocorticoids in early RA.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Glucocorticoids; Humans; Isoxazoles; Male; Meth | 2014 |
Glucocorticoid use is associated with increase in HDL and no change in other lipids in rheumatoid arthritis patients.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Drug Administration Schedule; Electronic He | 2015 |
Comment on: tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice: reply.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Glucocortico | 2015 |
Comment on: tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Glucocortico | 2015 |
Determinants of reaching drug-free remission in patients with early rheumatoid or undifferentiated arthritis after one year of remission-steered treatment.
Topics: Adult; Aged; Antibodies, Anti-Idiotypic; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Dru | 2015 |
Rituximab and Acute Retinal Necrosis in a Patient with Scleromalacia and Rheumatoid Arthritis.
Topics: Acyclovir; Antiviral Agents; Aqueous Humor; Arthritis, Rheumatoid; Drug Therapy, Combination; Eye In | 2016 |
Acute myocardial infarction in a young woman with rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Pressure; Coronary Angiography; Creatine K | 2015 |
Predictors of longterm changes in body mass index in rheumatoid arthritis.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; Cohort Studi | 2015 |
Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Interferon | 2015 |
Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study.
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Cardiovascular Diseases; Cohort Studies; Comorbidit | 2015 |
Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Herpes Zoster; Herpes | 2015 |
[Widespread pigmentation following long-term minocycline therapy].
Topics: Arthritis, Infectious; Arthritis, Rheumatoid; Denosumab; Drug Therapy, Combination; Female; Humans; | 2016 |
Autoimmune Pitfalls of Anti-Tumor Necrosis Factor-Alpha Therapy.
Topics: Arthritis, Rheumatoid; Autoantibodies; Autoimmunity; Etanercept; Humans; Immunoglobulin G; Immunosup | 2015 |
Protective role of theophylline and their interaction with nitric oxide (NO) in adjuvant-induced rheumatoid arthritis in rats.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Cytokines; Edema; | 2015 |
Is the Availability of Delayed-Release Prednisone an Important Clinical Advance?
Topics: Arthritis, Rheumatoid; Chemistry, Pharmaceutical; Cost-Benefit Analysis; Delayed-Action Preparations | 2016 |
Prednisone Use and Risk of Mortality in Patients With Rheumatoid Arthritis: Moderation by Use of Disease-Modifying Antirheumatic Drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 2016 |
Erythematous Plaques on the Buttock.
Topics: Acyclovir; Aged; Anti-Inflammatory Agents; Antiviral Agents; Arthritis, Rheumatoid; Buttocks; Cellul | 2016 |
[Immunodeficiency-associated Burkitt lymphoma developed in a patient receiving a long-term methotrexate therapy for rheumatoid arthritis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Arthritis, Rheumatoid; Burkitt | 2016 |
Effect of rituximab on pulmonary function in patients with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Carbon Monoxide; Female; Follow-Up Studies; Human | 2016 |
Changes in Body Mass Related to the Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; Body Weight; | 2016 |
Determining the Lowest Optimally Effective Methotrexate Dose for Individual RA Patients Using Their Dose Response Relation in a Tight Control Treatment Approach.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Re | 2016 |
Relation among anti-rheumatic drug therapy, CD14(+)CD16(+) blood monocytes and disease activity markers (DAS28 and US7 scores) in rheumatoid arthritis: A pilot study.
Topics: Adult; Antibodies; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Female; GPI-Linked Prote | 2016 |
Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
Topics: Abatacept; Adult; Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthri | 2016 |
Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Female; Fractures, Bone; Glucocorticoids; Humans; Incidence; Male; Mid | 2016 |
Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Incidence; Lung Diseases, Interst | 2016 |
Sarcoidosis during etanercept treatment for rheumatoid arthritis in women with a history of bilateral oophorectomy.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Female; Glucocorticoids; Humans; Midd | 2016 |
End-stage renal disease in patients with rheumatoid arthritis.
Topics: Adalimumab; Adolescent; Adult; Amyloidosis; Antirheumatic Agents; Arthritis, Rheumatoid; Biological | 2017 |
Moderating effects of immunosuppressive medications and risk factors for post-operative joint infection following total joint arthroplasty in patients with rheumatoid arthritis or osteoarthritis.
Topics: Aged; Allopurinol; Arthritis, Rheumatoid; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; | 2017 |
Subjective memory complaints and depression as clinical symptoms of disseminated nocardiosis by Nocardia abscessus.
Topics: Aged; Arthritis, Rheumatoid; Bacteremia; Depressive Disorder; Female; Follow-Up Studies; Humans; Inf | 2016 |
Identifying Clinical Factors Associated With Low Disease Activity and Remission of Rheumatoid Arthritis During Pregnancy.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; C-Reactive Protein; Female; Huma | 2017 |
Serum progranulin levels in Hispanic rheumatoid arthritis patients treated with TNF antagonists: a prospective, observational study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Hispani | 2017 |
Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) case presentation and comparison with other polyarthritides affecting older people.
Topics: Aged; Arthritis; Arthritis, Rheumatoid; Biomarkers; Diagnosis, Differential; Edema; Glucocorticoids; | 2017 |
Phaeohyphomycotic tenosynovitis after local steroid injection during methotrexate therapy for rheumatoid arthritis: A case-report.
Topics: Arthritis, Rheumatoid; Combined Modality Therapy; Drainage; Follow-Up Studies; Humans; Immunocomprom | 2017 |
Polymorphisms in the multidrug-resistance 1 gene related to glucocorticoid response in rheumatoid arthritis treatment.
Topics: Adult; Aged; Alleles; Arthritis, Rheumatoid; ATP Binding Cassette Transporter, Subfamily B, Member 1 | 2017 |
Rapid healing of peripheral ulcerative keratitis in rheumatoid arthritis with prednisone, methotrexate and adalimumab combination therapy.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Corneal Ulcer; Drug Therapy, Combination; H | 2017 |
Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients.
Topics: Adalimumab; Adult; Age Factors; Aged; Arthritis, Rheumatoid; Cyclosporine; Dermatologic Agents; Etan | 2017 |
Histoplasmosis clinically imitating cutaneous malignancy.
Topics: Aged; Antifungal Agents; Arthritis, Rheumatoid; Dermatitis, Seborrheic; Diagnosis, Differential; His | 2008 |
Hydroxychloroquine-induced hyperpigmentation: the staining pattern.
Topics: Aged; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents | 2008 |
Development of autoimmune diseases after vaccination.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Giant Cell Arteritis; | 2008 |
RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Female; Glucocortic | 2008 |
[Pneumocystis pneumonia among patients with systemic diseases].
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Cyclophosphamide; Drug Therapy, Combination; Granulo | 2009 |
Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2008 |
Septicemic arthritis with antibiotic resistance: a case study.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Arthritis, Infectious; Arthritis, Rheumatoid; Bacte | 2008 |
Obstructive bronchiolar disease identified by CT in the non-transplant population: analysis of 29 consecutive cases.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alveolitis, Extrinsic Allergic; Arthritis, | 2009 |
[Cutaneous leishmaniasis in rheumatoid arthritis].
Topics: Adult; Antiprotozoal Agents; Arthritis, Rheumatoid; Female; Glucocorticoids; Humans; Immunocompromis | 2009 |
Effect of low-dose prednisone on leukocyte counts and subpopulations in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cross-Sectional Studies; Dose-Response Relationship, Drug; Femal | 2009 |
Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Epidemiologic M | 2010 |
Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone Density; Bone Density | 2009 |
In-office magnetic resonance imaging to monitor responses to therapy in rheumatoid arthritis.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Age | 2009 |
The effect of infliximab on antiviral antibody profiles in patients with rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, | 2010 |
A rare cause of multiple cavitary nodules.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Female; Humans; Middle Aged; Multiple Pulmonary Nod | 2009 |
The Chinese herbal remedy Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2009 |
Images in clinical medicine. Baker's cyst in a patient with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Male; Methotrexate; Middle Aged; Popliteal Cyst | 2009 |
Rheumatoid arthritis in patient with homozygous haemoglobin C disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Glucocorticoids; Hem | 2011 |
QuantiFERON-TB Gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Case-Control Studies; Enzyme-Linked Immunos | 2009 |
Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study.
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Birth Weight; Female; Gestational Age; Human | 2009 |
[Cutaneous infection due to Mycobacterium chelonae during anti-TNF therapy].
Topics: Adalimumab; Aged; Amoxicillin-Potassium Clavulanate Combination; Antibodies, Monoclonal; Antibodies, | 2009 |
Peritoneal tuberculosis complicated by immune reconstitution inflammatory syndrome in a patient treated with infliximab?: a case for adjuvant immunosuppressive therapy.
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Arthritis, Rheumatoid; Humans; Immune Recons | 2009 |
"MAC" attack.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Arthritis, Rheumatoid; Azithromycin; Drug Therapy, Combina | 2009 |
A 47-year-old woman with rheumatoid arthritis and dyspnea on exertion.
Topics: Arthritis, Rheumatoid; Diagnosis, Differential; Dyspnea; Female; Glucocorticoids; Humans; Lung; Midd | 2009 |
Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease.
Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Idiopathic Pul | 2010 |
A case of dermatomyositis with "liver disease associated with rheumatoid diseases" positive for anti-liver-kidney microsome-1 antibody.
Topics: Antibodies, Anti-Idiotypic; Arthritis, Rheumatoid; Comorbidity; Dermatomyositis; Female; Humans; Kid | 2010 |
Inflammatory gene profile in early rheumatoid arthritis and modulation by leflunomide and prednisone treatment.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Studies; Cells, Cultured; Dose-Resp | 2010 |
Effect of novel therapeutic glucocorticoids on circadian rhythms of hormones and cytokines in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Circadian Rhythm; Cytokines; Delayed-Action Prepara | 2010 |
An endocrinologist's view on relative adrenocortical insufficiency in rheumatoid arthritis.
Topics: Adrenal Glands; Adrenal Insufficiency; Adrenocorticotropic Hormone; Adult; Arthritis, Rheumatoid; Bo | 2010 |
Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Blood Glucose; Cross-Sectional Studies; Diabetes Mellit | 2010 |
A case of normal-pressure hydrocephalus associated with rheumatoid arthritis.
Topics: Activities of Daily Living; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumat | 2010 |
HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; C | 2011 |
Borreliosis in a patient treated with anti-TNFα therapy: first case.
Topics: Anti-Bacterial Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Doxycycline; Drug Therapy, Combi | 2011 |
Modified release prednisone in patients with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Circadian Rhythm; Delayed-Action Preparations; Gluc | 2010 |
Rheumatoid arthritis and renal light-chain deposition disease: long-term effectiveness of TNF-α blockade with etanercept.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combinati | 2011 |
Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Etanercept; Female; Humans; Immunoglobuli | 2011 |
Serum cystatin C level in patients with rheumatoid arthritis after single infusion of infliximab.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cystatin C; Drug Therapy | 2011 |
Are there patients with inflammatory disease who do not respond to prednisone?
Topics: Adult; Aged; Arthritis, Rheumatoid; Drug Administration Routes; Female; Glucocorticoids; Humans; Mal | 2010 |
A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab.
Topics: Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Infliximab; Leuko | 2010 |
Ask the doctor. I have rheumatoid arthritis, and my doctor wants me to take prednisone for it. Will this drug be bad for my blood pressure, which is already high?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Delayed-Action Preparations; Glucocorticoids; Health Kn | 2010 |
How to reduce morbidity and mortality from chest infections in rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Protocols; Female; Glucocorticoids; Gran | 2010 |
Painful, swollen hands in a young woman.
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Comorbidity; Diagnosis, Differential; Female | 2010 |
Iatrogenic oral hairy leukoplakia: report of two cases.
Topics: Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Antifungal Agents; Arthritis, Rheumatoid; Clo | 2011 |
Older age of rheumatoid arthritis onset is associated with higher activation status of peripheral blood CD4(+) T cells and disease activity.
Topics: Adult; Age of Onset; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antirheumatic Agents; Ar | 2011 |
Ultraviolet light-induced Köbner phenomenon contributes to the development of skin eruptions in multicentric reticulohistiocytosis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Dermatologic Agents; Female; Histiocytosis; Humans; | 2011 |
Increased levels of rheumatoid factors after TNF inhibitor in rheumatoid arthritis.
Topics: Adalimumab; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthri | 2012 |
Crusted Norwegian scabies, an opportunistic infection, with tocilizumab in rheumatoid arthritis.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Arthr | 2011 |
Tumour necrosis factor-α inhibitors are glucocorticoid-sparing in rheumatoid arthritis.
Topics: Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Glucocorticoids; Health Stat | 2011 |
How should impaired morning function in rheumatoid arthritis be treated?
Topics: Activities of Daily Living; Arthritis, Rheumatoid; Circadian Rhythm; Delayed-Action Preparations; Do | 2011 |
Palisaded neutrophilic and granulomatous dermatitis presenting in a patient with rheumatoid arthritis on adalimumab.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2011 |
Where in the world is oral triamcinolone?
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Circadian Rhythm; Color Therapy; Female; Humans; Hy | 2011 |
[Amyloid goiter secondary to rheumatoid arthritis. a case report].
Topics: Amyloidosis; Antirheumatic Agents; Arthritis, Rheumatoid; Deglutition Disorders; Dyspnea; Female; Ga | 2012 |
Rheumatoid meningitis occurring during adalimumab and methotrexate treatment.
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antirheumatic | 2012 |
Cutaneous hyphomycosis due to Paecilomyces lilacinus.
Topics: Anti-Inflammatory Agents; Antifungal Agents; Arthritis, Rheumatoid; Dermatomycoses; Drug Resistance, | 2012 |
Plasma leptin and neuropeptide Y concentrations in patients with rheumatoid arthritis treated with infliximab, a TNF-α antagonist.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; Drug Th | 2012 |
Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive | 2012 |
Response to traditional disease-modifying anti-rheumatic drugs in indigent South Africans with early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Drug Therapy, Combination; Fe | 2012 |
Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients.
Topics: Abatacept; Adalimumab; Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2012 |
Combination therapy including glucocorticoids: the new gold standard for early treatment in rheumatoid arthritis?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Glucocorticoids; Humans; Male; Methotrexate; Pr | 2012 |
Summaries for patients. Adding low-dose prednisone to methotrexate therapy for early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Glucoco | 2012 |
Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort.
Topics: Arthritis, Rheumatoid; Bone Density Conservation Agents; Calcium; Cohort Studies; Databases, Factual | 2012 |
Activity study of a hydroxynaphthoquinone fraction from Arnebia euchroma in experimental arthritis.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Experimental; Arthri | 2012 |
Nocardia neocaledoniensis [corrected] as a cause of skin and soft tissue infection.
Topics: Adenosine Triphosphatases; Aged; Anti-Bacterial Agents; Arthritis, Rheumatoid; Bacterial Proteins; B | 2012 |
Vasculitis associated with tumor necrosis factor-α inhibitors.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, H | 2012 |
[Prednisone for rheumatoid arthritis: the detriment of the doubt].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Evidence-Based Medicine; Glucocorticoids; Humans; Pract | 2012 |
Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Glucocorticoids; Humans; Male; Methotrexate; Pr | 2012 |
Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Glucocorticoids; Humans; Male; Methotrexate; Pr | 2012 |
A safety analysis of oral prednisone as a pretreatment for rituximab in rheumatoid arthritis.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Art | 2012 |
Chronic inflammation and low-dose glucocorticoid effects on glucose metabolism in premenopausal females with rheumatoid arthritis free of conventional metabolic risk factors.
Topics: Adult; Analysis of Variance; Arthritis, Rheumatoid; Biomarkers; Blood Glucose; C-Reactive Protein; C | 2013 |
Impact of modified-release prednisone on functional ability in patients with rheumatoid arthritis.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Arthritis, Rhe | 2013 |
Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day.
Topics: Academic Medical Centers; Ambulatory Care; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Database | 2013 |
Effective initial and long-term prednisone in doses of less than 5 mg/day to treat rheumatoid arthritis--documentation using a patient self-report Multidimensional Health Assessment Questionnaire (MDHAQ).
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Documentation; Health Status Indicators; Humans; Pr | 2012 |
T-cell lymphoma manifesting as a uvular mass.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Biopsy; Cyclophosphamide; Dox | 2013 |
Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Studies; Cholesterol, HDL; Cholester | 2013 |
Interleukin 6 blockade-associated weight gain with abdominal enlargement in a patient with rheumatoid arthritis.
Topics: Abdominal Pain; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Fe | 2013 |
Clonal T-LGL population mimicking leukemia in Felty's syndrome--part of a continuous spectrum of T-LGL proliferations?
Topics: Adult; Aged; Arthralgia; Arthritis, Rheumatoid; Bone Marrow; Diagnosis, Differential; Exons; Felty S | 2013 |
High rate of preterm birth in pregnancies complicated by rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Congenital Abnormalities; Female; Fetal Distress | 2014 |
Treatment of an edentulous patient with a dry mouth.
Topics: Adhesives; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Ag | 2000 |
Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis.
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; | 2002 |
Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antigens, CD; Arthritis, Rheumatoid; Case-Control | 2002 |
HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias.
Topics: Alleles; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Epit | 2002 |
Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis.
Topics: Acetylcholine; Administration, Oral; Anti-Inflammatory Agents; Apoproteins; Arthritis, Rheumatoid; E | 2002 |
The role of tumor necrosis factor inhibitors in patients with RA.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid | 2002 |
Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice.
Topics: Academic Medical Centers; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Clinical | 2002 |
Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Fema | 2003 |
Comparative effects of prednisone and cortisone.
Topics: Arthritis; Arthritis, Rheumatoid; Cortisone; Prednisone; Steroids | 1955 |
[Metacortandracin in therapy of rheumatic diseases; study of 38 cases].
Topics: Arthritis; Arthritis, Rheumatoid; Periarthritis; Prednisone; Rheumatic Diseases; Rheumatic Heart Dis | 1955 |
[Further study of the therapeutic use of prednisone (metacortandracin) and 9-alpha-fluorohydrocortisone].
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Fludrocortisone; Gout; Hu | 1955 |
Effects of aldosterone (electrocortin), 9-alpha-fluorohydrocortisone acetate, and 1-dehydrocortisone (metacortandracin) in rheumatoid arthritis.
Topics: Acetates; Adrenal Cortex; Adrenal Cortex Hormones; Aldosterone; Arthritis; Arthritis, Rheumatoid; Pr | 1955 |
[First clinical trials of prednisone (metacortandracin or metacorten)].
Topics: Arthritis; Arthritis, Rheumatoid; Asthma; Nephrosis; Prednisone; Steroids | 1955 |
Prednisone and prednisolone as therapeutic agents; progress report on their integration into general medical practice.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone; Prednisone; Research Report; Steroids | 1955 |
Prednisone and prednisolone in the treatment of rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone; Prednisone; Steroids | 1955 |
Prednisone in the treatment of rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone; Steroids | 1955 |
[Influence of meticorten on carbohydrate metabolism in a case of primary chronic polyarthritis with diabetes mellitus].
Topics: Arthritis; Arthritis, Rheumatoid; Carbohydrate Metabolism; Diabetes Complications; Diabetes Mellitus | 1955 |
[Comparative studies on the clinical activity of hydrocortisone with relation to prednisone].
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Hydrocortisone; Prednison | 1955 |
[Various aspects of my first tests of prednisone].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone; Steroids | 1955 |
Prednisone and prednisolone therapy in rheumatoid arthritis; clinical evaluation based on continuous observations for periods of six to nine months.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Prednisolone; Prednisone; | 1956 |
Prednisone and prednisolone as suppressive agents for rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone; Prednisone; Steroids | 1956 |
Clinical and metabolic effects of prednisone and prednisolone in rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone; Prednisone; Steroids | 1956 |
[Meticorten in rheumatoid arthritis, psoriasis and other allergic diseases and diseases of the collagen system].
Topics: Arthritis, Rheumatoid; Collagen; Collagen Diseases; Humans; Hypersensitivity; Prednisone; Psoriasis; | 1955 |
Metabolic effects of metacortandracin (prednisone) and metacortandralone (prednisone): comparison with ACTH, cortisone, hydrocortisone and 9-alphafluorohydrocortisone.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumato | 1956 |
Relatively long term therapy of Still's disease with prednisone (meticorten); case report.
Topics: Arthritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Prednisone; Steroids | 1956 |
Perforated duodenal ulcer complicating prednisone therapy.
Topics: Arthritis; Arthritis, Rheumatoid; Duodenal Ulcer; Humans; Peptic Ulcer Perforation; Prednisone; Ster | 1956 |
[Hydrocortisone and prednisone therapy of a case of Felty's syndrome].
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Felty Syndrome; Hydrocort | 1955 |
[Experience with prednisone in primary chronic polyarthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone; Steroids | 1956 |
[Prolonged treatment of chronic inflammatory rheumatism with cortisone and affiliated steroids (hydrocortisone and prednisone)].
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Arthritis, Rheumatoid; Cortisone; Hydrocortisone; Prednison | 1956 |
[Clinical observations on prednisone in primary chronic polyarthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone; Steroids | 1956 |
Rheumatoid arthritis complicated by severe ulcerative colitis, successfully treated with prednisone and Rauwolfia: a case history.
Topics: Arthritis; Arthritis, Rheumatoid; Colitis; Colitis, Ulcerative; Humans; Prednisone; Rauwolfia; Secol | 1956 |
[Histomorphological study of synovial inflammation in rheumatoid arthritis treated with prednisone].
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Inflammation; Prednisone; Steroids; Synovitis | 1956 |
[Clinical experience with decortisal in rheumatic joint diseases].
Topics: Antacids; Arthritis; Arthritis, Reactive; Arthritis, Rheumatoid; Ascorbic Acid; Aspirin; Prednisone; | 1956 |
[Clinical experience with decortisal in rheumatic joint diseases].
Topics: Antacids; Arthritis; Arthritis, Reactive; Arthritis, Rheumatoid; Ascorbic Acid; Aspirin; Prednisone; | 1956 |
[Clinical experience with decortisal in rheumatic joint diseases].
Topics: Antacids; Arthritis; Arthritis, Reactive; Arthritis, Rheumatoid; Ascorbic Acid; Aspirin; Prednisone; | 1956 |
[Clinical experience with decortisal in rheumatic joint diseases].
Topics: Antacids; Arthritis; Arthritis, Reactive; Arthritis, Rheumatoid; Ascorbic Acid; Aspirin; Prednisone; | 1956 |
[Treatment of rheumatoid arthritis with prednisone].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone | 1956 |
[Treatment of rheumatoid arthritis with prednisone].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone | 1956 |
[Treatment of rheumatoid arthritis with prednisone].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone | 1956 |
[Treatment of rheumatoid arthritis with prednisone].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone | 1956 |
[Considerations on the association of prednisone with ACTH in the treatment of rheumatoid arthritis].
Topics: Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Prednisone | 1956 |
[Considerations on the association of prednisone with ACTH in the treatment of rheumatoid arthritis].
Topics: Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Prednisone | 1956 |
[Considerations on the association of prednisone with ACTH in the treatment of rheumatoid arthritis].
Topics: Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Prednisone | 1956 |
[Considerations on the association of prednisone with ACTH in the treatment of rheumatoid arthritis].
Topics: Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Prednisone | 1956 |
[Prednisone in rheumatic diseases in childhood].
Topics: Arthritis; Arthritis, Rheumatoid; Child; Chorea; Humans; Infant; Prednisone; Rheumatic Diseases | 1956 |
[Prednisone in rheumatic diseases in childhood].
Topics: Arthritis; Arthritis, Rheumatoid; Child; Chorea; Humans; Infant; Prednisone; Rheumatic Diseases | 1956 |
[Prednisone in rheumatic diseases in childhood].
Topics: Arthritis; Arthritis, Rheumatoid; Child; Chorea; Humans; Infant; Prednisone; Rheumatic Diseases | 1956 |
[Prednisone in rheumatic diseases in childhood].
Topics: Arthritis; Arthritis, Rheumatoid; Child; Chorea; Humans; Infant; Prednisone; Rheumatic Diseases | 1956 |
[Role of metacortandracin in the treatment of chronic active arthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone | 1956 |
[Role of metacortandracin in the treatment of chronic active arthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone | 1956 |
[Role of metacortandracin in the treatment of chronic active arthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone | 1956 |
[Role of metacortandracin in the treatment of chronic active arthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone | 1956 |
[Experiences with prednisone treatment of chronic polyarthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Prednisone | 1956 |
[Experiences with prednisone treatment of chronic polyarthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Prednisone | 1956 |
[Experiences with prednisone treatment of chronic polyarthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Prednisone | 1956 |
[Experiences with prednisone treatment of chronic polyarthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Prednisone | 1956 |
The metabolic effects of prednisone in patients with rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone | 1956 |
The metabolic effects of prednisone in patients with rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone | 1956 |
The metabolic effects of prednisone in patients with rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone | 1956 |
The metabolic effects of prednisone in patients with rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone | 1956 |
[Changes in prognosis of rheumatic disease in children after introduction of new hormones in therapy (hydrocortisone, prednisone, prednisolone); clinical and biological study of 25 treated cases].
Topics: Arthritis; Arthritis, Rheumatoid; Child; Humans; Hydrocortisone; Infant; Prednisolone; Prednisone; P | 1956 |
Prednisone and prednisolone in rheumatoid arthritis; an evaluation of their therapeutic efficiency.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Prednisolone; Prednisone | 1957 |
[Palliative therapy in rheumatic diseases in general praxis].
Topics: Aminopyrine; Arthritis; Arthritis, Rheumatoid; Humans; Palliative Care; Prednisone; Rheumatic Diseas | 1957 |
Delta-cortisone in chronic progressive polyarthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone | 1957 |
Effect of moist heat therapy and prednisone in the treatment of rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Hot Temperature; Humans; Hyperthermia, Induced; Pain Management; P | 1957 |
The effect of isoniazid and of iproniazid in patients with rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Cortisone; Iproniazid; Isomerism; Isoniazid; Niacin; Nicotinic Aci | 1957 |
Observations on new synthetic antirheumatic steroids and critical evaluation of prednisone therapy in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Fludrocortisone; Prednisone; Steroids | 1957 |
Massive gastrointestinal hemorrhage during prednisteroid therapy for rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Gastrointestinal Hemorrhage; Gastrointestinal Tract; Hemorrhage; H | 1957 |
Changes in serum sulfhydryl and serum glycoprotein in rheumatoid arthritis during treatment with adrenocortical steroids.
Topics: Arthritis; Arthritis, Rheumatoid; Cortisone; Glycoproteins; Humans; Prednisone; Sulfhydryl Compounds | 1957 |
[Use of delta cortisone in the treatment of progressive inflammatory rheumatism or chronic evolutive polyarthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Prednisone; Rheumatic Fever | 1957 |
A comparison of the effects of cortisone and prednisone in rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Cortisone; Prednisone | 1957 |
[Main complications of protracted prednisone therapy of rheumatoid arthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Prednisone | 1957 |
Prednisone and prednisolone in the management of rheumatoid arthritis; observations during the past 16 months.
Topics: Arthritis; Arthritis, Rheumatoid; Disease Management; Humans; Prednisolone; Prednisone | 1957 |
[Symptomatology & therapy of amyloidosis in chronic polyarthritis].
Topics: Amyloidosis; Arthritis; Arthritis, Rheumatoid; Gonadal Steroid Hormones; Humans; Prednisone; Sjogren | 1957 |
A COMPARISON of cortisone and prednisone in treatment of rheumatoid arthritis; a report by the Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone, ACTH and other therapeutic measures in chronic rheumati
Topics: Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Biomedical Research; Cortisone; Predn | 1957 |
Perforation of gall-bladder during prednisone treatment.
Topics: Amyloidosis; Arthritis; Arthritis, Rheumatoid; Gallbladder; Gallbladder Diseases; Humans; Prednisone | 1957 |
[Treatment of rheumatic diseases with prednisone].
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Lupus Erythematosus, Systemic; Prednisone; Rheumatic Disea | 1957 |
Prednisone alone and in combination with salicylates and phenylbutazone in the treatment of rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Aspirin; Humans; Phenylbutazone; Prednisone; Salicylates | 1957 |
[Local & intraarticular treatment of periosteal & tendinous irritations as well as arthrosis deformans with prednisone & prednisolone].
Topics: Arthritis; Arthritis, Rheumatoid; Periarthritis; Prednisolone; Prednisone; Tenosynovitis | 1957 |
The effect of corticosteroid administration upon blood histamine content.
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Asthma; Eosinophilia; Histamine; Humans; | 1957 |
Prednisone and prednisolone therapy in rheumatoid arthritis; clinical evaluation, with emphasis on gastrointestinal manifestations in one hundred fifty-six patients observed for periods of four to fourteen months.
Topics: Arthritis; Arthritis, Rheumatoid; Gastrointestinal Diseases; Peptic Ulcer; Prednisolone; Prednisone | 1957 |
Prolonged treatment of rheumatoid arthritis with prednisone (meticorten).
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone | 1957 |
[Local and intravenous prednisolone (decortin H) therapy].
Topics: Arthritis; Arthritis, Rheumatoid; Asthma; Dermatitis; Dermatitis, Contact; Humans; Hypersensitivity; | 1957 |
Hyperglobulinaemia in rheumatoid arthritis; its relationship with disease activity and its changes under adrenocortical treatment.
Topics: Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Cortisone; gamma-Globulins; Humans; M | 1957 |
Salicylates, glucocorticoids and salicylate-glucocorticoid combinations in the treatment of rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Glucocorticoids; Humans; Prednisolone; Prednisone; Salicylates | 1957 |
[Serochemical studies in chronic polyarthritis treated with butazolidine (phenylbutazone) & prednisone].
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Phenylbutazone; Prednisone; Research | 1957 |
Some observations on the clinical use of prednisone in rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone | 1957 |
Two years' experience of prednisone in rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone | 1957 |
[Thoughts on the so-called combined medicinal therapy of rheumatoid arthritis, with special reference to a goldhormone combination].
Topics: Arthritis; Arthritis, Rheumatoid; Aspirin; Gold; Humans; Prednisone | 1957 |
[Therapeutic effect of prednisone-salicylamide-ascorbic acid combination (prednicyl) in rheumatic polyarthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Ascorbic Acid; Humans; Prednisone; Salicylamides; Vitamins | 1957 |
[Practical management of delta-cortisone therapy in chronic inflammatory rheumatism].
Topics: Arthritis, Rheumatoid; Prednisone; Rheumatic Diseases; Rheumatic Fever | 1957 |
[Delta-Cortisone and peptic ulcers].
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Peptic Ulcer; Prednisone; Tuberculosis; Tuberculosis, Pulm | 1957 |
[Case of Still's disease treated with ultracorten].
Topics: Arthritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Child; Humans; Infant; Prednisone | 1957 |
[Treatment of various rheumatic diseases with delta 1-dehydrocortisone (prednisone, metacortandracin)].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone; Rheumatic Diseases | 1957 |
Prednisone and prednisolone in the treatment of rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Prednisolone; Prednisone | 1957 |
X-ray manifestations of peptic ulceration during corticosteroid therapy of rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Humans; Peptic Ulcer; Prednisone; X-Rays | 1958 |
Subcutaneous haemorrhages in rheumatoid patients treated with prednisone.
Topics: Arthritis; Arthritis, Rheumatoid; Hemorrhage; Humans; Prednisone | 1958 |
[Chronic progressive polyarthritis with a surgical problem during its development].
Topics: Arthritis; Arthritis, Rheumatoid; Cholelithiasis; Humans; Medical Records; Peptic Ulcer; Prednisone | 1957 |
[Treatment of Still's disease by delta cortisone].
Topics: Arthritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Child; Humans; Infant; Prednisone | 1958 |
[The Felty syndrome, its pathogenesis & therapy].
Topics: Arthritis; Arthritis, Rheumatoid; Felty Syndrome; Humans; Prednisone | 1958 |
[Possibilities, problems & technic of protracted or permanent treatment of progressive chronic polyarthritis with prednisone].
Topics: Arthritis; Arthritis, Rheumatoid; Dental Care; Humans; Prednisone | 1958 |
On the development of peptic ulcers in patients treated with prednisone or prednisolone.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Peptic Ulcer; Prednisolone; Prednisone | 1958 |
[Sodium metabolism in prednisone treatment].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone; Sodium | 1958 |
Prednisone in rheumatoid arthritis: metabolic and clinical effects.
Topics: Arthritis; Arthritis, Rheumatoid; Cortisone; Hydrocortisone; Prednisone | 1958 |
[Prolonged therapy of chronic rheumatism with a butazolidin-prednisone preparation].
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Phenylbutazone; Prednisone; Rheumatic Diseases | 1958 |
[Cortico-salicylic therapy of chronic rheumatic diseases].
Topics: Arthritis; Arthritis, Rheumatoid; Aspirin; Humans; Prednisone; Rheumatic Diseases; Salicylic Acid | 1958 |
Effectiveness of antacids in reducing digestive disturbances in patients treated with prednisone and prednisolone.
Topics: Aluminum Hydroxide; Antacids; Arthritis, Rheumatoid; Gastrointestinal Diseases; Humans; Prednisolone | 1958 |
[Serochemical tests in chronic polyarthritis treated with phenylbutazone & prednisone].
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Phenylbutazone; Prednisone | 1958 |
Peptic ulcer during treatment of rheumatoid arthritis with cortisone derivatives.
Topics: Arthritis; Arthritis, Rheumatoid; Cortisone; Humans; Peptic Ulcer; Prednisolone; Prednisone | 1958 |
Gastric ulcer during steroid therapy in a patient with persistent achlorhydria: effects of antirheumatic medication.
Topics: Achlorhydria; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Gastric Juice; Humans; Medical | 1958 |
[Efficacy of steroids in rheumatoid arthritis; prednisone, prednisolone-cortisone & hydrocortisone].
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Cortisone; Hydrocortisone; Prednisolone; | 1958 |
[Effects of the new anabolic 19-norsteroids; metabolic studies on combined prednisone & anabolic steroid treatment of chronic polyarthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Combined Modality Therapy; Health Services; Norsteroids; Prednison | 1958 |
Leonisone (601); a new anti-rheumatoid therapy.
Topics: Antacids; Arthritis; Arthritis, Rheumatoid; Phenylbutazone; Prednisone | 1959 |
[Adrenal steroid therapy of rheumatoid arthritis: collagen deterioration].
Topics: Arthritis; Arthritis, Rheumatoid; Collagen; Lupus Erythematosus, Systemic; Prednisone | 1959 |
Drug evaluation in rheumatoid arthritis; a comparative study of aspirin, phenylbutazone, cortisone, prednisone.
Topics: Arthritis; Arthritis, Rheumatoid; Aspirin; Cortisone; Drug Evaluation; Humans; Phenylbutazone; Predn | 1959 |
[Study of attacks of tetany and psychological disorders appearing during adrenal cortex hormone therapy: attacks of tetany and grave psychoses initiated by substitution of delta-cortisone for hydrocortisone and subsequently by ACTH].
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumato | 1958 |
Long-term use of prednisone and prednisolone in juvenile rheumatoid arthritis; a report of fifteen cases.
Topics: Arthritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Humans; Prednisolone; Prednisone | 1959 |
[Comparative studies on the effects of hexadecadrol & prednisone in the treatment of chronic rheumatism].
Topics: Arthritis; Arthritis, Rheumatoid; Dexamethasone; Prednisolone; Prednisone; Rheumatic Diseases | 1959 |
[Combined phenylbutazone and prednisone in therapy of rheumatic diseases and bronchial asthma].
Topics: Arthritis; Arthritis, Rheumatoid; Asthma; Humans; Phenylbutazone; Prednisone; Rheumatic Diseases; Rh | 1959 |
[Synergistic effects of isoniazid & prednisone in rheumatoid arthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Isoniazid; Prednisone | 1959 |
Corticosteroid therapy in rheumatoid arthritis; comparative study of effects of prednisone and prednisolone, methylprednisolone, triamcinolone, and dexamethasone.
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Dexamethasone; Humans; Methylprednisolone | 1959 |
[Report on experiences with elestol therapy of rheumatic syndromes].
Topics: Arthritis; Arthritis, Rheumatoid; Aspirin; Chloroquine; Humans; Prednisone; Spondylitis; Spondylitis | 1959 |
[Rational combination therapy of polyarthritis & arthrosis with delat-butazolidine].
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Joint Diseases; Osteoarthritis; Phenylbutazone; Prednisone | 1959 |
[Elastol in chronic polyarthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Aspirin; Chloroquine; Humans; Prednisone | 1959 |
Psoriatic erythroderma, rheumatoid arthritis, and death, as a sequence to a drug reaction.
Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Dermatitis, Exfoliative; Humans; Hypersensitivity; Me | 1961 |
[Comparative study of the clinical and metabolic effects of prednosteroids and corticofluorates in rheumatoid arthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone; Prednisone; Triamcinolone | 1961 |
Low dosage adrenocorticosteroid maintenance therapy of rheumatoid arthritis: icidence of peptic ulcer and osteoporosis.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Osteoporosis; Peptic Ulcer; Prednisone | 1961 |
[Balneological-hormonal combined therapy of polyarthritis chronica progressiva].
Topics: Arthritis; Arthritis, Rheumatoid; Balneology; Humans; Prednisone | 1960 |
The metabolic effect of new anabolic 19-nor-steroids. Metabolic studies on patients with chronic rheumatoid arthritis during combined therapy with prednisone and anabolic steroid.
Topics: Arthritis, Rheumatoid; Health Services; Prednisone; Steroids; Testosterone; Testosterone Congeners | 1959 |
A method of drug evaluation in rheumatoid arthritis: results with phenylbutazone, oxyphenylbutazone, cortisone, and prednisone.
Topics: Arthritis, Rheumatoid; Cortisone; Drug Evaluation; Oxyphenbutazone; Phenylbutazone; Prednisone | 1960 |
[Our experience with the association of butazolidine and prednisone (delta-butazolidine) in the rheumatological clinic].
Topics: Arthritis; Arthritis, Rheumatoid; Gout; Humans; Periarthritis; Phenylbutazone; Prednisone; Rheumatic | 1962 |
Clinical comparison of the newer anti-inflammatory corticosteroids.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Arthritis; Arthritis, Rheumatoid; Glucocorticoids | 1962 |
[A case report contribution to the subject of prednisone injury].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone | 1961 |
[Vertebral rheumatism. Comparative therapeutic, value of corticosteroids, phenylbutazone and the combination of butazolidine and prednisone].
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Humans; Intervertebral Disc Displacement; Osteoarthr | 1963 |
[Vertebral rheumatism. Comparative therapeutic value of corticosteroids, phenylbutazone and the association of butazolidine and prednisone].
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Humans; Phenylbutazone; Prednisone; Rheum | 1963 |
[Vertebral rheumatisms. Comparative therapeutic value of corticoids, phenylbutazone, and combined butazolidine and prednisone].
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Humans; Intervertebral Disc Displacement; Osteoarthr | 1963 |
[Ulcerogenic effect of steroid treatment in rheumatoid arthrits].
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Peptic Ulcer; Prednisone | 1962 |
[Immunologic determination of ACTH in the venous blood of man in some pathologic situations].
Topics: Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Dexamethasone; Hyperthyroidism; Immun | 1963 |
[Treatment of primary chronic arthritis (rheumatoid arthritis) with the combination of a pyrazol derivative and a steroid].
Topics: Arthritis; Arthritis, Gouty; Arthritis, Rheumatoid; Humans; Phenylbutazone; Prednisone; Pyrazoles | 1963 |
Long-term treatment with corticosteroids in rheumatoid arthritis (over a period of 9 to 12 years).
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Cortisone; Glucocorticoids; Humans; Predn | 1963 |
Some experiences with gold salts.
Topics: Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Blood Proteins; Gold; Prednisone; Salts | 1963 |
[Nephrotic syndrome after sanocrysin therapy].
Topics: Arthritis; Arthritis, Rheumatoid; Gold; Humans; Nephrotic Syndrome; Prednisone; Sodium; Sodium, Diet | 1962 |
RHEUMATOID ARTHRITIS AND ARTERITIS.
Topics: Adrenocorticotropic Hormone; Arteritis; Arthritis; Arthritis, Rheumatoid; Biopsy; Cortisone; Dexamet | 1963 |
COMBINATION OF CHLOROQUINE, PREDNISONE AND ASPIRIN IN THE TREATMENT OF ARTICULAR AND NON-ARTICULAR RHEUMATISM, AND LOW BACK PAIN AND SCIATICA.
Topics: Arthritis; Arthritis, Rheumatoid; Aspirin; Chloroquine; Humans; Intervertebral Disc Displacement; Jo | 1963 |
[COMBINED CHLOROQUINE, ASPIRIN AND PREDNISONE THERAPY OF PROGRESSIVE CHRONIC RHEUMATISM].
Topics: Arthritis; Arthritis, Rheumatoid; Aspirin; Chloroquine; Humans; Prednisone; Rheumatic Diseases | 1963 |
[CONSIDERATIONS ON THE MECHANISM OF ACTION OF GLUCOCORTICOID SUBSTANCES IN CASES OF INFECTIOUS ALLERGY].
Topics: Arthritis; Arthritis, Rheumatoid; Blood Sedimentation; Communicable Diseases; Enteritis; Glomerulone | 1963 |
THE OCCURRENCE OF POSTERIOR SUBCAPSULAR CATARACTS IN PATIENTS ON LONG-TERM SYSTEMIC CORTICOSTEROID THERAPY.
Topics: Addison Disease; Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Asthma; Breast Neoplasms | 1963 |
THE ESTIMATION OF MEAN POTENTIAL DURATION IN ENDOCRINE MYOPATHY.
Topics: Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Cushing Syndrome; Electrophysiology; | 1963 |
TREATMENT OF OSTEOPOROSIS WITH AN ANABOLIC COMPOUND AND L-LYSINE.
Topics: Amino Acids; Anabolic Agents; Appetite; Arthritis; Arthritis, Rheumatoid; Dietary Proteins; Emotions | 1963 |
[THE ALGOGENIC RECEPTIVITY OF MUSCLE IN VARIOUS PHYSIOLOGICAL AND PATHOLOGICAL CONDITIONS. III. ACTION OF PREDNISONE, ACETYLSALICYLIC ACID AND PHENYLBUTAZONE ON THE PERCEPTION OF MUSCULAR PAIN IN THE NORMAL SUBJECT AND IN THE RHEUMATIC SUBJECT].
Topics: Arthritis; Arthritis, Rheumatoid; Aspirin; Hyperesthesia; Muscles; Myalgia; Pain; Perception; Pharma | 1963 |
STEROID THERAPY IN COMMON RHEUMATIC DISEASES.
Topics: Arthritis; Arthritis, Rheumatoid; Aspirin; Hydrocortisone; Phenylbutazone; Prednisone; Procaine; Rhe | 1963 |
[TREATMENT OF COLLAGEN DISEASES].
Topics: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases; Chloroquine; Collagen Diseases; Dermatomyosit | 1963 |
THE ADRENAL CORTEX IN RHEUMATOID ARTHRITIS, RHEUMATIC FEVER, AND RHEUMATIC HEART DISEASE (A PRELIMINARY REPORT).
Topics: Adrenal Cortex; Adrenal Glands; Arthritis; Arthritis, Rheumatoid; Cortisone; Humans; Kidney Diseases | 1962 |
[POLYNEURITIS AND ARTERITIS IN RHEUMATOID ARTHRITIS].
Topics: Arteritis; Arthritis; Arthritis, Rheumatoid; Humans; Necrosis; Neuritis; Prednisone; Toxicology | 1963 |
[PHARMACOLOGY AND CHRONIC INFLAMMATIONS].
Topics: Arthritis; Arthritis, Rheumatoid; Drug Therapy; Granuloma; Hydroxychloroquine; Inflammation; Iodides | 1963 |
CORTICOSTEROID OSTEOPOROSIS AND TREATMENT WITH ANABOLIC HORMONE.
Topics: Adrenal Cortex Hormones; Anabolic Agents; Arthritis; Arthritis, Rheumatoid; Hormones; Osteoporosis; | 1963 |
DISSEMINATED COCCIDIOIDOMYCOSIS OCCURRENCE IN PATIENT RECEIVING STEROID THERAPY FOR RHEUMATOID ARTHRITIS--CASE REPORT.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Coccidioidom | 1963 |
[UNUSUAL OR RECENTLY DESCRIBED COMPLICATIONS OF CORTICOTHERAPY. II].
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Bone Diseases; Cortisone; Polyarteritis N | 1963 |
[TRANSARTICULAR CORTICOTHERAPY AND CHRONIC INFLAMMATORY RHEUMATISM].
Topics: Administration, Topical; Arthritis, Rheumatoid; Betamethasone; Humans; Hydrocortisone; Methylprednis | 1963 |
EFFECT OF CORTICOSTEROID THERAPY ON FIBRINOLYSIS IN PATIENTS WITH INFLAMMATORY AND NON-INFLAMMATORY CONDITIONS.
Topics: Addison Disease; Adenoma; Adenoma, Chromophobe; Adrenocorticotropic Hormone; Anemia; Anemia, Aplasti | 1964 |
[CURRENT ASPECTS OF THE TREATMENT OF RHEUMATOID ARTHRITIS].
Topics: Adrenal Cortex Hormones; Antimalarials; Arthritis; Arthritis, Rheumatoid; Aspirin; Gold; Humans; Phy | 1963 |
DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF SERUM ENZYMES. II. NEUROLOGIC DISEASES OTHER THAN MUSCULAR DYSTROPHY.
Topics: Adenosine Triphosphatases; Alanine Transaminase; Arthritis; Arthritis, Rheumatoid; Aspartate Aminotr | 1964 |
NONSPECIFIC ANTI-INFLAMMATORY AGENTS. SOME NOTES ON THEIR PRACTICAL APPLICATION, ESPECIALLY IN RHEUMATIC DISORDERS.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Arthritis; Arthritis, Rheumatoid; Betamethasone; | 1964 |
GLAUCOMA AND POSTERIOR SUBCAPSULAR CATARACT FOLLOWING TOPICAL PREDNISOLONE (ULTRACORTENOL) THERAPY.
Topics: Administration, Topical; Adolescent; Arthritis; Arthritis, Rheumatoid; Cataract; Glaucoma; Humans; K | 1964 |
OFFICE MANAGEMENT OF RHEUMATOID ARTHRITIS.
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Gold; Methylprednisolone; Office Manageme | 1964 |
[SOME EXPERIENCES WITH THE TREATMENT OF RHEUMATOID ARTHRITIS IN CHILDREN].
Topics: Adrenal Cortex Hormones; Aminopyrine; Arthritis; Arthritis, Rheumatoid; Child; Chloroquine; Cortison | 1963 |
CLINICAL TRIALS WITH TRIAMCINOLONE ACETONIDE IN THE TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS. PRELIMINARY REPORT.
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Biomedical Research; Injections, Intramus | 1964 |
PRESENT-DAY MANAGEMENT OF RHEUMATOID ARTHRITIS.
Topics: Anemia; Arthritis; Arthritis, Rheumatoid; Climate; Diet; Diet Therapy; Exercise Therapy; Gold; Hot T | 1964 |
DIFFUSE PULMONARY GRANULOMATOSES AND FIBROSES.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Beryllium; C | 1964 |
[ON THE USE OF HORMONAL PREPARATIONS IN COMBINED TREATMENT OF INFECTIOUS NONSPECIFIC POLYARTHRITIS IN CHILDREN].
Topics: Adolescent; Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Child; Chloroquine; Corti | 1963 |
[ON TREATMENT OF INFECTIOUS NON-SPECIFIC POLYARTHRITIS WITH PREDNISONE COMBINED WITH PYRAZOLIDINE].
Topics: Arthritis; Arthritis, Rheumatoid; Drug Therapy; Prednisone; Pyrazoles; Toxicology | 1964 |
STUDIES ON MOTOR NERVE CONDUCTION IN RHEUMATOID ARTHRITIS.
Topics: Arthritis; Arthritis, Rheumatoid; Electric Stimulation; Electromyography; Electrophysiology; Humans; | 1964 |
[SOME MANIFESTATIONS OF RHEUMATOID DISEASE FREQUENTLY NOT RECOGNIZED OR APPRECIATED].
Topics: Arthritis; Arthritis, Rheumatoid; Cervical Vertebrae; Cortisone; Deglutition Disorders; Hoarseness; | 1964 |
BILATERAL POPLITEAL CYSTS IN A PATIENT WITH RHEUMATOID ARTHRITIS.
Topics: Arthritis; Arthritis, Rheumatoid; Cervical Vertebrae; Cysts; Drug Therapy; Elbow; Elbow Joint; Human | 1964 |
[CHRONIC POLYARTHRITIS].
Topics: Arthritis; Arthritis, Rheumatoid; Diagnosis, Differential; Humans; Pathology; Phenylbutazone; Predni | 1964 |
[RHEUMATOID ARTHRITIS IN INFANCY].
Topics: Adolescent; Arthritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Child; Chloroquine; Clinical Labo | 1964 |
[ADRENAL RESPONSE TO ACTH FOLLOWING PROLONGED TREATMENT WITH PREDNISONE].
Topics: 17-Hydroxycorticosteroids; Adrenal Glands; Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheuma | 1964 |
[THE LONG-TERM EFFECTS OF CORTICOTHERAPY AND CORTICO-DEPENDENCE DURING CHRONIC EVOLUTIVE POLYARTHRITIS].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone; Time; Toxicology | 1964 |
EFFECT OF CORTICOSTEROIDS ON URINARY 5-BETA AND 5-ALPHA C19 STEROIDS IN MAN.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Androsterone; Arthritis; Arth | 1964 |
CORTICOSTEROID THERAPY IN RHEUMATOID ARTHRITIS. CRITERIA AND RESULTS.
Topics: Arthritis; Arthritis, Rheumatoid; Corticosterone; Dosage Forms; Drug Therapy; Fractures, Bone; Geria | 1964 |
[REFLECTIONS ON THE USE OF A CORTICOID-ASPIRIN-ANTIMALARIAL COMBINATION].
Topics: Adrenal Cortex Hormones; Amodiaquine; Antimalarials; Arthritis; Arthritis, Rheumatoid; Aspirin; Huma | 1964 |
[THE DELTACORTISONE-PHENYLBUTAZONE COMBINATION IN RHEUMATOLOGY. (APROPOS OF 80 CASES)].
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Phenylbutazone; Prednisone; Rheumatic Diseases; Rheumatolo | 1964 |
THE SIDE-EFFECTS OF CORTICOSTEROIDS.
Topics: Adrenal Cortex Hormones; Adrenal Gland Diseases; Arthritis; Arthritis, Rheumatoid; Dosage Forms; Fra | 1964 |
[CLINICAL ASPECTS AND THERAPY OF STEROID DIABETES].
Topics: Adrenal Cortex Hormones; Adrenal Gland Neoplasms; Adrenocorticotropic Hormone; Arthritis; Arthritis, | 1964 |
[STUDIES ON THE DOSE-EFFECT RELATIONSHIP OF VARIOUS CORTICOSTEROID DERIVATIVES].
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Biomedical Research; Dexamethasone; Drug | 1964 |
CLINICAL TEST OF INDOMETHACIN.
Topics: Analgesics; Analgesics, Non-Narcotic; Antimalarials; Antipyretics; Arthritis; Arthritis, Rheumatoid; | 1964 |
CONSTRICTIVE PERICARDITIS IN ASSOCIATION WITH RHEUMATOID ARTHRITIS.
Topics: Arthritis; Arthritis, Rheumatoid; Cardiac Surgical Procedures; Humans; Isoniazid; Pathology; Pericar | 1964 |
[MULTIPLE RETICULOHISTIOCYTOMA OF THE SKIN IN JOINT DISEASES].
Topics: Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Drug Therapy; Genetic Diseases, X-Lin | 1964 |
PHENFORMIN IN RHEUMATOID ARTHRITIS. A FIBRINOLYTIC APPROACH.
Topics: Arthritis; Arthritis, Rheumatoid; Biomedical Research; Blood Coagulation Tests; Blood Sedimentation; | 1965 |
[VISCERAL LUPUS ERYTHEMATOSUS AND TUBERCULOSIS].
Topics: Antitubercular Agents; Arthritis; Arthritis, Rheumatoid; Drug Therapy; Humans; Lupus Erythematosus, | 1964 |
[TREATMENT OF ACUTE RHEUMATOID ARTHRITIS IN ADULTS].
Topics: Arthritis; Arthritis, Rheumatoid; Drug Therapy; Israel; Prednisone; Salicylates; Toxicology | 1964 |
[DAMAGE DUE TO LONG-TERM THERAPY. 1. ANTIRHEUMATIC AGENTS].
Topics: Adrenal Cortex Hormones; Aminopyrine; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Chloro | 1964 |
CARE OF THE HAND IN RHEUMATOID ARTHRITIS.
Topics: Arthritis; Arthritis, Rheumatoid; Exercise Therapy; Hand Deformities; Humans; Prednisone; Splints; S | 1965 |
[SHARP INCREASE IN THE INCIDENCE OF PERIARTERIITIS NODOSA].
Topics: Arthritis; Arthritis, Rheumatoid; Drug Therapy; Epidemiology; Incidence; Methylprednisolone; Patholo | 1965 |
TREATMENT OF COMPLICATIONS OF GASTRODUODENAL "STEROID ULCERS".
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumato | 1965 |
PERIPHERAL NEUROPATHY IN RHEUMATOID ARTHRITIS.
Topics: Agglutination; Angiography; Arteritis; Arthritis; Arthritis, Rheumatoid; Brachial Artery; Classifica | 1965 |
[RHEUMATOID ARTHRITIS TREATED WITH BETAMETHASONE (CELESTONE). A CLINICAL TRIAL OF SHORTER DURATION].
Topics: Arthritis; Arthritis, Rheumatoid; Betamethasone; Drug Therapy; Humans; Prednisone; Time Factors | 1964 |
PERIOSTITIS DUE TO GIANT-CELL ARTERITIS.
Topics: Arteritis; Arthritis; Arthritis, Rheumatoid; Diagnosis, Differential; Drug Therapy; Geriatrics; Gian | 1965 |
CHILD CARE IN GENERAL PRACTICE. RHEUMATIC FEVER AND RHEUMATOID ARTHRITIS.
Topics: Adolescent; Arthritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Child; Child Care; Chloroquine; D | 1965 |
CLINICAL TRIAL WITH DELTA-BUTAZOLIDIN IN RHEUMATOID ARTHRITIS.
Topics: Arthritis; Arthritis, Rheumatoid; Biomedical Research; Drug Therapy; Phenylbutazone; Prednisone; Tox | 1965 |
PEPTIC ULCER AND RHEUMATOID ARTHRITIS: A PROSPECTIVE STUDY.
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Drug Therapy; Peptic Ulcer; Prednisone; P | 1965 |
THE PRESENT STATUS OF STEROID TREATMENT IN RHEUMATOID ARTHRITIS.
Topics: Adolescent; Arthritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Child; Drug Therapy; Humans; Pred | 1965 |
The clinical evaluation of meticorten in rheumatoid arthritis and allied conditions.
Topics: Arthritis; Arthritis, Rheumatoid; Arylsulfonates; Prednisone; Steroids | 1955 |
Effects of prednisone (meticorten) on manifestations of rheumatoid arthritis; report of early clinical observations.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisone; Steroids | 1955 |
Major undesirable side-effects resulting from prednisolone and prednisone.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone; Prednisone; Steroids | 1955 |
Metacortandracin and delta 1 dehydro-hydrocortisone in rheumatoid arthritis.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Arthritis, Rheumatoid; Hydrocortisone; Prednisone; Steroids | 1955 |
[Adrenal cortex hormones in combination with pyrazolone derivatives in the treatment of juvenile rheumatoid arthritis, rheumatoid arthritis and spondylitis ankylopoetica].
Topics: Adrenal Cortex Hormones; Arthritis, Juvenile; Arthritis, Rheumatoid; Phenylbutazone; Prednisone; Spo | 1959 |
[Clinical trial of a combination of chloroquine, prednisone and aspirin in rheumatoid arthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Aspirin; Chloroquine; Prednisone | 1962 |
The effect of low-dose prednisone on bone mineral density in Peruvian rheumatoid arthritis patients.
Topics: Adrenal Cortex Hormones; Adult; Arthritis, Rheumatoid; Bone Density; Female; Humans; Male; Middle Ag | 2005 |
Articular, B-cell, non-Hodgkin's lymphoma mimicking rheumatoid arthritis: synovial involvement in a small hand joint.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Infectious; Arthritis, Rheumatoid; | 2004 |
The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Colchici | 2003 |
Intractable pain in a rheumatoid wrist.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Fema | 2003 |
[Diagnostic image (176). A man with a black thumb. Necrosis of the thumb as a symptom of rheumatoid vasculitis].
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Humans; Male; Necrosis; Prednisone; | 2004 |
Glucocorticoids and insulin sensitivity in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Female; Glucocorticoids; Humans; Hyperinsulinism; Ma | 2004 |
Papillary muscle rupture complicating chronic steroid therapy.
Topics: Arthritis, Rheumatoid; Emergency Medicine; Glucocorticoids; Heart Rupture, Post-Infarction; Humans; | 2004 |
Cavitating pneumonia after treatment with infliximab and prednisone.
Topics: Antibodies, Monoclonal; Arthritis, Rheumatoid; Cryptococcosis; Female; Fluconazole; Follow-Up Studie | 2004 |
Disseminated histoplasmosis presenting as pancytopenia in a methotrexate-treated patient.
Topics: Aged; Arthritis, Rheumatoid; Diagnosis, Differential; Histoplasma; Histoplasmosis; Humans; Male; Met | 2004 |
Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Case Management; Cohort Studies; Femal | 2004 |
Palisaded neutrophilic and granulomatous dermatitis: an unusual cutaneous manifestation of immune-mediated disorders.
Topics: Adult; Arthritis, Rheumatoid; Dapsone; Dermatitis; Drug Therapy, Combination; Female; Granuloma; Hum | 2004 |
Multicentric reticulohistiocytosis associated with rheumatoid arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biopsy, Needle; Diagnosis, Dif | 2005 |
Bullous rheumatoid neutrophilic dermatosis.
Topics: Aged; Arthritis, Rheumatoid; Dermatitis Herpetiformis; Diagnosis, Differential; Etanercept; Female; | 2005 |
Type III cryoglobulinemia complicated by renal cortical necrosis.
Topics: Arthritis, Rheumatoid; Biopsy; Combined Modality Therapy; Cryoglobulinemia; Cyclophosphamide; Drug T | 2005 |
Practice patterns in patients at risk for glucocorticoid-induced osteoporosis.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Asthma; Bone De | 2005 |
Rheumatoid pleural effusion in the absence of arthritic disease.
Topics: Aged; Arthritis, Rheumatoid; Female; Glucocorticoids; Humans; Pleural Effusion; Prednisone; Radiogra | 2005 |
Cutaneous vasculitis associated with infliximab in the treatment of rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Follow-Up Studies; Gluc | 2005 |
Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Carcinoma, Basal Cell; | 2005 |
A 24-year-old woman with bilateral pulmonary infiltrates, pericardial effusion, and bilateral pleural effusions.
Topics: Adult; Arthritis, Rheumatoid; Biopsy, Needle; Bronchoalveolar Lavage; Cryptogenic Organizing Pneumon | 2005 |
Retrospective review of the clinical manifestations and outcomes in Puerto Ricans with idiopathic inflammatory myopathies.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Antibodies, Antinuclear; Arthritis, Rheumatoid; Biopsy; | 2005 |
Early rheumatoid arthritis treatments weighed.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Huma | 2005 |
Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agen | 2006 |
Treatment of recurrent Sweet's syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept.
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Comorbidity; Etanercept; Female; Humans; Imm | 2006 |
Naso-maxillary non-Hodgkin lymphoma associated with methotrexate treatment in a patient with rheumatoid arthritis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic | 2006 |
Technique in question.
Topics: Adjuvants, Anesthesia; Anesthesiology; Anesthetics, Intravenous; Anesthetics, Local; Arthritis, Rheu | 2006 |
Metastatic malignant melanoma in a patient taking interleukin-1 receptor antagonist.
Topics: Aged; Antimalarials; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Interleukin 1 Recepto | 2006 |
Initial combo therapy best way to treat RA. Study shows MTX plus prednisone or the biologic infliximab may stop RA in its tracks.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Huma | 2006 |
Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; C-Reacti | 2006 |
Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo.
Topics: Arthritis, Rheumatoid; Female; Follow-Up Studies; Glucocorticoids; Humans; Male; Middle Aged; Predni | 2006 |
Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study.
Topics: Arthritis, Rheumatoid; Case-Control Studies; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diet; | 2006 |
What is secondary adrenal insufficiency?
Topics: Acute Disease; Adrenal Insufficiency; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Female; Human | 2006 |
[Acute diarrhea in a patient with rheumatoid arthritis].
Topics: Acute Disease; Albendazole; Animals; Anthelmintics; Arthritis, Rheumatoid; Diarrhea; Gastritis; Huma | 2006 |
Tumour necrosis factor-alpha blockers: potential limitations in the management of advanced endometriosis? A case report.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 I | 2006 |
Anti-tumor necrosis factor-alpha-induced psoriasis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Diclofenac; Drug Therapy, Combination; Etanercep | 2006 |
Giant cell arteritis--the methotrexate debate revisited.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Blindness; Drug Therapy, Combination; Female; Giant | 2006 |
Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Aspartate Aminotransferases; Auto | 2006 |
Development of ulcerative colitis during the course of rheumatoid arthritis: Association with selective IgA deficiency.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Biopsy; Colitis, Ulcerative; Female; Humans; IgA De | 2006 |
Hypertrophic pachymeningitis in rheumatoid arthritis after adalimumab administration.
Topics: Adalimumab; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2006 |
Osteoporosis management in patients with rheumatoid arthritis: Evidence for improvement.
Topics: Aged; Arthritis, Rheumatoid; Bone Density; Comorbidity; Female; Glucocorticoids; Guideline Adherence | 2006 |
Neurologic and morphologic features of dural ectasia in ankylosing spondylitis and rheumatoid arthritis: a case report.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Arthroplasty, Replacement, Hip; Dilatation, Pathologic; | 2006 |
Barriers in the management of glucocorticoid-induced osteoporosis.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Calcium, Dietary; Clinical Competence; Female; Focus | 2007 |
[Modern strategy of diagnostics and management of patients with rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Biomarkers; Citrulline; Female; Humans; | 2006 |
Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes.
Topics: Adrenal Cortex Hormones; Aged; Arthritis, Rheumatoid; Cohort Studies; Disabled Persons; Drug Adminis | 2007 |
Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Apolipoproteins; Arthritis, Rheumatoid; C-Reactive Pro | 2007 |
The treatment of lymphoma complicating autoimmune disease: two birds with one stone?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2007 |
Summaries for patients. What is the best treatment plan for early rheumatoid arthritis?
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug | 2007 |
Massive spontaneous hemopneumothorax complicating rheumatoid lung disease.
Topics: Adult; Arthritis, Rheumatoid; Dyspnea; Female; Follow-Up Studies; Hemopneumothorax; Humans; Lung Dis | 2007 |
Clinical manifestations and treatment of rheumatoid pachymeningitis.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Brain; Female; Hearing | 2007 |
Prolactin and autoimmune diseases in humans.
Topics: Aminoquinolines; Animals; Arthritis, Rheumatoid; Autoimmune Diseases; Bromocriptine; Cabergoline; Cy | 2007 |
Pericarditis: a rare complication of methotrexate therapy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Diagnosis, Differential; Echocardiography, Doppler; Ele | 2007 |
Strongyloides stercoralis hyperinfection in a patient with rheumatoid arthritis after anti-TNF-alpha therapy.
Topics: Adalimumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents | 2007 |
[Progressive epidermal and mucosal skin lesions in a patient with rheumatoid arthritis].
Topics: Administration, Oral; Arthritis, Rheumatoid; Diagnosis, Differential; Dose-Response Relationship, Dr | 2007 |
Etanercept-related extensive pulmonary nodulosis in a patient with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Drug Therapy, C | 2007 |
A 57-year-old man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Decreased interleukin-1beta and elastase in the gingival crevicular fluid of individuals undergoing anti-inflammatory treatment for rheumatoid arthritis.
Topics: Acetaminophen; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumat | 2007 |
[Discussion on the necessity of treatment of rheumatoid arthritis with integrative Chinese and Western medicine].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Drugs, Chinese Herbal; Etane | 2007 |
[Thinking on the integrative Chinese and Western medicine in treating rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Drugs, Chinese Herbal; Femal | 2007 |
Fat suppression imaging in epidural lipomatosis: case report.
Topics: Adipose Tissue; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Epidural Space; Female; Glucocortic | 2007 |
Amygdala volume in patients receiving chronic corticosteroid therapy.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Amygdala; Anti-Inflammatory Agents; Arthritis, Rhe | 2008 |
Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheum | 2008 |
Risk of diabetes in patients with rheumatoid arthritis taking hydroxychloroquine.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Diabetes Mellitus; Glucocorticoids; Humans; Hydroxychlo | 2007 |
Cutaneous mucormycosis complicating methotrexate, prednisone, and infliximab therapy.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Dermatomycoses; Diagnos | 2007 |
Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Female; Humans; Immunosuppressive Agents; Mal | 2008 |
Influence of rituximab-CHOP therapy on clinical course and autoimmune parameters in rheumatoid arthritis associated with diffuse large B cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Polymyalgia rheumatica and elderly onset rheumatoid arthritis.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Blood Sedimentation; Cohort Studies; Humans; | 2008 |
Cutaneous cryptococcosis in a patient on corticosteroid therapy for rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Cryptococcosis; Cryptococcus neoformans; Dermatomycoses; Humans; Immuno | 2008 |
Adrenocorticosteroid therapy in pregnancy.
Topics: Adrenal Gland Diseases; Adult; Arthritis, Rheumatoid; Asthma; Birth Weight; Blood Group Incompatibil | 1966 |
Medical management of patients with disability due to arthritis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Bacterial Agents; Antimalarials; Arthritis, I | 1967 |
Gastrocolic fistula secondary to benign ulcer in a patient given steroids. Report of a case.
Topics: Aged; Arthritis, Rheumatoid; Gastric Fistula; Humans; Intestinal Fistula; Male; Peptic Ulcer Perfora | 1967 |
Bone dynamics of rheumatoid arthritis treated with adrenal corticosteroids.
Topics: Adult; Aged; Arthritis, Rheumatoid; Bone Development; Bone Resorption; Female; Humans; Male; Middle | 1967 |
Necrotizing panniculitis. Dermal vasculitis?
Topics: Adipose Tissue; Arthritis, Rheumatoid; Autoimmune Diseases; Biopsy; Collagen Diseases; Diagnosis, Di | 1967 |
Hypercortisonism, moniliasis and arthritis.
Topics: Adult; Arthritis, Rheumatoid; Candidiasis, Cutaneous; Candidiasis, Vulvovaginal; Dexamethasone; Fema | 1967 |
[Cortisone-induced neuromyopathies].
Topics: Arthritis, Rheumatoid; Chronaxy; Colitis; Dexamethasone; Electromyography; Glucocorticoids; Hepatole | 1967 |
Agranulocytosis and hydroxychloroquine.
Topics: Agranulocytosis; Arthritis, Rheumatoid; Hydroxychloroquine; Prednisone; Staphylococcal Infections; U | 1967 |
Interferon production of vitro by leucocytes from patients with systemic lupus erythematosus and rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Azathioprine; Cells, Cultured; Female; Humans; Interferon Inducers; In | 1981 |
Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro. Studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; B-Lymphocytes; Cell Line; Cytotoxicity, Immunologic; Female; Humans; I | 1982 |
Treatment of intractable rheumatoid arthritis with total lymphoid irradiation (TLI): immunological and clinical changes.
Topics: Animals; Antibodies, Bacterial; Arthritis, Rheumatoid; Autoantibodies; Humans; Immunoglobulins; Lymp | 1983 |
Cytomegalovirus-associated gastritis in a compromised host.
Topics: Arthritis, Rheumatoid; Cytomegalovirus Infections; Female; Gastritis; Humans; Immunosuppressive Agen | 1980 |
Oropharyngeal Epstein-Barr virus excretion in rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Viral; Arthritis, Rheumatoid; Female; | 1982 |
Digitalgia paresthetica with digital neuropathy in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Female; Fingers; Humans; Male; Middle Aged; Neural Conduction; Neuriti | 1983 |
[Treatment with corticoids administered in pulse therapy].
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Humans; Infusions, Parenteral; Lupus Erythematosus, | 1983 |
Low dose adrenocorticosteroids in the management of elderly patients with rheumatoid arthritis: selected examples and summary of efficacy in the long-term treatment of 97 patients.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cortisone; Female; Foll | 1983 |
A marathon runner with high fever, arthralgia.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Atlanto-Axial Joint; Gold; Humans; Joint Dislocation | 1983 |
Glucocorticoid use in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Drug Administration Schedule; Glucocorticoids; Humans; Methylprednisol | 1983 |
Treatment of intractable rheumatoid arthritis with total lymphoid irradiation.
Topics: Antibodies, Monoclonal; Arthritis, Rheumatoid; Chronic Disease; Feasibility Studies; Female; Follow- | 1981 |
Prevalence of decreased bone mass in rheumatoid arthritis. Relation to anti-inflammatory treatment.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone and Bones; Calcium; Female; Gold; | 1984 |
Corneomalacia perforans in a patient with rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Contact Lenses, Hydrophilic; Corneal Diseases; Female; Humans; Prednis | 1984 |
Synovial calcifications associated with long-term steroid therapy for chronic arthritis.
Topics: Aged; Arthritis, Rheumatoid; Calcinosis; Chondrocalcinosis; Humans; Joint Diseases; Male; Middle Age | 1984 |
Nephrotic syndrome with reversible severe renal failure after gold therapy.
Topics: Acute Kidney Injury; Aged; Arthritis, Rheumatoid; Blood Pressure; Cyclophosphamide; Female; Gold; Hu | 1984 |
[Lymphocyte subpopulations in patients with rheumatoid arthritis after anti-inflammatory and immunosuppressive treatment].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Humans; Immunosuppressive Agents; Prednisone; T-Lym | 1983 |
Total lymphoid irradiation therapy in refractory rheumatoid arthritis. Fifteen- to forty-month followup.
Topics: Adult; Aged; Anemia, Aplastic; Arthritis, Rheumatoid; Blood Transfusion; Bone Marrow; Drug Resistanc | 1984 |
Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis.
Topics: Acute Disease; Aged; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Female; Humans; Male; | 1983 |
[Effect of the 25-hydroxycholecalciferol in patients treated with corticoids].
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Calcifediol; Calcium; Female; Humans; Male; Middle A | 1983 |
Steroid-sparing action of flurbiprofen and indomethacin in rheumatoid arthritis: a nine-week study.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Flurbiprofen; Hum | 1983 |
Recovery from rheumatoid cerebral vasculitis.
Topics: Arthritis, Rheumatoid; Cerebral Angiography; Cerebral Arterial Diseases; Dexamethasone; Drug Therapy | 1984 |
Arthritis and autoimmune pancytopenia.
Topics: Adult; Arthritis, Rheumatoid; Autoantibodies; Blood Platelets; Cross Reactions; Erythrocytes; Humans | 1984 |
[Is myositis in chronic polyarthritis using d-penicillamine drug-induced?].
Topics: Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gold Sod | 1981 |
Serum C1q concentrations in rheumatic disorders. Early normalization during treatment of immunologically-mediated vasculitis.
Topics: Adolescent; Adult; Animals; Arthritis, Rheumatoid; Complement C1; Complement C3; Cryoglobulinemia; C | 1981 |
Jaw claudication. Its value as a diagnostic clue.
Topics: Aged; Arthritis, Rheumatoid; Diagnosis, Differential; Female; Giant Cell Arteritis; Humans; Jaw Dise | 1983 |
Prednisone therapy of gold-induced thrombocytopenia in a rheumatoid arthritis patient.
Topics: Aged; Arthritis, Rheumatoid; Female; Gold; Humans; Prednisone; Thrombocytopenia | 1980 |
Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Gold; Histocompatibility Antigens Class II; Humans; Male | 1981 |
Depressed T cell colony growth in systemic lupus erythematosus.
Topics: Adult; Aged; Arthritis, Rheumatoid; Colony-Forming Units Assay; Female; Humans; Lupus Erythematosus, | 1980 |
[Gastroduodenal lesions in rheumatoid arthritis, mesenchymopathies and other rheumatisms. Endoscopic study].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Female; Gastrointestinal Diseases; Gastros | 1982 |
Membranous nephropathy in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Glomerulonephritis; Humans; Hydroxychloroquine; Kidney Glomerulus; Mal | 1982 |
Concept of conservative treatment.
Topics: Antidepressive Agents; Arthritis, Rheumatoid; Azathioprine; Gold; Humans; Penicillamine; Prednisone | 1982 |
Rheumatoid arthritis with extra-articular manifestations.
Topics: Adult; Arthritis, Rheumatoid; Humans; Male; Prednisone; Pulmonary Fibrosis; Spinal Cord Compression | 1982 |
Rheumatoid scleritis.
Topics: Arthritis, Rheumatoid; Female; Humans; Inflammation; Middle Aged; Prednisone; Sclera | 1981 |
Spontaneous skin tearing during systemic corticosteroid treatment.
Topics: Arthritis, Rheumatoid; Female; Humans; Leg; Leg Ulcer; Middle Aged; Prednisone; Purpura; Skin; Synov | 1980 |
Pulse therapy in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Graft Rejection; Humans; Methylprednisolone; Prednisone | 1981 |
Serious adverse events with low-dose, long-term corticosteroid therapy in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Administration Schedule; Humans; Prednisone; T | 1995 |
High levels of antibodies to annexins V and VI in patients with rheumatoid arthritis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Annexin A5; Annexin A6; Arthritis, Rheumatoid; Autoanti | 1995 |
Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.
Topics: Acetaminophen; Adult; Aged; Arthritis, Psoriatic; Arthritis, Rheumatoid; Contrast Media; Deoxyglucos | 1995 |
Lichen planus in patients with rheumatoid arthritis treated with sulfasalazine.
Topics: Aged; Arthritis, Rheumatoid; Drug Eruptions; Female; Humans; Lichen Planus; Male; Middle Aged; Predn | 1995 |
[Iatrogenic osteoporsis: six case reports].
Topics: Adult; Arthritis, Rheumatoid; Asthma; Bone Resorption; Female; Follow-Up Studies; Humans; Iatrogenic | 1994 |
Normal pressure hydrocephalus associated with rheumatoid arthritis responding to prednisone.
Topics: Aged; Arthritis, Rheumatoid; Female; Gait; Humans; Hydrocephalus, Normal Pressure; Mental Health; Pr | 1995 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 20-1995. A 66-year-old man with a history of rheumatoid arthritis treated with adrenocorticosteroids, with the development of aphasia and right-sided weakness.
Topics: Aged; Aphasia; Arthritis, Rheumatoid; Diagnosis, Differential; Fatal Outcome; Hemiplegia; Humans; Hy | 1995 |
Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Deoxyglucose; Dose-Response Relationship, Drug; Female; Fluorine Radioisotope | 1995 |
Sacral insufficiency fractures in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Causality; Female; Fractures, Stress; Humans; Middle Aged; Osteo | 1994 |
Mycoplasma genitalium in the joints of two patients with arthritis.
Topics: Adult; Arthritis; Arthritis, Reactive; Arthritis, Rheumatoid; Ciprofloxacin; Humans; Knee Joint; Lup | 1994 |
Treatment of Mycobacterium haemophilum infection with an antibiotic regimen including clarithromycin.
Topics: Aged; Arthritis, Rheumatoid; Ciprofloxacin; Clarithromycin; Drug Therapy, Combination; Humans; Male; | 1994 |
[Estimation of benefits and risks of the treatment of rheumatoid polyarthritis with glucocorticoids using the health-related quality of life measurements].
Topics: Adult; Aged; Arthritis, Rheumatoid; Evaluation Studies as Topic; Female; Humans; Male; Methods; Midd | 1994 |
[Bone marrow aplasia and gold salts. Review of the literature apropos of 2 cases].
Topics: Anemia, Aplastic; Antilymphocyte Serum; Arthritis, Rheumatoid; Cyclosporine; Female; Gold Sodium Thi | 1994 |
Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Case-Control Studies; Cataract; C | 1994 |
[Corticosteroids in rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Humans; Prednisone | 1993 |
Serum keratan sulfate levels in rheumatoid arthritis: inverse correlation with radiographic staging.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Keratan Sulfat | 1994 |
Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance?
Topics: Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Arthritis, Rheumatoid; Blotting, Southern; Bone Ma | 1994 |
Long-term methotrexate in refractory rheumatoid arthritis; concurrent use of prednisone possibly improves drug-survival.
Topics: Arthritis, Rheumatoid; Drug Therapy, Combination; Follow-Up Studies; Humans; Methotrexate; Prednison | 1994 |
Variability in individual responses of 532 patients with rheumatoid arthritis to first-line and second-line drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; | 1993 |
Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events.
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Administration Schedule; Female; Follow | 1994 |
Prednisone in managing rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Humans; Osteoporosis; Prednisone | 1994 |
[Acquired factor VIII inhibitor in a patient with rheumatoid arthritis].
Topics: Aged; Arthritis, Rheumatoid; Autoantibodies; Autoimmune Diseases; Factor VIII; Female; Hematoma; Hem | 1993 |
Variation among rheumatologists in the use of prednisone and second-line agents for the treatment of rheumatoid arthritis.
Topics: Analysis of Variance; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Prescriptions; Drug Ther | 1994 |
Saved by a test result.
Topics: Adult; Arthritis, Rheumatoid; Autoantibodies; Cyclophosphamide; Diagnosis, Differential; Granulomato | 1994 |
Inverting the therapeutic pyramid: observations and recommendations on new directions in rheumatoid arthritis therapy based on the author's experience.
Topics: Adult; Aged; Arthritis, Rheumatoid; Auranofin; Drug Therapy, Combination; Female; Humans; Hydroxychl | 1993 |
Limitations of randomized clinical trials to recognize possible advantages of combination therapies in rheumatic diseases.
Topics: Arthritis, Rheumatoid; Auranofin; Azathioprine; Drug Combinations; Humans; Lupus Erythematosus, Syst | 1993 |
Fractures in rheumatoid arthritis: an evaluation of associated risk factors.
Topics: Aging; Arthritis, Rheumatoid; Body Mass Index; Disabled Persons; Female; Fractures, Bone; Humans; Ma | 1993 |
Measurement of gold treatment effect in clinical practice: evidence for effectiveness of intramuscular gold therapy.
Topics: Arthritis, Rheumatoid; Blood Sedimentation; Clinical Trials as Topic; Databases, Factual; Disability | 1993 |
Difficulties in treating rheumatoid arthritis in a battered husband.
Topics: Arthritis, Rheumatoid; Humans; Male; Prednisone; Spouse Abuse | 1993 |
Unstable angina in a man with joint pain.
Topics: Angina, Unstable; Arthritis, Rheumatoid; Coronary Disease; Diagnosis, Differential; Edema; Humans; M | 1993 |
Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Analysis of Variance; Arthritis, Rheumatoid; Bone D | 1993 |
Reflections on the use of unproven arthritis remedies.
Topics: Arthritis, Rheumatoid; Complementary Therapies; Dimethyl Sulfoxide; Female; Humans; Middle Aged; Pre | 1993 |
Differential effect of glucocorticoids on calcium absorption and bone mass.
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Betamethasone; Bone Density; Bone Resorption | 1993 |
[Acute ischemia of the lower limb in a patient with temporal arteritis and rheumatoid arthritis, carrier of anticardiolipin antibodies].
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Anticardiolipin; Arthritis, Rheumatoid; Blindness; Femor | 1995 |
Peripheral ulcerative keratitis in the setting of rheumatoid arthritis: treatment with immunosuppressive therapy.
Topics: Aged; Arthritis, Rheumatoid; Azathioprine; Corneal Ulcer; Cyclophosphamide; Drug Therapy, Combinatio | 1995 |
What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis?
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Gold; Humans; Hydroxy | 1995 |
CD8 lymphocyte subsets in active polymyalgia rheumatica: comparison with elderly-onset and adult rheumatoid arthritis and influence of prednisone therapy.
Topics: Age of Onset; Arthritis, Rheumatoid; CD4 Antigens; CD57 Antigens; CD8 Antigens; Female; Humans; Long | 1996 |
Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy.
Topics: Adult; Arthritis, Rheumatoid; Autoimmune Diseases; Biomarkers; Bone and Bones; Collagen; Female; Hum | 1996 |
Distinctive features of idiopathic inflammatory myopathies in French Canadians.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis, Rheumatoi | 1996 |
Results of "satisfaction with disease control" survey.
Topics: Arthritis, Rheumatoid; Drug Therapy, Combination; Health Surveys; Humans; Methotrexate; Patient Sati | 1996 |
Delay of corneal wound healing in patients treated with colchicine.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Colchic | 1997 |
Double filtration plasmapheresis for the treatment of rheumatoid arthritis: a study of 21 cases.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antigen-Antibody Complex; Arthritis, Rhe | 1997 |
Preoperative evaluation of a woman with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; He | 1997 |
Methods to score vertebral deformities in patients with rheumatoid arthritis.
Topics: Aged; Anthropometry; Arthritis, Rheumatoid; Bone and Bones; Female; Glucocorticoids; Humans; Lumbar | 1997 |
Response to therapy in rheumatoid arthritis is influenced by immediately prior therapy.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 1997 |
Relief of sensorineural hearing loss due to rheumatoid arthritis by endolymphatic sac decompression.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Audiometry; Decompression, Surgical; Endolymphatic | 1997 |
Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Gold; Humans; H | 1997 |
Aggressive therapy in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Aurothioglucose; Humans; Pred | 1998 |
TCRBV14S1 and rheumatoid arthritis revisited: abnormalities in the percentage of transcribed TCRBV14S1 family genes in PBMC from rheumatoid arthritis patients.
Topics: Arthritis, Rheumatoid; Cells, Cultured; DNA; Female; Genes, T-Cell Receptor beta; Glucocorticoids; H | 1998 |
Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 1998 |
A 15-year exercise program for rheumatoid vasculitis.
Topics: Arthritis, Rheumatoid; Blood Sedimentation; Disability Evaluation; Exercise Test; Exercise Therapy; | 1998 |
Dealing with drug-induced thrombocytopenia.
Topics: Algorithms; Anti-Inflammatory Agents; Anticoagulants; Antirheumatic Agents; Arthritis, Rheumatoid; D | 1998 |
Salivary testosterone in postmenopausal women with rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Biomarkers; Female; Humans; Middle Aged; Postmenopause; Prednisone; Sal | 1998 |
Intravascular lymphomatosis--an indolent or aggressive entity?
Topics: Aged; Arthritis, Rheumatoid; Asthma; Blood Sedimentation; Bone Marrow; Brain Neoplasms; Disease Prog | 1998 |
Nonsteroidal anti-inflammatory drugs and gastrocolic fistula.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Colonic Diseases; Female; G | 1998 |
A cross sectional analysis of 5 different markers of collagen degradation in rheumatoid arthritis.
Topics: Amino Acids; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Biomarkers; Case-Control Studies; Coll | 1998 |
The association between ocular cicatricial pemphigoid and rheumatoid arthritis.
Topics: Age of Onset; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Corneal Ulcer; C | 1998 |
[RS3PE: a clinical diagnosis, a prognosis more simple than its name].
Topics: Aged; Aged, 80 and over; Ankle Joint; Anti-Inflammatory Agents; Arthritis; Arthritis, Rheumatoid; Bl | 1998 |
Depression and the long-term risk of pain, fatigue, and disability in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Depression; Disability Evaluation; Fatigue; Humans; Methotrexate; Pain; Predn | 1998 |
Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Fatal Outcome; Hepatitis B; Hepatitis B virus; Hu | 1998 |
A survey of United States rheumatologists concerning effectiveness of disease-modifying antirheumatic drugs and prednisone in the treatment of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Attitude of Health Personnel; | 1998 |
Human phaeohyphomycotic osteomyelitis caused by the coelomycete Phomopsis saccardo 1905: criteria for identification, case history, and therapy.
Topics: Arthritis, Rheumatoid; Ascomycota; Female; Humans; Immunosuppression Therapy; Immunosuppressive Agen | 1999 |
POEMS syndrome, steroid-dependent diabetes mellitus, erythema elevatum diutinum, and rheumatoid arthritis as extramedullary manifestations of plasma cell dyscrasia.
Topics: Adult; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Erythema; Humans; Immunoglobulin A; Male; M | 1998 |
Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials.
Topics: Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Cyclosporine; Double-Blind Method; Dr | 1999 |
Two new cases of glucocorticoid-induced pancreatitis.
Topics: Acute Disease; Aged; Arthritis, Rheumatoid; Female; Glucocorticoids; Humans; Pancreatitis; Polymyalg | 1999 |
Tiopronin-induced myasthenia.
Topics: Aged; Arthritis, Rheumatoid; Female; Humans; Myasthenia Gravis; Neostigmine; Parasympathomimetics; P | 1999 |
Polymorphism of the vitamin D receptor gene and corticosteroid-related osteoporosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone De | 1999 |
[Picture of the month. Iatrogenic hernia].
Topics: Aged; Arthritis, Rheumatoid; Female; Hernia; Humans; Iatrogenic Disease; Ilium; Prednisone; Spinal F | 1999 |
Intermittent prednisone adequate for arthritis and lupus?
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Administration Schedule; Humans; Lupus Erythem | 1999 |
Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sch | 1999 |
Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity.
Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents, Second-Generation; Arthritis, Rheumatoid; Ch | 2000 |
Drugs for rheumatoid arthritis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Anorexia; Anti-Inflammatory Agents, Non-Steroidal; An | 2000 |
Aggressive strategies for treating aggressive rheumatoid arthritis: has the case been proven?
Topics: Alleles; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Ar | 2000 |
[RS3PE syndrome: report of 11 cases].
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Edema; Female; Humans; Mal | 2000 |
Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Infectious; Arthritis, Rheumatoid; | 2001 |
Change in bone mineral density in patients with rheumatoid arthritis during the first decade of the disease.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Arthritis, Rheumat | 2001 |
Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2001 |
[Lymphedema of the upper limb, a complication of rheumatoid polyarthritis].
Topics: Antirheumatic Agents; Arm; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Hydroxy | 2001 |
Fractures in adults on systemic steroid therapy: which prophylaxis?
Topics: Arthritis, Rheumatoid; Asthma; Bone Density; Calcitonin; Calcium; Clinical Trials as Topic; Diphosph | 1999 |
Inflammatory and hormonal measures predict neuropsychological functioning in systemic lupus erythematosus and rheumatoid arthritis patients.
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Attention; Case-Control Studies; Cognition; | 2001 |
[Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Human | 2001 |
Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful?.
Topics: Administration, Oral; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Administration Schedule; | 2002 |
[Infliximab in aggressive and refractory rheumatoid arthritis. A pilot study].
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheu | 2002 |
De novo CD5-positive diffuse large B cell lymphoma solely presenting as multiple subcutaneous nodules.
Topics: Adipose Tissue; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Arthritis, | 2002 |
Polyarthritis, polyarteritis and hepatitis B.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Biopsy, Needle; Female; Hepatitis A; Hepatitis B Antigens; | 1976 |
Limited plasmapheresis in rheumatoid arthritis with vasculitis.
Topics: Antigen-Antibody Complex; Arthritis, Rheumatoid; Azathioprine; Blood Sedimentation; Complement C3; C | 1979 |
Prednisone effect on microvascular permeability in patients with inflammatory rheumatic diseases.
Topics: Adult; Aged; Arthritis, Rheumatoid; Capillary Permeability; Dermatomyositis; Giant Cell Arteritis; H | 1979 |
[Panarteritis nodosa in rheumatoid arthritis. Report of a case].
Topics: Arthritis, Rheumatoid; Chlorambucil; Female; Humans; Middle Aged; Penicillamine; Polyarteritis Nodos | 1979 |
Elevated salivary and synovial fluid beta2-microglobulin in Sjogren's syndrome and rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Beta-Globulins; Humans; Prednisone; Radioimmunoassay; Sa | 1975 |
Spontaneous aortic rupture associated with chronic steroid therapy for rheumatoid arthritis in two cases.
Topics: Aged; Aorta, Thoracic; Aortic Rupture; Arthritis, Rheumatoid; Female; Humans; Middle Aged; Prednison | 1979 |
Effects of gold, dapsone, and prednisone on serum C-reactive protein and haptoglobin and the erythrocyte sedimentation rate in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Dapsone; Gold Sodium Thiomalate; Hap | 1979 |
Two cases of penicillamine-induced pemphigus erythematosus.
Topics: Aged; Arthritis, Rheumatoid; Azathioprine; Drug Eruptions; Female; Humans; Middle Aged; Pemphigus; P | 1979 |
Adrenocortical response upon repeated stimulation with corticotrophin in patients lacking endogenous corticotrophin secretion.
Topics: 17-Ketosteroids; Adrenal Cortex; Adrenal Glands; Adrenocorticotropic Hormone; Arthritis, Rheumatoid; | 1977 |
Gold-induced thrombocytopenia.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Arthritis, Rheumatoid; Dimercaprol; Female; Gold Sodium Th | 1978 |
Single daily dose prednisone therapy.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Arthritis, Rheumatoid; Asthma; Humans; Hydrocortisone; Met | 1979 |
Free serum ribonucleoprotein in mixed connective tissue disease and other connective tissue diseases.
Topics: Antibodies, Antinuclear; Arthritis, Rheumatoid; Dermatomyositis; Humans; Lupus Erythematosus, System | 1978 |
Fatty lesions of both humeri in a patient on corticosteroids and cyclophosphamide.
Topics: Adult; Arthritis, Rheumatoid; Biopsy; Bone Diseases; Bone Marrow Diseases; Cyclophosphamide; Humans; | 1979 |
Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Evaluation Studies as Topic; Female; Gold; Humans; Immunoglobulins; In | 1979 |
Resolution of renal amyloidosis secondary to rheumatoid arthritis.
Topics: Amyloidosis; Arthritis, Rheumatoid; Basement Membrane; Capillaries; Cyclophosphamide; Female; Follow | 1979 |
Actinomycotic pulmonary abscess in an immunosuppressed patient.
Topics: Actinomycosis; Arthritis, Rheumatoid; Female; Humans; Immunosuppression Therapy; Lung Abscess; Middl | 1979 |
Relationship between erythrocyte sedimentation rate and serum C-reactive protein in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Female; Hu | 1979 |
Steroid-induced femoral head necrosis.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Female; Femur Head Necrosis; Humans; Lymphoma, Non-H | 1977 |
Effect of 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on intestine and bone in glucocorticoid-treated patients.
Topics: Arthritis, Rheumatoid; Calcium; Dihydroxycholecalciferols; Humans; Hydroxycholecalciferols; Intestin | 1977 |
Serum protein-bound carbohydrate and seromucoids in rheumatoid arthritis.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Carbohydrates; Female; Humans; Male; Orosomucoid; Predniso | 1977 |
Osteomyelitis, septic arthritis and cortisone. A problem of mistaken diagnosis.
Topics: Adolescent; Arthritis, Infectious; Arthritis, Rheumatoid; Cortisone; Diagnostic Errors; Female; Gluc | 1977 |
[Fluoride osteosis after very prolonged treatment (9 and 10 years) with niflumic acid].
Topics: Adult; Aged; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Nicotinic Acids; Nifl | 1978 |
Erythema elevatum diutinum.
Topics: Aged; Arthritis, Rheumatoid; Dapsone; Erythema; Humans; Leg Ulcer; Male; Prednisone; Skin Diseases; | 1978 |
C-reactive protein in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; C-Reactive Protein; Follow-Up Studies; Humans; Prednisone | 1978 |
Skeletal manifestations of polymyalgia rheumatica.
Topics: Acromioclavicular Joint; Adult; Age Factors; Aged; Arthritis, Rheumatoid; Biopsy; Carpal Tunnel Synd | 1978 |
[Evaluation of the effectiveness of anti-inflammatory treatment of rheumatoid arthritis by means of thermography].
Topics: Adolescent; Adult; Aged; Ampicillin; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Body Temperatu | 1978 |
[Problems of disseminated lupus erythematosus in infants and children].
Topics: Arthritis, Rheumatoid; Azathioprine; Child; Child, Preschool; Chloroquine; Dermatomyositis; Female; | 1978 |
Fundus lesions in rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Female; Fundus Oculi; Humans; Pericarditis; Prednisone; Retinal Disease | 1978 |
Hyperbasophilic immunoblasts in circulating blood in chronic inflammatory rheumatic and collagen diseases.
Topics: Antibody-Producing Cells; Arthritis; Arthritis, Rheumatoid; Basophils; Fluorescent Antibody Techniqu | 1975 |
[A patient with muscle weakness].
Topics: Aged; Arthritis, Rheumatoid; Autoantibodies; Azathioprine; Complement System Proteins; Cryoglobulins | 1977 |
Serum 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid therapy.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Humans; Hydroxycholecalciferols; Prednisone; Radioli | 1977 |
Antirheumatic drugs, the ESR, and the hypohistidinemia of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aspirin; Blood Sedimentation; Gold; Histidine; Humans; Prednisone | 1977 |
[The Wissler-Fanconi syndrome (allergic subsepsis) in adults].
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Diagnosis, Differential; Female; Humans; Hypersensitivity; | 1977 |
Pericardial tamponade secondary to sudden steroid withdrawal in chronic rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiac Tamponade; Cervical Vertebrae; Chronic Disease; Female; Fractures, Bo | 1977 |
Rheumatoid arthritis treated with chlorambucil: a five-year follow-up.
Topics: Acute Disease; Aged; Arthritis, Rheumatoid; Chlorambucil; Chronic Disease; Female; Follow-Up Studies | 1976 |
The effect of anti-inflammatory agents and inflammation on granulocyte adherence. Evidence for regulation by plasma factors.
Topics: Adhesiveness; Adult; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Depression, | 1976 |
D-penicillamine-induced polymyositis in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Bundle-Branch Block; Electromyography; Female; Humans; Middle Aged; Myositis; | 1976 |
Chronic sarcoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Diagnosis, Differential; Humans; Male; Prednisone; Sarcoidosis | 1976 |
[Cytotoxic treatment of chronic joint diseases].
Topics: Adult; Arthritis; Arthritis, Rheumatoid; Azathioprine; Chronic Disease; Cyclophosphamide; Drug Evalu | 1976 |
Low free serum histidine concentration in rheumatoid arthritis. A measure of disease activity.
Topics: Antibodies, Antinuclear; Arthritis, Rheumatoid; Aspirin; Blood Sedimentation; Circadian Rhythm; Fema | 1975 |
Letter: Chronic thrombocytopenia following gold therapy.
Topics: Aged; Arthritis, Rheumatoid; Aurothioglucose; Gold; Humans; Male; Prednisone; Thrombocytopenia | 1975 |
Protrusio acetabuli in rheumatoid arthritis.
Topics: Acetabulum; Adult; Aged; Anthropometry; Arthritis, Rheumatoid; Bone Diseases; Female; Femur Head; Hi | 1975 |
Specificity of SLE serum antibody for single-stranded and double-stranded DNA configuration.
Topics: Adolescent; Ammonium Sulfate; Antibody Specificity; Arthritis, Rheumatoid; Chemical Precipitation; C | 1975 |
Rheumatoid arthritis, vasculitis and paroxysmal hypertension.
Topics: Adrenal Gland Neoplasms; Aged; Arteritis; Arthritis, Rheumatoid; Diagnosis, Differential; Gangrene; | 1975 |
Progressive multifocal leukoencephalopathy: a complication of immunosuppressive treatment.
Topics: Arthritis, Rheumatoid; Bronchopneumonia; Cerebral Cortex; Chlorambucil; Gold; Humans; Immunosuppress | 1975 |
Rheumatoid arthritis followed by systemic lupus erythematosus.
Topics: Arthritis, Rheumatoid; Cyclophosphamide; Gold; Humans; Lupus Erythematosus, Systemic; Male; Middle A | 1975 |
[Mitochondrial antibodies induced by drug administration in patients with and without pseudo LE syndrome (author's transl)].
Topics: Adult; Aged; Arthritis, Rheumatoid; Autoantibodies; Cardiac Glycosides; Drug Combinations; Humans; L | 1975 |
Avascular necrosis of bone mimicking symmetric polyarthritis in a patient with malignant lymphoma treated with high-dose steroids.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Bleomycin; Cyclophosph | 1992 |
Functional deficiency of antigen-presenting cells in the synovial fluid of rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antigen-Presenting Cells; Arthritis, Rheumatoid; Cell Adhesion; Fema | 1992 |
Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone.
Topics: Age Factors; Arthritis, Rheumatoid; Azathioprine; Drug Therapy, Combination; Gold; Humans; Hydroxych | 1992 |
Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids.
Topics: Adult; Aged; Aged, 80 and over; Androstenedione; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bo | 1992 |
Pituitary-adrenal axis responsiveness to ovine corticotropin releasing hormone in patients with rheumatoid arthritis treated with low dose prednisone.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Animals; Arthritis, Rheumatoid; Corticotropin-Releasing Ho | 1992 |
Successful treatment of disseminated strongyloidiasis.
Topics: Adult; Animals; Arthritis, Rheumatoid; Female; Humans; Mebendazole; Prednisone; Strongyloides sterco | 1992 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 37-1992. A 68-year-old woman with rheumatoid arthritis and pulmonary hypertension.
Topics: Aged; Arthritis, Rheumatoid; Cyclophosphamide; Female; Humans; Hypertension; Hypertension, Pulmonary | 1992 |
Necrotizing scleritis of scleral flaps after transscleral suture fixation of an intraocular lens.
Topics: Arthritis, Rheumatoid; Cataract Extraction; Cyclophosphamide; Female; Humans; Lenses, Intraocular; M | 1992 |
Suppression of autoantibodies to factor VIII and correction of factor VIII deficiency with a combined steroid-cyclophosphamide-porcine factor VIII treatment in a patient with rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Autoantibodies; Cyclophosphamide; Factor VIII; Female; Humans; Immunogl | 1992 |
Comment on the study of deflazacort versus prednisone in the treatment of chronic inflammatory disorders.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Chronic Disease; Female; Humans; Inflammation; Pred | 1992 |
A controlled study of lymphocyte subsets in rheumatoid arthritis.
Topics: Aging; Antineoplastic Agents; Arthritis, Rheumatoid; Gold; Humans; Hydroxychloroquine; Lymphocyte Su | 1992 |
Arthrodesis of the ankle in patients who have rheumatoid arthritis.
Topics: Adult; Aged; Ankle Joint; Arthritis, Rheumatoid; Arthrodesis; Bone Screws; Dose-Response Relationshi | 1992 |
Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy.
Topics: Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Humans; Osteoporosis; Prednisone | 1992 |
[Pulmonary toxicity of gold salts].
Topics: Alveolitis, Extrinsic Allergic; Arthritis, Rheumatoid; Female; Gold; Humans; Middle Aged; Prednisone | 1991 |
Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy.
Topics: Arthritis, Rheumatoid; Bone Density; Dose-Response Relationship, Drug; Female; Humans; Male; Menopau | 1992 |
Mortality predictors among 263 patients with rheumatoid arthritis.
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Cohort Studies; Female; Health Status Indicators; H | 1991 |
Treatment of elderly-onset rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Cardiovascular Diseases; Humans; Osteoporosis; Prednisone | 1991 |
The coexistence of active classic rheumatoid arthritis and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Arthritis, Rheumatoid; Cyclophosphamide; Humans; Male; Middle Ag | 1991 |
[Circulating lymphocyte populations and B-cell differentiation in a young female patient with multicentric giant lymph node hyperplasia].
Topics: Adult; Arthritis, Rheumatoid; B-Lymphocytes; Castleman Disease; Cell Differentiation; Diagnostic Err | 1991 |
Low dose prednisone does not affect calcium homeostasis or bone density in postmenopausal women with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Bone Density; Calcium; Dose-Response Relationship, Drug; Female; | 1991 |
Nocardia asteroides infection complicating rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Female; Humans; Lung Diseases; Methotrexate; Middle Aged; Nocardia Infections | 1991 |
Bone loss in patients with rheumatoid arthritis--effect of steroids measured by low dose quantitative computed tomography.
Topics: Adult; Aged; Arthritis, Rheumatoid; Bone Density; Female; Humans; Menopause; Middle Aged; Osteoporos | 1991 |
[Acute congestive heart failure due to malignant rheumatoid arthritis].
Topics: Antibodies, Antinuclear; Arthritis, Rheumatoid; Female; Heart Failure; Humans; Hypertension, Pulmona | 1991 |
Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, | 1991 |
Predictors of fractures in early rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Female; Fractures, Bone; Humans; | 1991 |
Human synovial mast cell involvement in rheumatoid arthritis and osteoarthritis. Relationship to disease type, clinical activity, and antirheumatic therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; A | 1991 |
Rheumatoid arthritis of the larynx: the importance of early diagnosis and corticosteroid therapy.
Topics: Adult; Arthritis, Rheumatoid; Cricoid Cartilage; Dexamethasone; Drug Administration Schedule; Evalua | 1991 |
Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Drug Therapy, Combin | 1991 |
Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of antirheumatic drugs.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Fibrosis; HLA-DR Antigen | 1991 |
Regression of an expanded subpopulation of large granular lymphocytes in a patient with rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Lymphocytosis; Neutropenia; Prednisone; Remission Indu | 1991 |
Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate.
Topics: Arthritis, Rheumatoid; Drug Administration Schedule; Female; Herpes Zoster; Humans; Incidence; Male; | 1991 |
Low-dose prednisone in rheumatoid arthritis patients: placebo treatment?
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Placebos; Prednisone | 1991 |
NSAID gastropathy revisited.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Contraindications; Humans; Prednison | 1990 |
Retroperitoneal air after routine hemorrhoidectomy. Report of a case.
Topics: Adult; Arthritis, Rheumatoid; Female; Hemorrhoids; Humans; Mediastinal Emphysema; Postoperative Comp | 1990 |
[Still's disease in adults with a pulmonary site].
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Prednisone; Pulmonary Fibrosis | 1990 |
A 61-year-old man with a painless red eye and decreased visual acuity.
Topics: Arthritis, Rheumatoid; Cornea; Corneal Ulcer; Cyclophosphamide; Eye Infections, Bacterial; Humans; M | 1990 |
Rheumatoid arthritis and hypercoagulable state.
Topics: Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Follow-Up Studies; Gold; Heparin; Humans; | 1990 |
[Reactivation of the alpha 1-fetoprotein synthesis in systemic lupus erythematosus].
Topics: Alanine Transaminase; alpha-Fetoproteins; Antibodies; Arthritis, Rheumatoid; Aspartate Aminotransfer | 1985 |
Rheumatoid arthritis with eosinophilic fasciitis and pure red cell aplasia.
Topics: Arthritis, Rheumatoid; Eosinophilia; Fasciitis; Female; Humans; Middle Aged; Prednisone; Red-Cell Ap | 1989 |
Penicillamine for interstitial lung disease in rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mid | 1989 |
Nonsteroidal antiinflammatory drugs in rheumatoid arthritis: duration of use as a measure of relative value.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Administration Schedule; Evalua | 1989 |
Bullous pemphigoid and rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Biopsy; Female; Hand Deformities, Acquired; Humans; Middle Aged; Pemphigoid, | 1989 |
Takayasu's arteritis diagnosed in a patient with long-standing arthralgias and arthritis.
Topics: Aortic Arch Syndromes; Arthritis; Arthritis, Rheumatoid; Female; Humans; Middle Aged; Prednisone; Re | 1987 |
Lymphoma chemotherapy as remission inducing treatment in rheumatoid arthritis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Cyclophosphamide; Doxorubicin | 1989 |
Effects of a new heterocyclic glucocorticoid, deflazacort (DFC), on the functions of lymphocytes from patients with rheumatoid arthritis (RA).
Topics: Arthritis, Rheumatoid; Female; Histocompatibility Antigens Class II; Humans; In Vitro Techniques; Ly | 1987 |
Gold-induced pneumonitis.
Topics: Aged; Arthritis, Rheumatoid; Aurothioglucose; Female; Gold; Humans; Pneumonia; Prednisone; Radiograp | 1988 |
Kaposi's sarcoma in a patient with rheumatoid arthritis and polymyositis treated with corticosteroids.
Topics: Arthritis, Rheumatoid; Humans; Male; Middle Aged; Myositis; Prednisone; Sarcoma, Kaposi | 1988 |
Muscle function in women with rheumatoid arthritis--the influence of glucocorticosteroids. A clinical and morphological investigation.
Topics: Arthritis, Rheumatoid; Disability Evaluation; Exercise Therapy; Female; Humans; Hydrotherapy; Muscle | 1988 |
Breath pentane excretion as a marker of disease activity in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Breath Tests; Gold; Humans; Lipid Pe | 1988 |
Prevalence of upper gastrointestinal mucosal abnormalities at a rheumatology clinic.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cross-Sectional Studies; Drug | 1988 |
Muscle function in women with rheumatoid arthritis--the influence of glucocorticosteroids. A clinical and morphological investigation.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Exercise Therapy; Female; Foot; Humans; Knee | 1988 |
Bone mass in patients with rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Bone Matrix; Bone Resorption; Female; Gold; Humans; Male; Metacarpus; | 1987 |
[Long-term administration of low doses of prednisone in the treatment of rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Humans; Prednisone | 1987 |
Abnormal calcium metabolism caused by increased circulating 1,25-dihydroxyvitamin D in a patient with rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Calcitriol; Calcium; Creatinine; Humans; Hypercalcemia; Male; Parathyr | 1986 |
Kaposi's sarcoma in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Humans; Male; Middle Aged; Prednisone; Sarcoma, Kaposi; Skin Neoplasms | 1987 |
Factors influencing the incidence of infections in Felty's syndrome.
Topics: Arthritis, Rheumatoid; Complement System Proteins; Disability Evaluation; Felty Syndrome; Humans; In | 1987 |
Acute congestive heart failure due to the arteritis of rheumatoid arthritis: early diagnosis by endomyocardial biopsy: a case report.
Topics: Arteritis; Arthritis, Rheumatoid; Biopsy; Heart Failure; Humans; Immunoglobulin M; Male; Middle Aged | 1986 |
The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Biopsy; Drug Administration Schedule; Female; HLA Antigens; Huma | 1986 |
Oral methotrexate therapy for chronic rheumatoid arthritis ulcerations.
Topics: Aged; Arthritis, Rheumatoid; Bacterial Infections; Female; Humans; Liver; Male; Methotrexate; Middle | 1986 |
Muscle morphology and enzymes in proximal and distal muscle groups of lower limb from patients with corticosteroid treated rheumatoid arthritis: the relationship to maximal isokinetic muscle strength.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Adult; Aged; Arthritis, Rheumatoid; Citrate (si)-Synthase; Female; | 1986 |
The influence of prednisone on the muscle morphology and muscle enzymes in patients with rheumatoid arthritis.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Adult; Aged; Arthritis, Rheumatoid; Citrate (si)-Synthase; Female; | 1986 |
Isokinetic and isometric muscle strength in patients with rheumatoid arthritis. The relationship to clinical parameters and the influence of corticosteroid.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Isometric Contraction; Middle Aged; Muscle Contr | 1986 |
The relationship between the leg muscle strength and physical capacity in patients with rheumatoid arthritis, with reference to the influence of corticosteroids.
Topics: Adult; Aged; Arthritis, Rheumatoid; Exercise Test; Female; Humans; Isometric Contraction; Middle Age | 1986 |
[Gold-induced fibrosing alveolitis].
Topics: Arthritis, Rheumatoid; Dyspnea; Gold; Histocompatibility Antigens Class II; Humans; Male; Middle Age | 1985 |
Human rheumatoid arthritic cartilage and its neutral proteoglycan-degrading proteases. The effects of antirheumatic drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cadaver; Cartilage, Articular; Endopep | 1985 |
Onset of type I diabetes mellitus, hypothyroidism, and hypogonadism on withdrawal of glucocorticoid therapy and remission on its resumption in a patient with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Diabetes Mellitus, Type 1; Humans; Hypogonadism; Hypothy | 1986 |
[Rheumatoid coxitis. Clinical study of 20 cases].
Topics: Administration, Oral; Adult; Arthritis, Rheumatoid; Female; Hip Joint; Humans; Male; Middle Aged; Pr | 1986 |
Rheumatoid arthritis associated with expanded populations of granular lymphocytes.
Topics: Aged; Antibody-Dependent Cell Cytotoxicity; Arthritis, Rheumatoid; Blood Cell Count; Bone Marrow; Cy | 1986 |
Hyperviscosity retinopathy secondary to polyclonal gammopathy in a patient with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Blood Viscosity; Female; Fluorescein Angiography; Humans; Hyperemia; Hypergam | 1986 |
Beneficial effect of intravenous cyclophosphamide and oral prednisone on D-penicillamine-associated bronchiolitis obliterans.
Topics: Administration, Oral; Adult; Arthritis, Rheumatoid; Bronchitis; Constriction, Pathologic; Cyclophosp | 1985 |
Cancer in rheumatoid arthritis: a prospective long-term study of mortality.
Topics: Adolescent; Adult; Age Factors; Aged; Arthritis, Rheumatoid; Female; Follow-Up Studies; Gold; Humans | 1985 |
Effect of antimalarial treatment on circulating immune complexes in rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antigen-Antibody Complex; Antimalarials; Arthritis, Rheumatoid; Chl | 1985 |
Hypercalcemia in leprosy.
Topics: Arthritis, Rheumatoid; Calcitonin; Calcium; Dapsone; Female; Humans; Hypercalcemia; Leprosy; Middle | 1985 |
Gold induced aplastic anemia. Complete response to corticosteroids, plasmapheresis, and N-acetylcysteine infusion.
Topics: Acetylcysteine; Anemia, Aplastic; Arthritis, Rheumatoid; Bone Marrow; Female; Gold; Humans; Middle A | 1985 |
C-reactive protein levels in patients with rheumatoid arthritis: the impact of therapy.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protei | 1985 |
[Behavior of lymphoid cells in rheumatic diseases].
Topics: Arthritis, Rheumatoid; Cell Differentiation; Humans; Leukocyte Count; Lymphocytes; Neutrophils; Phen | 1971 |
Systemic lupus erythematosus in the elderly.
Topics: Aged; Arthritis, Rheumatoid; Aspirin; Female; Humans; Lupus Erythematosus, Systemic; Male; Middle Ag | 1972 |
[Collagen-like protein as an activity criterion in the disease course observation of progressive chronic polyarthritis].
Topics: Adult; Aged; Alpha-Globulins; Arthritis, Rheumatoid; Blood Protein Electrophoresis; Blood Sedimentat | 1973 |
Drug-induced arthropathy and necrosis of the femoral head.
Topics: Adult; Aged; Alcoholism; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Asthma; Bone Regeneration; | 1973 |
[Periarteritis nodosa and colonic perforation].
Topics: Aged; Amputation, Surgical; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Autopsy; Colon | 1974 |
[Goiter formation due to phenylbutazone treatment of rheumatic arthritis].
Topics: Adolescent; Arthritis, Rheumatoid; Chloroquine; Goiter; Humans; Male; Phenylbutazone; Prednisone; Th | 1967 |
[On the question of generalized mesenchymal reaction in the glucocorticoid therapy of primary chronic polyarthritis].
Topics: Arthritis, Rheumatoid; Connective Tissue; Felty Syndrome; Female; Humans; Leg Ulcer; Leukopenia; Mal | 1968 |
Diagnostic aspects of lupus erythematosus cells and antinuclear factors in disease states.
Topics: Antibodies, Antinuclear; Arthritis, Rheumatoid; Autoantibodies; Azathioprine; Fluorescent Antibody T | 1969 |
Leucocyte migration inhibition to Mycoplasma fermentans in patients with rheumatoid arthritis.
Topics: Adult; Aged; Animals; Antigens, Bacterial; Arthritis, Rheumatoid; Autoantibodies; Bacteriological Te | 1973 |
[Detection of antibodies to soluble nucleoprotein and to deoxyribonucleic acid using a radioimmunologic method].
Topics: Antibodies; Antibodies, Antinuclear; Arthritis, Rheumatoid; Azathioprine; Collagen Diseases; Dermato | 1974 |
Urinary tetrahydrocortisone and tetrahydrocortisol in infants born of mothers treated with corticosteroids during pregnancy.
Topics: Abortion, Habitual; Adrenal Cortex Hormones; Adrenal Hyperplasia, Congenital; Adult; Arthritis, Rheu | 1966 |
[Testing of the antiphlogistic effect of antirheumatic drugs].
Topics: Antipyrine; Arthritis, Rheumatoid; Drug Synergism; Erythema; Humans; Injections, Intramuscular; Niac | 1966 |
[Rheumatic and rheumatoid joint inflammations. 1. Disease processes and conservative therapy].
Topics: Aged; Arthritis, Rheumatoid; Female; Glycosaminoglycans; Humans; Immobilization; Male; Middle Aged; | 1969 |
Chronic disease and disability: rheumatoid arthritis.
Topics: Activities of Daily Living; Arthritis, Rheumatoid; Ascorbic Acid; Aspirin; Disabled Persons; Female; | 1974 |
Abrupt withdrawal of adrenal corticosteroids in patients with rheumatoid arthritis: the clinical observations of twelve cases.
Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Adult; Aged; Arthritis, Rheumatoid; Female; Huma | 1967 |
Widespread necrotizing arteritis in rheumatoid arthritis: report of a patient who survived.
Topics: Adrenocorticotropic Hormone; Arteritis; Arthritis, Rheumatoid; Biopsy; Chlorambucil; Diabetes Mellit | 1967 |
Plasma "cortisol" response to Synacthen in patients on long-term small-dose prednisone therapy.
Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Arthritis, Rheumatoid; Humans; Hydrocortisone; P | 1968 |
[Results of therapy of the immunodepressive type in 40 patients with severe rheumatoid polyarthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Chlorambucil; Female; Humans; Immunosuppressive Agents; Male; Mi | 1967 |
[Rheumatoid polyarthritis and chronic lymphoid leukemia. Studies of 7 cases of association of these 2 diseases].
Topics: Adult; Age Factors; Aged; Animals; Antibodies; Arthritis, Rheumatoid; Autoimmune Diseases; Chlorambu | 1969 |
[Treatment of chronic polyarthritis].
Topics: Adrenocorticotropic Hormone; Arthritis, Rheumatoid; Chloroquine; Gold; Humans; Hydrotherapy; Immunos | 1967 |
Intermittent corticotrophin therapy. Integrity of pituitary-adrenal function.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Arthritis, Rheumatoid; Asthma; Female; Humans; Male; Middl | 1970 |
[Alternating corticotherapy of long duration (personal technic)].
Topics: Adrenocorticotropic Hormone; Arthritis, Rheumatoid; Glucocorticoids; Humans; Prednisone | 1971 |
Corticosteroid-induced avascular necrosis. A clinical study of seventy-seven patients.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Arthritis, Rheumatoid; Embolism, Fat; Female; | 1971 |
Scleritis and rheumatoid arthritis.
Topics: Adrenocorticotropic Hormone; Age Factors; Arteritis; Arthritis, Rheumatoid; Azathioprine; Betamethas | 1971 |
[Corticotherapy in rheumatoid polyarthritis].
Topics: Adrenocorticotropic Hormone; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Betamethasone; C | 1971 |
Effect of glucocorticoids on lysosomes in synovial lining cells in human rheumatoid arthritis.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Aminopeptidases; Arthritis, Rheumatoid; Biopsy; Female; Gl | 1974 |
The effects of some anti-inflammatory drugs on the acute-phase proteins in rheumatoid arthritis.
Topics: Adrenocorticotropic Hormone; Adult; Analgesics; Arthritis, Rheumatoid; Aspirin; Blood Sedimentation; | 1973 |
Anti-inflammatory drugs in rheumatic diseases.
Topics: Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Antimalarials; Arthritis, Rheumatoid; Aspirin | 1974 |
A case of rheumatoid arthritis with polyarteritis demonstrated at the Postgraduate Medical School of London.
Topics: Angiography; Arthritis, Rheumatoid; Diagnosis, Differential; Electrophoresis; Humans; Male; Middle A | 1966 |
[Periarteritic complications in a case of chronic evolutive polyarthritis treated with corticosteroids (Slocumb syndrome)].
Topics: Arthritis, Rheumatoid; Female; Humans; Middle Aged; Polyarteritis Nodosa; Prednisone | 1963 |
Rheumatoid arthritis with rheumatoid nodules and allergic granuloatosis.
Topics: Adult; Arthritis, Rheumatoid; Bacitracin; Chloroquine; Female; Humans; Indomethacin; Neomycin; Ointm | 1968 |
[Hydroxyproline excretion in urine in chronic connective tissue disease].
Topics: Adrenocorticotropic Hormone; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Collagen | 1970 |
Acute rheumatic fever.
Topics: Acute Disease; Adolescent; Antistreptolysin; Arthritis, Juvenile; Arthritis, Rheumatoid; Child; Chil | 1974 |
Proliferative cutaneous arteritis.
Topics: Arteritis; Arthritis, Rheumatoid; Diarrhea; Female; Humans; Middle Aged; Phenylbutazone; Prednisone; | 1974 |
Immunosuppressive drugs and acute leukemia.
Topics: Aged; Arthritis, Rheumatoid; Azathioprine; Cyclophosphamide; Dose-Response Relationship, Drug; Human | 1973 |
Rheumatoid arthritis and prednisone-induced scurvy.
Topics: Adult; Arthritis, Rheumatoid; Female; Gastrointestinal Hemorrhage; Humans; Prednisone; Scurvy | 1972 |
Leucocyte migration inhibition with aggregated gamma globulin in patients with rheumatoid arthritis.
Topics: Adult; Aged; Animals; Antibodies, Anti-Idiotypic; Arthritis, Rheumatoid; Cell Migration Inhibition; | 1973 |
Idiopathic pulmonary hemosiderosis with manifestations of multiple connective tissue and immune disorders. Treatment with cyclophosphamide.
Topics: Adolescent; Antibodies, Antinuclear; Arthritis, Rheumatoid; Biopsy; Collagen Diseases; Connective Ti | 1974 |
Observations on drug prescribing in rheumatoid arthritis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Aspirin; Drug Prescriptions | 1974 |
Dermatomyositis with cerebral vasculitis in a patient with agammaglobulinemia.
Topics: Adolescent; Agammaglobulinemia; Arthritis, Rheumatoid; Autopsy; Cerebral Angiography; Cerebrovascula | 1972 |
[Practical realization of corticoid therapy].
Topics: Adrenal Cortex Hormones; Adrenal Glands; Arthritis, Rheumatoid; Asthma; Circadian Rhythm; Colitis, U | 1972 |
Influence of long-term corticosteroid treatment on glucose tolerance in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Blood Glucose; Female; Glucose Tolerance Test; Humans; Islets of Langerhans; | 1973 |
Corticosteroids and femoral head necrosis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Femur Head Necrosis; Humans; Immunosuppressive Agents; I | 1973 |
Gold-associated thrombocytopenia. Report six cases.
Topics: Adult; Aged; Antibody Formation; Arthritis, Rheumatoid; Aurothioglucose; Blood Coagulation Factors; | 1974 |
[Peptic ulcers appearing and cured under uninterrupted corticoid therapy].
Topics: Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Dermatomyositis; Endoscopy; Female; Hep | 1974 |
Salivary gland immunoglobulin and rheumatoid factor synthesis in Sjögren's syndrome. Natural history and response to treatment.
Topics: Adult; Arthritis, Rheumatoid; Biopsy; Carbon Isotopes; Cells, Cultured; Cyclophosphamide; Fluorescen | 1972 |
[Polyneuropathy in a case of rheumatoid arthritis].
Topics: Aged; Arthritis, Rheumatoid; Ecchymosis; Female; Humans; Long-Term Care; Polyneuropathies; Prednison | 1972 |
[Optimal therapy for rheumatoid arthritis in the Peoples' Republic of Poland].
Topics: Arthritis, Rheumatoid; Aspirin; Cyclophosphamide; Gold; Health Resorts; Humans; Indomethacin; Penici | 1972 |
[Therapy of chronic polyarthritis. 2].
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Aspirin; Betamethasone; Dexamethasone; Flufenamic Ac | 1972 |
[Examination of various immunological tests in rheumatoid polyarthritis patients].
Topics: Age Factors; Aged; Agglutinins; Arthritis, Rheumatoid; Chlorambucil; Female; Humans; Male; Middle Ag | 1972 |
Reliability of seromucoid as an indicator of rheumatoid arthritis activity.
Topics: Adult; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Female; Humans; Middle Aged; | 1972 |
Gold-induced thrombocytopenia.
Topics: Arthritis, Rheumatoid; Blood Cell Count; Blood Platelets; Epistaxis; Female; Gold; Humans; Middle Ag | 1973 |
Lymphocyte responses to phytohemagglutinin in rheumatoid arthritis and glomerulonephritis and the effects of immunosuppression.
Topics: Arthritis, Rheumatoid; Cyclophosphamide; Glomerulonephritis; Immunosuppression Therapy; Lectins; Lym | 1973 |
Quadriceps femoris strength.
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Biomechanical Phenomena; Electronics, Medical; Fati | 1973 |
[Nephrotic syndrome due to penicillamine (author's transl)].
Topics: Adult; Arthritis, Rheumatoid; Biopsy; Exanthema; Female; Humans; Immunoglobulin G; Kidney; Nephrotic | 1973 |
[Comparison of therapeutic effects of various immunosuppressive drugs in rheumatoid arthritis].
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Azathioprine; Drug Therapy, Combination; Female; Hum | 1973 |
[Gold therapy and agranulocytosis].
Topics: Adult; Agranulocytosis; Aminopyrine; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspir | 1973 |
[Treatment of rheumatoid polyarthritis with antithymic and antilymphocyte globulins].
Topics: Adult; Antilymphocyte Serum; Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Female; Globulins; H | 1973 |
[Ulcer perforation of Meckel's diverticulum, without intestinal hemorrhage, during corticotherapy].
Topics: Arthritis, Rheumatoid; Child; Female; Humans; Meckel Diverticulum; Penicillins; Peptic Ulcer Perfora | 1973 |
Back diffusion of hydrogen ions across gastric mucosa of patients with gastric ulcer and rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Aspirin; Biological Transport, Active; Cell Membrane Permeability; Chl | 1974 |
Letter: Aspirin, gastritis, and antral ulcers.
Topics: Arthritis, Rheumatoid; Aspirin; Biopsy; Drug Combinations; Female; Gastritis; Gastroscopy; Humans; I | 1974 |
Grand rounds: Intraperitoneal infection and emergency operation in patients on long-term corticosteroid therapy.
Topics: Abscess; Arthritis, Rheumatoid; Emergencies; Humans; Laparotomy; Male; Methylprednisolone; Middle Ag | 1974 |
[Use of antilymphocyte globulin in the treatment of rheumatoid arthritis].
Topics: Animals; Anti-Inflammatory Agents; Antibodies; Antilymphocyte Serum; Arthritis, Rheumatoid; Drug The | 1974 |
Pyoderma gangrenosum successfully treated with aqueous silver nitrate (0.5 per cent) steroids, and skin autografts.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Gangrene; Humans; Hypersensitivity; Male; Middle Age | 1968 |
Rheumatoid arthritis associated with eosinophilia.
Topics: Aged; Antibodies, Anti-Idiotypic; Arthritis, Rheumatoid; Aspirin; Complement System Proteins; Eosino | 1971 |
[Quantitative-qualitative studies of a local inflammation].
Topics: Acute Disease; Arthritis, Rheumatoid; Cell Count; Cell Movement; Culture Techniques; Drug Hypersensi | 1971 |
The relationship between glucose tolerance, plasma insulin and corticosteroid therapy in patients with rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Blood Glucose; Cortisone; Female; Glucocorticoids; Glucose Tolerance T | 1968 |
[Osteomyelitis as complication of an aseptic femur head necrosis in long term prednisone therapy of progressive polyarthritis].
Topics: Arthritis, Rheumatoid; Diagnosis, Differential; Female; Femur Head; Humans; Long-Term Care; Middle A | 1968 |
Anti-DNA activity in systemic lupus erythematosus. A diagnostic and therapeutic guide.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Autoantibodies; Binding Sites; Complement System Proteins; | 1971 |
[Treatment of evolutive chronic polyarthritis with chrysotherapy. Reports. Conclusions. Summaries].
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Female; Glucocorticoids; Gold; Humans; | 1971 |
[Chlorambucil in rheumatoid polyarthritis].
Topics: Arthritis, Rheumatoid; Blood Cell Count; Chlorambucil; Humans; Long-Term Care; Prednisone; Rheumatoi | 1971 |
[Septic arthritis during rheumatoid arthritis].
Topics: Aged; Anti-Bacterial Agents; Arthritis, Infectious; Arthritis, Rheumatoid; Female; Humans; Male; Mid | 1972 |
A steroid-induced infectious complication of rheumatoid arthritis.
Topics: Arthritis, Infectious; Arthritis, Rheumatoid; Cryptococcosis; Humans; Hydrocortisone; Male; Meningit | 1972 |
[Bone metabolism and rheumatoid arthritis].
Topics: Adult; Aged; Alkaline Phosphatase; Analysis of Variance; Arthritis, Rheumatoid; Bone and Bones; Calc | 1972 |
Perforation of colonic diverticula. A life-threatening postoperative complication in patients receiving long-term corticosteroid therapy.
Topics: Arthritis, Rheumatoid; Arthroplasty; Diverticulum, Colon; Female; Hip; Humans; Intestinal Perforatio | 1972 |
Five year follow-up study of sixty cases of inflammatory diseases treated with alternate day corticosteroid therapy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Arthritis, Rheumatoid; Asthma; Autoimmune Diseases; C | 1972 |
[Controlled clinical trial of a preparation with steroid activity (prednisone) associated with xylamide, protective drug for the gastric mucosa].
Topics: Adolescent; Adult; Aged; Amides; Arthritis, Rheumatoid; Asthma; Benzoates; Bronchitis; Chronic Disea | 1972 |
[Gastrocolic fistulae after steroid ulcers].
Topics: Aged; Arthritis, Rheumatoid; Colonic Diseases; Gastric Fistula; Humans; Intestinal Fistula; Male; Mi | 1972 |
[Use of indomethacin in combination with other antirheumatic drugs in the therapy of chronic inflammatory rheumatism].
Topics: Arthritis, Rheumatoid; Aspirin; Chronic Disease; Dexamethasone; Drug Synergism; Flufenamic Acid; Gol | 1972 |
Psychological dependency on steroids?
Topics: Anxiety; Arthritis, Rheumatoid; Asthma; Brain; Depression; Female; Glucocorticoids; Humans; Middle A | 1971 |
[Study of niflumic acid in 20 cases of inflammatory rheumatism treated with corticoids].
Topics: Arthritis, Rheumatoid; Drug Synergism; Female; Humans; Indomethacin; Male; Middle Aged; Nicotinic Ac | 1971 |
Effect of corticosteroids on ulnar resonant frequency.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Biomechanical Phenomena; Bone and Bones; Female; Hum | 1971 |
Spontaneous fractures of pelvis in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Fractures, Spontaneous; Humans; Hydrocortisone; Injectio | 1971 |
Personality, disease parameters and medication in rheumatoid arthritis.
Topics: Adult; Antimalarials; Arthritis, Rheumatoid; Aspirin; Blood Sedimentation; Family Characteristics; F | 1971 |
[A case of pemphigus induced by D-penicillamine. Does iatrogenic pemphigus exist?].
Topics: Arthritis, Rheumatoid; Autoantibodies; Biopsy; Cytodiagnosis; Drug Synergism; Female; Fluorescent An | 1971 |
[Evaluation of a practical use of synthetic antimalarials in the treatment of rheumatoid polyarthritis].
Topics: Aged; Antimalarials; Arthritis, Rheumatoid; Aspirin; Chloroquine; Eye Diseases; Female; Follow-Up St | 1971 |
[Treatment of common rheumatoid polyarthritis with D-penicillamine].
Topics: Arthritis, Rheumatoid; Blood Sedimentation; Humans; Immunoglobulins; Lymphocyte Activation; Penicill | 1971 |
[Contribution to the study of exogenous steroid diabetes in children].
Topics: Adolescent; Arthritis, Rheumatoid; Diabetes Mellitus; Female; Glucose Tolerance Test; Humans; Leukem | 1971 |
[Combination of aspirin, chloroquine and prednisone in rheumatology].
Topics: Arthritis, Rheumatoid; Aspirin; Chloroquine; Prednisone; Rheumatic Diseases | 1965 |
[Critic of rheumatism therapy in the practice].
Topics: Adrenal Cortex Hormones; Ambulatory Care; Arthritis, Rheumatoid; Chloroquine; Chronic Disease; Famil | 1967 |
Rheumatoid vasculitis. Report of a second case treated with penicillamine.
Topics: Arteritis; Arthritis, Rheumatoid; Endophthalmitis; Gangrene; Humans; Latex Fixation Tests; Male; Mid | 1968 |
Discussion on clinical trials of the fenamates.
Topics: Analgesia; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Central Nervous System; Flufena | 1966 |
Dermal connective tissue permeability in rheumatoid arthritics.
Topics: Adult; Animals; Arthritis, Rheumatoid; Ascorbic Acid; Carbamates; Cell Membrane Permeability; Connec | 1966 |
[Research on the effects of azathioprine (Imuran) in rheumatoid arthritis and lupic diseases].
Topics: Adult; Arthritis, Rheumatoid; Azathioprine; Humans; Lupus Erythematosus, Systemic; Middle Aged; Pred | 1969 |
Systemic lupus erythematosus.
Topics: Adolescent; Aged; Animals; Antigen-Antibody Reactions; Arthritis, Rheumatoid; Azathioprine; Cortison | 1969 |
[Immunosuppressive treatment of collagen diseases].
Topics: Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Collagen Diseases; Cyclophosphamide; Dermatomyosi | 1969 |
Lupus erythematosus complicated by the Chiari-Frommel syndrome and autoimmune thyroiditis.
Topics: Adult; Arthritis, Rheumatoid; Autoimmune Diseases; Chiari-Frommel Syndrome; Diagnosis, Differential; | 1969 |
Rheumatoid disease. Adrenocortical function and intermittent steroid therapy.
Topics: 17-Hydroxycorticosteroids; Adult; Aged; Arthritis, Rheumatoid; Dexamethasone; Female; Humans; Male; | 1970 |
[Erythrocytes in active chronic progressive polyarthritis. II. Erythrocyte survival time].
Topics: Arthritis, Rheumatoid; Chronic Disease; Erythrocyte Aging; Humans; Prednisone; Time Factors | 1970 |
Rheumatoid arthritis and papilledema. Résumé of case.
Topics: Arthritis, Rheumatoid; Cerebrospinal Fluid; Diagnosis, Differential; Endocarditis, Subacute Bacteria | 1970 |
Pyoderma gangrenosum.
Topics: Arthritis, Rheumatoid; Colitis, Ulcerative; Female; Humans; Middle Aged; Prednisone; Pyoderma; Radio | 1970 |
Cutaneous amyloidosis. Classification, pathogenesis and relation to "collagen disease".
Topics: Aged; Amyloidosis; Arthritis, Rheumatoid; Biopsy; Female; Humans; Inflammation; Lupus Erythematosus, | 1970 |
Spontaneous rupture of the calcaneal tendon in rheumatoid arthritis after local steroid injection.
Topics: Achilles Tendon; Arthritis, Rheumatoid; Female; Glucocorticoids; Humans; Injections; Middle Aged; Pr | 1970 |
Serum and urine amino nitrogen and urinary amino acids during short-term treatment with prednisone.
Topics: Adolescent; Adult; Amino Acids; Arthritis, Rheumatoid; Asthma; Chromatography; Electrophoresis; Fema | 1970 |
Electrodiagnostic investigation of the neuro-muscular lesions in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Creatine Kinase; Dexamethasone; Electromyography; Female; Flumet | 1970 |
[Gastric gangrene in the course of encortone treatment].
Topics: Adult; Arthritis, Rheumatoid; Humans; Male; Necrosis; Prednisone; Stomach Diseases | 1970 |
[Primary chronic polyarthritis and diabetes mellitus].
Topics: Arthritis, Rheumatoid; Blood Glucose; Carbohydrate Metabolism; Chronic Disease; Diabetes Complicatio | 1970 |
[Rupture of the aorta in rheumatoid arthritis with vasculitis].
Topics: Aged; Aortic Aneurysm; Aortic Rupture; Arteritis; Arthritis, Rheumatoid; Autopsy; Female; Humans; Pr | 1970 |
[Effect of therapy on iron metabolism in patients with progressive chronic polyarthritis].
Topics: Anemia; Anemia, Hypochromic; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Blood Sedimentation; B | 1970 |
Steroid myopathy.
Topics: Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Cushing Syndrome; Electromyography; Fem | 1971 |
[Value of clofezone in the treatment of rheumatic diseases].
Topics: Amides; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bursitis; Ethylamines; Hip Joint; Humans; J | 1971 |
Empyema in rheumatoid pleuropulmonary disease.
Topics: Adult; Aged; Anemia; Arthritis, Rheumatoid; Bronchial Fistula; Empyema; Female; Glucose; Humans; Lun | 1971 |
[Diffuse interstitial pulmonary fibrosis (Hamman-Rich syndrome) and primary chronic polyarthritis].
Topics: Adult; Arthritis, Rheumatoid; Chloroquine; Chronic Disease; Female; Humans; Oxytetracycline; Phospha | 1971 |
[Progressive chronic polyarthritis and active body mass].
Topics: Adipose Tissue; Adult; Arthritis, Rheumatoid; Body Weight; Chloroquine; Creatinine; Humans; Methods; | 1971 |
Hemolytic assay of the ninth complement complement component: elevation and depletion in rheumatic diseases.
Topics: Animals; Arthritis, Rheumatoid; Barbiturates; Blood Sedimentation; Blood Urea Nitrogen; Buffers; Chr | 1971 |
Gastric ulcer and the anti-arthritic drugs.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Indomethacin; Male; Middle Aged; Peptic Ulcer He | 1971 |
[Experience in the management of rheumatic diseases using indomethacin].
Topics: Arthritis, Rheumatoid; Chloroquine; Drug Synergism; Humans; Indomethacin; Phenylbutazone; Prednisone | 1967 |
[On the cortisone withdrawal syndrome].
Topics: Adrenal Insufficiency; Aged; Arthritis, Rheumatoid; Female; Fluprednisolone; Glucocorticoids; Humans | 1967 |
[Experience with the rectal prednisone therapy in general practice with special reference to the prevention of spastic conditions of the respiratory tract].
Topics: Adolescent; Adult; Age Factors; Arthritis, Rheumatoid; Asthma; Bronchial Spasm; Child; Child, Presch | 1967 |
[Lens changes in rheumatic children with long term corticosteroid therapy].
Topics: Adolescent; Arthritis, Rheumatoid; Child; Child, Preschool; Dexamethasone; Diagnosis, Differential; | 1967 |
[Erythema nodosum].
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Erythema Nodosum; Female; Humans; Male; Middle Aged; Predn | 1967 |
[Treatment of chronic polyarthritis with corticoids].
Topics: Arthritis, Rheumatoid; Balneology; Chloroquine; Humans; Phenylbutazone; Prednisone | 1967 |
[Nonsteroid anti-inflammatory therapy. V. Therapeutic results using some drug combinations].
Topics: Arthritis, Rheumatoid; Drug Tolerance; Humans; Indomethacin; Prednisone; Spondylitis, Ankylosing | 1967 |
[Eliciting of lupus erythematosus by gold treatment in primary chronic polyarthritis?].
Topics: Adult; Arthritis, Rheumatoid; Female; Gold; Humans; Lupus Erythematosus, Systemic; Physical Therapy | 1967 |
Metabolic effects of human growth hormone in corticosteroid-treated children.
Topics: Adolescent; Arthritis, Rheumatoid; Asthma; Calcium; Child; Dwarfism; Dwarfism, Pituitary; Female; Gr | 1968 |
[Necrotizing arteritis in steroid treated rheumatoid polyarthritis with secondary amyloidosis].
Topics: Amyloidosis; Arteritis; Arthritis, Rheumatoid; Cortisone; Glucocorticoids; Humans; Male; Middle Aged | 1968 |
Immunological studies in a case of gold salt induced thrombocytopenia.
Topics: Aged; Arthritis, Rheumatoid; Blood Cell Count; Blood Coagulation Tests; Blood Platelets; Blood Trans | 1968 |
Delayed hypersensitivity in systemic lupus erythematosus.
Topics: Adolescent; Adult; Age Factors; Aged; Arthritis, Rheumatoid; Black or African American; Candida; DNA | 1968 |
[Role of corticotherapy in vertebral osteoporosis in rheumatoid arthritis].
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Female; Humans; Middle Aged; Osteoporosis; Prednison | 1968 |
[On the polymorphism of infectious complications of corticotherapy of rheumatoid arthritis].
Topics: Adult; Arthritis, Rheumatoid; Dexamethasone; Female; Humans; Infections; Male; Middle Aged; Predniso | 1968 |
[Effect of prednisone on the development of acute pancreatitis].
Topics: Acute Disease; Amylases; Arthritis, Rheumatoid; Gold; Humans; Liver; Pancreatitis; Prednisone | 1968 |
Phialophora gougerotii: an opportunistic fungus in a patient treated with steroids.
Topics: Arthritis, Rheumatoid; Candidiasis; Humans; Male; Middle Aged; Phialophora; Prednisone | 1968 |
[Polymyalgia rheumatica. A review and a report of personal cases].
Topics: Aged; Arthritis, Rheumatoid; Blood Protein Electrophoresis; Collagen Diseases; Diagnosis, Differenti | 1968 |
Rheumatoid arthritis: drug therapy.
Topics: Arthritis, Rheumatoid; Chloroquine; Gold; Humans; Phenylbutazone; Prednisone; Salicylates | 1968 |
[Polymyalgia rheumatica].
Topics: Aged; Arthritis, Rheumatoid; Diagnosis, Differential; Female; Humans; Middle Aged; Polymyalgia Rheum | 1968 |
Stomach ulcer and duodenal ulcer running a fatal course during steroid treatment.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Glucocorticoids; Humans; Male; Middle Aged; Peptic Ulcer | 1968 |
[Some problems in chronic treatment with corticoids in rheumatoid arthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Bone Diseases; Female; Humans; Middle Aged; Muscular Diseases; N | 1968 |
[The immunopathogenesis of chronic rheumatoid polyarhtritis and new ways of its treatment].
Topics: Adult; Aged; Antigen-Antibody Reactions; Arthritis, Rheumatoid; Autoantibodies; Chloroquine; Drug Sy | 1968 |
The effect of long-term treatment with prednisone upon the state of the human gastric mucosa.
Topics: Adult; Arthritis, Rheumatoid; Biopsy; Female; Gastric Acidity Determination; Gastric Mucosa; Gastrit | 1968 |
Rheumatoid heart disease.
Topics: Adult; Aortic Valve Insufficiency; Arthritis, Rheumatoid; Female; Humans; Male; Prednisone; Rheumati | 1968 |
[Experiences with Elestol in general practice].
Topics: Arthritis, Rheumatoid; Aspirin; Chloroquine; Humans; Joint Diseases; Prednisone | 1968 |
A study of capillary resistance in rheumatoid arthritis with special reference to the effects of long-term low-dosage oral corticosteroid therapy.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Capillary Resistance; Child; Dosage Forms; Female; H | 1968 |
Complicated rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Biopsy; Corticosterone; Diabetes Complications; Eye Manifestations; Female; H | 1968 |
Separation and fractionation of hyaluronic acid from human synovial fluid on agarose gels.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Carbazoles; Chemical Phenomena; Chemistry; | 1969 |
[Side effects of prednisone therapy in hematologic diseases].
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Cushing Syndrome; Female; Hematologic Diseases; Huma | 1969 |
Barium perforation of a peptic ulcer and barium granuloma of the colon. A report of two rare complications in radiological examination.
Topics: Arthritis, Rheumatoid; Barium; Colon; Duodenum; Esophagus; Granuloma; Humans; Indomethacin; Male; Mi | 1969 |
Preoperative evaluation of the arthritic patient.
Topics: Age Factors; Aged; Arthritis, Rheumatoid; Humans; Postoperative Care; Prednisone; Preoperative Care | 1969 |
[Observations on atypical rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Humans; Phenylbutazone; Prednisone; Serologic Tests | 1965 |
[Treatment of rheumatoid polyarthritis by a delta-butazolidine combination].
Topics: Arthritis, Rheumatoid; Humans; Phenylbutazone; Prednisone | 1965 |
Serum complement levels in rheumatoid arthritis. A longitudinal study of 43 cases with correlation of clinical and serological data including rheumatoid factor and thermolabile inhibitor of the F-II L.P. test.
Topics: Adult; Aged; Arthritis, Rheumatoid; Complement System Proteins; Female; Gold; Humans; Latex Fixation | 1965 |
[Importance of some facts in the hormone therapy of rheumatism].
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Humans; Leukocyte Count; Prednisone; Rheumatic Fever; Rheu | 1965 |
[Value of antimalarial, corticoid and aspirin combination in the supporting treatment of chronic rheumatic polyarthritis].
Topics: Adult; Aged; Amodiaquine; Arthritis, Rheumatoid; Aspirin; Female; Humans; Male; Middle Aged; Prednis | 1965 |
[Aseptic bone necrosis following steroid therapy].
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Middle Aged; Osteochondritis; Prednisone | 1965 |
[The antalgic and antirheumatic action of a neurotropic vitamin, aspirin and corticoid association].
Topics: Analgesics; Arthritis, Rheumatoid; Aspirin; Humans; Neuralgia; Prednisone; Vitamin B Complex | 1965 |
[Problems of the steroid ulcer].
Topics: Arthritis, Rheumatoid; Cortisone; Glucocorticoids; Humans; Hydrocortisone; Liver Diseases; Peptic Ul | 1965 |
Steroid arthropathy.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Joint Diseases; Lupus Erythematosus, | 1966 |
New drugs. VII. A controlled trial of flufenamic acid therapy in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Blood Sedimentation; Female; Flufenamic Acid; Human | 1966 |
Structure of the adrenal cortex in rheumatoid diseases, including some observations on the adenohypophysis.
Topics: Adrenal Glands; Arthritis, Rheumatoid; Cortisone; Dexamethasone; Humans; Lupus Erythematosus, System | 1966 |
[Antiphlogistics in rheumatology].
Topics: Analgesics; Arthritis, Rheumatoid; Humans; Prednisone | 1966 |
[Long-term prednisone treatment of chronic polyarthritis. A 6-year report].
Topics: Arthritis, Rheumatoid; Female; Follow-Up Studies; Humans; Male; Prednisone | 1966 |
Corticosteroids in general medicine.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Collagen Diseases; Gastrointestinal Diseases; Hemato | 1966 |
[Course of multiple complications following common bile duct reexamination in a patient treated with cortisone].
Topics: Arthritis, Rheumatoid; Common Bile Duct; Female; Humans; Middle Aged; Postoperative Complications; P | 1966 |
[Pulmonary tuberculosis following ambulatory prednisone treatment].
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Antitubercular Agents; Arthritis, Rheumatoid; A | 1966 |
[The risk in therapy. Asymptomatic diverticulosis of the colon discovered by chance by perforation during corticoid treatment].
Topics: Adrenal Cortex Hormones; Aged; Arthritis, Rheumatoid; Asthma; Diverticulum, Colon; Female; Humans; I | 1966 |